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Abstract  
 
The enzyme peptide: N-glycanase (EC 3.5.1.52) is an endoglycosidase which cleaves N-linked 
glycans from incorrectly folded glycoproteins exported from the endoplasmic reticulum 
during ER-associated degradation (ERAD). Clinical mutations in this enzyme (resulting in loss 
or decrease in function) are responsible for the rare congenital disorder termed N-GLY1. N-
GLY1 disorder was first identified by next generation sequencing in 2012, and as such there 
exists little information as to the cellular effects of N-glycanase deficiency. 
In this study, N-glycanase deficiency was examined in a well-characterised cell model (HEK-
293).  Cellular effects were examined following pharmacological inhibition of N-glycanase 
using carbobenzoxy-valyl-ananyl-aspartyl-[O-methyl]-fluoromethylketone (Z-VAD-fmk) and, 
genetic knockdown by siRNA.  Attempts were also made to generate a knockout cell line 
using CRISPR/Cas9.       
Using molecular and cellular techniques, this study has confirmed that in HEK-293, 
pharmacological N-glycanase inhibition or siRNA knockdown does not activate ER stress, 
oxidative stress or change the glycoprotein profile of the cell. Both treatments were 
associated with a small increase in ThT fluorescence associated with protein aggregates and 
identified that autophagy was increased in pharmacological N-glycanase inhibition and siRNA 
knockdown, and that this likely represents a protective measure. Autophagy dysregulation 
using ATG13 KO MEF cells found a change in the redox environment of the cell. This effect 
was further exacerbated in both HEK293, WT MEFs and ATG13 KO MEFs by growth in 
glucose-free media supplemented with galactose to reduce glycolysis as an energy source. 
This is suggestive of mitochondrial dysregulation, although no changes in mitochondrial 
membrane potential or mitochondrial content were identified. Proteomics analysis of 
immuno-precipitated autophagosomes induced under pharmacological N-glycanase 
inhibition and siRNA knockdown revealed increased intensity of mitochondrial proteins in 
these samples indicative of mitophagy which may play a role in the cellular response to 
impairments of N-glycanase function.  
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Chapter 1 
1.1 Structural and functional diversity of proteins 
 
Proteins have exceptionally diverse roles, from acting as biological catalysts, to performing 
structural functions (such as actin in the cytoskeleton, and laminin in the extracellular 
matrix).  This diversity of function arises from multiple factors, such as structure (Fu et al. 
2000), size (Fischer et al. 2004), charge (Gitlin et al. 2006), the presence or absence of post-
translational modification (PTMs) (Yu-Chieh Wang et al. 2013) and locale (Hung and Link 
2011). Proteins are often classified into families and super-families which demonstrate high 
levels of structural and functional homology (Schlick 2002).  The structures a protein can 
adopt are often essential to the functional role; the primary structure (the sequence of amino 
acids) determining the higher levels of fixed and dynamic structural organisation ultimately 
responsible for function. This “sequence-structure-function” paradigm has long been 
regarded as a cornerstone of structural biology (Shenoy and Jayaram 2010, Sadowski and 
Jones 2009). 
The structure of a protein is generally described in terms of levels of structural organisation. 
First is the linear sequence of amino acids (encoded by DNA). The secondary structure 
involves the folding of polypeptides into α-helices, β-sheets or random coil structures. The 
tertiary structure where the polypeptide is assembled to form the final conformation which 
can be stabilised by hydrophobic interactions and disulphide bonds (Pace et al. 2014). 
Perturbations in protein structure arising from mutation or damage can result in drastic 
functional changes. One such example is reduced oxygen binding in sickle cell anaemia; β-
globin subunits bind heme which stabilises the protein structure and binds O2 to transport 
around the body. A single mutation of p.Val6Glutamic acid in the β-globin heme binding 
pocket results in polymerisation of the protein under deoxygenated conditions leading to 
reducing O2 binding (Thom et al. 2013, Nath and Hebbel 2015, Kassim and DeBaun 2013, 
Wonder et al. 2017). Likewise, changes in amino acid sequence can result in changes in the 
overall charge or region of a protein (such as a binding site) which may have an adverse effect 
on ligand binding interactions (Huang and Briggs 2002). For example, nicotinic acetylcholine 
receptor function relies on a ring of negatively charged amino acids on the external face; and 
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mutation of a single negatively charged glutamate or aspartate to a positively charged lysine 
results in a reduction in  ion conductivity (Wilson et al. 2000).  
1.1.2 Post-Translational Modifications  
Further levels of complexity are introduced into the proteome through covalent attachment 
of additional modifications to protein structures. These are termed post-translational 
modifications (PTMs) or in some cases, co-translational modifications if they are introduced 
as proteins are synthesised. A variety of different post- and co-translational modifications 
are commonly found on protein structures, such as phosphorylation, ubiquitination, and 
glycosylation.  
1.1.3 Phosphorylation 
Phosphorylation allows cells to react to their environment by modifying internal pathways in 
response to external stimuli. It is the process of the addition of a phosphate group to a 
tyrosine or serine/threonine residue by tyrosine protein kinases (TPK) or a serine/threonine 
protein kinases (STPK) respectively.  These modifications can be removed by phosphatases. 
It is a dynamic process with phosphate groups being cycled on and off throughout the 
lifespan of the protein.  
Phosphorylation is extremely widespread and it is estimated that one third of all proteins 
(Olsen et al. 2006) are regulated via phosphorylation (Nishi et al. 2011), with many proteins 
bearing large numbers of potential phospho-sites.  For example, the tumour suppression 
protein p53 is a transcription factor with a half-life of less than 20 minutes (Pant and Lozano 
2014) and bears a high number of different post-translation modifications (Maclaine and 
Hupp 2009) including over twenty phospho-sites(Figure 1.1).  
 
Figure 1.1 Post-translation modification sites of p53. (Maclaine and Hupp 2009) Open 
access article distributed under Creative Commons Attribution Licence (CC-BY).
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 Under cellular stress stimuli (such as DNA damage) p53 is phosphorylated, which serves to 
increase its activity as a transcription factor. Mutation studies of serine 20 to an aspartic acid 
residue (which mimics the presence of phospho-modified serine) found increased 
transcription activity (Maclaine and Hupp 2009).  As well as individual proteins being 
regulated there are large networks of signalling cascades controlled by phosphorylation such 
as the mitogen-activated protein kinase MAPK cascade and, signalling induced by GPCR 
activation (Brzostowski et al. 2013, Cargnello and Roux 2011, Kim and Choi 2010). The MAPK 
cascade regulates diverse cellular functions including proliferation, apoptosis and various 
stress responses; often by induction of gene expression (Plotnikov et al. 2011). The MAPK 
cascade consists of three core kinases, MAP3K, MAPKK and MAPK (although others including 
MAP4K and MAPKAPK can also be involved) (Plotnikov et al. 2011). Signals are generated by 
sequential phosphorylation and activation of multiple kinases. Activation of extracellular 
receptors, including receptor tyrosine kinases (RTKs) and GPCRs results in the activation of 
the small GTPase Ras which recruits Raf protein kinases to the plasma membrane, which are 
then phosphorylated. Rafs then phosphorylate the MAPKKs, MEK 1 and MEK 2 which go on 
to phosphorylate ERK1/2 on both a tyrosine and threonine residue. MEK1/2 are part of a 
small number of dual specificity kinases, able to phosphorylate either threonine or tyrosine 
residue on ERK1/2. MEK1/2 also provide specificity for this cascade, as ERK1/2 is the only 
known target (Plotnikov et al. 2011).  ERK1/2 then activates transcription factors in the 
nucleus and upregulates expression of several target genes including erthroblastosis virus 
twenty-six (ETS) and AP1 transcription factor (AP-1/FOS) both involved in cell cycle 
progression (Little et al. 2013).  
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Figure 1.2 Diagram showing the key components of the ERK1/2 signalling cascade. 
Reprinted with permission from Nature: Oncogene (Little et al. 2013). 
 
1.1.4 Ubiquitination 
Ubiquitin is a small globular protein of 76 amino acids, of which multiple copies can form 
chains conjugated to proteins via any of its seven lysine residues or the N-terminal 
methionine.  This post-translational modification results in K6, 11, 27, 29, 33, 48 or 63 linked 
chains of ubiquitin (Figure 1.3). As well as homogenous linkages, ubiquitin chains can contain 
mixed linkages, which serves to increase the diversity of the signal. Proteins bearing K48 and 
K63 linked ubiquitin have been extensively studied as this modification is associated with 
protein degradation signals via the proteasome and autophagy respectively. Ubiquitination 
has also been implicated in other cell signalling mediated events, such as the response to 
DNA damage (Brinkmann et al. 2015), protein trafficking (Pizarro and Norambuena 2014) 
and activation of NF-κB (Iwai et al. 2014). 
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Figure 1.3 Linkage examples of ubiquitin chains. Homogenous linkages contain ubiquitin 
linked via one lysine residue. Mixed linkages contain ubiquitin linked via different lysine 
residues. Branched chains consist of multiple ubiquitin proteins linked via different 
linkages to a single ubiquitin protein. (Scott et al. 2015) Open access article distributed 
under Creative Commons Attribution Licence (CC-BY). 
 
Ubiquitination is controlled by the E1, E2 and E3 proteins; these are involved in ubiquitin 
activation, ubiquitin transfer, and ubiquitin ligation. The ubiquitin signal is highly dynamic, 
and ubiquitin chains can be cycled on and off the target substrate. This removal of ubiquitin 
is controlled by deubiquitinating enzymes (DUBs) (Amerik and Hochstrasser 2004, He et al. 
2016).  
As well as ubiquitin chains acting to modulate protein function, ubiquitin itself can also bear 
further modifications such as acetylation and phosphorylation (Figure 1.4). Ubiquitin can also 
be modified by SUMOylation, the modification by the small ubiquitin-like modifier (SUMO) 
family further diversifying the ubiquitin signal (Henley et al. 2014). Many ubiquitin 
modifications have been discovered by proteomics experiments (Udeshi et al. 2013, Elia et 
al. 2015) however, the kinases/phosphatases and acetyltransferases/deactylases involved in 
these modifications are largely unknown (Swatek and Komander 2016).  
homogenous
mixed 
linkage
branched
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Figure 1.4 Modification of ubiquitin (Swatek and Komander 2016). Open access article 
distributed under Creative Commons Attribution Licence (CC-BY). 
 
To decode the ubiquitin signal, proteins contain an ubiquitin binding domain (UBD) of which 
there are more than twenty families (Scott et al. 2015). The structure of the ubiquitin chain 
can lead to the specific recruitment of downstream ubiquitin-recognising proteins that 
modulate different cellular effects.  
Ubiquitin often regulates protein function by influencing stability and protein lifespan. For 
example, as well as phosphorylation, p53 is also regulated by ubiquitination. Under regular 
conditions, the E3 ubiquitin ligase, MDM2 ubiquitinates p53 and targets it to proteasomal 
degradation. Knockout studies of Mdm2 in mice have found increased cell death induced by 
p53 (Pant and Lozano 2014).  
1.1.5 Glycosylation 
Glycosylation is the term used to describe the covalent attachment of carbohydrates 
(glycans) to biological molecules including proteins and lipids, and is one of the most 
common protein modifications. Although protein glycosylation is commonly described as a 
post translational modification (Lanctôt et al. 2006, Fabbro et al. 2015), under many 
conditions it is more accurately described as a co-translational modification, as the glycan is 
added during protein synthesis rather than following synthesis and folding events. Protein 
bound glycans are involved in protein folding (Ellgaard et al. 2016), molecular recognition 
events (Scott and Panin 2014) and cellular adhesion (Ghoshal et al. 2014). There are 
numerous different types of glycosylation but commonly encountered modifications are 
glycophasphaditylinositol anchors (GPI anchors), O-linked glycosylation and N-linked 
glycosylation. 
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1.1.6 GPI anchors  
GPI anchors are glycolipid based modifications for cell surface proteins such as receptors, 
structural proteins and adhesion molecules (Kinoshita 2016). GPI anchors consist of a 
phosphatidylinositol and a glycan core made up of a single glucosamine and three mannose 
residues topped with phosphoethanolamine which is linked to the protein via an amide bond 
(Kinoshita 2016) which occurs in the ER (Fujita et al. 2011). Figure 1.5 shows the basic 
structure of a GPI-anchor. 
 
Figure 1.5 Basic structure of a GPI-linked protein. Reprinted under the Creative Commons 
Attribution Licence (Zoltewicz et al. 2009)  
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1.1.6 O-linked glycosylation 
O-linked glycans are carbohydrates covalently attached to the hydroxyl group of a serine or 
threonine residue via an O-glycosidic bond.  A number of carbohydrates can be linked to 
serine or threonine in this manner. One of the most common structural motifs is the 
attachment of N-acetylgalactosamine (GalNAc).  Such structures are classified as mucins, and 
glycoproteins bearing modifications of this type are important from a physiological 
standpoint as they often coat and protect epithelial surfaces (Stanley 2011).  O-linked 
glycosylation is a complex co-translational modification; sugars are added sequentially, 
starting with GalNAc in the ER/cis Golgi, which is transferred to the protein substrate from 
the UDP-GalNAc donor by enzymes from the polypeptide N-acetylgalactosaminyltransferase 
family in the trans- Golgi, a galactose residue is added, and typically the chain is terminated 
by addition of two sialic acid residues (Lodish et al. 2000).  
The simplest O-linked glycosylation event is the addition of a single, post-translational, O-
GlcNAc residue to a serine or threonine residue in a protein. This process is termed O-
GlcNAcylation and is a dynamic process; O-GlcNAc being attached and removed from target 
molecules by O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA) respectively. This 
switchable glycan modification has been described as more akin to phosphorylation than 
other types of glycosylation (Bond and Hanover 2015). O-GlcNAc signalling has been linked 
to a variety of pathological states, including some neurodegenerative disorders (Wani et al. 
2017). In p53, O-GlcNAcylation of serine 149 prevents phosphorylation of threonine 155 
which increases stability by reducing ubiquitination (Yang et al. 2006).  
1.1.7 N-linked glycosylation  
N-linked glycosylation is the addition of a glycan moiety to an asparagine residue in the 
consensus sequence Asn-X-Ser/Thr where X is any amino acid except proline. Compared to 
O-linked glycosylation, N-linked glycosylation is better understood in terms of assembly and 
its roles in processes such as protein folding, although other functions remain obscure. N-
linked glycosylation is ubiquitous and is found in all three domains in life (Aebi 2013), 
however, only mammalian glycosylation will be reviewed here.  
N-linked glycosylation has a key role in protein folding and the ER quality control system, 
where the structure of the glycan acts as a signal to indicate if a protein is correctly folded. 
This determines if the protein is retained or exported from the folding environment of the 
ER. During this folding process N-linked glycans may also aid folding by changing the local 
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environment at the site of glycosylation and play a role in the function of mature 
glycoproteins (Tannous et al. 2015).  
N-linked protein glycosylation can be viewed as a sequential pathway with three main steps; 
production of a lipid-linked oligosaccharide (LLO), transfer of the LLO en bloc by 
oligosaccharyltransferase (OST) to a peptide with the consensus sequence Asn-X-Ser/Thr and 
transport to the Golgi for further processing which is summarised in figure 1.6. The first step 
of N-linked glycosylation is the production of a set of oligosaccharides joined to a lipid carrier. 
Activated nucleotides carrying sugars in the cytoplasm attach the sugars to a dolichol 
phosphate molecule embedded in the ER membrane. The sugars are attached on the 
cytoplasmic side of the dolichol phosphate to form an oligosaccharide formed of two N-
acetylglucosamine residues with five mannose residues (GlcNAc2Man5). This structure is 
then flipped into the ER lumen (Lehrman 2015). Within the ER, further mannose and glucose 
residues are attached to form the core Glc3Man9GlcNAc2 structure. The Glc3Man9GlcNAc2 
oligosaccharide is transferred en bloc via the oligosaccharyltransferase (OST) to an 
asparagine residue on the peptide (Aebi 2013). 
After the glycan is covalently linked to the peptide, ER-resident glucosidases act to 
successively trim glucose residues from the glycan structure. Glucosidase I removes a single 
terminal glucose, whilst glucosidase II then removes a further glucose, leaving a glycan 
structure bearing a single glucose cap (Figure 1.11). Removing these moieties allow 
interaction with ER protein chaperones.   
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Figure 1.6 Glycan structures of the lipid-linked oligosaccharide in the cytosol and ER 
luminal face. After the production of a GlcNAc2Man5, glycan structures are flipped to the 
ER lumen, further modified and attached to a nascent polypeptide (Wang et al. 2015). 
Open access article distributed under Creative Commons Attribution Licence (CC-BY).
Once glycosylated and correctly folded, proteins are trafficked through the Golgi, where they 
are further elaborated.  Processing by mannosidases initially occurs in the ER but continues 
in the cis-Golgi resulting in a number of different classes of structures. Glycans containing 
between five and nine mannose residues are termed high mannose glycans. Other glycans 
can be further processed into complex and hybrid glycans shown in figure 1.7. 
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Figure 1.7 Structures of different types of N-glycans, including oligomannose, complex and 
hybrid. Oxford notation. 
 
 The cis, medial and trans-Golgi contain enzymes that modify glycan chains. Bi-antennary 
glycans are the most commonly found but tri- and tetra- is not uncommon. The branches are 
extended by galactose and sialic acid residues which are added later in the trans-Golgi by 
specific galactosyltransferases and sialytransferases. Further processing of the glycans is 
linked with the secretory pathway and allows monitoring of protein progress (Schwarz and 
Aebi 2011).  
Most glycoproteins are synthesised with a heterogeneous array of glycans and many bear 
multiple glycosylation sites. These differential glycan profiles of the same protein are termed 
glycoforms (Rudd and Dwek 1997) and can exhibit functional differences.  It is thought that 
there is usually a dominant glycoform (Scott et al. 2013). Glycan heterogeneity can arise from 
various factors. The glycan profile of a protein may be different depending on the species, 
organ or tissue it is produced in (Edberg and Kimberly 1997, Raju et al. 2000). Growth 
conditions also influence the glycan profiles produced. For example, reducing the 
temperature of CHO cells (which are commonly used as an expression host in 
biopharmaceutical production) in culture from 37 °C to 33 °C during stationary growth has 
been shown to increase levels of sialyation and decrease levels of fucosylation of a secreted 
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human placental alkaline phosphatase (SEAP) (Nam et al. 2008). The rate of transit through 
the secretory pathway also effects the final glycan profile of a protein. As proteins travel 
through the Golgi they are in contact with different glycan modifying enzymes for different 
amounts of time (Hossler et al. 2007). Under disease conditions, different glycan profiles 
have been recorded. Control of glycan heterogeneity is especially important during the 
production of biopharmaceuticals as a change in expression conditions can change the 
properties of the therapeutic (Jefferis 2013).  
1.1.8 Congenital disorders of glycosylation 
The importance of glycosylation can be illustrated by the fact that 1-2 % of the entire genome 
is dedicated to proteins involved in glycosylation (Freeze et al. 2009). Consequently, when 
mutations occur in any of these genes it results in severe, global pathological effects. Such 
disorders are termed congenital disorders of glycosylation (CDG), and increasing numbers of 
these disorders have been identified (Figure 1.8). As glycosylation occurs in all cells these 
disorders affect multiple organ systems especially the brain, liver and heart (Grünewald 
2009, Caglayan et al. 2015, Malm and Nilssen 2008, Lefeber et al. 2011). CDGs are 
categorised as rare disorders according to the criteria set by Rare Diseases Europe 
(EURODIS), who categorise rare diseases as affecting less than 1 in 2000 people. CDGs can 
vary in severity from patient to patient making symptoms difficult to characterise. As of 2015, 
The National Centre for Rare Disorders (NORD) describes 25 CDGs related to N-linked 
glycosylation, 18 of O-linked glycosylation and 7 defects of glycosphingolipids and GPI 
anchors (NORD 2015).  
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Figure 1.8 Number of congenital disorders of glycosylation discovered over the last 30 
years has increased, the majority of CDGs identified have been in N-linked glycosylation. 
Reprinted with permission from The American Journal of Human Genetics, 94:2, (Freeze et 
al. 2014).  
Proteins are the major workhorses of the cell and are regulated in various ways. As 
mentioned, dysregulation of these processes can have major implications, not just for the 
protein but for the cell and body. Problems can also arise from the synthesis of proteins and 
strict quality control measures are in place to stop misfolded proteins from entering the 
proteome of the cell.  
1.2.1. Protein folding  
 
The primary amino acid sequence is the key determinant of the final three-dimensional 
structure of a protein. Folding occurs in stages, with the formation of folding intermediates 
which are more likely to aggregate in aqueous solutions due to exposed hydrophobic or 
unordered regions, which in the final conformation are hidden. Aggregation is typically 
driven by hydrophobic interactions and can result in amorphous structures or, in some cases 
(such as amyloid-β), a highly ordered and stable fibril structure via β-sheet interactions. The 
number of possible three-dimensional conformations a protein can adopt is wide-ranging 
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although, as the function of proteins relies heavily on the structure, few of these will result 
in a functional end product.  
Correct folding relies heavily on hydrophobic interactions and weak non-covalent bonds. 
During folding, peptides can collapse due to these hydrophobic forces resulting in 
intermediate or misfolded states. The energy of this folding landscape is shown in figure 1.9. 
It may be energetically favourable for intermediate or misfolded structures to form 
aggregates through reactions with other species. Consequently, cellular mechanisms exist to 
reduce protein aggregation or the production of misfolded and potentially toxic protein 
species. In vivo, chaperone proteins can act to increase protein folding and prevent 
aggregation through binding. It is estimated that around 20 -30 % of the total protein 
complement of mammalian cells do not have a tertiary structure until bound to binding 
partners (Hartl et al. 2011).  
A large number of diseases, including neurodegenerative disorders including Alzheimer’s, 
Huntington’s and Parkinson’s (Irvine et al. 2008, Hashimoto et al. 2003, Gundersen 2010, 
Arrasate and Finkbeiner 2012), are associated with protein aggregates indicating a toxicity 
associated with these structures. Aggregation does not necessarily mean a protein will need 
to be degraded, refolding of protein aggregates via the action of protein chaperones has 
been observed in mammalian cells (Tyedmers et al. 2010). 
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Figure 1.9 Misfolded or partially folded peptides are prone to aggregation which is often 
driven by hydrophobic interactions. The purple area shows energy states moving towards 
a native conformation while pink shows the formation of aggregates. Reprinted, with 
permission of Macmillan Publishers Ltd. from (Hartl and Hayer-Hartl 2009).
Translated peptide sequences in the cytoplasm are at a high risk of aggregation as the 
peptide cannot fold correctly until it has been fully synthesised. Intra-chain interactions may 
also block native folding. Chaperones in the cytoplasm (such as heat shock proteins (HSP) 
HSP70 and HSP60) recognise hydrophobic amino acid side chains and bind nascent peptides 
to inhibit misfolding and prevent aggregation. (Hartl and Hayer-Hartl 2009, Marcinowski et 
al. 2013).  
1.2.3 Protein folding in the ER   
Proteins can also contain signal sequences which target the protein to the ER secretory 
pathway or, to other organelles including mitochondria. The ER is involved in post- and co-
translational modifications, disulphide bond formation, and the attachment of moieties such 
as GPI anchors which are needed for correct protein function. Similarly to protein folding in 
the cytoplasm, the ER contains protein chaperones (such as BiP, calnexin, calreticulin and 
GRP94), the action of which can increase protein solubility and decrease the tendency of 
structures to aggregate. Binding to these chaperones serves to retain the protein in the 
folding environment of the ER. Proteins containing an N-terminal signal sequence recognised 
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by the signal recognition particle (SRP) which slows translation and enables the peptide to 
be co-translationally transported into the ER via the SEC61 complex (Mason et al. 2000). 
Although these signal sequences are extremely diverse and vary in length and amino acid 
sequence, they are all hydrophobic. Once the ribosome nascent chain complex (RNC) binds 
to the SEC61 complex, translation continues and the nascent protein is delivered into the ER 
lumen (Nyathi et al. 2013). Once in the ER, the protein enters the quality control (QC) cycle 
which prevents the release of unfolded or misfolded proteins that may exert toxic effects on 
the cell.  
1.2.4. Glycoprotein folding in the ER  
The calnexin/calreticulin (CNX/CRT) cycle ensures quality glycoprotein folding within the ER.  
This process is shown schematically in figure 1.10. 
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Figure 1.10 Diagram showing the calreticulin cycle of glycoprotein folding. Reprinted with 
permission from Springer Nature: Nature reviews molecular cell biology (Ellgaard and 
Helenius 2003). 
During translation, N-linked glycans (Glc3Man9GlcNAc2) are transferred to proteins 
containing an N-glycan consensus site.  These glycans are trimmed by ER resident glucosidase 
I to yield protein bound Glc2Man9GlcNAc2 which prevents rebinding to the OST complex 
(Ferris et al. 2014). A further terminal glucose residue is trimmed by glucosidase II allowing 
binding to the lectin chaperones CNX/CRT, which bind nascent mono-glucosylated 
glycoproteins. Generally, if the glycosylation site is within the first fifty amino acid residues 
the protein interacts with membrane-bound CNX, whereas if the site is after the first fifty 
amino acids it binds the soluble CRT (Helenius and Aebi 2001). Upon binding to CNX or CRT, 
other chaperones (including ERp57) are recruited. ERp57 is an oxidoreductase that binds 
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stably to CNX and CRT and assists the formation of disulphide bonds in glycoproteins (Mason 
et al. 2000).  
Glucosidase II breaks the CNX/CRT cycle by removing the terminal glucose from the 
Glc1Man7-9GlcNAc2 glycan, which results in the release of the protein from the chaperone. 
If the protein is folded correctly it leaves the CNX/CRT cycle and exits the ER. If, however, the 
protein is incorrectly or incompletely folded, UDP-glucuronosyltransferase (UDP-GT) 
catalyses the transfer of a glucose residue from the UDP-glucose donor onto Man7-9GlcNAc2 
and the protein is targeted back to the CNX/CRT cycle. In this context, UDP-GT acts as a 
folding sensor which recognises both the specific glycan moiety and biophysical 
characteristics like exposed hydrophobic areas (Ritter et al. 2005). This also ensures, de-
glucosylated, folded substrates are not targeted back to the CNX/CRT cycle. UDP-GT 
recognises the innermost GlcNAc residue of the N-glycan and non-native protein 
conformations such as exposed hydrophobic amino acid side chains (Sousa and Parodi 1995).  
The rate of folding differs substantially between proteins; some proteins spend minutes, 
others spend hours in the CNX/CRT cycle (Helenius and Aebi 2001). If proteins fail to fold 
correctly following repeated recycling through the CNX/CRT cycle, they are termed 
terminally misfolded. Terminally misfolded proteins exit the CNX/CRT and are targeted for 
degradation by the proteasome in a tightly coupled process, termed ER-associated 
degradation (ERAD).  
 
Figure 1.11 N-linked glycan Glc3Man9GlcNAc2, showing the target site of glucosidase I and 
II and ER mannosidase I (Oxford notation). 
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ER Mannosidase I is involved in the removal of proteins from the CNX/CRT cycle by catalysing 
the removal of a terminal mannose residue (figure 1.11). The Man8GlcNAc2 glycan product 
of this cleavage is recognised by the ER degradation-enhancing 1, 2-mannosidase-like protein 
(EDEM), which directs the protein for degradation. Mannosidase I has a slow reaction time 
and it has been hypothesised that this may effectively act as a “timer” for ERAD substrates. 
If a protein remains in the CNX/CRT cycle then ER mannosidase I will eventually remove the 
terminal mannose and release the protein from the cycle (Avezov et al. 2008). The 
interaction with EDEM acts as a signal for protein degradation (Ruggiano et al. 2014, Olzmann 
et al. 2013, Meusser et al. 2005).  
Other chaperones are also involved in the processing of glycoproteins. Malectin is an ER 
membrane bound protein which interacts with high mannose glycans bearing terminal 
glucose residues prior to the CNX/CRT cycle. During ER stress, Malectin is upregulated and 
may provide an extra means to halt the secretion of misfolded proteins under ER dysfunction 
(Galli et al. 2011).  
Proteins entering the ER that are not glycosylated behave in much the same way, although 
the pathways which act to identify and target terminally misfolded proteins to degradative 
pathways are less defined. BiP is one of the most abundant ER chaperones and recognises 
hydrophobic regions. BiP has two domains (an ATPase activity domain and a substrate 
binding domain), and binds to and releases target substrates in an ATP dependent manner. 
Although chaperones act to increase protein solubility and reduces aggregation, folding 
cannot occur whilst the structure undergoing folding is bound (Mason et al. 2000). 
Glycosylation is also only evident on the surface of proteins, although how this is achieved is 
poorly understood. Glycan transfer occurs on the nascent, unfolded polypeptide as it is 
translocated into the lumen of the ER. In this case it would be expected all Asn-X-Thr/Ser 
sequences would be targeted, however this is not the case (Medzihradszky 2008). Initial 
proposals included the polarity of asparagine, serine and threonine as a mechanism to 
control N-linked glycosylation. Polar residues are most commonly on the exterior surface 
(Lodish H 2000). It may be that rapid folding of the protein restricts access of the internal 
consensus sequences to the OST (Stanley 2011).  
1.3.1 Protein degradation pathways 
 
Old or dysfunctional proteins and organelles need to be removed from the cell to maintain 
efficient functioning and homeostasis. There are two main degradation pathways that 
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maintain cellular health, the ubiquitin-proteasome system (UPS) and autophagy. The UPS is 
made up of a number of ubiquitin ligases, modifiers and binding proteins that recognise 
ubiquitin bound proteins and targets them for degradation by the proteasome. The UPS is 
responsible for the degradation of 80-90 % of proteins including short-lived or damaged and 
denatured proteins (Lilienbaum 2013). Autophagy is mainly important for degrading long-
lived proteins and aggregates and organelles but both are important for maintaining pools 
of amino acids for making new proteins and maintaining quality control.  
Dysfunction in either the UPS or autophagy results in the build-up of ubiquitin coated protein 
aggregates. The protein degradation pathways have been shown to have a compensatory 
mechanism, when one pathway is impaired the other increases its function (Kageyama et al. 
2014) 
1.3.2 Ubiquitin Proteasome System – ERAD 
ER quality control and protein folding is tightly linked to the UPS. During ER quality control, 
misfolded proteins are identified and signalled to leave the CNX/CRT pathway. Terminally 
misfolded proteins targeted for degradation by ubiquitination and degraded by the 26S 
proteasome. This degradation process, termed ER-associated degradation (ERAD) acts to 
avoid the release of potentially toxic misfolded/incorrectly folded proteins into the cytosol. 
Signals from N-linked glycans divert misfolded proteins to degradation. There are four 
aspects of the UPS; substrate recognition, translocation from the ER, substrate targeting and 
degradation, which will be discussed in the context of ERAD.  
Misfolded proteins are extremely diverse in nature as these are not just one protein species. 
Therefore the machinery dealing with them needs to either recognise the sugar chain or have 
a broad specificity for peptides. During protein folding in the ER, the structure of N-linked 
proteins can relay information about the folding status of polypeptides. The machinery 
linking recognition, retro-translocation and ubiquitination are closely coupled. This can be 
seen in the organisation of the large multimeric complex called the dislocon. Membrane 
bound ubiquitin ligases are organised around the channels for transporting proteins out of 
the ER, along with several different adaptors used to link glycan recognition as shown in 
figure 1.12.  
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Figure 1.12 Schematic representation of ERAD showing proteins involved in recognition, 
retro-translocation/dislocation, ubiquitination and targeting for proteasome degradation. 
Reprinted by permission from Springer Nature: Nature structural and molecular biology 
(Christianson and Ye 2014). 
The mammalian ER membrane contains at least 24 RING-finger E3 ubiquitin ligases involved 
in ubiquitinating substrate proteins, although only a few have been identified as being 
specifically involved in ERAD. The dislocon is a channel that exports proteins from the ER 
back into the cytoplasm. Proteins are targeted for degradation by the 26S proteasome by a 
polyubiquitin chain. Three main enzymes are needed to ubiquitinate proteins; E1, E2 and E3. 
Specificity comes mainly from the E3 ligases which attaches the ubiquitin moiety to the 
substrate peptide (Lecker et al 2006). In yeast, two E3 ligases have been identified to be 
involved in ERAD, Hrd1 and Doa10 which targets transmembrane/luminal regions and 
cytosolic, regions respectively (Hirsch et al. 2009). Homologues of Hrd1 in mammalian cells 
are HRD1 and gp79 (figure 1.12). Less is known about the mammalian orthologue to Doa10 
but TEB4 shares similar protein structure and sequence (Hassink et al. 2005).  HRD1 forms a 
complex with SEL1L, DERLIN, HERP and OS-9. SEL1L is an ER luminal glycoprotein which acts 
as a scaffold to link substrates to HRD1. SEL1L binds to OS-9 and EDEM1 and 3 (both are ER 
resident lectins) and ERFAD-ERp90, an ER-PDI (Olzmann et al. 2013), thus linking substrate 
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recognition to ubiquitination. The E3 ligase also controls the speed of degradation as the rate 
limiting enzyme. In HeLa cells, upon ER stress the E3 ligase HRD1 is upregulated (Kaneko et 
al. 2016).  
Contradictory evidence has been shown for the requirement of unfolding for retro-
translocation. At this point the proteins are retro-translocated into the cytosol via the ATP 
dependent VCP motor, also called p97 and CDC48. This is complexed with UFD1 and NPL4. 
Once in the cytosol a chaperone containing complex of BAG6, UBL4A and TRC35 maintain 
solubility of proteins containing hydrophobic regions.  
The K48 ubiquitin chain is the most abundant ubiquitin chain and is used predominantly for 
UPS degradation of misfolded proteins. Under proteasome inhibition, K48 rapidly 
accumulates however, linkages 6, 11, 27 and 29 also increase, indicating involvement in 
proteasome degradation. 
The ERAD substrates are moved to the proteasome by shuttling proteins including 
RAD23A/B, UBQLIN1-4 and DDI1/2 which all contain UBL and UBA domains. RAD23 contains 
two UBA domains which are specific for K48 linked ubiquitin (Nathan et al. 2013). RAD23 can 
interact with the proteasome via its UBL domain (Liang et al. 2014). The proteasome is also 
able to bind directly to ubiquitin chains. The 26S proteasome is a large structure of around 
2.4 MDa with a 20S core subunit where linearized peptides are degraded, and one or two 
19S regulatory subunits that allow binding of shuttle proteins such as Rad23 an ubiquitin 
chains. PSMD4 (y-rpn10) and ADRM1 (y-rpn13) contain a ubiquitin interacting motif (UIM) 
(Saeki 2017).  
Prior to degradation, proteins need to be linearized. As shown in figure 1.13, the proteasome 
contains a narrow channel that does not allow folded structures to enter. Degradation starts 
at disordered regions and unfolding starts from this point by ATPase subunits that unfold 
peptides (Inobe and Matouschek 2014). Unfolded proteins are able to be degraded 
independent of ATP with the exposed hydrophobic areas thought to replace the ubiquitin 
signal for targeting (Lilienbaum 2013). 
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Figure 1.13 Atomic structure of human 26S proteasome (generated from PDB ID: 5GJR 
(Huang et al. 2016) using NGL Viewer)
Out of the context of ERAD, signals for degradation can arise at several levels, including 
during translation to recognise defective mRNA. Incorrectly incorporated amino acids are 
not rare. It is estimated that 5-10 % of proteins contain a wrongly incorporated amino acid 
(F. Wang et al. 2015). Ubiquitin linkage to substrate proteins is related to the structure of the 
substrate itself. E3 ligases can recognise old/damaged proteins and target them to the UPS 
(Kevei et al. 2017). Some substrates also contain sequence dependent affinity for the E3 
ligases (known as the N-end rule) proteins with an α-amino group at the N-terminus have a 
higher affinity for E3 ligases which targets them for degradation faster than proteins with a 
blocked N-terminus (Ravid and Hochstrasser 2008). For structurally disordered, small (150 
aa or shorter) protein substrates, presence of a single mono-ubiquitin is enough to target to 
the proteasome.  
The UPS usually degrades single proteins and not aggregates. These larger structures are 
usually tackled by the autophagy-lysosome degradation pathway. However, the role of 
ubiquitin in autophagy signalling is not completely understood. Ubiquitin is also found in 
protein aggregates, with staining most pronounced at the periphery of aggregates (Skibinski 
and Boyd 2012), which may perhaps be an indication that ubiquitin is conjugated to exposed 
surfaces after the aggregates have been formed.  
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1.3.3 Autophagy 
The UPS is relatively ineffective at removing proteins which have formed aggregates since 
the proteins need to be unfolded and linearized for degradation (Meusser et al. 2005). The 
linearization of aggregated proteins takes more energy compared to partially folded proteins 
(figure 1.14). Autophagy is the main process cells remove organelles and larger cellular debris 
and protein aggregates that are resistant to proteasome degradation. There are three main 
types of autophagy (Galluzzi et al. 2017); macroautophagy (Feng et al. 2013), 
microautophagy (Li et al. 2012) and chaperone mediated autophagy (CMA) (Kaushik et al. 
2011) although macroautophagy is the best characterised (and subsequent mention of 
autophagy in this work refers to macroautophagy). Autophagy was originally thought to be 
a general disposal system for cellular material, however it is becoming increasingly clear that 
autophagy is a highly specific and regulated process that is important for cellular homeostasis 
under basal and stress conditions (Zaffagnini and Martens 2016).  
Autophagy is the formation of a double membrane bound vesicle, called the autophagosome 
(figure 1.14), which engulfs cellular debris, damaged organelles and misfolded proteins. 
Autophagosomes fuse with lysosomes to form autolysosomes. The cellular material 
originally engulfed by the autophagosome is degraded by hydrolytic enzymes in the 
autolysosome. The resulting material can be used to fuel anabolic processes (Hewitt and 
Korolchuk).  
Figure 1.14 Schematic representation of autophagy. A double membrane bound vesicle 
engulfs cellular material. The vesicle then fuses with a lysosome to form an autolysosome 
and cellular material is degraded by hydrolytic enzymes found in the lysosome.
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The canonical autophagy system is shown in Figure 1.15. Autophagy induction is negatively 
regulated by the mechanistic target of rapamycin (mTOR), which is part of the mTOR complex 
(mTORC) (Manifava et al. 2016). Under normal conditions mTOR is not phosphorylated and 
actively phosphorylates ATG13, part of the ULK1 kinase complex which also contains ULK1 
(or ULK2) and FIP200 leading to a suppression in autophagy activity. Under stress conditions 
mTOR is phosphorylated at T2446, S2448 and S2481 (Copp et al. 2009) and activity is reduced 
(Jung et al. 2010, Nazio et al. 2013).  
Once the signal for autophagy has been initiated, the first stage of autophagy is nucleation. 
Nucleation has been associated with different cellular membranes including the ER (Ktistakis 
et al. 2016) and Golgi (Ge and Schekman 2014, Ge et al. 2013). Elongation and closure of the 
autophagosome membrane requires the ATG12-ATG5 complex and is necessary for the 
addition of phosphatidylethnaolamine (PE) conjugated LC3 (LC3-II) to the autophagosome 
membrane (Patrice Codogno 2012).  
Autophagic pathways that do not include all the components shown in figure 1.15 have also 
been observed. These pathways include autophagy-inducing steps that bypass the ULK1/2 
complex, and are independent of ATG5 and BECLIN-1 (Patrice Codogno 2012). Although they 
have different signalling steps these pathways serve the same cellular function of stimulating 
the turnover of cellular constituents via the formation of autophagosomes.  
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Figure 1.15 Diagram showing the protein interactions and regulation during 
autophagy.Reprinted with permission from Cell Technology (Hu 2016). 
The autophagosome forms at a phagophore assembly site (PAS) away from the lysosome. 
Upon autophagy activation, ULK1 translocates to the membrane and stimulates the 
production of phosphatidylinositol 3-phosphate (PI3P) which is essential to autophagic 
membrane dynamics. As the membrane develops, core autophagy machinery is recruited to 
the membrane and the ubiquitin-like LC3 is covalently attached to 
phosphatidylethanolamine which promotes autophagosome membrane expansion (Hanson 
et al. 2010), closure and fusion to lysosomes (Karanasios et al. 2016).  
The selectivity of autophagic degradation is mediated by autophagic adapter proteins. The 
human autophagy adaptor, p62/SQSTM1 has been implicated in the removal of protein 
aggregates, mitochondria and bacteria (Zaffagnini and Martens 2016). Degradation relies on 
the interaction between the LC3 interacting region (LIR) on adaptor proteins and 
LC3/GABARAP family proteins. p62 contains a number of functional domains including UB-
27 
 
associated (UBA) domain, LIR and PB1 domain which allows interactions with various kinases 
(Johansen and Lamark 2011). The UBA domain allows interactions with mono and poly 
ubiquitin chains but has a preference for K63 linked ubiquitin, suggesting K63 ubiquitin 
targets substrates to autophagy over the UPS. Accumulation of p62 has also been seen in 
protein aggregates in neurodegenerative disorders. Next to BRCA1 gene 1 (NBR1) has also 
been associated with the recruitment of cargo for selective autophagy which also interacts 
with p62 via the PB1 domain, and also contains a UBA domain to allow recognition of 
ubiquitin and two LIR domains (Ichimura et al. 2008).  
1.3.4. Proteostasis  
Proteostasis describes the process of maintaining a healthy pool of proteins in terms of 
concentration, location and function (Yerbury et al. 2016).  This is managed by a number of 
protein chaperones and the interaction of protein degradation pathways to avoid toxicity 
that is associated with increased protein misfolding and aggregation. Proteostasis is often 
discussed in the context of ageing due to decreased activity of both the UPS and autophagy 
during ageing. This can seen in the brain, a number of age-related neurodegenerative 
disorders are associated with increased protein aggregation.  
Figure 1.16 shows a schematic representation of the proteostasis network. Misfolded or 
aggregated proteins are degraded by the UPS and autophagic pathways. Misfolded secretory 
proteins are recognised by extracellular chaperones which target them to the lysosome or 
are degraded by extracellular proteases (Yerbury et al. 2016).  
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Figure 1.16 Proteostasis maintains the proteome in the correct conformations. As proteins 
are synthesised and misfolded proteins are degraded via ERAD. Aggregated proteins are 
bound to chaperones which target them to the UPS or form larger aggregates which are 
degraded by autophagy. A further measure includes extracellular proteostasis that 
controls secreted proteins which are recognised by chaperones and targeted to the 
lysosome or degraded via extracellular proteases. Reprinted with permission from the 
Journal of Neurochemistry (Yerbury et al. 2016). 
 
During aging the activity of the proteasome decreases, especially in the brain including 
cerebral cortex, hippocampus and spinal cord but not in the cerebellum or brainstem in rats.  
(Lilienbaum 2013) With this, comes an increase in the number of ubiquitinated proteins 
which are not removed efficiently.  
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Similar to the proteasome, autophagy activity decreases as we age (Lilienbaum 2013). 
Autophagy has been implicated in a number of diseases including cancers, 
neurodegenerative disorders, liver, muscle and heart disorders and ageing (Nixon 2013a). 
Reduced autophagy has been seen in neurodegenerative disorders including Parkinson’s, 
Alzheimer’s, Huntington’s and prion diseases. Issues facing these disorders range from the 
different steps of autophagy including autophagosome formation, cargo recognition and 
trafficking to lysosomes. Correct proteostasis is especially important in post-mitotic cells 
such as neurons. Neurons have a large amount of axonal and dendritic cytosol and they must 
get rid of dysfunctional components without the aid of cellular division which can dilute 
cellular waste. Lysosomes are concentrated in the cell body. Autophagic vesicles clear waste 
by removing it at the source and trafficking back to the lysosomes. Without autophagy, 
ubiquitinated protein aggregates build-up, causing cell death. Autophagy is important in 
neurodegenerative function, loss of autophagy can cause neurodegeneration even in the 
absence of a disease causing mutant protein (Hara et al. 2006), in mouse models of ATG5 
and ATG7 KO usually results in an embryonic lethal or neonatal lethal (Yoshii et al. 2016). The 
hypothesis that autophagy is necessary for the disposal of protein aggregates is supported 
by observations that conditional knockouts of ATG5 and ATG7 in mice, proteins important in 
the formation of autophagosomes, lead to the formation of protein aggregates in the liver 
(Takamura et al. 2011) and the development of neurodegenerative-like phenotypes 
(Tyedmers et al. 2010). Defects in different autophagy pathways can lead to different 
pathologies. The build-up of aggregates caused by reduced proteasome activity is especially 
toxic to neurons and cardio myocytes. These cells are post-mitotic and therefore cannot 
reduce stress caused by aggregates by diluting aggregates by cell division. 
As well as decreased degradation activity this imbalance of proteostasis can also be the result 
of protein mutations that promote aggregation. In inherited forms of neurodegenerative 
disorders there is often an associated mutation in the aggregated protein, such as 
Alzheimer’s which is associated with mutations in the APP and PSEN 1 and 2 genes (Ryan and 
Rossor 2010).  
Under conditions of imbalance in proteostasis or stress, cross-talk between the UPS and 
autophagy results in the increase or decrease in function accordingly. For example, under 
liver proteasome dysfunction in mice, autophagy was upregulated locally. This led to 
increased protein aggregates containing p62 and ubiquitin. Proteasome dysfunction inducing 
ER stress activates the unfolded protein response (UPR). The UPR signals through three main 
pathways, the ER resident PERK, IRE1 and ATF6 proteins. After activation these transcription 
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factors activate genes to reduce ER stress such as protein chaperones BiP and EDEM. As well 
as increasing protein folding elements, activation of IRE1 results in activation of JNK. This 
promotes autophagy by phosphorylating BCL-2, releasing BECLIN-1 to activate autophagy 
(Song et al. 2018) as shown in figure 1.15. While PERK activation leads to increased 
transcription of ATF4 which regulates transcription of ATG12 (Song et al. 2018).  
1.3.5. Deglycosylation of misfolded proteins  
As mentioned, many of the proteins traversing the degradation pathways are glycoproteins. 
During degradation by the proteasome, folded proteins are not able to enter the catalytic 
channel and it has been hypothesised that proteins bearing glycan chains are also not able 
to be processed in this manner. The enzyme N-glycanase (also known as PNGase and Peptide: 
N-glycanase, EC 3.5.1.52) is a glycan modifying enzyme which removes N-linked glycans at 
the base GlcNAc residue (provided it does not bear a core fucose modification) shown in 
figure 1.17.  
 
Figure 1.17 Site of N-glycanase action on N-linked glycans
 
N-glycanase is found in complexes associated with the dislocon and facilitates proteasome 
clearance by removal of N-linked glycans prior to degradation (Olzmann et al. 2013).  Figure 
1.18 shows the interaction partners of N-glycanase including DERLIN-1, VCP, RAD23A/B and 
the proteasome subunits PSMC2 and PSMC1 (Suzuki et al. 2016).  
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Figure 1.18 Protein interactions for N-glycanase (NGLY1) (Generated by string-db.org)
N-glycanase (yPng1 in yeast) activity was first identified as an important process in protein 
quality control and ERAD in yeast (Suzuki et al. 1998). N-glycanase has since been identified 
in other eukaryotes including mammals, insects and plants. It has a conserved 
transglutaminase-like core (TG) (Figure 1.19), which in yeast crystal studies of the protein is 
located in a deep cleft with three amino acids essential to enzyme function, cysteine, 
histidine and aspartic acid (Hirayama et al. 2014). Figure 1.19 shows the interaction of 
GlcNAc2-IAc with yeast PNGase. Mutation analysis showed that the cysteine residues were 
critical to activity (Suzuki 2015). 
 
Figure 1.19 X-ray diffraction model of yeast PNGase in complex with GlcNAc2-IAc. 
(Generated from PDB (Zhao et al. 2009)).  
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N-glycanase is found throughout the body with studies in mice isolating N-glycanase in 
several organs including the brain, kidneys, liver and spleen with varying activity levels 
(Kitajima et al. 1995). In higher eukaryotes the enzyme also contains a ubiquitin binding 
(PUB) domain present at the N-terminus which is responsible for interactions with ERAD 
components on the ER membrane (Hirayama et al. 2014). This indicates that the link 
between yPng1 to the proteasome is important for efficient clearance of ERAD substrates 
which is mediated by Rad23.  
 Mammalian N-glycanase is around twice the size of its yeast and bacterial homologues 
(Suzuki 2015). The domains found in N-glycanase are shown in figure 1.20. This also shows 
sites of mutations on human N-glycanase associated with disease.   
 
 
Figure 1.20 Schematic of N-glycanase structure in fungi, yeast, mice and humans. Red 
crosses indicate mutations associated with disease in human N-glycanase. Reprinted from 
Gene, 577, (Suzuki et al. 2016) with permission from Elsevier. 
 
N-glycanase has been shown to have a role during ERAD (Chantret et al. 2010, Hosomi and 
Suzuki 2015, Huang et al. 2015) (Suzuki et al. 2000). In yeast PNGase KO cells it was found 
that the ERAD glycoprotein substrate, mutant carboxypeptidase Y protein (CPY) exhibited a 
decreased rate of degradation (Suzuki et al. 2000), leading to hypothesis that glycoproteins 
cannot be efficiently degraded if the glycan chain is still attached to the protein. However, in 
mammalian cells the degradation rate of other proteasome degradation dependent proteins 
including class I HCs and TCRα did not show a decreased rate of degradation under inhibition 
of N-glycanase (Misaghi et al. 2004, Hirsch et al. 2003).  
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1.4.1 N-GLY1 disorder 
 
Due to the varying pathologies and differences in severity, along with the high number of 
individual CDGs, speed and accurate methods of diagnosis are currently limited (Lefeber et 
al. 2011). The apparently low frequency of CDGs may indicate severity, with a low survival 
rate and underdiagnoses. N-GLY1 deficiency disorder is the first disorder of 
deglycosylation identified and is caused by a mutation in the NGLY1 gene. N-glycanase 
is an enzyme involved in the degradation of terminally misfolded N-linked glycoproteins. 
A variety of effects of reduced N-glycanase activity have been described in model organisms 
(Table 1.1).  
Table 1.1 Effect of N-glycanase knockout in various organisms 
Organism Observed phenotypes References 
S. cerevisiae Defect in ERAD; no growth/viability 
defects 
(Suzuki et al. 2000, Kim et al. 
2006 
, Hosomi et al. 2010) 
N. crassa Temperature sensitive growth with 
strong polarity defects 
(Maerz et al. 2010) 
A..thaliana No obvious defect (Maeda and Kimura 2014, 
Zielinska et al. 2012) 
D. discoideum Slow growth and development; 
defect in cell aggregation during 
multicellular development 
(Gosain et al. 2012) 
C. elegans Abnormal axon branching of 
VC4/VC5 egg-laying neurons, 
defective egg laying  
(Habibi-Babadi et al. 2010) 
D. 
melanogaster 
Severe developmental delay (Funakoshi et al. 2010) 
(Owings et al. 2018) 
M. musculus Embryonically lethal (C57BL/6), 
reduced body weight.  
(Fujihira et al. 2017) 
 
In humans, the congenital disorder of deglycosylation (CDDG) termed N-GLY1 was first 
described in a publication in 2012 (Need et al. 2012). Similar to CDGs, N-GLY1 has a complex 
and varied clinical presentation.  Symptoms include global developmental delay (observed 
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in all documented cases), movement disorders, hypotonia and alacrimia (Enns et al. 2014, 
Lam et al. 2016, Caglayan et al. 2015, He et al. 2015). A summary of symptoms observed in 
eight N-GLY1 patients is shown in figure 1.21.   
 
Figure 1.21 Symptoms observed in eight N-GLY1 patients with prevalence indicated 
underneath. Reprinted by permission from Macmillan Publishers Ltd: Genetics in Medicine 
(Enns et al. 2014).
N-GLY1 disorder results from mutations in the NGLY1 gene which encodes N-glycanase 1 and 
as of 2017, a minimum of 46 patients have been described in the literature (Lam et al. 2016, 
Enns et al. 2014, Caglayan et al. 2015). The most common mutation identified was 
c1201A>T/pR401X as a homozygous mutation in 5/8 patients and heterozygous mutation in 
1/8 patients in the first description of the symptoms of N-GLY1 deficiency (Enns et al. 2014). 
Several other mutations have also been identified summarised in Table 1.2.  
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Table 1.2 Confirmed mutations in the NGLY1 gene, c indicates chromosomal mutation and 
p indicates the effect of the protein sequence in amino acids. Information taken from (Enns 
et al. 2014, Lam et al. 2016, Caglayan et al. 2015) 
Chromosomal mutations 
(maternal/paternal allele) 
Effect on protein 
maternal/paternal 
c1201A>T homozygous pR401X 
c1891del/c1201A>T pQ631S/pR401X 
c1370dupG homozygous pR458 frameshift 
c1205_1207del/c1570G>A p402_403del/pR542X 
c953T>C/1169G>C pL318P/pR390P 
c931G>A/730T>C pE311K/pW244R 
c1604G>A/ c1910delT pW535/ pL637 
c622C>T/ c930C>T pQ208/ pG310G (splice site) 
c347C>G/ c881+5G>T pS116/ pIVS5+5G>T 
 
Patients with the c1201A>T mutation were assessed as moderately to severely impaired 
which is a higher severity compared to those with other mutations (Enns et al. 2014). Using 
dermal fibroblasts derived from N-GLY1 patients, it was found that N-glycanase mRNA levels 
were reduced by 30-97%. The c1201A>T mutation in NGLY1 was the most detrimental 
resulting in 87-97% reduction in NGLY1 mRNA as measured by qPCR (He et al. 2015).  
1.4.2 Molecular impact of N-glycanase deficiency 
The molecular impact of N-glycanase deficiency has been examined in cellular, model 
organisms and murine models. N-glycanase has shown to be involved in the degradation of 
N-glycoproteins during ERAD (Chantret et al. 2010, Hosomi and Suzuki 2015, Huang et al. 
2015) but has also been linked to other functions in the cell such as generation of free 
oligosaccharides (fOS) and Nrf1 activation (Owings et al. 2018, Tomlin et al. 2017). 
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1.4.3 Deglycosylation regulates protein activity  
Deglycosylation has recently been identified as a process of post-translational modification 
and has been identified in the stabilisation of tyrosinase-derived peptides for presentation 
to MHC Class I molecules and Nrf1 activation. Generation of the HLA-A*0201 epitope (which 
is presented as asparagine or aspartic acid isoform) is formed by glycosylation in the ER then 
subsequent deglycosylation by N-glycanase (Altrich-VanLith et al. 2006). Likewise, the 
nuclear respiratory factor (NRF1) is present as an ER-anchored glycoprotein. Under basal 
conditions NRF1 is quickly degraded by the proteasome. Under proteasome dysfunction 
NRF1 is cleaved, deglycosylated by N-glycanase and transported to the nucleus where it acts 
to upregulate genetic factors related to proteasomal degradation. In N-glycanase deficient 
cells, NRF1 is excluded from the nucleus (Tomlin et al. 2017). Other protein species are likely 
to be regulated in this manner. 
1.4.4 N-glycanase is involved in the generation of free oligosaccharides  
Removal of the N-glycans from a peptide results in the conversion of the peptide asparagine 
residue to aspartic acid and, the release free oligosaccharides (fOS) bearing terminal α 1-
amino-GlcNAc. There are two main sources of fOS in cellular systems; those released from 
misfolded proteins and those acting as glycan donors for nascent proteins during protein 
folding in the ER. The structures released from misfolded proteins by N-glycanase are usually 
Man9-7GlcNAc2 structures. Those acting as donors to nascent proteins by OST complex are 
mainly Glc3Man9GlcNAc2. In mammalian cells the Glc3Man9GlcNAc2 structures are 
trimmed in the ER by ER α-glucosidases I and II and α-mannosidase to form Man8GlcNAc2 
which is exported into the cytosol. Cytosolic fOS are further catabolised by ENGase and 
Man2C1 to produce Man5GlcNAc1. These are then broken down by lysosomes. The 
biological role of fOS in normal cellular health is currently undetermined, although 
perturbations in fOS distribution and levels can be indicative of certain cell stress (Alonzi et 
al. 2008, Alonzi et al. 2013).  
In yeast, the majority of fOS are generated by the yeast N-glycanase, ypng1 (96%) (Hirayama 
et al. 2014), whereas significantly lower total levels of fOS are generated by N-glycanase 
action in mammalian cells. Upon N-glycanase ablation in  human HepG2 cells the total fOS 
levels were measured by pulse-chase radiolabelling methods, and an inhibition of total fOS 
of 25 % for N-glycanase inhibition by Z-VAD-fmk treated cells and 12 % following siRNA 
knockdown (Chantret et al. 2010) was observed in an ENGase deficient background. 
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Knockdown by siRNA of N-glycanase resulted in a reduction in Glc1Man9GlcNAc2 and 
Man9GlcNAc2 fOS species, but levels of Man8GlcNAc2 remained the same in an ENGase 
deficient background. Similar results were also seen in cells pre-treated with Z-VAD-fmk 
(Chantret et al. 2010). Under N-glycanase knockdown fOS can also be generated by ENGase. 
Suzuki et al. (2015) identified cytosolic endo-β-N-acetylglucosaminidase (ENGase) 
(EC:3.2.1.96) as a glycosyl hydrolase acting in the absence of N-glycanase activity. This study 
used an ERAD glycoprotein substrate, ricin A nontoxic mutant (RTAΔm) which contains an ER 
targeting and retention KDEL seqeunce.  Following expression of RTAΔm in WT, ENGase-/-, 
NGLY1-/-, or double knockout MEF cells the ratio of deglycosylated/glycosylated RTAΔm 
found 10 % of the protein was deglycosylated in the double knockout. Whereas N-glycanase 
deficient cells had increased, around 35 %  of the deglycosylated form. ENGase deficient cells 
exhibited 29 % deglycosylated RTAΔm, indicating other glycan processing enzymes have the 
capacity to effect the deglycosylatation of proteins.  
1.5 Aims and Objectives 
 
N-GLY1 deficiency is a relatively new disorder and little is known about the molecular effects 
of N-glycanase deficiency in cells. N-glycanase has already been shown to participate in ER-
associated degradation and it is clear from multiple disorders that precisely functioning 
proteostasis is pivotal to cellular health. An understanding of which is necessary for new 
treatment targets of not only N-GLY1 disorder but also protein misfolding and aggregation 
disorders.  
This thesis is divided into these objectives found in each chapter: Chapter 3 – the effect on 
cellular pathways under inhibition of N-glycanase using Z-VAD-fmk, Chapter 4 – the effect on 
cellular pathways under genetic ablation of N-glycanase using siRNA, Chapter 5- the pursuit 
of a stable N-glycanase knockout using CRISPR gene editing techniques to study long term 
effects of N-glycanase deficiency, Chapter 6 – identification of cargo and autophagy related 
proteins under N-glycanase inhibition and siRNA knockdown and Chapter 7- the effect on 
mitochondrial function.  
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Chapter 2.  
2.1 Introduction 
 
This chapter details the reagents, materials and methods employed in this thesis. 
 
2.2 Reagents 
 
Z-VAD-fmk (CAS: 187389-52-2, catalogue no. A1902) and Q-VD-OPh (CAS: 1135695-98-5 
catalogue no. A1901), 3-MA (CAS: 5142-23-4, catalogue no. A8353) were purchased from 
APExBIO.  MTT (InvitrogenTM Molecular ProbesTM, CAS: 298-93-1, catalogue no. 10133722), 
DMSO (Fisher BioreagentsTM, CAS: 67-68-5, catalogue no. 10103483), menadione (MP 
Biomedicals, CAS: 58-27-5, catalogue no. 11453490), RPMI media (GibcoTM, catalogue no. 
31870025), FBS (GibcoTM, catalogue no. 15140122), L-glutamine (GibcoTM, catalogue no. 
25030081), 1% penicillin/streptomycin (GibcoTM, catalogue no. 15140122), Trypsin-EDTA 
(0.25%) phenol red (GibcoTM, catalogue no. 25200056), MG132 (Alfa AesarTM, CAS: 133407-
82-6, catalogue no. 15465519), Thioflavin T (ACROS Organics TM, CAS: 2390-54-7, catalogue 
no. 211760250), MEM Amino Acids Solution (GibcoTM, catalogue no. 11130036) and MEM 
Non-Essential Amino Acids (GibcoTM, catalogue no. 11140050), Bafilomycin A1 (Tocris 
BioscienceTM, CAS: 88899-55-2, catalogue no. 13429173), NovexTM WedgewellTM Tris-Glycine 
Mini Gels (InvitrogenTM, catalogue no. XP04120BOX), FURA-2 AM (InvitrogenTM Molecular 
ProbesTM, CAS: 108964-32-5, catalogue no. 10308392), Thapsigargin (InvitrogenTM Molecular 
ProbesTM, CAS: 67526-95-8, catalogue no. 10226822), DH5αTM Competent Cells (InvitrogenTM, 
catalogue no. 18265017), Phusion High-Fidelity DNA Polymerase (ThermoScientificTM, 
catalogue no. 10402678), MS Grade Trypsin Protease (Thermo Scientific™ Pierce™, catalogue 
no. 13464189), Dead Cell Apoptosis Kit with Annexin V FITC and PI, for flow cytometry 
(InvitrogenTM Molecular ProbesTM, catalogue no. 10267392), Mitochondria Isolation Kit for 
Cultured Cells (ThermoScientificTM, catalogue no. 89874), MitoTrackerTM Deep Red FM 
(InvitrogenTM Molecular ProbesTM, catalogue no. 12010156), along with general 
consumables, buffer components, salts and solvents, were purchased from Fisher Scientific.  
RNase B (CAS: 9001-99-4, catalogue no. J61996, EC 3.1.4.22) was purchased from Alfa 
AesarTM. 
JetPEI® HTS DNA transfection reagent (Polyplus-transfection®, catalogue no. 89129-914), 
JetPRIME® DNA and SiRNA transfection reagent (Polyplus-transfection®, catalogue no. 
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89129-920) was purchased from VWR.  Fluorescein (FITC) conjugated lectin panels, Lectin Kit 
1 (catalogue no. FLK-2100) and Lectin Kit II (catalogue no. FLK-3100) were purchased from 
Vector Laboratories.  
Bio-Rad Protein Assay Dye Reagent Concentrate (for assessment of protein concentration via 
the Bradford method) (catalogue no. 5000006), LDS sample buffer (catalogue no. 1610747), 
10x Tris/Glycine/SDS electrophoresis running buffer (catalogue no. 1610732), ClarityTM ECL 
Western Substrate solution (catalogue no. 170506), Bio-Rad CriterionTM Empty Cassettes 
(catalogue no. 3459904) were purchased from Bio-Rad.  
SMARTpool: ON-TARGETplus NGLY1 siRNA (DharmaconTM, catalogue no. L-016457-01) and 
ON-TARGETplus non-targeting control (DharmaconTM, catalogue no. D-001810-01), 
DharmaFECT 1 (catalogue no. T-2001-01) were purchased from DharmaconTM. Sequnces of 
NGLY1 siRNA are shown in Table 2.1. 
RT-qPCR primers (Table 2.2) and cloning primers (Table 2.3) were purchased from Eurofins 
Genomics.  
Sequencing primers (Table 2.5) and guide DNA sequences (Table 2.4) for CRISPR mediated 
knockout of N-glycanase were purchased from Sigma Aldrich. 
One-Step Luna® Universal qPCR Master Mix (catalogue no. M3003), Monarch PCR and DNA 
cleanup kit (catalogue no. T1030S), BamHI (catalogue no. R0136S), XHoI (catalogue no. 
R0146S), T4 DNA ligase (catalogue no. M0202S) were purchased from New England Biolabs 
Inc®. 
RNeasy Mini Kit (catalogue no. 74104), DNeasy Blood and Tissue Kit (catalogue no. 69504), 
QIAquick Gel Extraction Kit (catalogue no. 28704), QIAprep Spin Miniprep Lit (catalogue no. 
27104) was purchased from Qiagen.   
ROSBriteTM 570 (catalogue no. 160000-AAT) was purchased from Stratech. 
Midori green Direct DNA stain (catalogue no. S6-0018) was purchased from Geneflow.  
GFP-Trap agarose beads (catalogue no. gta-20), agarose beads (catalogue no. bab-20) and 
spin columns (sct-20) was purchased from Chromoteck.  
CYTO-ID autophagy detection kit (catalogue no. ENS-51031-K200) was purchased from Enzo 
Life Sciences.  
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2.3 Plasmids 
 
The pOPH6 plasmid encoding for bacterial PNGase F was a kind gift from Shaun Lott 
(Addgene plasmid # 40315).  
The N-terminal mAPPLE tag mammalian expression vector, mAPPLE-N1 was a kind gift from 
Michael Davidson (Addgene plasmid # 54567). 
Construct encoding for GFP-LC3 (sequence presented in appendix A.1.2) was a kind gift from 
Martin Bootman. Construct encoding for the tandem LC3 reporter, GFP-RFP-LC3 was a kind 
gift from Martin Bootman.  
The deglycosylation dependent VENUS (ddVENUS) plasmid was a kind gift from J.E. Grotzke, 
(Grotzke et al. 2013).  
Plasmids containing the CRISPR WT and Nickase Cas9, pSpCas9(BB)-2A-GFP (PX458) from 
Addgene (Addgene plasmid # 48138) and pspCas9n(BB)-2A-GFO (PX461) (Addgene plasmid 
# 48140) respectively, were kind gifts from Feng Zhang.  
All plasmids were transformed into DH5α E. coli with the exception of the pOPH6 plasmid 
encoding bacterial PNGase F which was also transformed into BL21 DE3 E. coli. 
2.4 Cell culture 
 
Cells were maintained in RPMI media supplemented with FBS (10 %), L-glutamine (2 mM) 
and penicillin/streptomycin (1 %). To subculture, media was removed and the cell monolayer 
washed with warm PBS. The PBS was removed and warm 0.25% EDTA-Trypsin was added 
until all cells detached (approx. 2 min). Fresh media was added and the cells were split at 
1:10 dilution. Cells were maintained at 37 °C at 5% CO2. Cells were frozen at 80 % confluency. 
As before, cells were detached from flasks by trypsin and trypsin inactivated by the addition 
of fresh media. Cells were pelleted by soft centrifugation (4 °C, 1000 rpm, 5 min). The 
supernatant was discarded and the pellet re-suspended in freezing media (1 ml, 90 % FBS, 
10 % DMSO) and aliquoted into cryovials. Vials were frozen overnight at -80 °C in a freezing 
container. After 24 h, cryovials were moved to liquid nitrogen for long-term storage.  
2.5 Characterisation of the effects of pharmacological inhibition and genetic ablation 
of N-glycanase 
 
The methods described in this section were employed to characterise the effects on cell 
viability, N-glycanase activity, glycoprotein profile, Thioflavin T fluorescence, autophagy 
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calculation by imaging, CYTO ID, western blot or in-gel fluorescence. Markers for the 
unfolded protein response and OGA/OGT expression levels were calculated by real-time 
qPCR, primers sequences can be found in Table 2.2. ER Ca2+ handling and ROS levels were 
also examined following treatment with Z-VAD-fmk or, siRNA knockdown of N-glycanase. 
Finally, generation of a bacterial PNGase F, cloned into a mammalian expression vector is 
outlined.  
  
2.5.1 Pharmacological inhibition of N-glycanase using Z-VAD-fmk  
Where pharmacological inhibitors were employed, cells were plated at 20 000 in 12-well 
plates or glass cover slips where appropriate and left to adhere for 24 h prior to treatment 
with Z-VAD-fmk or Q-VD-OPh.  
 
2.5.2 Genetic ablation of N-glycanase   
 
The sequence of the SMARTpool NGLY1 siRNA used in throughout is presented in Table 2.1. 
Where siRNA was employed, cells were plated at 10 000 in 12-well plates or glass cover slips 
where appropriate and left to adhere for 24 h prior to transfection with NGLY1 siRNA (25 
nM) or the corresponding ON-TARGETplus Non-targeting control siRNA (25 nM).  
Table 2.1 Sequence of SMARTpool NGLY1 siRNA 
ON-TARGET plus 
SMARTpool 
siRNA 
Sequence Molecular 
Weight 
(g/mol) 
Extinction 
coefficient 
(L/mol.cm) 
1 GCGAGUGGGCCAAUUGUUU 13444.9 362408 
2 CUGCCGAGCUGUAGGGUUU 13459.8 359649 
3 CCAUAAUUGUGGAGCUUGU 13414.9 375402 
4 GGAGAAUGGCGUGUGGAAA 13444.8 364277 
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2.5.3 MTT assay 
Cells were plated in a 96 well plate (Greiner) at a density of 2000 cells per well. Cells were 
incubated with treatments as indicated per experiment. Following treatment, media was 
aspirated and replaced with fresh media (100 µl) containing MTT (final concentration 0.2 
mg/ml). Plates were incubated at 37 °C for 2 h. Following incubation, media containing MTT 
was carefully removed and DMSO (100 µL) was added to each well.  The plates were then 
shaken for 20 min at RT. The absorbance was read using a BMG Labtech FLUOstar OPTIMA 
plate reader at 570 nm. Treatment with menadione (20 µM, 24 h) was included as a positive 
control to confirm decreased absorbance in non-viable cells.  
2.5.4 Deglycosylation Dependent Venus (ddVENUS) assay 
HEK 293 cells plated in 12 well plates (Greiner) at a density of 80 000 cells per well were 
transfected with ddVENUS plasmid DNA (2 µg per well) using JetPEI® HTS DNA transfection 
reagent (Polyplus-transfection®) in accordance with the manufacturer protocol. After 24 h, 
Z-VAD-fmk (0-300 µM) was added and the cells incubated for a further 24 h. For genetic 
ablation of N-glycanase, HEK 293 cells were transfected with SMARTpool: ON-TARGETplus 
NGLY1 siRNA (25 nM) or an ON-TARGETplus non-targeting control (25 nM) using JetPRIME® 
DNA and SiRNA transfection reagent (Polyplus-transfection®) as per the manufacturer 
instructions.  Cells were analysed 3d post-transfection.  
The proteasome inhibitor, MG132 (8 µM) was added for 6 h before the cells were trypsinised, 
collected by centrifugation and re-suspended in HBSS (500 µl).  Cells were kept on ice before 
measurement. Fluorescence intensity was measured by flow cytometry on a BD FACSCalibur 
(BD Biosciences) and analysed using BD CellQuestTM. A minimum of 10 000 cells were 
analysed for each condition. A non-transfected well was used as a control to determine 
background fluorescence. Cells were analysed using the FL1 filter at 400 V. The non-
transfected cells were gated out of analysis and the median fluorescence intensity of 
transfected cells was plotted.  
2.5.5 Lectin dot blots 
Cells were treated as described in the data. Wells were trypsinised and washed twice in ice-
cold PBS and lysed in 1% triton in PBS at 4 °C with constant agitation for 30 min. Lysate was 
centrifuged at 15 000 g for 15 min. Protein concentration was determined by Bradford assay. 
Protein solution was spotted (2 µl) with an equal final concentration of 1, 0.5 and 0.25 µg 
onto nitrocellulose membrane and allowed to air dry for 1 h. Membranes were blocked in 
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0.1 % PBS-T for 1 h. Membranes were exposed to fluorescein-labelled lectins (Vector 
laboratories) and incubated for 2 h at RT at a final concentration of 2 µg/ml. Membranes 
were washed with PBS-T (3 x 10 min) and imaged using Syngene Gel:Doc imaging system.  
Images were analysed using Syngene GeneTools software for dot blot fluorescence analysis. 
Post-imaging protein concentration was confirmed by visible, total protein amido black 
staining. Nitrocellulose membranes were incubated in amido black staining solution (0.1 % 
amido black, 40 % methanol, 5% acetic acid) for 15 s and de-stained (40 % methanol, 10% 
acetic acid) for 20 min at RT. Membranes were imaged using a Syngene Gel:Doc imaging 
system and analysed using Syngene GeneTools software for dot blot absorbance analysis. 
2.5.6 Quantitation of levels Thioflavin T (ThT)  fluorescence 
HEK cells were plated at 40 000 cells per well in a 12 well plate and treated with either Q-VD-
OPh or Z-VAD-fmk (50 µM, 24-72 h) or a vehicle control (DMSO). For genetic ablation, HEK 
cells were transfected with SMARTpool: ON-TARGETplus NGLY1 siRNA (DharmaconTM, 
catalogue no. L-016457-01) or ON-TARGETplus non-targeting control (DharmaconTM, 
catalogue no. D-001810-01) (25 nM, 3-5 d). Cells were incubated with ThT (1 µM, 0.5 h).  
Following ThT staining, cells were washed three times in imaging buffer (121 mM NaCl, 5.4 
mM KCl, 0.8 mM MgCl2, 1.8 mM CaCl2, 6 mM NaHCO3, 5.5 mM D-glucose, 25 mM HEPES, pH 
7.4 supplemented with Gibco MEM Amino Acids Solution and MEM Non-Essential Amino 
Acids. Coverslips were imaged using a Leica DMI6000 fluorescence microscope under 63x oil 
immersion objective. A minimum of three images (ex 485 nm, em 520 nm) were taken per 
condition. Areas were selected in bright field to ensure ThT fluorescence was unbiased. 
Images were analysed using ImageJ. The images were background subtracted by selection of 
areas adjacent to cells and subtracting the mean fluorescence from the image. The perimeter 
of the cells were defined and, the mean fluorescence per cell was calculated. 
2.5.7 Quantitation of Thioflavin T (ThT) fluorescence by flow cytometry 
Flow cytometry was also used to determine ThT fluorescence. HEK cells were treated with 
either Q-VD-OPh or Z-VAD-fmk (50 µM, 24-72 h) or a vehicle control (DMSO). For genetic 
ablation, HEK cells were transfected with SMARTpool: ON-TARGETplus NGLY1 siRNA or an 
ON-TARGETplus non-targeting control (25 nM, 3-5 d). Cells were loaded with Thioflavin T (5 
µM, 30 m) at 37 °C in complete media. Cells were detached with trypsin and washed in HBSS 
three time by centrifugation. Cells were re-suspended in HBSS (500 µl) and analysed using 
BD FACSCalibur on the FL1 channel (ex 488 em 530), at 440 V, 10 000 cells were counted per 
condition.  
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2.5.8 Quantitation of levels GFP-LC3 positive puncta  
GFP-LC3 HEK cells were plated on uncoated 16 mm glass coverslips at (40 000 cells per well) 
and treated with Z-VAD-fmk or Q-VD-OPh (50 µM, 24-72 h) or a vehicle control. For genetic 
ablation, HEK cells were transfected with SMARTpool: ON-TARGETplus NGLY1 siRNA or an 
ON-TARGETplus non-targeting control (25 nM, 3-5 d). Cells were imaged on the oil immersion 
63x objective. A minimum of three areas per coverslip were imaged and were selected under 
bright field. The number of GFP-LC3 positive puncta were counted manually and, the average 
number of puncta per cell was calculated per condition. To measure flux, GFP-LC3 HEK cells 
were treated with Bafilomycin A1 (100 nM, 1 h) or 3-MA (5 mM, 1 h) at 37 °C at 5% CO2. Cells 
were re-imaged and the number of GFP-LC3 puncta was calculated. 
2.5.9 Use of CYTO-ID® autophagy detection kit with a TALI image -based 
cytometer 
HEK cells were plated in a 12 well plate at a density of 20 000 cells and left to adhere for 24 
h.  After 48 h cells were treated with Bafilomycin A1 (100 nM) or amino acid starvation (121 
mM NaCl, 5.4 mM KCl, 0.8 mM MgCl2, 1.8 mM CaCl2, 6 mM NaHCO3, 11 mM D-glucose, 25 
mM HEPES, 2 mM L-Glutamine, pH 7.4) for 4 h or amino acid starvation with Bafilomycin A1 
treatment. Cells were detached with trypsin, collected and washed (3X HBSS).  Cells were 
then incubated with ENZO CYTO-ID® autophagy detection kit stain (ENZ-51031-K200) as per 
the manufacturer instructions. Following staining, cells were washed in HBSS (3X HBSS). 
Sample was loaded into TALI cellular analysis slides (25 µl). Cells were analysed under the 
green channel and the mean fluorescence per region plotted. Nine regions were imaged per 
condition.  
2.5.10 Assessment of transfection efficiency  
To identify the most effective transfection condition in HEK 293 cells, the transfection 
efficiencies for several transfection reagents were tested using the GFP-RFP-LC3 plasmid. 
Transfections were undertaken as per manufacturer instructions in triplicate and efficiency 
assessed by fluorescence imaging 48 h post-transfection. 
2.5.11 Trypan blue exclusion measurement of cell viability  
Trypan blue exclusion was used to determine cell viability. Cells were detached from cell 
culture plates with trypsin, which was deactivated by the addition of complete media. Equal 
volumes of cell suspension and 0.4 % trypan blue solution were added. The cell suspension 
was loaded onto a haemocytometer and the percentage of cells with dye inclusion evident 
was determined.  
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2.5.12 G418 cell survival 
HEK cells were plated at 20 % confluency in a 48 well plate and treated with up to 2 mg /ml 
G418 over 11 days. Wells were classified as either viable or non-viable. Non-viable wells were 
determined by eye at >80 % of the cells unattached to the well bottom.  
2.5.13 Generation of GFP-RFP-LC3 stably transfected cells 
Stable transfection of GFP-RFP-LC3 construct in HEK293 cells was carried out in accordance 
with the following protocol. HEK cells were seeded at 60% confluence into a 10 cm cell 
culture dish (Greiner) and left to adhere overnight. The cells were transfected with GFP-RFP-
LC3 construct using JetPEI® HTS DNA transfection reagent as per manufacturer’s instructions. 
After 48 h, the dish was split into 6 x 10 cm dishes supplemented with G418 (1mg/ml) diluted 
in PBS in complete media. Once distinct colonies could be observed, individual colonies were 
transferred into single wells in a 48 well plate using a sterile P1000 filter pipette tip. 
Expression was examined by fluorescence microscopy (Leica DMI6000, 20x objective) once 
cells reached confluency. Colonies expressing fluorescence under green (ex 485 nm, em 520 
nm) and red channel (ex 541-551, em 565-605 nm) were expanded. Fluorescence was 
compared to the GFP-LC3 HEK cells under the same excitation conditions. These were further 
characterised, and cell populations that showed 50 % positive green and red cells were with 
cells that showed equivalent GFP signal as the GFP-LC3 HEK cells were used in future 
experiments and a stock was frozen down and cells were characterised with Bafilomycin and 
3-MA. Autophagy calculation was done as described by section 2.5.8, however, the red and 
green channels were merged and yellow and red puncta were counted manually.  
2.5.14 Quantitation of GFP-LC3 levels using in-gel fluorescence  
Cells were treated as indicated in the experiment. Cells were trypsinised and collected by 
centrifugation and washed 3 times in ice-cold PBS. Cells were lysed in 1 % Triton X 100 for 30 
min at 4 °C and centrifuged at 16 000 g for 20 min at 4 °C. The protein lysate concentration 
was calculated by Bradford Assay. Lysate was added to 4X LDS-loading dye (3:1 lysate:dye) 
to a final concentration of 10-20 µg/20 µl. Samples were run on 4:15% Tris-Glycine Mini Gels 
at 150 V for 1 h in Tris/Glycine/SDS running buffer (BioRad). The gel was removed and imaged 
using the GFP filter on a Syngene Gel:Doc.  
2.5.15 Quantitation of protein levels by Western blot  
Cells were treated as indicated in the experiment. Cells were trypsinised and collected by 
centrifugation and washed 3 times in ice-cold PBS. Cells were lysed in 1 % Triton X 100 for 30 
min at 4 °C and centrifuged at 16 000 g for 20 min at 4 °C. The protein lysate concentration 
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was calculated by Bradford Assay (BioRad Cat#5000006). Lysate was added to 4X LDS-loading 
dye 3:1 lysate:dye to a final concentration 10-20 µg/20 µl. Samples were boiled at 95 °C for 
10 m. The protein lysate concentration was calculated by Bradford Assay (BioRad 
Cat#5000006). Lysate was added to 4x LDS-loading dye 3:1 lysate:dye to a final concentration 
10-20 µg/20 µl. Samples were run on 4:15% Tris-Glycine Mini Gels at 150 V for 1 h in 
Tris/Glycine/SDS running buffer (BioRad). The gel was soaked in cathode buffer (25 mM Tris-
Base pH 9.4, 40 mM Glycine, 10 % MeOH) for 15 minutes. PVDF membrane was cut to size 
and soaked in Methanol for 30 s, washed in dH20 for 2 min and soaked in Anode II buffer (25 
mM Tris-Base, pH 10.4, 10 % MeOH) for 5 m. To create the sandwich, two filter papers were 
soaked in Anode I (0.3 M Tris-Base pH 10.4, 10 % MeOH) and placed on the Bio-Rad Semi-
Dry Transfer apparatus, followed by a filter paper soaked in anode II buffer, the PVDF 
membrane, the gel and 3 filter papers in cathode buffer. Air bubbles were gently rolled out 
and excess buffer removed from the semi-dry plate. The gel was transferred for 1 h at 74 
mA. Transfer efficiency was tested using Ponceau S staining and Coomassie staining of the 
gel after transfer. The membrane was blocked in 5 % semi-skimmed milk solution in TBS with 
0.1 % Tween 20 (TBS-T) for 1 h at RT. Anti-GFP antibody (Santa Cruz, mouse monoclonal anti-
GFP antibody (#18A11): sc-69779) was incubated at 1/200 dilution at 4 °C overnight. The 
membrane was washed 3 times at 10 min each in TBS-T followed by incubation of secondary 
antibody for 2 h at RT (1/8000 dilution, Vector Laboratories, HRP Horse anti-mouse IgG 
antibody peroxidase, cat#PI-2000). Membranes were soaked in Clarity Western ECL 
substrate solution (Bio-Rad) as per manufacturer’s instructions. Excess solution was removed 
by touching the corner of the membrane to a tissue and the membrane was imaged using 
the Syngene Gel:Doc.  
2.5.16 Assessment of ER stress markers by real-time quantitative PCR (RT-
qPCR) 
RT-qPCR was used to determine changes in ER stress markers, N-glycanase downregulation 
for siRNA mediated knockdown, OGA and OGT expression in HEK cells and the presence of 
ATG13 in ATG13 KO and WT MEF cells. The sequences of all primers used can be found in 
Table 2.1. RT-qPCR was carried out using the MJ Opticom real time PCR machine.  
For analysis of ER stress markers, cells were treated with Z-VAD-fmk or Q-VD-OPh (50 µM, 
24-72 h) or a vehicle control and MG132 (5 µM, 18 h). For genetic ablation of N-glycanase, 
HEK cells were transfected with SMARTpool: ON-TARGETplus ngly1 siRNA or an ON-
TARGETplus non-targeting control (25 nM, 3-5 d). For the analysis of OGA and OGT 
expression, cells were treated with Z-VAD-fmk or Q-VD-OPh (50 µM, 24-72 h) or a vehicle 
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control. For genetic ablation of N-glycanase, HEK cells were transfected with SMARTpool: 
ON-TARGETplus ngly1 siRNA or an ON-TAGRETplus non-targeting control (25 nM, 3-5 d). For 
the analysis of ATG13 expression levels in ATG13 KO and WT MEF cells, no treatment was 
added. For confirmation of siRNA knockdown of N-glycanase, HEK cells were transfected with 
10-40 nM siRNA using JetPrimeTM or DharmaFECT® according to manufacturer’s instructions. 
Control samples were transfected with 40 nM non-targeting siRNA with either DharmaFECT® 
or JetPrimeTM. Quantities were normalised to GAPDH and percentage knockdown was 
calculated from the non-targeting control.  
RNA was extracted using RNeasy Mini Kit. RNA (100 ng) was used with the One-Step Luna® 
Universal qPCR Master Mix per manufacturer’s instructions. Samples were heated to 55 °C, 
10 min to convert RNA to cDNA followed by an initial denaturation 98°C, 5 min followed by 
denaturation at 95 ⁰C, 30 s, annealing at 58 °C, 30s, extension at 72°C, 30 s for 42 cycles. The 
threshold was taken over the global minimum over 10 standard deviations and analysed 
using the double delta Ct method. GAPDH was employed as a housekeeping gene and an 
untreated control was used as the baseline. A melting curve was undertaken post run to 
confirm specificity of primers from 50-90 °C reading every 0.5 °C.  
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Table 2.2 Sequences of primers used in RT-qPCR  
Species Gene Sequence 
Human GAPDH Forward 5’-AGGGCTGCTTTTAACTCTGGT-3’ 
GAPDH Reverse 5’-CCCCACTTGATTTTGGAGGGA-3’ 
BiP (Grp78) Forward 5’-ACGTGGAATGACCCGTCTGT-3’ 
BiP (Grp78) Reverse 5’-AACCACCTTGAACGGCAAGA-3’ 
CHOP Forward 5’-ACCAAGGGAGAACCAGGAAACG-3’ 
CHOP Reverse 5’-TCACCATTCGGTCAATCAGAGC-3’ 
ATF4 Forward 5’- TTGAGGATAGTCAGGAGCGT -3’ 
ATF4 Reverse 5’-TGGAACACACAGCTACAGCA-3’ 
EDEM Forward 5’-CAAGTGTGGGTACGCCACG-3’ 
EDEM Reverse 5’-AAAGAAGCTCTCCATCCGGTC-3’ 
OGA Forward 5’-TTCACTGAAGGCTAATGGCTCCCG-3’ 
OGA Reverse 5’-ATGTCACAGGCTCCGACCAAGT-3’ 
OGT Forward 5’-CATCGAGAATATCAGGCAGGAG-3’ 
OGT Reverse 5’-CCTTCGACACTGGAAGTGTATAG-3’ 
NGLY Forward 5’-GGTTTGAAGCTCGCTATGTTTGGGATTAC-3’ 
NGLY1 Reverse 5’-CTTGTCACAGACATCTTCACATGCATCAC-3’ 
Mouse ATG13 Forward 5’- AGGGCGGGAGAGATCGTTTG-3’ 
ATG13 Reverse 5’- CAGCACAGGTCGCAGAGAGA-3’ 
 
2.5.17 Assessment of cellular calcium handling by fluorescence imaging  
GFP-LC3 HEK cells were plated on uncoated 16 mm glass coverslips at (40 000 cells per well) 
and treated with Z-VAD-fmk or Q-VD-OPh (50 µM, 24-72 h) or a vehicle control. For genetic 
ablation, HEK cells were transfected with SMARTpool: ON-TARGETplus ngly1 siRNA or an ON-
TARGETplus non-targeting control (25 nM, 3-5 d). Cells were incubated in FURA-2 AM (1 µM) 
in imaging buffer supplemented with Gibco MEM Amino Acids Solution and MEM Non-
essential Amino Acids Solution for 20 min at 37°C. Cells were washed three times in imaging 
buffer and incubated for a further 20 m. Coverslips were imaged using a Leica DMI6000 
fluorescence microscope on the 20x objective. Calcium was mobilised from the ER using 
Thapsigargin (1 µM) after 180 s. Images were taken every 20 s for 12 m. Time lapse videos 
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were analysed using ImageJ. Cytosolic areas of cells were selected plus a background region 
for 340 and 380 nm. A minimum of 20 cellular regions were analysed per coverslip. The 
340/380 ratio was calculated. The area under the curve, baseline average of first eight images 
and peak height were calculated using GraphPad Prism 7.  
2.5.18 Quantitation of oxidative stress by flow cytometry  
Flow cytometry was used to determine RosBrite 570 fluorescence. HEK cells were treated 
with either Q-VD-OPh or Z-VAD-fmk (50 µM, 24-72 h) or a vehicle control (DMSO). For genetic 
ablation, HEK cells were transfected with SMARTpool: ON-TARGETplus ngly1 siRNA or an ON-
TAGRETplus non-targeting control (25 nM, 3-5 d). Cells were loaded with RosBrite 570 (5 µM, 
30 m) at 37 ⁰C in complete media. Cells were detached with trypsin and washed in HBSS 
three time by centrifugation. Cells were re-suspended in HBSS (500 µl) and analysed using 
BD FACSCalibur on the FL2 channel (ex 488 em 585-642), at 440 V, 10 000 cells were counted 
per condition. 
2.5.19 Expression and purification of recombinant PNGase F 
Overnight cultures were grown at 37 °C in LB media supplemented with ampicillin (100 
µg/ml). The overnight culture (0.8 % final volume) was used to inoculate fresh LB media 
supplemented with ampicillin (100 µg/ml). Large scale cultures (500 ml) were grown at 37 °C 
until OD600 0.5-0.7. Protein expression was induced by the addition of IPTG (1 mM final 
concentration). Following induction, cultures were left to grow overnight with shaking (30 
°C, 210 rpm). PNGase F was purified using a variation of the methodology described by Loo 
et al. (2002). Cells were pelleted at 600 g and washed in half the original volume of ice-cold 
PBS, and the cell pellet re-suspended in 2% culture volume of chilled sucrose (0.5 M) in Tris-
HCl at (0.1 M, pH 8). The resultant lysate was pelleted at 8000 g (20 min, 4°C) and re-
suspended in 2% original culture volume chilled sdH2O.  The suspension was incubated on a 
tube roller (4 °C, 20 min). MgCl2 (200 µl of 1 M solution) was added to a final concentration 
of 20 mM and incubated on a tube roller for a further 20 minutes. The suspension was 
pelleted by centrifugation (8000g, 20 min, 4°C). The supernatant was filtered through a 
Nalgene PES 0.45 µm syringe filter (725-2545) before being manually loaded on a nickel 
affinity column (HisTrap HP histidine tagged protein purification column, 5 ml, 
cat#17524701) by syringe pre-equilibrated with 20 ml wash buffer (20 mM HEPES, 300 mM 
NaCl, 20 mM imidazole). Contaminants were washed with 2 column volumes of wash buffer. 
Protein material was eluted with 4 column volumes of elution buffer (20 mM HEPES, NaCl 
(300 mM) and imidazole (300 mM).  Fractions were analysed for target protein by SDS-Page 
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gel (Novex 12 % Tris-Glycine Mini Gels Cat#XP00122BOX). Fractions containing target protein 
were dialysed (10 kDa) overnight into 2 L storage buffer (20 mM Tris-HCl, 50 mM NaCl, 5 mM 
Na2EDTA, pH 7.5 at 4°C). The dialysed samples were concentrated by centrifugation (3000 g) 
to 35 mg/ml and stored at 4 °C. 
2.5.20 PNGase F activity assay 
Activity of purified recombinant PNGase F was tested using RNaseB as a substrate. RNAse B 
(20 µg, Alfa Aesar) was added to denaturing buffer (1 µl, 0.5% SDS in 40 mM DTT) to a final 
volume of 10 µL. Samples were heated (95 °C, 10 min). The mixture was cooled on ice and 
PNGase F (5 µg) was added, with 50 mM sodium phosphate (pH 7) to a final volume of 20 µl. 
The sample was incubated at 37 °C while shaking for 1.5 h. Digestion was stopped with the 
addition of 4 x LDS loading dye. Samples were analysed on a denaturing SDS-PAGE gel (4:15%, 
polyacrylamide gel set in BioRad Criterion Empty Cassettes.  
2.5.21 Generation of mAPPLE tagged Z-VAD-fmk insensitive PNGase plasmid 
(bacpng) 
PCR based cloning was used to clone PNGase F from the poPH6 plasmid to be inserted into 
a mammalian expression vector with a C-terminal linked mAPPLE fluorescent marker, 
mAPPLE-N1. This would allow transfection of a Z-VAD-fmk insensitive PNGase into HEK cells. 
The poPH6 plasmid (1 ng) underwent PCR with the Phusion High-Fidelity DNA polymerase 
with the forward and reverse cloning primers found in Table 2.3 using the following protocol: 
Initial denaturing (95 °C,  3 min), 98 °C (20 s), annealing (60 °C for 15 s), extension (72 °C for 
30 s) for 34 cycles. The resulting product was excised from the gel and extracted using 
QIAquick Gel Extraction Kit. The isolated PCR product and N1-mAPPLE plasmid were double 
digested with BamHI and XHoI. The mAPPLE-N1 plasmid (1 µg) or PCR product (1 µg) was 
digested with 10 units of restriction enzyme in 1xNEB Buffer 3.1 at (37 °C, 4 h) in a final 
volume of 50 µL. Digestion was confirmed by 1.5 % TAE agarose gel. The PNGase F PCR 
product was ligated into the mAPPLE-N1 plasmid using T4 DNA ligase. Vector DNA (50 ng) 
and insert DNA (50 ng) was incubated with 10X T4 DNA ligase buffer (2 µL) and T4 DNA ligase 
(1 µL) in nuclease free water (20 µL) for 48 h at 4°C.  The reaction mixture (2 µL) was 
transformed into DH5αTM Competent Cells (50 µl). E. coli were plated on agar plates 
supplemented with Kanamycin (50 µg/ml). The plasmid was extracted from E. coli using 
QIAprep Spin Miniprep Lit. Plasmid DNA was digested with BamHI and XHoI as before and 
colonies exhibiting the correct predicted sized bands were submitted for sequence analysis 
and termed bacpng 1-6. 
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Table 2.3 Cloning primers for generation of bacterial PNGase F into N1-mAPPLE 
mammalian expression vector
 
 
  
Forward cloning primer 5’-GCAGCTCGAGACCATGGCTCCGGCAGATAATAC-3’ 
Reverse cloning primer 5’-GATGCGGATCCAAGTTTG-3’ 
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2.6 Generation of CRISPR targeting plasmids 
 
Plasmid maps for CRISPR plasmids are available in Appendix, figure A.3 and figure A.4.  
2.6.1 Design of guide sequences  
Guide sequences were designed using crispr.mit.edu web tool (using the nickase analysis) 
and are presented in Table 2.4.  
Table 2.4 sgDNA sequences were designed usign crispr.mit.edu 
Batch # Oligo name Length Sequence 5’-3’ 
HA09093690 PNGrx-sgB-T 25 CACCGTACTTCGAGACACTATTAAT 
HA09093691 PNGrx-sgB-B 25 AAACATTAATAGTGTCTCGAAGTAC 
HA09093692 PNGrx-sgA-T 25 CACCGTTCTTTAACCTTAGTTCTTC 
HA09093693 PNGrx-sgA-B 25 AAACGAAGAACTAAGGTTAAAGAAC 
HA09093694 ENGko-sgB-T 25 CACCGGGCGTGGAAGCCCCGCTTGG 
HA09093695 ENGko-sgB-B 25 AAACCCAAGCGGGGCTTCCACGCCC 
HA09093696 ENGko-sgA-T 25 CACCGCAAGTAAAAGCTGATTGGTT 
HA09093697 ENGko-sgA-B 25 AAACAACCAATCAGCTTTTACTTGA 
HA09093698 PNGko-sgB-T 25 CACCGACTAGACTCTTGCCTGTCAG 
HA09093699 PNGko-sgB-B 25 AAACCTGACAGGCAAGAGTCTAGTC 
HA09093700 PNGko-sgA-T 25 CACCGGGCTGTGTTTCCAATCCGGA 
HA09093701 PNGko-sgA-B 25 AAACTCCGGATTGGAAACACAGCCC 
 
For the PNGko guide, sequences were selected from gDNA 4801-5041. For the RX mutation 
gDNA 49602-49842 were used (which overlapped the R401X mutation site). The ENGase 
mutation was calculated for gDNA 2729-2969. Figure 2.1-2.3 shows the design tool, 
crispr.mit.edu out for PNGrx, PNGko and ENG guide sequences respectively indicating the 
number of off-target effects for both WT and Nickase variety Cas9 plasmids.  
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Figure 2.1 PNGrx guide sequence calculation. Diagram showing the schematic position of 
guide sequences A and B with off target effects. 
 
Figure 2.2 PNGko guide sequence calculation Diagram showing the schematic position of 
guide sequences A and B with off target effects.
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Figure 2.3 ENGko guide sequence calculation. Diagram showing the schematic position of 
guide sequences A and B with off target effects.
Table 2.5 lists the PCR/sequencing primers used to amplify gDNA regions around the 
expected CRISPR/Cas9 mutation sites.  
Table 2.5 Sequencing primers over regions of CRISPR editing supplied by Sigma Aldrich
Batch # Primer Name Length Sequence 5’-3’ Tm 
HA09093684 PNGko-seq-F 21 GTACCTTAACAGCACAGAATG 59.15 
HA09093685 PNGko-seq-R 19 CCTACTACAGACAGGTAGC 45.40 
HA09093686 PNGrx-seq-F 18 TCTTGACCCTGGGAAGTG 55.3 
HA09093687 PNGrx-seq-R 20 GTCAGGTACTACCAATACTG 45.31 
HA09093688 ENGko-seq-F 22 GAATACCGATCCACCTTCACAC 59.15 
HA09093689 ENGko-seq-R 22 CTGGTCTCAAACTCCTGAGGTC 58.79 
 
2.6.2 Phosphorylation and annealing of oligonucleotides  
Oligonucleotides were phosphorylated and annealed to form double stranded 
oligonucleotides. Two corresponding single stranded oligonucleotides were annealed by 
adding polynucleotide kinase (1 µl), 10X T4 ligation buffer 1µl), the top and bottom 
oligonucleotides (1 µl of 100 µM stock) were added to a final volume of 8 µl in dH2O in a PCR 
tube. The oligonucleotides were phosphorylated and annealed using a thermocycler at 37 °C 
for 30 min, 95 °C for 5 min, 25 °C for 5 min. The annealed oligonucleotides were diluted 1:200 
in ddH2O.  
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2.6.3 Cloning of the sgDNA products into appropriate vectors  
The phosphorylated and annealed sgDNA product was cloned into both pSpCas9(BB)2A-GFP 
and pSpCas9n(BB)2A-GFP.  Plasmid DNA was diluted to 50 ng/ml (2µl) and mixed with the 
annealed oligonucleotides (2 µl), 10X tango buffer (2 µl), DTT (10 mM, 1 µl), ATP (10 mM, 1 
µl), Bpi1 (1 µl), T7 ligase (0.5 µl) to a final volume of 20 µl in ddH2O. The ligation reaction was 
incubated for 1 h at 37 °C, 5 min 21 °C. Linear DNA was eliminated by Plasmidsafe 
exonuclease activity. The ligation reaction (11 µl) was added to 10X PlasmidSafe buffer (1.5 
µl), ATP (10 mM, 1.5 µl) and PlasmidSafe exonuclease (1 µl). The reaction was incubated at 
37 °C for 30 min followed by 70 °C for 30 min.  
2.6.4 Transformation of plasmids into an E.coli  expression host 
Plasmids were transformed by heat shock into E. coli DH5α. Briefly, plasmid product (15 µl) 
was incubated with E. coli DH5α (100 µl) for 10 min on ice. Cells were heat shocked at 42 °C 
for 45 s and placed on ice for 2 min. Pre-warmed SOC media (900 µl) was added to the 
bacteria and incubated at 37 °C for 1 h. Cells were plated on LB agar containing 100 µg/ml 
ampicillin and incubated overnight at 37 C.   
2.6.5 Determination of sequence 
Plasmids were extracted by Qiagen maxi prep kit per manufacturer’s instruction. Plasmid 
construct and transformation was confirmed by DNA sequencing. Two colonies were picked 
for each transformation and Qiagen maxi prep was performed according to manufacturer’s 
instructions. Plasmid DNA was sent to MRC PPU DNA sequencing and services at Dundee 
University using U6-Fwd primer or sequencing primers described in Table 3. Sequences 
available in appendix A.2.  
2.6.6 PCR 
Genomic DNA was extracted from HEK 293 cells using Qiagen DNeasy Blood and Tissue kit 
and PCR was done using the Phusion High fidelity polymerase kit. PCR products were 
separated by 1.5% agarose gel in TAE buffer (40 mM Tris, pH 7.6, 20 mM acetic acid, 1 mM 
EDTA) at 150 V for 1 h. DNA was stained with Midori Green. Images were taken on the 
Synegne G:Box imaging system.   
2.6.7 Transfection of CRISPR constructs  
CRISPR plasmids were transfected using JetPeiTM according to the manufacturers guidelines 
(2:1 mixture of transfection reagent:plasmid DNA,  incubated in 150 mM NaCl solution at RT 
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for 0.5 h).  For CRISPR transfections including the specific mutation oligo, for every 1 µg of 
plasmid DNA, 1 µl of 10 mM oligo was added to the DNA.  
Table 2.6 R401X homology directed repair sequence 
R401X 
oligonucleotide 
insertion 
sequence 
5’-
TAATCTTGTTAAGTATTTGTATTCTGTTATTTGTTTCAGGTAGTTGATGTCACT
TGGCGATATTCCTGCAAACATGAAGAGGTGATTGCCAGAAGAACTAAGGTT
AAAGAAGCATTACTTCGAGACACTATTAATGGGCTTAATAAGCAGGTATGGT
GTGGCTATCTTTTTTGAAAGAACAGTTGACATTTTTTATGTAATC-3’ 
 
2.2.7 Shotgun proteomics analysis of CRISPR clones (ThermoScientific 
QExactive) 
Following desalting of protein digests by reverse phase C18 solid phase extraction (C18-SPE), 
samples were resolubilised in 0.1 % TFA (20 l) by shaking (30 min, 1200 rpm) and sonication 
(10min). The solutions were centrifuged (17,000 g, 10 min, 5 °C) and transferred to LC-MS 
sample vials. Peptides were separated using an Ultimate 3000 RSLC nano liquid 
chromatography system (Thermo Scientific) coupled to a Q-Exactive mass spectrometer 
(Thermo Scientific) via an EASY-Spray source. Injected sample volumes were loaded onto a 
trapping column (Acclaim PepMap 100 C18, 100 μm × 2 cm) at 8 μL/min in 2 % acetonitrile, 
0.1% TFA. Peptides were then eluted on-line to an analytical column (EASY-Spray PepMap 
C18, 75 μm × 75 cm). Peptides were separated using a ramped 80 minute gradient, 4-70 % 
of buffer B (buffer A: 2% acetonitrile, 0.1% FA; buffer B: 80% acetonitrile, 0.1% FA). Eluted 
peptides were analysed by the Q-Exactive operating in positive polarity using a data-
dependent acquisition mode. Ions for fragmentation were determined from an initial MS1 
survey scan at 70,000 resolution (determined at m/z 200), followed by HCD (Higher-energy 
collisional dissociation) of the top 12 most abundant ions at a MS2 resolution of 17,500 
(determined at m/z 200). MS1 and MS2 scan AGC targets set to 1e6 and 1e5 for a maximum 
injection time of 50 ms and 110 ms respectively. A survey scan m/z range of 350 – 1800 m/z 
was used, with a normalised collision energy set to 27 %, underfill ratio – 1%, charge state 
exclusion enabled for unassigned, +1, +8 and >+8 ions. LC-MS/MS analysis was carried out in 
technical duplicate runs. 
57 
 
Data was processed using the MaxQuant software platform (v1.5.8.3), with database 
searches carried out by the in-built Andromeda search engine against the Swissprot Human 
database. A reverse decoy database approach was used at a 1% false discovery rate (FDR) 
for peptide-spectrum matches and protein identification. Search parameters included: 
maximum number of missed cleavages set to 2, fixed modifications: cysteine 
carbamidomethylation and variable modifications: methionine oxidation, protein N-terminal 
acetylation. Label-free quantification was enabled with an LFQ minimum ratio count of 2. For 
data analysis protein and peptide identifications and relative quantification outputs from 
Maxquant were further processed in Excel, with protein and peptides hits to the ‘reverse 
database’, ‘potential contaminants’ (peptide list only) and ‘Only identified by site’ field 
removed. 
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2.7 Proteomics analysis of autophagosomes 
 
This section describes the protocols used for isolation of autophagosomes and settings 
associated with mass spectrometer analysis.  
2.7.1 Autophagosome isolation using GFP-linked magnetic beads  
GFP-LC3 HEK cells were cultured as before, washed twice with ice cold PBS and collected. 
Pellets were re-suspended in ice cold 0.25 M sucrose, 1 mM EDTA, 20 mM HEPES, pH 7.4 and 
lysed by dounce homogenisation and vortexed every 10 minutes for 30 minutes on ice. Cells 
were centrifuged at 10 000g for 20 minutes at 4 °C and the pellet washed twice in 0.1% BSA 
in PBS and re-suspended in PBS. Autophagosomes were isolated using BioRad SureBeads 
Protein G magnetic beads coupled to anti-GFP antibody at 2-4 µg antibody per 1 mg beads. 
Protein concentration was determined by Nanodrop and visual inspection under a 
fluorescence microscope.  
2.7.2. Autophagosome isolation using Chromotek GFP-Trap® agarose beads 
GFP-LC3 HEK cells were cultured as before and washed twice with ice cold PBS and collected. 
Cells were lysed in 1 % Triton in PBS by dounce homogenisation and incubated for 30 min at 
4°C. Lysate was centrifuged at 6000 g for 10 min at 4 °C. The supernatant was removed and 
centrifuged again at 20 000 g for 20 min at 4 °C. The supernatant was discarded and the 
pellet re-suspended in PBS (500 µl) and added to filter spin column with GFPTrap® agarose 
beads (50 µl) or agarose bead control (50 µl) washed 3x in PBS. Samples were tumbled for 1 
h at 4°C. Samples were then centrifuged at 2 500 g for 2 min and, the flow through was 
discarded. Samples were washed 7x in ice-cold PBS-T by centrifugation. Samples were eluted 
by 0.2 M glycine, pH 2.5 (50 µl) for 1 min with constant vortexing. Beads were centrifuged 
into a fresh, low protein binding tube. Elution was repeated and samples pooled. Samples 
were neutralised by the addition of 1 M phosphate buffer (pH 7.4).  
2.7.3 In-gel trypsin digestion 
Autophagosomes were enriched by anti-GFP immunoprecipitation of GFP-LC3 in HEK cells 
treated with basal control, amino acid starvation, rapamycin (5 µM) and Z-VAD-fmk (50 µM, 
72 h) followed by Bafilomycin treatment (100 nM, 4 h). The eluent was run on a 12 % 
Tris:Glycine SDS Page gel. Bands were cut into 1mm2 squares and washed overnight in wash 
solution (50% MeOH, 5% acetic acid, 200 µl), the wash solution was changed after 24 h and 
incubated for 2-3 h at RT while shaking. The wash solution was removed and acetonitrile 
(200 µl) was added to dehydrate the gel for 5 min at RT. This step was then repeated. DTT 
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solution (10 mM in 100 mM ammonium bicarbonate, 30 µl) was added and samples were 
reduced for 30 min. DTT was removed and iodoacetamide (50 mM, 30 µl) was added to 
alkylate cysteine residues for 30 min. This solution was then removed and acetonitrile (200 
µl) was added for 5 min. The acetonitrile was removed and ammonium bicarbonate (50 mM, 
200 µl) was added for 10 min. The trypsin reagent was prepared on ice by adding ice-cold 50 
mM ammonium bicarbonate (2 ml) to sequencing grade modified trypsin (20 µg). Trypsin 
solution (30 µl) was added to each gel piece and incubated at RT for 10 min before 
centrifugation to remove excess trypsin. Ammonium bicarbonate (50 mM, 5 µl) was added 
to stop the gel pieces drying out and the gel pieces were incubated at 37° C overnight. Any 
liquid left in the tube was removed and, ammonium bicarbonate (50 mM, 50 µl) was added 
for 10 min.  The supernatant was collected and extraction buffer I (50% acetonitrile, 5% 
formic acid, 50 µl) was added.  The samples were incubated for 10 min, then the supernatant 
was collected. Extraction buffer II (85% acetonitrile, 5% formic acid, 50 µl) was added for 10 
min and the supernatant collected and pooled.  The combined supernatants were dried in a 
vacuum centrifuge. The pellet was re-suspended in 2% acetonitrile and 0.1% formic acid (20 
µl) and transferred to LC-MS sampling tubes.  
2.7.4 Analysis of samples following in-gel digestion (Bruker AmaZon Ion Trap 
LCMS-MS system) 
Protein samples were combined with reducing SDS-PAGE sample buffer, heat denatured and 
resolved on a Tris-Glycine 4:12% gel. Following Coomassie blue staining, each lane was 
excised to generate five equally sized sections which were cut into 1 – 2 mm3 gel pieces and 
placed into 1.5 ml sample tubes. Gel pieces were rinsed twice with wash solution for 18 h in 
total (200 μL, 50% methanol, 5% acetic acid). The solutions were removed and gel pieces 
were dehydrated in acetonitrile (200 μL, 5 min). The supernatant was removed and gel pieces 
were dried in a vacuum centrifuge for 3 min. Disulfide reduction was performed with 10 mM 
DTT (30 μL) for 0.5 h, followed by alkylation with 100 mM iodoacetamide (30 μL) for 0.5 h. 
Supernatants were removed from the gel samples and dehydration with acetonitrile and 
evaporation performed as described above. Gel pieces were washed with 100 mM 
ammonium bicarbonate (200 μL, 10 min). Supernatants were removed and dehydration 
performed with acetonitrile and evaporation as above. The gel samples were then 
rehydrated on ice with freshly prepared trypsin solution (30 μL, 20 ng/μL sequencing grade 
trypsin in 50 mM ammonium bicarbonate). After rehydration excess trypsin solution was 
removed and 50 mM ammonium bicarbonate (10 μL) was added to prevent dehydration of 
gel pieces. Gel samples were digested at 37 °C for 18 h. The gel pieces were then extracted 
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sequentially with 50 mM ammonium bicarbonate (60 μL), 50 % acetonitrile, 5 % formic acid 
(FA) (60 μL) and 85 % acetonitrile, 5 % FA (60 μL). The combined extracts were evaporated 
in a vacuum centrifuge and were redissolved in 5% acetonitrile, 0.1% FA (20 μL) on an 
ultrasonic bath and transferred into LC-MS sample vials. 
For the LC-MS/MS analysis of in-gel digested protein material, liquid chromatography was 
performed using an Ultimate 3000 nano-HPLC system (Dionex, Sunnyvale, CA, USA) 
comprising a WPS-3000 micro auto sampler, a FLM-3000 flow manager and column 
compartment, a UVD-3000 UV detector, an LPG-3600 dual-gradient micro-pump, and an 
SRD-3600 solvent rack controlled by Hystar (Bruker Daltonics, Billerica, MA, USA) and DCMS 
link 2.0 software. Samples were concentrated on a trapping column Dionex (Sunnyvale, CA, 
USA, 300μm i.d., 0.1cm) at a flow rate of 20 μL/min. For the separation with a C18 Pepmap 
column (75 μm i.d., 15 cm, Dionex), a flow rate of 250 nL/min was used as generated by a 
cap-flow splitter cartridge (1/1000). Peptides were eluted by the application of a 0.5 h multi-
step gradient using solvents A (98% H2O, 2% acetonitrile, 0.1% FA) and B (80% acetonitrile, 
20% water, 0.1% FA). 
Composition 
(% solvent B) 
Run time 
(min) 
2-10 0-3 
10-25 3-18 
25-50 18-30 
50-90 30-30.2 
 
The liquid chromatography was interfaced directly with a 3D high capacity ion trap mass 
spectrometer (amaZon; Bruker Daltonics) utilizing 10 μm i.d. distal coated SilicaTips (New 
Objective, Woburn, MA, USA) and nano-ESI mode. SPS parameter settings on the ion trap 
were tuned for a target mass of 850 m/z, compound stability 100 % and a smart ICC target 
of 250,000. MS/MS analysis was initiated on a contact closure signal triggered by HyStar 
software (version 3.2). Up to five precursor ions were selected per cycle with active exclusion 
(0.5 min) in collision-induced dissociation (CID) mode. CID fragmentation was achieved using 
helium gas and a 30 %-200 % collision energy sweep with amplitude 1.0 (ions are ejected 
from the trap as soon as they fragment). 
Raw LC-MS/MS data were processed and Mascot compatible files were created using 
DataAnalysis 4.0 software (Bruker Daltonics). Database searches were performed using the 
61 
 
Mascot algorithm (version 2.4) and the UniProt_SwissProt database with mammalian 
taxonomy restriction (v2015.11.26, number of entries 549,832). The following parameters 
were applied: 2+, 3+ and 4+ ions, peptide mass tolerance 0.3 Da, 13C = 2, fragment mass 
tolerance 0.6 Da, number of missed cleavages: two, instrument type: ESI-TRAP, fixed 
modifications: Carbamidomethylation (Cys), variable modifications: Oxidation (Met). 
2.7.6 In-house FASP digestion protocol 
Autophagosomes were isolated as before. Spin filters (30 kDa) were conditioned with mQ 
water (50 µL) and centrifuged at 12 000 g for 2 min. Protein lysates were loaded onto the 
filter and centrifuged at 12 000 g for 5 min. UA buffer (8M urea in 0.1M Tris/Hcl, pH5) (200 
µl) was added and centrifuged at 12 000 g for 15 min. This was repeated twice. DTT (10 mM, 
100 µl) in UA was added and shaken for 1 min followed by static incubation for 30 min at 40 
⁰C. The sample was centrifuged at 12 000 g for 10 min. Iodoacetamide solution in UA (50 
mM, 100 µl) was added to the filter and shaken for 1 min before being incubated for 20 min 
at RT. UA (100 µL) was added and centrifuged at 12 000 g for 15 min. This was repeated 
twice. Ammonium bicarbonate (50 mM, 100 µL) was added and centrifuged at 12 000 g for 
10 min. This was repeated twice. The trypsin reagent was prepared on ice by adding ice-cold 
50 mM ammonium bicarbonate (2 ml) to sequencing grade modified trypsin (20 µg). The 
trypsin solution (200 µL) was added at 6 ng/µl in ammonium bicarbonate (50 mM) and 
shaken for 1 min and incubated overnight at 37 ⁰C. The spin filter was transferred to a new 
collection tube and centrifuged at 12 000 g for 10 min. NaCl solution (0.5 M, 50 µL) was added 
to the filter and centrifuged for a further 10 min. TFA (1 %, 50 µL) was added and the samples 
were desalted using C18 tips.  
2.7.7 Expedeon FASP TM  protocol 
The Expedeon FASPTM kit (Expedeon, catalogue no. 44250) was used per manufacturer 
instructions. Briefly, autophagosomes were isolated as before. Lysate solution (30 µL) was 
added to a urea sample solution (200 µL) then transferred to a spin filter and centrifuged at 
14 000 g for 15 min. 10 x iodoacatemide stock (10 µL) was added to a urea solution (90 µL) 
and added to the filter.  The samples were vortexed for 1 min and incubated (protected from 
light) for 20 min at RT then centrifuged at 14 000 g for 10 min. The filter was washed three 
times with urea solution (100 µl) and centrifuged at 14 000 g for 15 min. Followed by three 
ammonium bicarbonate (50 mM, 100 µl) washes and centrifuged at 14 000 g for 10 min. 
Digestion solution (75 µl) was added to the filter and vortexed for 1 min. The tubes were 
wrapped in parafilm and incubated overnight at 37 ⁰C. Spin filters were transferred to a new 
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collection tube and ammonium bicarbonate solution (40 µl) was added and centrifuged at 
14 000 g for 10 min. This step was repeated and the samples pooled. NaCl solution (0.5 M, 
50 µL) was added and centrifuged at 14 000 g for 10 min. The pooled eluate was acidified 
with TFA (1 %, 50 µL). Samples were desalted using C18 tips.  
2.7.8 Analysis of in-house and Expedeon FASP protocols (ThermoScientific LTQ 
Orbitrap XL) 
Following desalting of protein digests by reverse phase C18 solid phase extraction (C18-SPE), 
samples were resolubilised in 0.1 % trifluoroacetic acid (TFA) (20 l) by shaking (30 min, 1200 
rpm) and sonication (10 min). The solutions were centrifuged (17,000 g, 10 min, 5 °C) and 
transferred to LC-MS sample vials. Sample aliquots were injected and separated using an 
Ultimate 3000 RSLC nano liquid chromatography system (Thermo Scientific) coupled to a LTQ 
Orbitrap XL mass spectrometer (Thermo Scientific) via a Proxeon nano-spray source. Injected 
sample volumes were loaded onto a trapping column (Acclaim PepMap 100 C18, 100 μm × 2 
cm) at 8 μL/min in 2 % acetonitrile, 0.1 % TFA. Peptides were eluted on-line to an analytical 
column (Acclaim Pepmap RSLC C18, 75 μm × 50 cm) and separated using a stepped 90 minute 
gradient, 4-25% of buffer B for 60 minutes, 25-65 % buffer B for 30 minutes (buffer A: 2 % 
acetonitrile, 0.1 % FA; buffer B: 80 % acetonitrile, 0.1 % FA). Eluted peptides were analysed 
by the LTQ Orbitrap XL operating in positive polarity using a data-dependent acquisition 
mode. Ions for fragmentation were determined from an initial MS1 survey scan at 30,000 
resolution (determined at m/z 200), followed by Ion Trap CID (collision-induced dissociation) 
of the top 6 most abundant ions. MS1 and MS2 scan AGC targets set to 1e6 and 1e4 for a 
maximum injection time of 500 ms and 100 ms respectively. A survey scan m/z range of 350 
– 1800 was used, with a normalised collision energy set to 35 %, charge state rejection 
enabled for singly charged precursor ions and a minimum threshold for triggering 
fragmentation of 500 counts.  
Data was processed using the MaxQuant software platform (v1.5.8.3), with database 
searches carried out by the in-built Andromeda search engine against the Swissprot Human 
database. A reverse decoy database approach was used at a 1 % false discovery rate (FDR) 
for peptide-spectrum matches and protein identification. Search parameters included: 
maximum number of missed cleavages set to 2, fixed modifications: cysteine 
carbamidomethylation and variable modifications: methionine oxidation, protein N-terminal 
acetylation. Label-free quantification was enabled with an LFQ minimum ratio count of 2. For 
data analysis protein and peptide identifications and relative quantification outputs from 
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MaxQuant were further processed in Excel, with protein and peptides hits to the ‘reverse 
database’, ‘potential contaminants’ (peptide list only) and ‘Only identified by site’ field 
removed. 
2.7.9 Analysis of in-house FASP samples (ThermoScientific LTQ Orbitrap Velos)  
Following desalting of protein digests by reverse phase C18 solid phase extraction (C18-SPE), 
samples were resolubilised in 0.1% trifluoroacetic acid (20 l) by shaking (30 min, 1200 rpm) 
and sonication (10 min). The solutions were centrifuged (17,000 g, 10 min, 5°C) and 
transferred to LC-MS sample vials. Sample aliquots were injected and separated using an 
Ultimate 3000 RSLC nano liquid chromatography system (Thermo Scientific) coupled to a LTQ 
Orbitrap Velos mass spectrometer (Thermo Scientific) via the EASY-Spray ion source. 
Injected sample volumes were loaded onto a trapping column (Acclaim PepMap 100 C18, 
100 μm × 2 cm) at 8 μL/min in 2 % acetonitrile, 0.1 % TFA. Peptides were eluted on-line to an 
analytical column (EASY-Spray PepMap C18, 75 μm × 50 cm) and separated using a stepped 
90 minute gradient, 4-25 % of buffer B for 60 minutes, 25-65 % buffer B for 30 minutes (buffer 
A: 2 % acetonitrile, 0.1 % FA; buffer B: 80 % acetonitrile, 0.1 % FA). Eluted peptides were 
analysed by the LTQ Orbitrap Velos operating in positive polarity using a data-dependent 
acquisition mode. Ions for fragmentation were determined from an initial MS1 survey scan 
at 15,000 resolution (determined at m/z 200), followed by Ion Trap CID (collision-induced 
dissociation) of the top 10 most abundant ions. MS1 and MS2 scan AGC targets set to 1e6 
and 1e4 for a maximum injection time of 500 ms and 100 ms respectively. A survey scan m/z 
range of 350 – 1600 was used, with a normalised collision energy set to 35 %, charge state 
rejection enabled for singly charged precursor ions and a minimum threshold for triggering 
fragmentation of 500 counts. LC-MS/MS analysis was carried out in technical duplicate runs. 
Data was processed using the MaxQuant software platform (v1.5.8.3), with database 
searches carried out by the in-built Andromeda search engine against the Swissprot Human 
database. A reverse decoy database approach was used at a 1 % false discovery rate (FDR) 
for peptide-spectrum matches and protein identification. Search parameters included: 
maximum number of missed cleavages set to 2, fixed modifications: cysteine 
carbamidomethylation and variable modifications: methionine oxidation, protein N-terminal 
acetylation. Label-free quantification was enabled with an LFQ minimum ratio count of 2. For 
data analysis protein and peptide identifications and relative quantification outputs from 
MaxQuant were further processed in Excel, with protein and peptides hits to the ‘reverse 
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database’, ‘potential contaminants’ (peptide list only) and ‘Only identified by site’ field 
removed. 
2.8 Characterisation of mitochondrial function under inhibition and genetic ablation 
of N-glycanase 
 
This section describes the characterisation of mitochondrial function following the 
characterisation of MTT reduction in both glucose and galactose containing media with 
confirmation of cell viability by measurement of PI exclusion, annexin V staining and cell 
number confirmation. Mitochondrial membrane potential and mitochondrial content and 
mitochondrial glycoprotein analysis was performed after treatment with either Z-VAD-fmk, 
Q-VD-OPh or NGLY1 siRNA transfection.  
2.8.1 Growth curves 
Cells were grown in either high glucose DMEM media or glucose free media supplemented 
with galactose (10 mM) or a glucose:galactose 50:50 mix for 6 d prior to experimentation.  
Cells were then plated at 1000 cells per well in a 48 well plate. Cells were detached using 
trypsin-EDTA solution (100 µl) and diluted with complete media (400 µl). Cell suspensions 
were counted by haemocytometer.  Four individual wells were counted for each cell line at 
each time point.  
2.8.2 Quantification of PI/Annexin V staining 
Cells were grown in either high glucose DMEM media or glucose free media supplemented 
with galactose (10 mM) for 6 d prior to experimentation and plated into 12 well plate. HEK 
cells were treated with either Q-VD-OPh or Z-VAD-fmk (50 µM, 24-72 h) or a vehicle control 
(DMSO). For genetic ablation, HEK cells were transfected with SMARTpool: ON-TARGETplus 
NGLY1 siRNA or an ON-TARGETplus non-targeting control (25 nM, 3-5 d). Menadione (20 µM, 
18 h) was used as a positive control for cell death and apoptosis inducer. Samples were 
trypsinised to detach cells and washed three times in PBS. Cells were incubated with the 
Molecular ProbesTM Dead Cell Apoptosis Kit with Annexin V FITC and PI, for flow cytometry. 
Cells were re-suspended in 1x annexin binding buffer (100 µl). FITC annexin V (5 µl) and 
Propidium iodide (PI) (1 µl, 100 µg/ml) was added for 15 min at RT. Samples were diluted 
with annexin binding buffer (400 µl) and red/green signal was analysed using a TALI image 
based cytometer. The percentage of annexin V positive and PI negative cells were calculated. 
Cell number was also recorded.  
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2.8.3 Assessment of mitochondrial membrane polarisation using TMRE  
To measure mitochondrial depolarisation, HEK cells were plated in 12 well plates and treated 
as described. Cells were trypsinised, washed twice in PBS and incubated for 20 min with 
TMRE (100 nM, 0.5 h). Cells were depolarised using FCCP (20 µM). The cell suspension (25 
µl) was loaded onto TALI cytometer slides and measured using the red filter. The threshold 
was set at unstained HEK 293 cells and the average RFU was plotted. The delta measurement 
was calculated as the difference between untreated and FCCP treated samples.  
2.8.4 Assessment of mitochondrial membrane polarisation by flow cytometry 
using TMRE 
To measure mitochondrial depolarisation HEK cells were plated in 12 well plates and treated 
as described in the data. Cells were trypsinised and washed twice in PBS and incubated with 
TMRE (50 nM, 20 min). Cells were depolarised using FCCP (20 µM). Cells were detached with 
trypsin and washed in HBSS three times by centrifugation. Cells were re-suspended in HBSS 
(500 µl) and analysed using BD FACSCaliburTM on the FL2 channel (ex 488 em 585-642), at 
440 V, 10 000 cells were counted per condition. Median cellular fluorescence was plotted.  
2.8.5 Determination of non-quenching concentrations of TMRE by fluorescence 
imaging 
HEK cells were plated on uncoated 16 mm glass coverslips at (40 000 cells per well). Cells 
were incubated with increasing amounts of TMRE (25-400 nM) in imaging buffer 
supplemented with Gibco MEM Amino Acids Solution and MEM Non-essential Amino Acids 
Solution for 20 min at 37°C. Cells were washed three times in imaging buffer. Coverslips were 
then imaged using a Leica DMI6000 fluorescence microscope on the 20x objective. TMRE 
was mobilised from the mitochondria using FCCP (10 µM) after 180 s. Images were taken 
every 20 s for 12 min. Time lapse videos were analysed using ImageJ. Cytosolic areas of cells 
were selected plus a background region. A minimum of 20 cellular regions were analysed per 
coverslip.  
2.8.6 Assessment of levels of mitophagy by flow cytometry 
HEK cells were treated as indicated, in the presence or absence of Bafilomycin (50 nM, 18 h). 
Cells were trypsinised and washed twice in PBS and loaded with MitotrackerTM Deep Red FM 
(75 µM) for 30 minutes at 37 ⁰C in complete media. The signal from MitotrackerTM Deep Red 
was collected at 440 V using FL3 (ex 635 nm em 670 nm LP). Median fluorescence was 
plotted.  
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2.8.7 Isolation of mitochondria 
Mitochondria were isolated using ThermoScientific Mitochondria Isolation Kit for Cultured 
Cells as per the manufacturer instructions.  Cells were grown as previously described and 
washed in PBS. The cells were scraped and collected by centrifugation at 1000 rpm for 5 min. 
Cells were counted and re-suspended at 20 X 106 in Reagent A (800 µl) and incubated for 2 
min on ice. Reagent B (10 µl) was added and incubated for a further 5 min on ice vortexing 
every minute. Reagent C (800 µl) was added and centrifuged at 700 g for 10 min at 4 ⁰C. The 
supernatant was collected and centrifuged for a further 15 min at 12 000 g at 4 ⁰C. The 
presence of mitochondria in the isolated fraction was determined by immunoblotting as 
described in section 2.5.15. Protein samples were treated as before and incubated with the 
mouse monoclonal Tim23 Antibody (H-8): sc-514463 at 1/200 dilution or mouse monoclonal 
β-actin (C-4): sc-47778 at 1/1000 dilution.  
2.5 Statistical Analysis 
 
Data was tested for normal distribution using the Shapiro-Wilk normality test. For data 
comparing conditions and time a Two-way ANOVA was done followed by Tukey’s or 
Dunnett’s post hoc test as indicated in the figure legend. For samples comparing one 
condition, a One-way ANOVA was performed followed by a Tukey’s or Dunnett’s post hoc. 
For all tests *p<0.05, **p<0.01, ***p<0.001 ****p<0.0001. For shotgun proteomics analysis 
of cell lines, significance was tested using multiple t-tests with Benjamini-Hochberg 
correction.  
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Chapter 3.  
3.1 Introduction 
 
Caspases are a class of important cysteine proteases which are involved in the regulation of 
cell death, cytokine release and inflammation (Shi 2004) and can be broadly classified 
according to function.  Mammalian caspases 3, 6, 7, 8 and 9 have been linked to apoptotic 
pathways whereas caspases 1, 4, 5 and 12 have been linked to inflammation (Jimenez 
Fernandez and Lamkanfi 2015).  The functional roles of caspases 2, 10 and 14 are less well 
defined, and as such, they are more difficult to categorise (McIlwain et al. 2013).  Caspases 
implicated in apoptosis are designated as either initiator caspases (caspases 8 and 9) or 
effector (sometimes-termed executioner) caspases (caspases 3, 6 and 7).  In resting states, 
all caspases exist as inactive zymogens, and are activated by either dimerization or cleavage. 
Initiator caspases are responsible for the initial cleavage (and hence activation) of the 
effector caspases 3, 6 and 7, which once cleaved, can themselves effect cleavage of other 
effector caspases.  In the inactive form, (prior to cleavage) the active site of effector caspases 
(such as caspase 7, shown in figure 3.1) is hidden. Upon cleavage, the enzyme undergoes 
conformational change in the active site which exposes the catalytic groove (Shi 2004).   
Initiator caspases (caspases 2, 8, 9, 10) also undergo cleavage, however, unlike effecter 
caspases this does not lead to increased catalytic activity. Initiator caspases are activated by 
dimerization through interactions with adaptor proteins (Chang and Yang 2000).  
a     b  
 
Figure 3.1 Structure of pro-caspase 7 and caspase 7. a) Inactivated pro-caspase 7 b) close 
up of position of the surface loops at inactivated and activated caspase 7. Reproduced from 
(Shi 2004) under Creative Commons Attribution Licence (CC-BY). 
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Two main apoptotic pathways are recognised in humans, termed intrinsic and extrinsic 
apoptosis respectively (Brentnall et al. 2013, Nair et al. 2014).  These two pathways are 
presented schematically in figure 3.2.   
 
Figure 3.2 Extrinsic and intrinsic apoptosis pathways. 
 
Intrinsic apoptosis can be independently mediated by stress factors (such as cytochrome c) 
released following permeabilisation of the mitochondrial membrane.  Mitochondrial outer 
membrane permeabilisation (MOMP) can be triggered by exposure to intrinsic stress stimuli, 
which can include hypoxic insult and ER stress arising from the accumulation of misfolded 
proteins.  Caspase-9, which exists in the cell in an inactive monomeric form, is activated by 
dimerization (Pop et al. 2006). This dimerization is mediated by the interaction of caspase-9 
CARD pro-domain with the apoptotic protease-activating factor containing 1 (APAF1) 
apoptosome (Bao and Shi 2007, Su et al. 2017).  The activation of caspase 9 in turn activates 
the effector caspases 3, 6 and 7 and results in the induction of apoptosis.   
The extrinsic pathway involves the activation of caspase 8 via ligand-activated death 
receptors on the plasma membrane (TNF family receptors) and the death-inducing signalling 
complex (DISC).  DISC has also been linked to the activation of caspase 10 (Bao and Shi 2007).  
The activation of caspase 8 may result in either the direct induction of apoptosis by the 
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activation of effector caspases, or through the activation of intrinsic apoptosis pathways. 
Intrinsic apoptosis pathways are activated through the interaction of activated caspase-8 
with BID (a BCL-2 family member).  Once cleaved, BID is translocated to the mitochondria 
and activates BAX and BAK. This results in MOMP, the concomitant activation of caspase 9, 
activation of the effector caspases and ultimately apoptosis. 
 
3.1.2 Pharmacological inhibition of caspases  
Carbobenzoxy-valyl-alanyl-aspartyl-(O-methyl)-fluoromethylketone (Z-VAD-fmk1, 1) is a 
poly-caspase inhibitor used extensively as a tool to study apoptosis in cell culture (Cowburn 
et al. 2005, Fransolet et al. 2015, Karl et al. 2014, Niu et al. 2016, Yang et al. 2004). 
 
 
1 
Synthetic caspase inhibitors such as Z-VAD-fmk 1 are competitive inhibitors which act as 
pseudo-substrates and react with the catalytic cysteine residue in the active site (Callus and 
Vaux 2006). They are predominantly based upon partially protected peptidic structures 
bearing non-native functionality and vary in length from single amino acids (such as Boc-D-
fmk 2 and Boc-D-OPh 3) to tetrapeptide structures. The protecting groups serve to improve 
properties such as stability (resistance to proteolytic cleavage) and cell permeability, 
whereas the non-native electrophilic functional groups interact with the nucleophilic 
cysteine residue in the enzyme active site.   
   
                                                          
1 It is noted that in the literature, Z-VAD-fmk is used interchangeably to describe both the cell 
permeable methyl ester form, carbobenzoxy-valyl-alanyl-aspartyl-(O-methyl)-fluoromethylketone 
(CAS: 187389-52-2) and the free acid carbobenzoxy-valyl-alanyl-aspartyl-fluoromethylketone (CAS: 
634911-81-2). Throughout this thesis, Z-VAD-fmk is used to denote the methyl ester form 1 (CAS: 
187389-52-2).   
70 
 
2     3 
Aldehyde functionalised caspase inhibitors, such as Ac-DEVD-CHO 4, tend to exhibit 
reversible inhibition profiles. In contrast, halomethylketones, such as Z-VAD-fmk 1 and Z-
VAE-fmk 6 and the chloromethylketone Ac-YVAD-CMK 5 (along with similar 
diazomethylketone, acyloxymethylketone and phenoxymethylketone bearing structures), 
act as irreversible inhibitors by binding covalently to the active site cysteine residue.   
 
  
4      5 
 
 
6 
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Pharmacological inhibitors of caspases often show activity across multiple protein targets 
within this class.  Table 3.1 shows the inhibition profiles of three structurally distinct peptidyl 
caspase inhibitors, (Z-VAD-fmk 1, Ac-DEVD-CHO 4 and the difluorophenoxy methylketone 
inhibitor, quinolyl-valyl-O-methylaspartyl-[2,6-difluorophenoxy]-methyl ketone, Q-VD-OPh 
7) is commonly employed in cell-based studies. 
 
7 
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Table 3.1 Poly-caspase inhibition data for four commonly used pharmacological caspase 
inhibitors
 Z-VAD-fmk 1 Z-VAE-fmk 6 Ac-DEVD-CHO 4 Q-VD-OPh 7 
Caspase 1 No data found No data found No data found IC50 25-400 nM (in 
vitro) 
(Caserta et al. 2003) 
Caspase 2 IC50 = 200 nM (in 
vitro) 
(Chauvier et al. 
2006) 
No data found No data found IC50 = 80 nM (in 
vitro) 
(Chauvier et al. 
2006) 
Caspase 3 Ki = 18.4 µM (in 
vitro) 
(Zhigang Wang et 
al. 2010) 
Ki = 1200 µM (in 
vitro) 
(Sadhukhan et al. 
2006) 
Ki = 2 nM (in vitro) 
(Garcia-Calvo et 
al. 1998) 
IC50 25-400 nM (in 
vitro) 
(Caserta et al. 2003) 
 
Caspase 7 No data found No data found Ki = 2 nM (in vitro) 
(Garcia-Calvo et 
al. 1998) 
No data found 
Caspase 8 Ki = 0.45 µM (in 
vitro) 
(Zhigang Wang et 
al. 2010) 
Ki = 27.8 µM (in 
vitro) 
(Sadhukhan et al. 
2006) 
No data found IC50 25-400 nM (in 
vitro) 
(Caserta et al. 2003) 
Caspase 9 Ki = 17.1 µM (in 
vitro) 
(Zhigang Wang et 
al. 2010) 
Ki = 14.16 µM (in 
vitro) 
(Sadhukhan et al. 
2006) 
No data found IC50 25-400 nM (in 
vitro) 
(Caserta et al. 2003) 
 
Both the leaving group and the peptide chain can influence the specificity and efficacy of the 
inhibitor. Studies comparing Boc-D-fmk 2 and Boc-D-OPh 3 found lower concentrations of 
Boc-D-OPh 3 were needed to inhibit caspases 2, 3, 7, 8, 9 and 10 compared to Boc-D-fmk 2 
(Chauvier et al. 2006). Q-VD-OPh 7, which bears a hydrophobic quinoline substituent 
(Chauvier et al. 2006), is a more potent inhibitor of caspase 2 than Boc-D-OPh 3 both in vitro 
and in vivo with Boc-D-fmk 2 showing nearly double the inhibitory effect of Q-VD-OPh 7 for 
caspases 2, 7, 8 at 25 µM in vitro (Chauvier et al. 2006). In cellular models treated with 100 
µM caspase inhibitors, Q-VD-OPh 7 abolished caspase 3, 7 and 9 activity by greater than 90 
%, whereas Boc-D-OPh reduced caspase 3 and 9 activity by around 80 % (Chauvier et al. 
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2006). Some selected examples of pharmacological inhibitors of caspases and their targets 
are shown in figure 3.3.  
 
Figure 3.3 Selected examples of points of action of pharmacological caspase inhibitors
 
3.1.3 Other targets of pharmacological caspase inhibitors  
Although pharmacological inhibition is a useful tool to probe cellular processes, many 
inhibitors exhibit a spectrum of effects that may or may not be related to the primary 
mechanism or target of inhibition.  For example, in addition to the inhibition of caspase 
proteases, Z-VAD-fmk 1 has also been shown to inhibit a number of other non-caspase 
cysteine proteases, including cathepsin B, H and L (Schotte et al. 1999, Chauvier et al. 2006), 
and picornaviral 2A proteinases (Deszcz et al. 2004).  
Q-VD-OPh 7 has also been shown to act as an inhibitor of cathepsin H, albeit to a lesser extent 
then Z-VAD-fmk 1 (at 1 µM Z-VAD-fmk abolishes almost 75 % of cathepsin H activity whereas 
Q-VD-OPh 7 only decreases cathepsin H activity by 50 %) (Chauvier et al. 2006).  Both the 
nature of the functionalisation and the peptide backbone have been linked to differing 
inhibitory profiles or effectiveness. Boc-D-fmk 3 (100 µM)  has been shown to be a less potent 
inhibitor of cathepsin B than Z-VAD-fmk 1; the former resulting in < 10 % reduced activity, 
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whereas treatment with Z-VAD-fmk 1 (100 µM) resulted in a > 80 % reduction in activity. 
Table 3.2 details examples of studies where treatment of cells with Z-VAD-fmk 1 has resulted 
in the observation of effects not expected with inhibition of caspases and apoptosis. 
Table 3.2 Effects of Z-VAD-fmk in different cell lines other than caspase inhibition and 
inhibition of apoptosis
Cell line Treatment Observation 
Mouse macrophage 
J774A.1 
 
Z-VAD-fmk 
(100 µM, 8 h) 
Induction of autophagy and necrotic cell 
death. Increase of TNFα secretion. 
(Martinet et al. 2006a).  
L929 mouse 
fibrosarcoma 
Z-VAD-fmk 
(10 µM, 24 h) 
Necroptosis mediated by increased 
TNFα production (Wu et al. 2011). 
Photoreceptors of 
Male Sprague-
Dawley rats 
Z-VAD-fmk (300 µM) 
with 
Necrostatin-1 (400 µM) 
72 h 
In vivo activation of autophagy and 
subsequent necrosis (Dong et al. 2013) 
3T9 MEF  
 
Z-VAD-fmk (50 µM) with 
Etoposide (85 µM) 
12 h 
Increase in number of cells with 
mitochondrial membrane 
depolarisation. 
Increase of ROS and cytochrome c 
release (Rodríguez-Enfedaque et al. 
2012) 
Neutrophils 
(primary human) 
Z-VAD-fmk (>100µM, 
0.5 h) 
Increase of TNFα induced cell death  
(Cowburn et al. 2005). 
Neutrophils 
(primary human) 
Z-VAD-fmk 
(1-30µM, 0.5 h) 
Inhibition of TNFα induced ROS 
production 
Blockage of TNFα induced apoptosis 
(Cowburn et al. 2005). 
B16-F10 melanoma 
 
Z-VAD-fmk (50 µM, 72 
h) 
In vitro induction of necrosis 
(Werthmoller et al. 2015). 
C57/BL6 mice Z-VAD-fmk (2mg/kg, 72 
h) 
In vivo decrease of tumour growth and 
reduction of infiltration (Werthmoller et 
al. 2015). 
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Porcine Renal 
tubular epithelial 
cells (LLC-PK1) 
Z-VAD-fmk (20 µM) with 
cisplatin (50 µM) 
0-30 h 
Blockage of autophagic flux 
Decrease of cell viability  
Inhibition of calpain and cathepsin 
activity (Herzog et al. 2012).  
MEF Z-VAD-fmk (20 µM) 
mouse recombinant 
TNF (30 ng/mL) and 
cyclohexamide (10 
µg/mL) 24 h 
Observation of necrosis in vitro 
Increase of ROS production 
(Lin et al. 2004) 
L929 Z-VAD-fmk (10 µM) or 
ALLM (calpain inhibitor) 
(10 µM) with 
oridonin (50 µM) 
24 h 
In vitro treatment failed to rescue 
oridonin damage.  
(Cheng et al. 2008) 
L929 Z-VAD-fmk (20 µM) 
5-10 h 
Autophagic cell death observed in vitro 
(Chen et al. 2011) 
   
Several studies have shown that Z-VAD-fmk exerts toxic effects and, that treatment with the 
inhibitor results in necrosis in vitro (Werthmoller et al. 2015, Dong et al. 2013, Wu et al. 2011, 
Martinet et al. 2006b). These studies have also shown necrosis is often accompanied by 
autophagic features, indicating possible autophagy mediated cell death (Martinet et al. 
2006a, Dong et al. 2013). Treatment of the macrophage cell lines, J774A.1 and RAW264.7 
with Z-VAD-fmk resulted in increased autophagy markers followed by activation of caspase 
8 and necrosis (Lin et al. 2004). Increased secretion of TNFα in macrophages following Z-VAD-
fmk treatment has also been observed, which could result in increased cell death in these 
cell lines through an increase in ROS production (Kim et al. 2010). However, another study 
looking to clarify the effect of TNFα mediated necrosis following treatment with Z-VAD-fmk 
found no increase in cellular ROS (Cowburn et al. 2005). In this study, necrosis was only 
observed following treatment with high concentrations of Z-VAD-fmk (> 100 µM). Lower 
concentrations (1-30 µM)  resulted in the inhibition of TNFα induced cell death (Cowburn et 
al. 2005).  
The effects of Z-VAD-fmk treatment on L929 murine fibrosarcoma cells also include changes 
in the levels of markers linked to autophagy (Chen et al. 2011). Upon treatment with Z-VAD-
fmk increased levels of the autophagy marker LC3 II and induction of necrosis was found 
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(Chen et al. 2011). Autophagic flux was determined to be intact and knockdown of BECLIN-1 
and ATG5, important factors involved in the function of autophagy, rescued the cell death 
phenotype.  These results suggest that autophagy activation was implicit in cell death (Chen 
et al. 2011).  
Contradictory evidence has been presented in other studies. A 2008 study (Wu et al. 2008b) 
demonstrated that Z-VAD-fmk treatment resulted in the induction of necrosis, whereas 
treatment with the autophagy inducer rapamycin or serum starvation blocked cell death. 
Treatment with chloroquine, an autophagy inhibitor, increased the sensitivity of L929 cells 
to Z-VAD-fmk induced necrosis. Cell death was determined to result from the inhibition of 
lysosomal cathepsin B which blocked autophagic flux by inhibiting maturation of 
autolysosomes. Using a GFP-mRFP-LC3 tandem reporter construct as a tool, a block in 
lysosomal maturation was reported following treatment with Z-VAD-fmk (Herzog et al. 
2012). This study also reported reduced cathepsin activity of RTEC cells treated with Z-VAD-
fmk (10 µM, 12 h), whereas (Chen et al. 2011) found no inhibition of cathepsin B or calpain 
following treatment of Z-VAD-fmk (20 µM, 6-12 h) in L929 cells. 
It may be hypothesised that, if Z-VAD-fmk toxicity is due to cathepsin inhibition, then similar 
results should be observed with cathepsin inhibitors. However, (Wu et al. 2008a) showed 
that treatment with cathepsin inhibitors either alone or, in combination with other caspase 
inhibitors, Z-IETD-CHO (an inhibitor of caspase 8) or Z-DEVD-CHO (an inhibitor of caspase 3) 
did not reduce cell viability.  These results suggest that other factors other than caspase 
inhibition and cathepsin inhibition lead to necrosis in these cell types.  
In combination, these studies indicate that a number of different effects are observed with 
Z-VAD-fmk, both when employed alone and in conjunction with other cell stressors. These 
effects appear to show some dependency upon treatment regimens and cell type. In this 
study, the effects of Z-VAD-fmk will be compared with pan-caspase inhibitor Q-VD-OPh to 
gain insight into the effects of Z-VAD-fmk in cells.  
3.1.4 Pharmacological inhibition of N-glycanase 
In 2004, Z-VAD-fmk was identified as an inhibitor of yeast N-glycanase (Misaghi et al. 2004) 
following a high-throughput screen of over 100 000 compounds. This study employed a 
fluorescence based screening platform based upon the commonly used RNAse B 
deglycosylation assay used to assess the activity of glycosidases capable of cleaving 
mammalian N-glycans. In the standard assay, bovine pancreatic RNAseB (a globular 
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glycoprotein of ~15 KDa containing a single N-linked glycosylation site at Asn34) (Prien et al. 
2009) is incubated with N-glycanase, which results in the cleavage of the carbohydrate 
moiety.  The extent of deglycosylation can be quantified by SDS-Page, the molecular mass of 
the deglycosylated protein being less than its glycosylated counterpart. 
Figure 3.4 shows the modified assay, which utilises FITC-labelled RNAse B as a substrate for 
yeast N-glycanase. Under conditions of inhibition of N-glycanase, RNase B remains 
glycosylated. Glycosylated structures are detected by the binding of Concanavalin A (ConA), 
a lectin originally extracted from the jack-bean, Canavalia ensiformis which exhibits binding 
towards glucosyl and mannosyl residues. Binding of ConA to fluorescein labelled RNAse B 
increases fluorescence polarisation, allowing detection of inhibited yeast N-glycanase.  
 
Figure 3.4 Schematic diagram of the fluorescence polarisation assay of N-glycanase 
function. Reprinted from (Misaghi et al. 2004), p1677, with permission from Elsevier.
 
After initial identification of Z-VAD-fmk as an inhibitor of yeast N-glycanase, further studies 
were set out to confirm this. MALDI-MS analysis of yeast N-glycanase (yPng1) treated with 
Z-VAD-fmk (and subsequently dialysed to remove excess Z-VAD-fmk) resulted in the 
detection of an intact mass of 43 613 Da. This indicates 1:1 binding stoichiometry when 
compared with the native protein mass of (43 208 Da), and demonstrates irreversible binding 
as the inhibitor was not removed after dialysis. Yeast N-glycanase treated with Z-VAD-fmk 
proved unable deglycosylate RNAse B (Misaghi et al. 2004).  Further studies using yPng1 
bearing a C191A mutation of the active site cysteine demonstrated that no mass increase by 
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MALDI-MS was observed and therefore the active site cysteine, C191 residue is critical to 
inhibitor binding. 
As with cysteine proteases (such as caspases), Z-VAD-fmk interacts with the cysteine residue 
to form a stable thioether bond. The binding mechanism proposed by Misaghi et al. (2004) 
is shown in figure 3.5.  Upon binding of the aspartyl side chain, the enzyme undergoes 
conformational changes resulting in the aspartic acid, histidine and cysteine residues of the 
active site catalytic triad being drawn closer together, and the deprotonation of the cysteine 
thiol. Rotation of the inhibitor at the aspartyl chain brings the electrophilic carbon atom in 
close proximity to activate the cysteine.  Nucleophilic attack of the cysteine results in the 
formation of a carbon-cysteine thioether bond.  
 
 
Figure 3.5 Proposed mechanism of Z-VAD-fmk binding to yeast PNGase. Reprinted from 
(Misaghi et al. 2004), p1677, Copyright (2004), with permission from Elsevier.
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Few inhibitors of N-glycanase have been identified and characterised. Known inhibitors can 
be divided into two distinct structural classes. Peptidyl inhibitors include Z-VAD-fmk, 1 and 
the peptide vinyl sulfone WRR139 8 (IC50 = 5.5 µM) (Tomlin et al. 2017).  WRR139 was initially 
identified from a screen of peptide-based thiol reactive electrophiles using a deglycosylation-
dependent VENUS (ddVENUS) fluorescence assay as a reporter (Grotzke et al. 2013, Tomlin 
et al. 2017). Other peptide vinyl sulfones examined in this study demonstrated no inhibitory 
activity towards N-glycanase.  
 
8 
The other distinct structural class of inhibitors are those based on the N,N’ diacetylchitobiose 
core (Witte et al. 2009). N,N’ diacetylchitobiose based inhibitors (such as those based on 
structures 9 and 10) mimic the natural N-glycan substrates of N-glycanase, the point of 
enzymatic cleavage is shown in figure 3.6.  
 
   
9      10 
 
 
Figure 3.6 N-glycanase cleavage of protein bound N-glycans 
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Table 3.3 shows examples of synthetically produced N-glycanase inhibitors based on the N,N’ 
diacetylchitobiose core (containing N,N’ diacetylchitobiose and leaving group) and the 
corresponding IC50 values for the in vitro inhibition of yeast N-glycanase. 
Table 3.3 IC50 for inhibitors of yeast N-glycanase based on chitobiose structures 8 and 9 
(determined in vitro using an RNase B deglycosylation assay) adapted from (Witte et al. 
2009)
R Inhibitor 8 Inhibitor 9 
 
IC50 (µM) = 563 ± 50  IC50 (µM) = > 1000 
 
IC50 (µM) = 1.6 ± 0.5 IC50 (µM) = 0.74 ± 0.1 
 
IC50 (µM) = > 1000 IC50 (µM) = > 1000 
 
IC50 (µM) = > 1000 IC50 (µM) = > 1000 
 
IC50 (µM) = 1.2 ± 0.1 Not determined 
 
Whereas N,N’ diacetylchitobiose based inhibitors are thought to bind to the carbohydrate 
binding site of N-glycanase (Figure 3.7), Z-VAD-fmk associates with the peptide binding site 
(Witte et al. 2009).  
 
Figure 3.7 Crystal structure of yeast N-glycanase in complex with N-GlcNAc  (generated 
from PDB ID: 3ESW (Zhao et al. 2009) using JsMol) 
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Unlike N,N’ diacetylchitobiose based inhibitors,  Z-VAD-fmk is not structurally similar to the 
natural N-glycan substrates and is therefore not an immediately intuitive inhibitor of N-
glycanase. However, the natural N-glycan substrates are bound to asparagine residues and 
once cleaved, leave an aspartic acid (as shown in Figure 3.8). The aspartyl side chain of Z-
VAD-fmk and the presence of a peptide chain therefore may be sufficient for N-glycanase to 
recognise the inhibitor.   
 
 
Figure 3.8 Products of the N-glycanase cleavage of protein bound N-glycans 
 
The selectivity of inhibitors such as Z-VAD-fmk 1 and WRR139 2 for N-glycanase may be 
attributed to the structure of the peptidyl portion of the molecule. Similar peptidyl inhibitors 
of caspases such as Q-VD-OPh 6 do not demonstrate activity against N-glycanase (Tomlin et 
al. 2017). As previously shown in Table 3.1 Q-VD-OPh has a similar caspase inhibition profile 
as Z-VAD-fmk (Chauvier et al. 2006), yet does not inhibit N-glycanase. Previously reported 
IC50 of N-glycanase for yeast and human N-glycanase under different experimental 
conditions are shown in Table 3.4.   
Table 3.4 IC50 values of Z-VAD-fmk under different experimental conditions 
Condition IC50 
Yeast N-glycanase (in vitro) (Misaghi et al. 2004) IC50 = 50 µM  
Human N-glycanase in US2 expressing U373 astrocytoma cells (Misaghi et 
al. 2004) 
IC50 = 7 µM  
 
Human N-glycanase in K562 (human immortalised myelogenous 
leukaemia RRID:CVCL_0004) (Tomlin et al. 2017) 
IC50 = 4.4 µM  
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An IC50 of 50 µM was reported for yeast N-glycanase in vitro (Misaghi et al. 2004).  The IC50 
value for human N-glycanase was determined in US2 expressing U373 astrocytoma cells 
using pulse chase in the presence of the proteasome inhibitor ZL3VS (100 µM). In the absence 
of Z-VAD-fmk, all Major Histocompatibility Complex (MHC) heavy chains (HCs) were 
deglycosylated within 0.5 h, whereas complete inhibition of deglycosylation was observed at 
30 µM of Z-VAD-fmk. It is noted that in this study, inhibition of deglycosylation did not 
impede proteasome degradation of class I HCs (Misaghi et al. 2004). In a study carried out by 
(Tomlin et al. 2017), the IC50 values of Z-VAD-fmk and WRR139 were established in K562 
(human immortalised myelogenous leukaemia) cells. IC50 values were determined for Z-VAD-
fmk and WRR139 (4.4 µM and 5.5 µM respectively) using the ddVENUS assay with detection 
of the fluorescence signal by FACS (Tomlin et al. 2017).  In this study, cells were treated with 
Z-VAD-fmk (24 h) followed by MG132 (6 h, 5 µM). 
3.2 Aims and objectives 
 
This aim of this chapter is to characterise the cellular effects of Z-VAD-fmk.  As N-glycanase 
deficiency can be regarded as a disorder of ERAD, much of this chapter will examine effects 
linked to protein degradation; including the accumulation of misfolded proteins (which often 
arise from dysfunction in proteostasis) and potential stress responses (such as ER stress and 
oxidative stress responses). Furthermore, since Z-VAD-fmk has been linked to the induction 
of autophagy, the effect of Z-VAD-fmk on autophagic induction and autophagic flux will be 
investigated in an attempt to elucidate whether this is linked to caspase inhibition or to the 
inhibition of N-glycanase.  
Throughout this chapter, Q-VD-OPh has been employed as a control for caspase inhibition 
due to the similarities in the caspase inhibition profile observed with these two 
pharmacological inhibitors. 
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3.3 Results 
 
In this section, the effects of Z-VAD-fmk on HEK cells are characterised and the results 
summarised below.  Firstly, the effects on cell viability were established using an MTT 
cytotoxicity assay. The effects of Z-VAD-fmk on HEK cells was further characterised by 
examination of the inhibition profile of N-glycanase using a deglycosylation dependent 
fluorescence assay. Due to the role of N-glycanase in glycan processing and quality 
control, the glycan profile following Z-VAD-fmk treatment has been examined using 
lectin dot blots to quantify specific glycan moieties.  
It has also been proposed that a deficiency in N-glycanase can result in the accumulation 
of GlcNAc-positive protein aggregates. However, no conclusive evidence has been 
presented which indicates the presence of aggregates in cell culture models. In this 
study, cells were examined for evidence of protein aggregation using Thioflavin T. As 
protein aggregates also have a role in ER stress and the activation of the unfolded 
protein response (UPR), and Z-VAD-fmk has been shown to act as an inhibitor of N-
glycanase. Genes upregulated during the UPR were examined under Z-VAD-fmk 
inhibition. ER calcium levels have also been noted in ER stress responses, as stress can 
lead to increased ‘leakiness’ in ER calcium channels. ER calcium was quantified using 
Fura-2 following the inhibition of SERCA channels by Thapsigargin. As protein 
aggregation has also been linked to increased oxidative stress, oxidative stress was 
measured by flow cytometry fluorescence intensity of ROS Brite 57. The activation of 
autophagy has been also linked to proteasome function, and increased autophagy has 
been observed in various cell lines following Z-VAD-fmk treatment. To study the effect 
of Z-VAD-fmk on autophagy, GFP-LC3 HEK293 cells were treated with Z-VAD-fmk.  In 
order to determine if any changes in the level of autophagy could be attributed to 
caspase inhibition or the inhibition of other cellular targets, cells were also treated with 
Q-VD-OPh as a comparison. Finally, a bacterial N-glycanase (Z-VAD-fmk insensitive) was 
cloned into a mammalian expression vector, in an attempt to rescue any effects of Z -
VAD-fmk which could perhaps be attributed to N-glycanase inhibition.  
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3.3.1 No effects on cell viability are observed when cells are treated with < 100 µM Z-
VAD-fmk 
To confirm that Z-VAD-fmk treatment was not inducing any cytotoxic effects, HEK cells were 
treated with 1-200 µM Z-VAD-fmk at 24, 48 and 72 h. Cell viability was assessed using the 
MTT (3-(4,5-dimethylthiozol-2-yl)-2-5 diphenyltetrazolium bromide) based assay, shown in 
Figure 3.9. No cytotoxic effects were observed for Z-VAD-fmk at concentrations ≤ 100 µM, 
although there was a decrease in viability above 200 µM at 48 h (Figure 3.9b) and 72 h (Figure 
3.9c) at 63.5 % and 73.5% respectively (compared to 129 % and 109 % with Q-VD-OPh at 200 
µM). 
 
 
 
 
 
 
 
 
 
 
 
 
85 
 
 
1 0 -1 1 0 0 1 0 1 1 0 2 1 0 3
0
5 0
1 0 0
1 5 0
2 0 0
lo g  c o n c e n tra tio n  ( M )
a
b
s
o
rb
a
n
c
e
z -V A D -fm k
Q -V D -O P h
* *
*
*
 
1 0 -1 1 0 0 1 0 1 1 0 2 1 0 3
0
5 0
1 0 0
1 5 0
2 0 0
lo g  c o n c e n tra tio n  ( M )
a
b
s
o
rb
a
n
c
e
z -V A D -fm k
Q -V D -O P h
*
 
 
Figure 3.9 MTT assay of HEK 293 cells were treated with Z-VAD-fmk or Q-VD-OPh for a) 24 
h b) 48 h c) 72 h.  Data was normalised to the vehicle. One-way ANOVA, followed by a 
Dunnett’s post hoc test against the vehicle. n=3, P < 0.05, error bars ± SEM.
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3.3.2 Z-VAD-fmk treatment shows decreased fluorescence of the deglycosylation 
dependent VENUS  
A deglycosylation dependent VENUS (ddVENUS) fluorescence assay was employed to 
quantify the effects of Z-VAD-fmk on N-glycanase function. This assay was originally 
developed by Grotzke et al. (2013) as a tool to probe ERAD function (Grotzke et al. 2013).  
Following publication, the assay was employed to detect deglycosylation activity of N-
glycanase (Tomlin et al. 2017, He et al. 2015).  In these studies, cells were transfected with 
the ddVENUS plasmid which encodes a modified VENUS protein bearing a single N-
glycosylation consensus site and an ER targeting sequence which acts as a substrate for 
ERAD.  The protein is co-translationally modified on translocation into the ER, and the 
glycosylated form exported into the cytosol.  Following retro-translocation into the cytosol, 
the glycan is cleaved by N-glycanase which results in the release of a free glycan and the 
fluorescence form of the VENUS protein. When glycosylated, the protein exhibits little basal 
fluorescence. The VENUS fluorescence also requires co-treatment of a proteasome inhibitor 
to prevent degradation by the proteasome. The principle of the assay is shown schematically 
in Figure 3.10.    
 
Figure 3.10 Schematic representation of the ddVENUS assay. The ddVENUS construct is 
transfected into cells. Upon protein synthesis, the N-linked glycosylation site is 
glycosylated. The glycoprotein is translocated to the cytoplasm where it (upon 
deglycosylation) gives a fluorescent signal. 
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The ddVENUS fluorescence assay describe above (Grotzke et al. 2013, He et al. 2015, Tomlin 
et al. 2017) has been used in the literature to confirm Z-VAD-fmk as an inhibitor of N-
glycanase activity and, confirm activity in patient fibroblasts. In these studies, patient 
fibroblasts were transfected with the ddVENUS construct and treated with MG132 (6 h). 
Positively transfected cells were gated and the number of positive cells were calculated and 
compared to a Venus construct fluorescence. Patients with N-GLY1 with no detectable levels 
of N-glycanase protein (as determined by immunoblotting) exhibited between 40-80 % 
reduction in median fluorescence of ddVENUS (He et al. 2015).  
In this study, HEK cells were transfected with the ddVENUS construct and after 24 h were 
treated with Z-VAD-fmk (1-300 µM, 24 h) followed by MG132 (8 µM, 5 h) to prevent 
degradation of the VENUS fluorescent signal. Cells were gated as shown in Figure 3.11a. Cells 
were then sorted against the FL1 filter. Un-transfected cells were gated out of the analysis 
(Figure 3.11b) and the median fluorescence of samples were calculated for Gate R2. The 
fluorescent intensity was plotted for the transfected cells. Figure 3.11c shows the 
fluorescence of the vehicle control and Figure 3.11d shows samples treated with Z-VAD-fmk 
(200 µM, 24 h). The histogram presented in Figure 3.11e shows the shift to the left upon 
treatment with Z-VAD-fmk (200 µM, 24 h) (pink) compared to the vehicle control (green).  
C 
D 
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Figure 3.11 Representative dot plots of the ddVENUS deglycosylation assay a) whole cell 
sample showing position of cell gating against forward and side scatter b) Un-transfected 
cells in gate R1 against side scatter and FL1 filter  c) Vehicle control HEK cells transfected 
with the ddVENUS construct and treated with MG132 for 6 h d) treated with 200 µM Z-
VAD-fmk for 24 h and MG132 for 6 h. e) representative histogram of ddVENUS fluorescence 
of the vehicle control (green) and Z-VAD-fmk (200 µM, pink). 
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To calculate the range of Z-VAD-fmk inhibition of deglycosylation, ddVENUS was transfected 
in HEK cells and treated with Z-VAD-fmk (1-300 µM, 24 h). The median fluorescence was 
calculated and normalised to the vehicle control (Figure 3.12). The IC50 was calculated at 
68.72 µM.  
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Figure 3.12 ddVENUS assay for Z-VAD-fmk. HEK cells were transfected with ddEVNUS 
construct and treated with 1-300 µM Z-VAD-fmk for 24 h followed by 8 µM MG132 for 6 h. 
The median ddVENUS fluorescence was calculated. Error bars ± SEM, n=3, R square = 0.908, 
IC50 68.72. 
To confirm that Q-VD-OPh did not affect the deglycosylation of ddVENUS, transfected HEK 
cells were treated with either Q-VD-OPh or Z-VAD-fmk (50 µM, 24 h). The median 
fluorescence intensity was calculated and normalised to the vehicle control. Treatment with 
Z-VAD-fmk exhibited a decrease in 72 % of the fluorescence of the control whereas Q-VD-
OPh showed a non-significant 12 % average increase (Figure 3.13).  
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Figure 3.13 Comparison of Q-VD-OPh and Z-VAD-fmk deglycosyation dependent assay. HEK 
cells were transfected with the ddVENUS construct and treated with 50 µM Z-VAD-fmk or 
Q-VD-OPh for 24 h, and 8 µM MG132 for 6 h. The median ddVENUS fluorescence was 
calculated and normalised to the vehicle. One-way ANOVA followed by Tukey’s post hoc. 
Error bars ± SEM, n=3, P < 0.05. Q-VD-OPh = 112 %, Z-VAD-fmk = 28 %.
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3.3.3 Glycan profile of cells is not affected following treatment with Z-VAD-fmk  
Due to the role of N-glycanase in glycan processing, the potential for changes in cellular 
glycan profile were examined. This was investigated using fluorescein labelled lectin dot 
blots. Lectins are proteins which exhibit specific binding to different carbohydrates. To 
investigate the global glycan profile of treated cells the following lectins were used: lens 
culinaris agglutinin (LCA), concanavalin A (ConA), phaseolus vulgaris erythroagglutinin (PHA-
E), succinylated wheat germ agglutinin (sWGA) and wheat germ agglutinin (WGA). ConA and 
LCA have a broad specificity to high mannose glycans, whereas LCA specifically recognises α-
linked mannose. ConA also recognises α-linked mannose residues and was used as a control 
for LCA staining. PHA-E recognises complex glycan structures and galactose. WGA and sWGA 
both have a specificity for terminal N-GlcNAc residues. WGA has also been shown to bind 
terminal sialic acid residues, whereas sWGA binds solely to terminal N-GlcNAc without 
interacting with sialic acids. In order to first establish the linear range of the assay, whole 
cells were lysed using 1 % triton in PBS and cleared by centrifugation. The resultant protein 
solution was spotted onto nitrocellulose membrane at 0.25, 0.5, 1 and 2 µg (total protein 
concentration, as established by Bradford assay). Membranes were incubated with 2 µg/mL 
of each FITC-labelled lectin at 4 °C overnight. The fluorescence intensity of the bound lectin 
was quantified using Syngene GeneTools software. The blots were then stained with amido 
black to establish the total protein levels and the extent of staining quantified using Syngene 
GeneTools. Figure 3.14 shows the fluorescence signal intensity against protein concentration 
for each lectin. 
  
92 
 
 
 
 
 
Figure 3.14 Linear range of lectin fluroescence. Lectin fluorescence intensity presented 
against protein concentration and protein concentration measured by amido black 
staining. a) Protein stained by amido black and measured by absorabnce. b) FITC-LCA 
labelling, c) FITC-sWGA labelling, d) FITC-ConA labelling e) FITC-PHA-E labelling, f) FITC-
WGA labelling.  Error bars ± SEM, n=3. 
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All lectin fluorescence intensities were calculated as within the linear range of the assay at 1 
µg total protein concentration, with the exception of LCA (which was calculated at 0.5 µg). 
Following the establishment of suitable protein concentrations within the linear range of the 
assay, cells treated with Z-VAD-fmk and Q-VD-OPh (50 µM, 24 - 72 h) were examined, and 
the results presented in Figure 3.15 (a-e). No significant difference was observed in the lectin 
binding profiles for ConA, PHA-E, LCA, sWGA and WGA upon treatment with either inhibitor. 
These results are in accordance with previous studies which have examined the binding of 
sWGA and ConA to proteins from N-glycanase KO MEF cells (Huang et al. 2015, Fujihira et al. 
2017), which also demonstrated no observable difference with these two lectins (Huang et 
al. 2015). 
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Figure 3.15 FITC-lectin staining of whole cell lysate treated with Z-VAD-fmk or Q-VD-OPh 
(50 µM, 24-72 h). Log2 fold change of a) FITC-ConA b) FITC-LCA c) FITC-PHAE d) FITC-WGA 
e) FITC-sWGA fluorescence normalised to untreated control.  Total protein concentration 
(1 ug except LCA which is 0.5 µg). Error bars ± SEM, n=3, Two way ANOVA.
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3.3.4 Thioflavin T fluorescence is transiently increases after Z-VAD-fmk treatment 
Thioflavin T (ThT, 11) is a fluorescent benzothiazole which has been shown to exhibit 
preferential binding to β-sheet motifs.  It is commonly employed as a tool in the study of 
neurodegenerative diseases (such as Alzheimer’s disease) where it has been used to visualise 
protein aggregates including amyloid plaques (Beriault and Werstuck 2013, Biancalana and 
Koide 2010, Lindberg et al. 2015, Veloso and Kerman 2013).  
 
 
11 
It has been proposed that misfolded proteins have a higher level of exposed β-sheets than 
correctly folded proteins and, that this may increase the aggregation through hydrophobic 
interactions. β-sheets are highly hydrophobic and readily bind to other exposed β-sheets 
(Nault et al. 2013).  The intensity of ThT fluorescence can provide a relative measure of their 
abundance. 
Analysis of ThT fluorescence can be problematic. It is well documented that protein 
aggregates have been associated with ER stress (Ogen-Shtern et al. 2016, Genereux and 
Wiseman 2015, Hyrskyluoto et al. 2014, Lawless and Greene 2012).  Studies have found a 
positive correlation between ThT fluorescence intensity and ER stress markers (Teixeira et 
al. 2006) such as GRP78 and GADD153 following treatment with the known ER stress inducer 
Thapsigargin (Beriault and Werstuck 2013). The authors of this study concluded ThT can be 
used as a real-time measure of ER stress. Under Thapsigargin induced stress, ThT 
fluorescence was also found to be localised to ER targeting anti-KDEL sequences (Ming Yuan 
Li et al. 2015) indicating fluorescence localisation to misfolded proteins in the ER (Beriault 
and Werstuck 2013).  
In cellular models, it has been suggested that deficiency in N-glycanase results in other glycan 
processing enzymes acting upon the N-linked glycans still present upon misfolded proteins 
during ERAD. Suzuki et al. (2015) identified cytosolic endo-β-N-acetylglucosaminidase 
(ENGase) (EC:3.2.1.96) as a glycosyl hydrolase acting in the absence of N-glycanase activity. 
This study used an ERAD glycoprotein substrate, ricin A nontoxic mutant (RTAΔm), which 
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contains an ER targeting and retention KDEL seqeunce.  Following expression of RTAΔm in 
WT, ENGase KO, NGLY1 KO, or double knockout MEF cells the ratio of 
deglycosylated/glycosylated RTAΔm found 10 % of the protein was deglycosylated in the 
double knockout. Whereas N-glycanase deficient cells had increased, around 35 % 
deglycosylatd form. ENGase deficient cells had 29 % deglycosylated RTAΔm. Indicating other 
enzymes are able to deglycosylate proteins.  Furthmore, cells expressing ENGase found 
increased RIPA insoluble fractions compared to the double knockout in which the 
deglycosylated form of rtaΔm was stabilised supporting the role of protein aggregates in N-
glycanase deficient cells (Huang et al. 2015).  
In this study, ThT fluorescence was used to quantify endogenous levels of protein aggregates 
under N-glycanase inhibition and was quantified using a combination of fluorescence 
imaging and flow cytometry. HEK cells were treated with Z-VAD-fmk or Q-VD-OPh (50 µM, 
24-72 h) and stained with ThT (1 µM, 0.5 h). ThT fluorescence increased after 48 hours of 50 
µM Z-VAD-fmk treatment, and then decreased back to near control levels after 72 h (Figure 
3.16a). Figure 3.16b shows representative images of ThT that did not present distinct 
aggregated structures and showed fluorescence profiles localised to the perinuclear space. 
This suggests that no large aggregates are formed following pharmacological inhibition of N-
glycanase, but these patterns could be a result of a build-up of misfolded proteins or a 
slowing in ER translocation upon N-glycanase inhibition; ThT has been shown to co-localise 
with KDEL sequences in the ER (Beriault and Werstuck 2013). This is in accordance with other 
studies which have examined N-glycanase deficiency which have not reported evidence of 
distinct protein aggregates in cell culture models (Fujihira et al. 2017, Huang et al. 2015) or 
in histological slices acquired from N-glycanase KO mice visualised with Congo red or periodic 
acid stain (PAS) (Fujihira et al. 2017).  
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Figure 3.16 Z-VAD-fmk caused a transient increase in ThT fluroescence. HEK cells treated 
with Z-VAD-fmk (50 µM, 24-72 h) showed transient increase in fluorescence (48 h) with no 
change in vehicle or Q-VD-OPh (50 µM, 24-72 h). Cells were stained with ThT (1 µM, 0.5 h), 
washed twice with imaging buffer. a) Fluorescence intensity per cell was calculated and 
normalised to an untreated control. A minimum of three images were taken per coverslip 
and three biological replicates were analysed for each condition.  Error bars ± SEM, n=3, P 
< 0.05. Two way ANOVA, Tukey’s post hoc b) Representative images of HEK cells stained 
with ThT (1 µM). Scale bar indicates 8 µm. 
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ThT fluorescence intensity was also quantified using flow cytometry (Figure 3.17). HEK cells 
were treated with either Z-VAD-fmk or Q-VD-OPh along with the proteasome inhibitor 
MG132, a known inducer of protein aggregates (Kim et al. 2011, Cheng et al. 2013, Velentzas 
et al. 2013). A significant increase in ThT fluorescence in cells treated with MG132 compared 
with all other treatments except Z-VAD-fmk at 48 h was observed. The cells treated with Z-
VAD-fmk at 48 h exhibited significantly higher levels of fluorescence than those treated with 
Z-VAD-fmk at 72 h and Q-VD-OPh at 48 h and 72. Figure 3.17b shows a representative 
histogram of the data collected by flow cytometry. 
 
 
Figure 3.17 Z-VAD-fmk caused a transient increase in ThT fluroescence as measured by flow 
cytometry. a) Flow Cytometric analysis of HEK cells visualised with ThT after treatment 
with Z-VAD-fmk or Q-VD-OPh (50 µM, 24-72 h) or MG132 (100 nM). 10 000 cells were 
calculated per condition (three biological replicates). Two-way ANOVA, Tukey’s post hoc. 
Error bars ± SEM, P < 0.05, n=3. b) Representative histogram of ThT fluorescence measured 
by flow cytometry (48 h).
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3.3.4 Treatment with Z-VAD-fmk induces autophagy 
HEK cells stably transfected with a GFP-LC3 construct were employed to examine autophagy. 
LC3 is expressed on the outer and inner membranes of autophagosomes and, when linked 
to GFP, allows autophagosomes to be visualised as distinct bright puncta. To confirm if cells 
expressing this construct can be used to examine the effects of pharmacological N-glycanase 
inhibition, cells were first treated with agents with known and predictable actions on 
autophagy. Modulators of autophagic activity include Bafilomycin A1 and 3-MA (Mauvezin 
and Neufeld 2015). Bafilomycin A1, an inhibitor of the lysosomal vacuolar-type H+-ATPase 
(V+ATPase), inhibits the acidification of autolysosomes and prevents autophagosome 
degradation. This ultimately results in an observable accumulation of autophagosomes in the 
cell shown in Figure 3.19. 3-MA is an inhibitor of class I and III PI3K, one of the major signalling 
pathways controlling mTOR activity. 3-MA inhibits autophagy by suppressing the production 
of PI3P which is involved in the recruitment of autophagy related proteins for phagophore 
membrane (R. Chen et al. 2014). Treatment with 3-MA is expected to result in a reduction in 
the number of autophagosomes present.  The effects of these modulators are presented 
schematically in (Figure 3.18).  
 
Figure 3.18 Schematic representation of autophagy indicating points of inhibition of 3-MA 
and bafilomycin A1. Bafilomycin A1 is an inhibitor of the lysosomal V+ATPase which 
inhibits fusion of autophagosomes to lysosomes and inhibits autophagosome degradation. 
3-MA inhibits PI3P production and recruitment of autophagy related proteins to the 
phagophore membrane, consequently inhibiting the formation of autophagosomes. 
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In order to induce autophagy, cells were either treated with rapamycin, an inhibitor of mTOR 
that induces autophagy (Harder et al. 2014, L. Q. Wang et al. 2015) or exposed to amino acid 
starvation conditions (R. Chen et al. 2014), and co-treated with Bafilomycin A1  
Autophagosomes were visualised as green punctate structures, representative images 
shown in Figure 3.19. 
 
 
Figure 3.19 Representative images of GFP-LC3 HEK cells exposed to different inducers of 
autophagy (rapamycin treatment and amino acid starvation) and co-treated with 
Bafilomycin A1. Scale bar indicates 10 µm. 
GFP-LC3 HEK cells treated with rapamycin and exposed to amino acid starvation conditions 
show increased numbers of puncta compared to untreated cells. Figure 3.20 shows the 
quantification of the average number of puncta per cell.  
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Figure 3.20 Number of GFP-LC3 puncta under basal, rapamycin (5 µM) and amino acid 
starvation conditions. One-way ANOVA, Dunnet’s post hoc. Error bars ± SEM, n=3, **** P 
< 0.0001
Co-treatment with Bafilomycin A1 results in a further increase in the number of punctate 
structures observed (Figure 3.21) 
 
Figure 3.21 Quantitation of puncta in GFP-LC3 HEK cells under different autophagy 
induction conditions. Rapamycin (5 µM) treatment and amino acid starvation co-treated 
with Bafilomycin A1 (100 nM, 1 h). A minimum of 3 images were taken per coverslip. Error 
bars ± SEM, n=3, **** indicates P < 0.0001. Two-way ANOVA, Dunnett’s post hoc.
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A number of commercial assays for autophagy are available, including the CytoID® 
Autophagy Detection Kit (Enzo) which is based upon the selective accumulation of a 
proprietary cationic amphiphilic dye in autophagic vesicles.  The suitability of this kit was also 
examined using  the TALI image based cytometer (Invitrogen). HEK cells were exposed to 
amino acid starvation, co-treated with Bafilomycin A1 and incubated with CytoID® as per the 
manufacturer’s protocol. Green fluorescence was recorded on a TALI image based 
cytometer. However, no significant differences were observed between any of the 
conditions. Figure 3.22a shows the histograms obtained and representative images. The 
mean fluorescence intensity per cell is presented in Figure 3.23b.  On the basis of these 
results, the use of GFP-LC3 expressing HEK cells was deemed more suitable than the CytoID® 
Autophagy Detection Kit and was therefore used in subsequent experiments.      
 
 
Figure 3.22 CytoID kit is not compatible with TALI cytometer a) Representative histograms 
and images acquired on a TALI image-based cytometer (Invitrogen) of HEK cells stained 
with CytoID® autophagy detection kit (Enzo) b) mean fluorescence intensity per cell  
(CytoID®  autophagy detection kit).  A minimum of 9 images were taken per condition, 
one–way ANOVA, Tukey’s post hoc, error bars ± SEM.
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Figure 3.23a shows the number of GFP-LC3 positive puncta observed following treatment 
with Q-VD-OPh or Z-VAD-fmk (50 µM). A significant increase in GFP-LC3 puncta was observed 
after 72 h. No similar increase was observed in cells treated with vehicle or with broad 
spectrum caspase inhibitor, Q-VD-OPh.   Figure 3.23b shows representative images of the 
GFP-LC3 HEK cells.  
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Figure 3.23 Z-VAD-fmk increased autophagy after 72 h. a) GFP-LC3 puncta are increased 
after 72 h treatment with Z-VAD-fmk (50 µM), no increase was seen under vehicle or Q-
VD-OPh (50 µM). Minimum of three images per coverslip. Error bars indicate ± SEM, n=3, 
P < 0.05, Two-way ANOVA, Tukey’s post hoc b) Representative images of treatment of Z-
VAD-fmk or Q-VD-OPh after 72 h. Scale bar indicates 10 µm.
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As an increase in the number of puncta observed could result from other effects, such as 
aberrant vesicle trafficking or blockage of lysosomal fusion, it was necessary to examine 
autophagic flux. HEK cells were treated with Bafilomycin A1 and 3-methyladenine (3-MA).  
As well as being present on the membrane of autophagosomes, LC3 has been shown to have 
a functional role in the clearence of proten aggregates and can form interactions with 
ubiqutininated aggregates via p62 (L. Wang et al. 2013, Bjørkøy et al. 2005) (Pankiv et al. 
2007).  To determine if puncta observed in the GFP-LC3 HEK cells reflect genuine autophagy, 
and not protein aggregation, cells were treated with 3-MA, an early stage autophagy 
inhibitor. If the LC3 puncta visible in the Z-VAD-fmk treated cells were due to LC3 binding 
protein aggregates, a greater number of LC3 puncta would be expected in the presence of 3-
MA compared to that of the control conditions. As shown in Figure 3.24, 3-MA inhibits LC3 
puncta formation during Z-VAD-fmk treatment. Treatment with Bafilomycin A1 results in an 
increase in the number of GFP-LC3 puncta observed. The results suggest that autophagic flux 
is maintained, as well as the LC3 puncta observed in the Z-VAD-fmk treated HEK cells are 
autophagosomes, and not a consequence of protein aggregation. 
 
Figure 3.24 Z-VAD-fmk and Q-VD-OPh do not inhibit autophagic flux. GFP-LC3 puncta per 
cell after treatment with Z-VAD-fmk or Q-VD-OPh (50 µM, 72 h) followed by Bafilomycin 
A1 treatment (1 h, 100 nM) or 3-MA (1 h, 5 mM). Error bars indicate ± SEM, * indicates P < 
0.05, ** indicates P<0.01, *** indicates P < 0.001.  One way ANOVA within each condition, 
Tukey’s post hoc. 
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3.3.5 Autophagic flux is maintained following treatment with Z-VAD-fmk  
A tandem RFP-GFP reporter for LC3 has also been employed as a tool for quantitation of 
autophagic flux (Kimura et al. 2007). GFP is acid sensitive (Roberts et al. 2016) so, as 
autophagosomes fuse with lysosomes, the GFP signal is quenched by the acidic environment. 
RFP is not as sensitive to acidic environments so is not quenched during autophagosome and 
lysosome fusion. LC3 puncta that show GFP and RFP co-localisation (yellow) indicate 
autophagosomes, whereas RFP puncta (red) alone indicate autolysosomes where the GFP 
signal has been quenched. Cells with a functional autophagic pathway show a combination 
of yellow (RFP+GFP) and red (RFP only) puncta. A diagram showing the localisation and 
quenching of GFP-RFP-LC3 is shown in Figure 3.25. 
 
Figure 3.25 Diagram showing the localisation GFP-RFP-LC3 on autophagosome membranes 
through maturation and degradation. 
The tandem RFP-GFP-LC3 reporter was transfected into HEK293 cells. Various transfection 
reagents were tested to optimise transfection efficiency. After 48 h, transfection efficiency 
was determined by the percentage of GFP positive cells. Figure 3.26a shows the percentage 
of transfected cells under different transfection reagents, representative images for each 
reagent are shown in Figure 3.26b. JetPei was found to give to most transfection with >70% 
efficiency and was chosen for subsequent transfections. 
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Figure 3.26 JetPEI has the highest transfection efficency in HEK cells a) Percentage of 
transfected cells after 48 hours. HEK cells were transfected with the GFP-RFP-LC3 construct 
and imaged under the GFP filter. A minimum of three images were taken per condition. 
Error bars ± SEM b)  Representative images demonstrating transfection efficiency for each 
trasfection reagent (composite images showing bright-field image overlaid with GFP 
signal). Scale bar indicates 10 µm. 
It was observed that a number of the transfection reagents exhibited varying levels of cellular 
toxicity. Cell viability was quantified using trypan blue exclusion. The percentage of viable 
cells was calculated and shown in Figure 3.27. Whilst most reagents were found to be non- 
toxic, Fugene HD displayed significantly more cell death compared to the other reagents with 
only 45 % viability. 
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Figure 3.27 Fugene HD causes cell death. Trypan blue exclusion of non-viable cells. One-
way ANOVA, Tukey’s post hoc, error bars ± SEM, n=3, P < 0.05
To generate a stable cell line, successfully transfected cells were selected for with the 
mammalian antibiotic marker G418. To determine the lowest level of G418 to induce death 
of non-transfected cells after 6 days in culture, cells were plated in 24 well plate and 
subjected to increasing concentrations of G418. Cell death was assessed by eye when cells 
detached from the cell culture plate. Figure 3.28 shows the survivability of HEK cells in G418.  
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Figure 3.28 Survival chart of HEK cells treated with 50-1000 µg/ml G418. Cells were plated 
in 48 well plate and treated with G418. Survival was determined when > 90 % of the cells 
were detached from the well.
To generate a stable cell line, HEK cells were transfected with the GFP-RFP-LC3 construct and 
treated with 800 µg/ml G418 for 7 d. Cells were then serially diluted to generate single 
clones. However, HEK cells under this condition showed increased cell death and the cells 
that survived were mostly polyclonal lines. A well was selected that had similar fluorescence 
intensity to the GFP-LC3 HEK cells under the same excitation conditions. To test the 
appropriateness of this construct HEK cells transfected with GFP-RFP-LC3 were treated with 
Bafilomycin for 1 h.  Representative images are presented in Figure 3.29.  
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Figure 3.29 Representative images of HEK cells transfected with GFP-RFP-LC3 construct 
treated with Bafilomycin A1 (100 nM, 1h) and basal (untreated cells). Scale bar indicates 
10 µm. 
As Bafilomycin blocks lysosomal degradation and acidification of lysosomes, only green and 
red co-localised puncta were observed with few RFP signals. The addition of 3-MA blocks 
autophagosome formation, resulting in an overall decrease in both the GFP and RFP signal 
(Figure 3.30). 
 
Figure 3.30 The GFP-RFP-LC3 construct behaves as predicted using bafilomycin A1 and 3-
MA. A minimum of three images were taken per coverlip. Two-way ANOVA, Tukey’s post 
hoc, error bars ± SEM, n=2, **** indicates P < 0.0001, *** indicates P < 0.001. 
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HEK cells expressing the tandem GFP-RFP-LC3 reporter showed a significant increase in the 
number of autophagosomes at 48 h and 72 h when treated with Z-VAD-fmk (50 µM). At every 
time point, red puncta were observed. The presence of red punctate structures indicates 
that autophagosome and autolysosome fusion remained active and, that autophagic flux was 
maintained (Figure 3.31a). Representative images of cells treated with vehicle control and Z-
VAD-fmk at 72 h are shown in Figure 3.31b. 
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Figure 3.31 Z-VAD-fmk induces autophagy in GFP-RFP-LC3 HEK model. a) Quantitation of 
punctate structures. A minimum of three images were recorded per coverslip and two 
biological replicates. Two-way ANOVA between autophagosome and autolysosome 
quantitation, followed by Tukey’s post hoc b) Representative images of HEK cells 
tranefected with GFP-RFP-LC3 construct treated with Z-VAD-fmk (50 µM, 72 h). Scale bar 
indicates 10 µm.
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3.3.6 Western blot analysis LC3 in HEK cells was unsuccessful 
Western blot analysis of LC3 is a common method used to quantify relative levels of LC3, LC3I 
and LC3II in cells (Streeter et al. 2016, Chen et al. 2011, Barth et al. 2010, Pugsley 2017). In 
order to examine if this method was applicable in this case, samples of cleared HEK cell lysate 
(5 – 50 µg total protein concentration) were prepared for analysis. Attempts were also made 
to determine the levels of LC3I and LC3II in GFP-LC3 HEK cells by monitoring the in-gel 
fluorescence of GFP (thus negating any potential issues with transfer efficiency, antibody 
specificity and antibody binding efficiency). For this method, cells were lysed with 1 % Triton 
X-100 and analysed SDS-page gel. Figure 3.32a shows the in-gel fluorescence of GFP-LC3 HEK 
lysate (10 or 20 µg per well) treated with Bafilomycin or amino acid starvation. LC3 I was 
observed to be much brighter than the LC3 II band, which did not allow the intensity of LC3 
II to be quantified. Western blot against GFP produced similar results (Figure 3.32b), the LC3I 
band was clearly visible. Treatment with Bafilomycin A1 increased the intensity of the LC3II 
signal, however it was not possible to resolve the bands clearly, resulting in difficulty in 
quantifying both the levels of LC3I and LC3II.  
 
 
Figure 3.32 Western blot and in-gel GFP-LC3 fluorescence was unable to resolve LC3I and 
LC3II bands.a) in-gel fluorescence of GFP-LC3, top 20 µg total protein loaded, bottom panel 
shows 10 µg total protein loaded per well b) anti-GFP western blot (10 µg total protein 
loaded).
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3.3.8 Autophagy is protective response during N-glycanase inhibition  
Autophagy was shown to be increased under Z-VAD-fmk treatment. The role of autophagy 
under these conditions was examined using an ATG13 deficient cell line (a kind gift from Prof. 
Nicholas Ktistakis, Babraham Institute, Cambridge). ATG13 is an autophagy factor critical to 
autophagosome formation (Kaizuka and Mizushima 2016, Suzuki et al. 2003). ATG13 KO 
MEFs were first confirmed as deficient by RT-qPCR for murine ATG13 mRNA. A significant 
difference in ATG13 mRNA compared to the WT MEF line was observed (Figure 3.33).  
 
Figure 3.33 rt-qPCR measurement of ATG13 in WT MEF and ATG13 KO MEF. Student’s t-
test, P < 0.001, error bars ± SEM, n=3. 
The cell viability of ATG13 KO MEF cells and corresponding WT MEF cells was measured by 
MTT assay in the presence of Z-VAD-fmk (Figure 3.34a) or Q-VD-OPh (Figure 3.34b) after 24 
h. It was observed that Z-VAD-fmk treatment in ATG13 deficient MEF cells was toxic within 
24 h. However, following treatment with the corresponding caspase inhibitor, Q-VD-OPh, no 
toxicity was observed. This suggests that the toxicity observed was due to N-glycanase 
inhibition rather than caspase inhibition and, that autophagy acts as a protective measure 
under N-glycanase inhibition.  The calculated CC50 values are summarised in Table 3.5.  
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Figure 3.34 Z-VAD-fmk increases cell toxicity in ATG13 KO MEFS. MTT of ATG13 KO MEF 
and WT MEF treated with a) Z-VAD-fmk (1-200 µM) or b) Q-VD-OPh (1-200 µM)  for 24 h.  
One way ANOVA, Dunnett’s post hoc. Error bars ± SEM, n =3, P < 0.05.
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Table 3.5 CC50 of Z-VAD-fmk for WT and ATG13 KO MEFs  
Cell line CC50 (µM) 
ATG13 KO MEF 14.96 ± 12.53 
WT MEF 289.30 ± 88.08 
 
To further confirm the effect of autophagy modulating Z-VAD-fmk toxicity, the 
autophagy inhibitor 3-MA was used to block autophagy in HEK cells and the viability 
measured after Z-VAD-fmk treatment. The viability of HEK cells treated with 3-MA alone 
was first determined by MTT assay for 24 h and had a CC50 value of 21.64 ± 18.67 mM 
(Figure 3.35a). Unlike genetic manipulation, pharmacological inhibitors can often not 
be used for long periods. HEK cells were treated with Z-VAD-fmk (50 µM) over 72 h, then 
treated with 3-MA (10 mM) for 6 h.  Viability was measured by MTT assay (Figure 3.35b). 
There were no significant differences observed between the 3-MA treated and 
untreated conditions.  A small significant difference between Z-VAD-fmk treated cells at 
24 and 72 h was noted, although neither of these were significantly different from the 
vehicle control. This may be due to initial treatments with Z-VAD-fmk and Q-VD-OPh 
resulting in an initial increase in absorbance at low concentrations.  
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Figure 3.35 3-MA causes cell toxicity. a) MTT of HEK cells treated with 3-MA (24 h). One-
way ANOVA, Dunnett’s post hoc, error bars ± SEM, n=3, P < 0.05. b) MTT of cells treated 
with Z-VAD-fmk (50 µM, 24-72 h) followed by 3-MA (10 mM, 6 h). Two-way ANOVA, 
Tukey’s post hoc. Error bars ± SEM, n=3, P < 0.05.
3.3.8 Z-VAD-fmk treatment of HEK cells does not induce ER stress or oxidative stress  
The UPR is activated by the accumulation of unfolded proteins in the ER and is often linked 
to changes in degradation pathways including autophagy (Senft and Ronai 2015, Sovolyova 
et al. 2014). Increased ThT fluorescence has been linked with increased in β-sheet motifs 
commonly associated with misfolded or unfolded protein structures (Beriault and Werstuck 
2013, Groenning et al. 2007).  As NGLY1 deficiency is regarded as a defect of ERAD (Enns et 
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al. 2014), and as there is some evidence to suggest a build-up of misfolded proteins resulting 
from lower enzyme activity, there have been suggestions that inhibition of or deficiency in 
N-glycanase can result in ER stress (Martinet et al. 2006b, Misaghi et al. 2005). Little direct 
evidence, however, has been presented for this.  
The UPR has been well-defined and the components involved well characterised (Kennedy 
et al. 2015, Shapiro et al. 2016, Taylor 2016, Nishitoh 2012). To test whether Z-VAD-fmk 
inhibition of N-glycanase activated the UPR, RT-qPCR was performed using several markers 
upregulated during the UPR. During the accumulation of misfolded proteins, the UPR is 
activated by three key ER membrane proteins: PERK, ATF6 and IRE1 (Figure 3.36) which result 
in the activation of ATF4, cleavage of ATF6 and splice activation of XBP1.  This results in 
increased transcription of various chaperones and proteins involved in protein folding and 
secretion with the aim of reducing ER ‘load’. These chaperones include BiP, CHOP and EDEM. 
 
Figure 3.36 Diagram of unfolded protein response activation. The three main arms of the 
UPR: ATF6, PERK and IRE1 are shown in the ER membrane followed by increased 
expression of several effectors including BiP, CHOP and EDEM1. Reprinted by permission 
from Springer Nature: Diabetologia (Eizirik et al. 2013).
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During ER stress, BiP (a well-characterised ER chaperone important in protein quality control) 
disassociates from the ER transmembrane sensors, PERK, IRE1 and ATF6 leading to their 
activation and, concomitant activation of the UPR response. This results in an increase in 
transcription of BiP by cleaved ATF6 (Wang et al. 2009, Haze et al. 1999). Other ERAD 
associated proteins, such as EDEM are also upregulated.  Under severe or prolonged ER 
stress, cells can undergo apoptosis. This mechanism is controlled by CHOP, JNK and caspase-
12 (Li et al. 2014). CHOP and ATF4 were included specifically because they have been shown 
to regulate the transcription of several ATG proteins (B’chir et al. 2013). ATF4 binds to C/EBP-
ATF response element (CARE) to affect transcription. During amino acid starvation, these are 
referred to as amino acid response elements (AARE). ATF4 and CHOP bind to the p62 AARE 
to induce transcription of p62 and precedes its induction in amino acid starved cells (B’chir 
et al. 2013).  
Z-VAD-fmk and Q-VD-OPh treated cells were analysed for up-regulation of the UPR 
associated proteins CHOP, BiP, ATF4 and EDEM. Figure 3.37 shows the log10 fold change in 
mRNA expression of each gene. No significant increase in any of the markers was observed.  
The proteasome inhibitor MG132 was used as a positive control, inhibition of the 
proteasome results in activation of the UPR (Obeng et al. 2006, Nakajima et al. 2011).  
Treatment with MG132 results in up-regulation of a significant increase in ER stress markers 
CHOP, BiP and ATF4 however, EDEM was not significantly upregulated after MG132 
treatment. 
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Figure 3.37 Z-VAD-fmk or Q-VD-OPh does not activate the UPR. rt-qPCR anlaysis of CHOP, 
BiP, ATF4 and EDEM levels in cells treated with Z-VAD-fmk or Q-VD-OPh (50 µM, 24-72 h). 
mRNA levels normalised to GAPDH and an untreated control using ΔΔCt method. Log2 fold 
change is presented with error bars ± SEM, P < 0.05, n=3. Two-way ANOVA, Tukey’s post 
hoc within each mRNA target.  
The sensors for detection of misfolded proteins are located on the ER luminal side of the ER 
and the signal is then transduced to the cytosol (Wang et al. 2016). As misfolded proteins are 
exported from the ER into the cytosol to be degraded by the proteasome the ER may not 
invoke mechanisms to respond to misfolded proteins which are not accumulating or delayed 
in the ER lumen.  In conclusion, it does not appear that activation of ER stress and the UPR is 
associated with activation of autophagy in HEK cells exposed to Z-VAD-fmk treatment.  
As well as being a site of protein folding and secretion, the ER is a major cellular Ca2+ store. 
Perturbations in the ER homeostasis are often marked by changes in Ca2+ handling within the 
organelle, especially ER ‘leakiness’ (Kania et al. 2015, Hammadi et al. 2013, Mekahli et al. 
2011). To determine the baseline calcium levels in the cell, HEK cells were loaded with the 
ratiometric dye Fura-2-AM (1 µM), then treated with various concentrations of Thapsigargin 
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(10.0, 5, 1, 0.5 µM). Thapsigargin (an inhibitor of SERCA) to block reuptake of Ca2+ into the 
ER. Treatement with Thapsigargin results in an increase in cytosolic Ca2+ levels. Calcium 
traces are presented in Figure 3.38. Treatment with higher concentrations of Thapsigargin 
resulted in a more rapid and sharper increase in cytosolic Ca2+ concentration (as shown by a 
higher amplitude). The area under the curve, which reflects the total increase in cytosolic 
Ca2+ concentration remained the same for each concentration of Thapsigargin examined, 
despite differences in the rate of increase and initial onset. For subsequent studies a 1 µM 
concentration of thapsigargin was employed, to allow for any changes in both rate and initial 
onset of effects to be examined.  
 
Figure 3.38 Thapsigargin increases cytosolic Ca2+. HEK cells loaded with Fura-2 AM (1 µM) 
in Ca2+ free imaging buffer. After 3 min, Thapsigargin (10, 5, 1, 0.5 µM) was added. n=1, 
average of 16 cells, error bars ± SEM.  
HEK cells were treated with either Z-VAD-fmk (24-72 h, 50 µM) or Q-VD-OPh (24-72 h, 50 
µM) and loaded with Fura-2 (1 µM).  Baseline ER calcium levels were calculated from the first 
eight readings, the height of the peak was used as a measure of the rate of release. Total 
peak area was used a measure of the total release from the ER. Figure 3.39 shows the traces 
of three independent experiments for each treatment. No significant difference in the levels 
of ER Ca2+ release was observed in HEK cells treated with Z-VAD-fmk (compared to vehicle 
and cells treated with Q-VD-OPh (50 µM)) (Figure 3.40a-c). 
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Figure 3.39 Z-VAD-fmk or Q-VD-OPh does not affect Ca2+ handling. Traces of HEK cells 
treated with Z-VAD-fmk or Q-VD-OPh (50 µM, 24-72 h), loaded with Fura-2 AM (1 µM, 0.5 
h) and treated with Thapsigargin (1 µM, 180 s). Error bars ± SEM, n=3.
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Figure 3.40 Quantitation of Ca2+ handling. HEK cells treated with Z-VAD-fmk or Q-VD-OPh 
(50 µM, 24-72 h). a) shows the baseline Ca2+ levels calculated from the first eight readings 
b) shows peak height c) total peak area of the traces.  Two-way ANOVA. Error bars ± SEM, 
n=3.
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Certain ER stress events have been shown to be linked to oxidative stress.  Oxidative stress 
has been defined as a dysfunction in the homeostasis between reactive oxidant species 
production and antioxidant defences (Betteridge 2000) and is initiated by the presence of 
reactive oxygen species (ROS), such as hydrogen peroxide, nitric oxide, superoxide, hydroxyl 
and monoxide radicals. In the ER, glutathione (GSH) is responsible for reducing erroneous 
disulphide bond formation during protein folding. When protein folding in the ER is disrupted 
(for example, by accumulation of misfolded proteins) the increased need to reduce disulfide 
bonds leads to a reduction in antioxidant capacity and subsequent oxidative stress. 
Therefore, if there is a higher level of misfolded protein in the ER an increase in levels of ROS 
may be expected.  
The level of ROS was measured by flow cytometry using the cell-permanent fluorogenic 
probe ROS Brite™ 570 (ATT Bioquest). Menadione, which has been reported to induce 
apoptosis via ROS (Loor et al. 2010, Kim et al. 2014, Criddle et al. 2006) was used a positive 
control for ROS production (Figure 3.41). There were no significant differences found in HEK 
cells treated with Z-VAD-fmk or Q-VD-OPh compared to the vehicle and untreated cells. 
Menadione (5 µM, 18 h) produced a significant increase in ROS Brite fluorescence. 
 
Figure 3.41 Z-VAD-fmk or Q-VD-OPh does not increase ROS. HEK cells treated with Z-VAD-
fmk or Q-VD-OPh (50 µM, 24-72 h). Cells were stained with ROS Brite 570 (5 µM, 0.5 h). 
Two-way ANOVA, Tukey’s post hoc, error bars ± SEM, n=3, ** P < 0.01. 
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3.3.9 Treatment with Z-VAD-fmk does not change O-GlcNAc modifying enzyme homeostasis 
It has been reported that in NGLY1 deficient MEF cells, ENGase is able to act on N-glycanase 
substrates. This results in proteins modified with a single N-GlcNAc residue (Huang et al. 
2015, Fujihira et al. 2017). It has been hypothesised that this increase in N-GlcNAc 
modifications may interfere with O-GlcNAc signalling. Increased levels of O-GlcNAc have 
been shown to influence the expression of the O-GlcNAc modifying enzymes such as O-
GlcNAcase (OGA) which adds O-GlcNAc and, O-GlcNAc transferase (OGT) which removes it. 
Inhibition of OGA using Thiamet G, results in an increase in O-GlcNAc and OGA (as 
determined by western blot) (Zhang et al. 2014). It was also confirmed that treatment with 
Thiamet G also resulted in increased mRNA transcript level of OGA after 6 h in HELA, SH-SY5Y 
and K562 cell lines.  
Therefore, if there is an increase in the levels of protein bound N-GlcNAc in the cell as a result 
of ENGase action, this may have an impact upon the systems responsible for cellular O-
GlcNAc cycling (particularly OGA). To investigate this hypothesis, RT-qPCR was employed to 
measure the levels of mRNA associated OGA and OGT in HEK cells treated with Z-VAD-fmk 
(50 µM) and Q-VD-OPh (50 µM). Figure 3.42a and b shows the log10 fold change in mRNA 
OGA and OGT levels respectively after treatment with Q-VD-OPh or Z-VAD-fmk. No 
significant changes were observed. 
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Figure 3.42 Z-VAD-fmk or Q-VD-OPh does not affect OGA or OGT expression levels.Log2 fold 
change of a) OGA and, b) OGT mRNA expression levels in HEK cells treated with Z-VAD-fmk 
or Q-VD-OPh (50 µM, 24-72 h). OGA and OGT levels were normalised to GAPDH and an 
untreated control.Two-way ANOVA, error bars ± SEM, n=3.  
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3.3.10 Bacterial N-glycanase (PNGase F) is insensitive to Z -VAD-fmk 
Bacterial N-glycanase (PNGase F) is commonly employed in the biopharmaceutical industry 
in workflows where removal of protein bound N-glycans is advantageous, for example, in 
protein structural studies (where glycans can interfere with protein crystallisation) or, in 
biopharmaceutical quality control analysis. Unlike the mammalian orthologue, bacterial 
PNGase F is not inhibited by Z-VAD-fmk.  Z-VAD-fmk is proposed to covalently bind to the 
cysteine in the active site of mammalian N-glycanase (Misaghi et al. 2004), thus inhibiting 
the enzyme. This conserved cysteine residue is present in human, mouse and yeast N-
glycanase enzymes but is not present in bacterial forms of the enzyme (as highlighted in 
Figure 3.43). 
 
Figure 3.43 Bacterial PNGase F does not contain conserved cysteine residue in active site. 
Alignment of yeast, mouse and bacterial PNGase F amino acid sequences (generated using 
Clustal Omega). The conserved cysteine residue of yeast and mouse N-glycanase (marked) 
is not found in bacterial PNGase F (Flavobacterium). 
In order to explore if over-expression of a Z-VAD-fmk insensitive N-glycanase could rescue 
the effects observed following treatment with Z-VAD-fmk, efforts were made to clone 
bacterial PNGase F into a suitable mammalian expression vector for transfection into HEK 
cells. The bacterial construct was first characterised to confirm the Z-VAD-fmk insensitivity. 
Recombinant PNGase F (a kind gift from Shaun Lott (Addgene plasmid #40315) bearing a 
hexa-histidine tag was expressed and purified in E. coli BL21 (DE3). Recombinant PNGase F 
contained an Outer Membrane Protein A3 (OmpA3) leader sequence to localise the protein 
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to the periplasm to allow purification by osmotic shock (Confer and Ayalew 2013) (Missiakas 
and Raina 1997). The enzymatic activity of the isolated protein was confirmed using an RNase 
B deglycosylation assay. Figure 3.44 shows the glycosylated RNase B around 17 kDa. 
Deglycosylated RNase B migrates at around 15 kDa.  
 
 
 
 
Figure 3.44 PNGase F deglycosylation assay. PNGase F was incubated with denatured 
RNase B (24 h at 37 °C) and samples were analysed by SDS-PAGE (4-15 % Tris-Glycine). 
In order to confirm the expressed protein was insensitive to Z-VAD-fmk, purified 
recombinant bacterial PNGase F was incubated with increasing concentrations of Z-VAD-fmk 
(1 h, room temperature).  RNase B was then added and the reaction mixture incubated at 37 
°C for 1 h.  The samples were then analysed by SDS-Page, and it was observed that there was 
no inhibition of deglycosylation (Figure 3.45).  
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Figure 3.45 PNGase F is not inhibited by Z-VAD-fmk. Purified bacterial PNGase F was tested 
for Z-VAD-fmk sensitivity using the RNAse B deglycosylation assay. Bacterial PNGase F was 
incubated with Z-VAD-fmk (1-200 µM) for 1 h prior to RNAse B deglycosylation assay. 
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3.3.11 PNGase F was successfully cloned into a mammalian expression vector but 
transfection proved fatal to HEK 293 cells 
Z-VAD-fmk is not a specific inhibitor for N-glycanase but is commonly employed and an 
inhibitor of caspases. To provide further evidence that the effects seen in these studies were 
due to the inhibition of N-glycanase (rather than caspase inhibition) the Z-VAD-fmk 
insensitive bacterial PNGase was cloned into a mammalian expression vector, with a view to 
examining if over-expression of a Z-VAD-fmk insensitive N-glycanase could successfully 
rescue the observed phenotypes. Bacterial PNGase F was cloned by PCR and ligated into a 
(N1-mAPPLE, Addgene cat#54567) mammalian expression vector containing an N-terminal 
N1-mAPPLE fluorescent tag. The cloning strategy is shown schematically in Figure 3.46. 
 
Figure 3.46 Schematic diagram showing the cloning protocol for generation of Z-VAD-fmk 
insensitive N1-mAPPLE tagged protein in N1-mAPPLE.
The cloning strategy is described in detail below. 
1. Primers were generated to clone the PNGase F from the POPH6 bacterial expression 
vector. Primers were designed with a four base pair match to the 5’ end with the addition of 
a XHOI restriction site, a new ATG sequence and an eighteen base pair matching at the 3’ 
end.  
2. The PCR product was extracted from the agarose gel and digested with XHOI and 
BAMHI 
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3. N1-mAPPLE plasmid was co-digested with BAMHI and XHOI to generate 
complementary sticky ends.  
4. The digested N1-mAPPLE plasmid was purified and extracted from an agarose gel. 
The N1-mAPPLE backbone was added to the digested PNGase F and ligated using T4 ligase 
(48 h,  4 °C).  
5. Plasmid was transformed into DH5α E. coli. Several single colonies were isolated, 
termed bacterial PNGase (bacpng) 1-6 plasmid and sequenced. 
Plasmids were sequenced to confirm the incorporation of the bacterial PNGase F insert into 
N1-mAPPLE backbone (Appendix A2). Transfection of the Z-VAD-fmk insensitive plasmid into 
HEK cells, however, proved inefficient compared with the control transfection of HEK cells 
with the empty N1-mAPPLE vector, with only 20 % transfection efficiency compared to the 
N1-mAPPLE backbone (Figure 3.47). 
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Figure 3.47 Transfection of BacPng plasmid caused increased cell death and poor 
transfection. HEK cells were transfected with plasmid DNA (3 µg) per well in a 12 well plate. 
The transfection efficiency of the N1-mAPPLE backbone was set at 100 % and the 
transfection efficiency of the Z-VAD-fmk insensitive PNGase plasmid was normalised to 
this. One-way ANOVA, Tukey’s post hoc, error bars ± SEM, P < 0.05. Lower panel contains 
representative images of cells using the TALI cytometer for (left to right) un-transfected 
cells, cells transfected with the vector containing the bacterial PNGase insert and cells 
transfected with N1-mAPPLE backbone. 
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It was noted that transfection with the Z-VAD-fmk insensitive PNGase plasmid resulted in 
decreased cell viability and little transfection even at low plasmid levels. Figure 3.48 shows 
that cell viability was decreased in HEK cells transfected with bacterial PNGase plasmid 
compared to the backbone control.  The effect of Z-VAD-fmk could not be investigated by 
the introduction of a Z-VAD-fmk insensitive bacterial PNGase due to the poor 
transfection efficiency and the decrease in cell viability post transfection.  
 
Figure 3.48 BacPng plasmid caused cell death even at low concentrations.MTT assay of HEK 
cells transfected with increasing amounts of N1-mAPPLE plasmid DNA or BacPng4 plasmid 
DNA. Absorbance was normalised to vehicle control. Two-way ANOVA, Tukey’s post hoc 
test, error bars ± SEM, n=3, P < 0.05. 
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3.3 Discussion 
 
Z-VAD-fmk has been reported to exhibit a broad spectrum of cellular effects.  Commonly 
employed in cell culture as a pan-caspase inhibitor, it has also been shown to act as an 
inhibitor of N-glycanase.  The aim of this chapter was to characterise the effects observed 
upon Z-VAD-fmk treatment of HEK 293 cells, compared to those observed upon treatment 
with Q-VD-OPh.  Q-VD-OPh has a similar caspase inhibition profile, but does not act as an 
inhibitor of N-glycanase.     
The effects of treatment with both pharmacological agents on cell viability, N-glycanase 
activity, glycan profile, ER stress, ER Ca2+ handling and ROS levels was determined.  There is 
some debate as to whether effects noted in N-glycanase deficiency are related to ERAD 
dysfunction.  One of the hypotheses linked to effects noted in N-glycanase deficiency is that 
inhibition is not directly related to the dysfunction of ERAD but instead, changes in O-GlcNAc 
homeostasis. This was examined by testing the expression levels of the enzymes OGA and 
OGT. In addition, the effects Z-VAD-fmk and Q-VD-OPh on protein aggregation and 
autophagy were also examined. Finally, a Z-VAD-fmk insensitive bacterial PNGase was cloned 
into a mammalian expression vector with the aim of rescuing effects of Z-VAD-fmk by 
increasing levels of Z-VAD-fmk insensitive PNGase.   
To establish a suitable working range, cell viability assays (using MTT) were carried out using 
Z-VAD-fmk and Q-VD-OPh.  MTT assays are commonly used as a measure of viability, but 
results can be misinterpreted. Other studies have reported that treatment with Z-VAD-fmk 
results cell death in different cell lines (Table 3.2) (Martinet et al. 2006b, Wu et al. 2011, 
Dong et al. 2013, Cowburn et al. 2005, Werthmoller et al. 2015, Herzog et al. 2012, Chen et 
al. 2011). However, no decrease in MTT reduction was observed in the concentration range 
examined in HEK cells. MTT reduction can be influenced by factors such as changes in the 
cellular redox environment, and are often cell line specific (Berridge et al. 2005).   
There are very few options available to directly quantify cellular N-glycanase activity. Initial 
studies identifying Z-VAD-fmk as an inhibitor of yPng1 used purified yeast PNGase and a 
glycoprotein substrate, RNase B.  In this assay, enzymatic deglycosylation was identified by 
gel shift. This method was later adapted by other studies to examine N-glycanase activity in 
MEF cell extracts. In these instances, cell lysate was incubated with RNase B and, both the 
glycosylated and deglycosylated forms detected by western blot (Suzuki 2005, Huang 2015, 
Fujihira et al. 2017)}.  A similar assay was attempted in this study employing FITC-conjugated 
RNase B as the substrate to allow in-gel fluorescence detection. The FITC label did not 
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interfere with deglycosylation of RNAse B by PNGaseF as shown in Appendix A5. However, 
upon incubation with HEK lysate for 18-72 h, no deglycosylation was observed using this 
method. The method has only been reported twice in the literature, both in MEF cell lines 
(Huang et al. 2015, Fujihira et al. 2017) indicating a possible cell dependency.  
Inhibition of N-glycanase activity can reportedly be measured using the ddVENUS assay 
developed by Grotzke et al. 2013. The ddVENUS assay was originally developed to study 
ERAD (Grotzke et al. 2013) but was first used as a measure of N-glycanase activity in He et al. 
2015. This assay has been used several times since to measure the activity of N-glycanase in 
multiple models (Tomlin et al. 2017, Kong et al. 2018). In HEK cells, this assay exhibited a 
higher level of background fluorescence compared to other published models and had a 
higher calculated IC50 value compared to other cell types. This may be due to cell dependent 
or differences in experimental design. In the study by (Tomlin et al. 2017) Z-VAD-fmk was 
added to K562 cells for 7 h whereas in HEK cells, incubation times below 18 h found no 
change in fluorescence. Furthermore, this method has not been validated against other 
glycan processing enzymes (such as ENGase) against which a number of inhibitors have been 
identified (Y. Bi et al. 2017).  
The glycan profile of cells treated with both pharmacological agents was also examined. 
Previous studies have looked at the lectin profile of MEF cells N-glycanase KO cells (Huang et 
al. 2015, Fujihira et al. 2017). FITC-ConA staining of N-glycanase KO MEF glycoproteins 
showed similar levels of fluorescence intensity compared to WT and ENGase KOs, however, 
double KOs showed an increase in fluorescence indicating more high mannose bound 
glycoproteins (Huang et al. 2015), although this was not quantified. Measurements of O-
GlcNAc by western blot in N-glycanase KO, ENGase and double KO MEF cells found no 
differences in O-GlcNAc levels (Fujihira et al. 2017). This study looks at the overall 
glycoprotein population against a panel of different lectins in HEK cells using two high 
mannose binding lectins, two GlcNAc binding lectins and a complex structure binding lectin. 
No differences in lectin binding were observed. This is perhaps not surprising, as it may be 
hypothesised that inhibition of N-glycanase would preferentially influence proteins to be 
degraded rather than interfere in the glycosylation of correctly folded proteins. In addition, 
if proteins were not being degraded efficiently only an increase in N-linked high mannose 
glycans would be expected. A lectin dot blot is a simple method for determining glycan 
populations and is more commonly used as a qualitative technique rather than a means of 
absolute quantitation.  To increase resolution, proteins can be separated by SDS-Page prior 
to blotting.  
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One hypothesis which has been mooted to explain the effects noted in N-glycanase 
deficiency is the possibility of N-GlcNAc positive aggregates interfering with O-GlcNAc 
mediated signalling pathways. Literature reporting changes in OGA and OGT found (after 
exposure to Thiamet G) there was a significant increase in OGA but no change in OGT; 
indicating OGA would be more of a measure of disruption of O-GlcNAcylation than OGT. No 
positive control, however, was used in this study to identify if OGA would be increased 
following Thiamet G inhibition (Zhang et al. 2014).   
To explore potential changes in O-GlcNAc mediated signalling, gene expression of O-GlcNAc 
modifying enzymes OGA and OGT was employed. This method is likely to only detect large, 
global changes in O-GlcNAc levels, and no change in OGA or OGT post Z-VAD-fmk or Q-VD-
OPh treatment was observed in HEK cells. There is not likely to be any significant change in 
O-GlcNAc when these results are considered alongside the lectin blots of WGA and sWGA. 
This does not completely rule out a disruption in O-GlcNAcylation, but is suggestive that any 
effects are more likely to involve a specific substrate rather than a global change in 
population.  
ERAD dysfunction is often accompanied by ER stress, and this has been suggested as a 
consequence of N-glycanase inhibition (Martinet et al. 2006a, Misaghi et al. 2005).  In this 
study, ER stress was measured by quantification of expression levels of well-characterised 
UPR markers and, assessment of ER Ca2+ handling.  Together these results can be used to 
identify ER stress in a cellular model.  Cells treated with Z-VAD-fmk and Q-VD-OPh were 
analysed for up-regulation of the UPR associated proteins CHOP, BiP, ATF4 and EDEM. No 
significant increase in any of these markers was observed.   As many studies have found 
associations with Ca2+ handling and stress, ER Ca2+ handling was also examined.  In this study, 
Ca2+ levels were measured using the ratiometric dye Fura-2 and leak was induced using the 
SERCA inhibitor Thapsigargin (Gerasimenko et al. 2014, Lomax et al. 2002, Kopach et al. 
2005). No significant differences were found in the levels of ER Ca2+ release in HEK cells 
treated with Z-VAD-fmk.  In addition, ROS are often present during numerous types of 
cellular stress and, in this study, was examined by flow cytometry.  ROS was measured using 
flow cytometry analysis of the fluorescence intensity of the ROS indicator ROS Brite 570.  
There were no significant differences found in HEK cells treated with Z-VAD-fmk or Q-VD-
OPh when compared to the vehicle and untreated cells.  Combined, these results suggest 
that treatment with Z-VAD-fmk does not induce significant ER stress.  
137 
 
Increased ER stress and increased ROS has been linked to the presence of protein aggregates.  
A recent study has suggested the presence of aggregates in N-glycanase KO cells in culture 
(Huang et al. 2015), although it should be noted that this involved transfection of a model 
ERAD substrate (which has the potential to cause stress in itself by increasing protein load). 
Other studies have found links between N-glycanase and aggregation determined by Congo 
Red visualisation (Fujihira et al. 2017) a technique commonly used to detect amyloid fibril 
aggregates (Gregoire et al. 2012).  In this study, the presence of protein aggregates was 
examined through quantification of ThT fluorescence and these results further validated 
using flow cytometry. By using a general stain, endogenous protein aggregates can be 
studied in live cells.  An increase in ThT fluorescence intensity per cell was identified in both 
methods, although no distinct aggregates were found.   By using flow cytometry methods it 
could also be confirmed that there were no discrete sub-populations more susceptible to Z-
VAD-fmk treatment.  These results could perhaps be attributed to increased soluble 
misfolded proteins or, by an increase in ER luminal size and binding to proteins that have not 
folded correctly yet in the lumen. To fully identify if there is a role for protein aggregates in 
this model, another method would need to be used (for example, examination of the 
presence of ubiquitinated proteins or a measure of ER content).  
Activation of autophagy is often accompanied by a stress signal (Guo and White 2016).  
Despite the absence of discrete protein aggregates and lack of ER stress markers, there was 
an induction of autophagy at 72 h in cells treated with Z-VAD-fmk (but not Q-VD-OPh). 
Autophagy was assessed by the production of GFP-LC3 positive-puncta in a stably-
transfected HEK cell-line.  A stable cell line was used over transient transfections due to a 
more homogenous population and a higher number of cells expressing the construct. 
Although both methods cause increased levels of LC3 (which can promote aggregates) using 
a stable cell line avoids potential stress resulting from transfection.  The increase in levels of 
autophagy resulting from Z-VAD-fmk treatment was also confirmed using a GFP-RFP-LC3 
construct.  The effects on autophagy following Z-VAD-fmk treatment were consistent across 
both cell lines. Efforts to further confirm autophagy activation using immunoblotting were 
unsuccessful.  
Further support for the induction of autophagy following Z-VAD-fmk treatment (but not Q-
VD-OPh treatment) comes from the use of genetic KO MEFs. ATG13 KO MEF cells showed 
increased cell toxicity measured by MTT in the presence of Z-VAD-fmk but not to Q-VD-OPh.  
Although not a direct measurement of autophagy, this serves to confirm Z-VAD-fmk has toxic 
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effects on cells which cannot undergo autophagy, and is suggestive of a mechanism whereby 
autophagy is protective under conditions of Z-VAD-fmk exposure.  
To examine if the effects observed on Z-VAD-fmk treatment on autophagy and ThT 
fluorescence could be rescued by over expression of a Z-VAD-fmk insensitive form of the 
enzyme, a Z-VAD-fmk insensitive PNGase construct suitable for mammalian expression was 
constructed.  Cloning and sequence analysis of the plasmid found correct incorporation of 
bacterial PNGase F into the backbone plasmid.  However, transfection of the plasmid into 
HEK cells resulted in high levels of cell death.  It is possible that these toxic effects were a 
result of large quantities of the enzyme being produced, or the incompatibility of bacterial 
proteins with the expression host (similar levels of toxicity were observed when transfection 
was tested with a plasmid from another bacterial colony which had the same sequences and 
the effects were the same indicating it is not just a single plasmid effect but general to 
transfections of bacterial PNGase).  
Pharmacological inhibitors are rarely specific and as previously explored, Z-VAD-fmk has a 
high number of potential targets.  These include multiple caspases, N-glycanase and various 
lysosomal cathepsins. To further confirm that the effects found under Z-VAD-fmk 
treatment were linked to N-glycanase inhibition, the effects following genetic ablation 
of N-glycanase were examined using siRNA. 
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Chapter 4. 
4.1 Introduction 
 
The interplay between autophagy and apoptosis is key to cellular maintenance and survival. 
Autophagy has been implicated in apoptosis in several cases (termed autophagic cell death) 
(Button et al. 2015). Caspases can also play a role in the regulation of autophagy via 
interactions with BECLIN-1. Caspase 3 mediates BECLIN-1 cleavage, decreasing autophagy 
and promoting apoptosis (Zhu et al. 2010, Wirawan et al. 2010, Button et al. 2015). 
Therefore, inhibition of caspases may increase levels of active BECLIN-1 inducing autophagy. 
To induce apoptosis, the c-terminal fragment of BECLIN-1 localises to the mitochondria and 
induces the release of cytochrome c (Li et al. 2011). 
 
Cathepsin inhibition halts autophagic flux through lysosomal dysfunction. Several caspase 
inhibitors including Z-VAD-fmk have been identified as inhibitors of cathepsins (Schotte et al. 
1999). Cathepsins are lysosomal proteases involved in cargo degradation (Turk et al. 2012).  
The IC50 of cathepsins by Z-VAD-fmk and other caspase inhibitors with similar structures (Z-
DVED-fmk 12 and Z-YVAD-fmk 13) are shown in Table 4.1. The IC50 was determined using 
crude lysate from rat liver incubated with inhibitors (30 min, 25 °C). Active cathepsins were 
labelled with 125I-DCG-04 which covalently binds the active site of cathepsins. Loss of 
labelling indicates inhibition of the cathepsins by the caspase inhibitors (Rozman-Pungerčar 
et al. 2003).  The same group also examined at cathepsin inhibition in a cell culture model. 
In Jurkat T cells treatment with Z-VAD-fmk (100 µM, 24 h) followed by addition of Z-FR-AMC 
and Z-RR-AMC (cathepsin B substrates) the amount of AMC released was measured. Z-VAD-
fmk treatment resulted in a loss of more than 50 % activity. In HEK293 cells, treatment 
resulted in a loss of 88-96 % cathepsin activity (Rozman-Pungerčar et al. 2003). This crossover 
of inhibition is likely due to the cysteine residue in the active sites of both caspases and 
cathepsin.  
12 
 
13
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Table 4.1 IC50 of Cathepsin inhibition of caspase inhibitors 
 Z-DEVD-fmk 11 Z-YVAD-fmk 12 Z-VAD-fmk 1 
Cathepsin X 0.63 µM 0.65 µM 1.9 µM 
Cathepsin B 0.62 µM 1.4 µM 3.1 µM 
Cathepsin C 100-170 µM 100-170 µM Data not found 
Cathepsin J 100-170 µM 100-170 µM Data not found 
Cathepsin H >200 µM >200 µM >200 µM 
 
Lysosomes are an important component of autophagy as well as antigen signalling and 
cellular stress signalling (Man and Kanneganti 2016).  Lysosomes fuse with autophagosomes 
to produce autolysosomes which contain cathepsins, as well as other hydrolytic enzymes and 
degrades cargo. Inhibition of cathepsins results in an increase in LC3II due to the protein not 
being degraded completely in multiple cells types (Jung et al. 2015, Herzog et al. 2012). 
Treatment with Z-VAD-fmk (50 µM, 72 h) found an increase in autophagosomes although 
this was not found with pan-caspase inhibition (Q-VD-OPh, 50 µM, 72 h) but also no 
increased ROS production which could be due to inhibition of BECLIN-1 cleavage.  
Exploring the effects Z-VAD-fmk on N-glycanase is therefore complicated, as Z-VAD-fmk has 
been shown to exert inhibitory effects on a number of other proteins implicated in the 
regulation of autophagy and apoptosis (including caspases, cathepsins and proteinases).  In 
order to determine if the effects of Z-VAD-fmk treatment are specifically linked to the 
inhibition of N-glycanase in HEK cells, siRNA was used as tool to selectively reduce the levels 
of N-glycanase expression in the cell.  
RNA interference (RNAi) is a powerful tool which can be employed to effect transient 
reduction in levels of specific proteins within the cell. This mechanism relies upon the 
capacity of anti-sense RNA to inhibit gene expression (Kim and Rossi 2008) and can be 
employed in an experimental setting to selectively silence or knock-down the expression of 
a target gene, allowing the assessment of the individual contribution of genes to a specific 
observed cellular effect. RNAi is an umbrella term for different mechanisms of RNA based 
gene regulation via the degradation of specific mRNA. RNAi is mediated by double stranded 
RNA (dsRNA) including siRNA and shRNA. 
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Figure 4.1 Diagram depicting the mode of action of siRNA and shRNA gene silencing. 
 
Eukaryotic cells contain micro RNAs (miRNA), an endogenous system of gene silencing via 
mRNA degradation. Figure 4.1 shows the processing of synthetic miRNA which start as large 
primary RNA (pri-mRNA) which are processed in the nucleus by Drosha and Pasha to produce 
~ 65-75 nucleotides long hairpin pre-miRNAs (Redfern et al. 2013, Tan et al. 2011). These are 
exported into the cytoplasm by Exportin 5 where they interact with the Dicer complex 
containing TRBP and PACT which are involved in miRNA processing (Wilson et al. 2015). Dicer 
further processes these dsRNA molecules in shorter, around 22 nucleotide long mature 
miRNA. The guide RNA sequence can then interact with the RNA-induced silencing complex 
(RISC). The RISC complex is composed of many different proteins. Guide RNA sequences are 
loaded onto Argonaute proteins, the catalytic enzyme required for miRNA processing 
(Redfern et al. 2013). Under experimental conditions, synthetic double stranded RNA is 
introduced into cells in the form of siRNA or shRNA. This can be achieved by a variety of 
methods, including by electroporation, viral mediated delivery or the use of cationic 
liposome based transfection agents or by modified siRNA that can be taken up by cells in a 
passive manner (Jie Wang et al. 2010). Exogenous siRNAs are usually around 21-23 base pairs 
of dsRNA with symmetric 2-3 base pair overhangs. The siRNA structures also contain a 5’ 
phosphate group and a 3’ hydroxyl group (Pham and Sontheimer 2005). Once inside the cell 
the siRNA forms a complex with RISC. RISC is composed of proteins including Argonaute 2, 
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Dicer and the Tar RNA binding protein (TRBP) (Daniels et al. 2009).  Collectively, this forms 
the minimal RNA-induced silencing complex (RISC) assembly. The siRNA is unzipped and the 
anti-sense strand is retained as a guide. This guide RNA binds to complementary target mRNA 
creating a new dsRNA which is degraded by Dicer complex (Bartlett and Davis 2006, Hannus 
et al. 2014). Without the mRNA of a protein it cannot be translated resulting in a knockdown 
of the protein.  
There are a number of factors that interfere with the efficacy of siRNA silencing. Efficient 
siRNA knockdown relies on efficient delivery into cells, the efficiency of the siRNA molecules 
to knockdown the target gene and the specificity of that pool. The first is that the efficient 
delivery of siRNA into cells is dependent upon the method of transfection. Different 
transfection strategies are available as shown in Table 4.2. Transfection is a common way of 
introducing exogenous DNA into cell culture, and has been employed in this study. However, 
the method used can impact cellular health and metabolic efficiency. If cells are not 
amenable to common transfection methods, electroporation or viral mediated methods may 
be used as alternatives.  
Table 4.2 Transfection strategies for siRNA  
Cellular Uptake 
Strategy 
Advantages Disadvantages 
Transfection 
(Cationic liposomes 
/ polymer) 
 Fast 
 Many cell types 
 Use for plasmid DNA, 
ssDNA, siRNA and shRNA 
 Not all cells are 
favourable to 
transfection 
methods 
Electroporation  Recommended for difficult 
to transfect cells 
 Increased cell 
death 
Viral-mediated  Good for difficult to 
transfect cells 
 Used for stable 
transfections 
 Undertaken 
under Biosafety 2 
conditions 
 
Increased siRNA concentration increases the amplitude and duration of siRNA mediated 
knockdown in vitro and in vivo (Bartlett and Davis 2006, Caffrey et al. 2011, Hannus et al. 
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2014). As well as concentration, the doubling time of the cell line can affect the duration of 
gene silencing. Fast doubling times (~ 1 day) have a silencing duration of approximately 7 
days. In non-dividing cells knockdown is predicted to last around 21 days (Bartlett and Davis 
2006). Indicating dilution via cell division of the siRNA impacts the ability to knockdown 
target proteins significantly.  
Small interfering RNA is not completely specific to the target gene and off target effects are 
sometimes seen which can lead to complications in interpretations if other mRNAs are also 
being knocked down. Off-target effects can be due to partial complementarity to other 
mRNA sequences apart from the intended target, inflammatory response caused by delivery 
technique used such as lipid transfection reagents or changes in endogenous microRNA 
processing by saturation of the machinery with synthetic siRNA (Jackson and Linsley 2010).  
Increased doses of siRNA correlates with increased number of off-target gene silencing 
(Caffrey et al. 2011). Pooling siRNAs can also help to reduce off-target effects. All the siRNA 
sequences target the specific gene but will have different levels of off-target effects meaning 
that there is efficient target knockdown but less off-target silencing (Jackson and Linsley 
2010). The siRNA used in this study was a pool of four different siRNA species targeting N-
glycanase each with different levels of off-targeting. A blast search of the siRNA sequences 
have shown the highest sequence homology of 78 % homology of sequence 1 and 3 targeting 
adhesion G protein-coupled receptor D2 (ADGRD2) and RUN domain containing 3B 
(RUNDC3B) respectively and sequences 2 and 4 with 73 % targeting GRIP and coiled-coil 
domain containing 2 (GCC2) and GDNF family receptor alpha 1 (GFRA1) respectively.  
Factors involving the stability or the introduction of secondary structures in the siRNA 
molecule can affect interactions with the target mRNA decreasing silencing. However, there 
are now a number of companies dedicated to the design of siRNA products that remove 
secondary structures and increase intracellular stability.  
Other than sequence design and transfection optimisation, factors innate to the target or 
cell line effects the efficiency of gene silencing that are still not well understood. For example, 
knockdown studies using the KRT7 gene found knockdown of greater the 90 % In HeLa cells 
but only around 30 % decrease in HEK 293 cells compared to controls (Hong et al. 2014). 
Although the reason for these differences is still unclear, one reason could be changes in 
target concentration or life-span of the target in different cell types. 
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4.2 Aims and Objectives 
 
The aim of this chapter is to look at the effect of genetically downregulating N-glycanase in 
HEK cells. This will allow confirmation of the cause of the effects of treatment with the 
pharmacological agent Z-VAD-fmk and enable the further characterisation of the effects of 
N-glycanase deficiency in a standard cell culture model.  
4.3 Results 
 
In this section, the effects of siRNA mediated knockdown in HEK cells were characterised. 
The efficiency of siRNA mediated knockdown was assessed by quantification of N-glycanase 
mRNA levels. The effects on cell viability were established by MTT cytotoxicity assay. N-
glycanase activity was measured using the ddVENUS fluorescence assay 72 h post 
transfection. The effect on the glycoprotein population was assessed by lectin binding profile 
of whole cell lysates. Evidence of protein aggregates was studied using the β-sheet binding 
dye, ThT 11. The level of autophagy following N-glycanase deficiency was studied 
through quantification of the number of GFP-LC3 positive puncta in HEK cells.  
 
Protein aggregates or dysfunction in protein degradation as hypothesised to occur in N-
glycanase deficiency (Huang et al. 2015, Martinet et al. 2006b, Misaghi et al. 2005) also 
play a role in the activation of ER stress and the unfolded protein response (UPR). Genes 
upregulated during the UPR were tested under siRNA knockdown of N-glycanase. 
Another measure of ER functioning and stress is Ca2+ handling in the ER. Stress can lead 
to a ‘leakiness’ in ER Ca2+ channels. ER Ca2+ was quantified by the ratiometric Fura-2 
under inhibition of SERCA channels by Thapsigargin. Protein aggregation has also been 
linked in other disorders with increased oxidative stress. Oxidative stress was measured 
by flow cytometry fluorescence intensity of the ROS indictor, ROS Brite 570.  
 
As in the previous chapter, the effect on O-GlcNAc modifying enzymes was examined.  
Evidence has been presented that supports the hypothesis that under N-glycanase 
deficiency, another glycan processing enzyme ENGase can act on the glycans of 
misfolded proteins leaving N-GlcNAc positive proteins and this may lead to O-GlcNAc 
dysfunction in cells (Huang et al. 2015). O-GlcNAc modifying enzymes, OGA and OGT 
were used as an indicator of changes in O-GlcNAc signalling homeostasis.   
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4.3.1 No effects on cell viability are observed in cells transfected with NGLY1 siRNA 
To test the efficiency of N-glycanase knockdown, HEK cells were transfected using 
DharmafectTM or jetPRIME® with 10-40 nM ON-TARGET plus siRNA smart pool (Dharmacon 
L-016457-01-0005) containing four sequences of siRNA targeting N-glycanase. RNA was 
extracted 48 h post-transfection and N-glycanase mRNA was measured by RT-qPCR. The 
control was a non-targeting siRNA control of 40 nM transfected with either DharmafectTM or 
jetPRIME®. Transfection using DharmafectTM resulted in a reduction in N-glycanase mRNA by 
16 %, 48.4 % and 47.4 % at 10 nM, 25 nM and 40 nM respectively (figure 4.2). JetPRIME® 
transfection resulted in a reduction of N-glycanase mRNA by 64 %, 79 % and 71 % at 10 nM, 
25 nM and 40 nM respectively (figure 4.2). To minimise off-target effects, the minimum 
amount to still provide maximal knockdown was used, 25 nM siRNA with jetPRIME® was used 
for subsequent tests. 
 
Figure 4.2 Transfection of NGLY1 siRNA in HEK cells.  Data represents the % KD compared 
to a non-targeting control. Two-way ANOVA, Dunnett’s post hoc compared to non-
targeting siRNA. ** P < 0.01, *** P < 0.001, Error bars ± SEM, n=3. IC50 calculated for 
Dharmafect = 29.73 nM. IC50 calculated for JetPRIME®  = 1.4 nM from three concentrations.
Z-VAD-fmk did not show a decrease in cell viability, although this could be due to its role in 
caspase inhibition. Cell viability was assessed using an MTT assay comparing siRNA 
knockdown to a non-targeting control matched to the same time post-transfection. Figure 
4.3 shows no significant decrease in cell viability after 7 d post-transfection when compared 
to day 0.  
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Figure 4.3 MTT cell viability assay. HEK cells transfected with 25 nM NGLY1 siRNA over 7 
days. Data normalised to non-targeting control of the same time and Day 0 represented as 
100 %. One-way ANOVA. No significant differences were found compared to time 0.
4.3.2 Knockdown of N-glycanase decreased fluorescence of the deglycosylation dependent 
VENUS protein  
The levels of mRNA do not always reflect protein and activity levels. Western blotting can 
determine the level of specific proteins in a sample, however, western blotting of N-
glycanase proved unsuccessful. The deglycosylation dependent activity of the ddVENUS 
fluorescence assay was used to determine effective knockdown of N-glycanase activity. 
Fluorescence signal in HEK cells was measured three days post-transfection. Figure 4.4 shows 
the significant reduction in fluorescence intensity as a percentage compared to the non-
targeting control. There was a significant different in median fluorescence intensity with a 
68 % reduction. 
 
 
0 1 2 3 4 5 6 7
0
5 0
1 0 0
1 5 0
t im e  (d )
a
b
s
o
rb
a
n
c
e
147 
 
 
Figure 4.4 ddVENUS fluorescence is reduced by 68 % 72 h post-transfection. HEK cells were 
transfected with NGLY1 siRNA or non-targeting siRNA (25 nM) with JetPRIME® for 3 d 
followed by transfection with ddVENUS construct with JetPEI. After 72 h fluorescence 
intensity was analysed by flow cytometry. Data represents percentage of fluorescence 
normalised to non-targeting control. Students t-test, ** P < 0.01, error bars ± SEM, n=3.
4.3.3 Glycan profile of cells transfected with NGLY1 siRNA is not affected 
Due to N-glycanase role as a glycan processing enzyme, the glycoprotein profile was tested 
using lectin dot blots. HEK cells were transfected with N-glycanase or non-targeting siRNA 
over 5 d. Cells were collected, lysed and whole cell lysates were applied to a nitrocellulose 
membrane and incubated with ConA, LCA, PHA-E, WGA and sWGA. Figure 4.5 shows the 
fluorescence intensity of each fluorescein labelled lectin binding to 1 µg of whole cell lysate. 
There was no significant difference in lectin binding compared to the non-targeting controls.  
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Figure 4.5 Log2 fold change of fluorescein-labelled  a) ConA, b) LCA, c)  PHA-E, d) WGA, e) 
sWGA biondign to 1 µg of whole cell lysate. Fluorescence normalised to untransfected 
control. Error bars ± SEM, n=3, Two way ANOVA, P > 0.05.
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4.3.4 Differences in Thioflavin T fluorescence are observed following NGLY1 siRNA 
knockdown 
Inhibition of N-glycanase using Z-VAD-fmk exhibited a transient increase in ThT fluorescence 
after 48 h, decreasing to basal levels at 72 h. To determine whether this was an effect caused 
by decreased N-glycanase activity and not caspase/cathepsin inhibition, the staining of ThT 
was studied after siRNA knockdown of N-glycanase. HEK cells were transfected with N-
glycanase siRNA or the non-targeting control for 3-5 d followed by incubation with ThT (1 
µM, 30 min) and imaged. Figure 4.6a shows the fluorescence intensity per cell was 
normalised to an untreated control. There was a significant difference between non-
targeting 4 d and N-glycanase siRNA 4 d. However, there was increased variation within the 
non-targeting control group with significant differences occurring between days 3, 4 and 5. 
It is the variation in the non-targeting controls which caused this significance leading to 
unreliable results. This could be due to the transfection causing cellular stress and the cells 
recovering at different rates over time or variations in transfections on different days. Figure 
4.6b shows representative images of ThT staining day 4 post-transfection.  
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Figure 4.6 ThT fluorescence in cells transfected with NGLY1 siRNA or non-targeting siRNA 
over 3-5 d. a) HEK cells were stained with ThT (1 µM, 0.5 h). Fluorescence intensity per cell 
was calculated and normalised to an untreated control. A minimum of three images were 
taken per coverslip and three biological replicates were analysed for each condition.  Error 
bars ± SEM, n=3, P < 0.05. Two-way ANOVA, Tukey’s post hoc b) Representative images of 
HEK cells 4 d post-transfection with the non-targeting control or NGLY1 siRNA. 
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Flow cytometry analysis of ThT was also employed to confirm changes seen in fluorescence 
microscopy, allowing an increased number of cells to be analysed with 10 000 cells gated per 
condition with three biological replicates. Figure 4.7a shows the flow cytometric analysis of 
ThT which included the treatment with the proteasome inhibitor MG132 (100 nM, 18 h) to 
induce the formation of protein aggregates. There was no significant increase in fluorescence 
within or between the siRNA groups. However, there was a slight increase in ThT intensity 
after day 5 of 21 % of the siRNA knockdown which resulted in a non-significant difference 
between ngly1 siRNA day 5 and MG132. A representative histogram of the ThT fluorescence 
at day 5 post-transfection is shown in Figure 4.7b.  
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Figure 4.7 Flow Cytometric analysis of ThT after transfection with 25 nM NGLY1 siRNA or 
non-targeting siRNA over 3-5 days or MG132 (100 nM, 18 h). a) 10 000 cells were calculated 
per condition with three biological replicates. Median fluorescence intensity of ThT is 
presented. A significant increase in ThT fluorescence of cells treated with MG132 
compared to non-targeting siRNA days 3-5 and NGLY1 siRNA days 3 and 4 was found. 
MG132 acts as a positive control to increase misfolded proteins. Two-way ANOVA, Tukey’s 
post hoc Error bars ± SEM, P < 0.05, n=3. b) Representative histogram of ThT fluorescence 
of Ngly1 siRNA, non-targeting siRNA (25 nM, 5 d) and MG132 (100 nM, 18 h). 
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4.3.5 Knockdown of N-glycanase with siRNA induces autophagy  
In order to establish whether siRNA knockdown of N-glycanase results in an increase in levels 
of autophagy, GFP-LC3 labelled autophagosomes were quantified. Figure 4.8 shows the 
quantitation of GFP positive puncta 3-5 d post-transfection with N-glycanase siRNA and non-
targeting siRNA control. Five days post-transfection with N-glycanase siRNA there was a 
significant increase in the number of GFP positive puncta compared to the non-targeting 
siRNA control (with an increase of an average of 2 puncta per cell to 5.8 puncta per cell).  
 
Figure 4.8 GFP-LC3 puncta are increased after 5 d post-transfection with NGLY1 siRNA (25 
nM). Quantitation of the average GFP-LC3 puncta per cell, minimum of three images per 
coverslip with three biological replicates. Error bars indicate ± SEM, ** P < 0.01, *** P < 
0.001, Two way ANOVA, Tukey’s post hoc.
Figure 4.9 shows representative images of GFP-LC3 HEK cells 5 d post-transfection with both 
N-glycanase and non-targeting siRNA control. This shows an increase in GFP-LC3 puncta in 
the N-glycanase knockdown.  
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Figure 4.9 Representative images of HEK cells transfected with NGLY1 siRNA or non-
targeting siRNA after 5 days. Scale bar indicates 10 µm.
To determine if the puncta observed are due to a blockage in autophagosome degradation, 
autophagic flux was examined using the autophagic modifiers Bafilomycin A1 and 3-MA. 
Figure 4.10 quantified the number of puncta following Bafilomycin and 3-MA treatment. A 
significant increase in GFP positive puncta following Bafilomycin treatment was observed in 
both the non-targeting control cells and N-glycanase siRNA cells. Following treatment with 
3-MA a significant drop the average number of GFP-LC3 positive puncta per cell is observed. 
This indicates that autophagic flux is not inhibited and the increase in autophagosomes 
represents a true increase in autophagic activity.  
 
ngly1 siRNA non-targetingNGLY1 iRNA Non-targeting siRNA 
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Figure 4.10 GFP-LC3 puncta per cell after transfection with NGLY1 siRNA of non-targeting 
siRNA (25 nM, 5 d) with Bafilomycin A1 (100 nM, 1 h) or 3-MA (5 mM, 1 h). Error bars ± 
SEM, ** indicates P < 0.01, *** indicates P<0.001, **** indicates P < 0.0001.  Two-way 
ANOVA, Tukeys post hoc.
 
4.3.6 Autophagy is a protective measure during N-glycanase knockdown 
ATG13 KO MEFs were sensitive to Z-VAD-fmk treatment and resulted in decreased formazan 
absorbance. In order to examine if ATG13 KO MEF cells showed sensitivity to genetic ablation 
of N-glycanase, cell viability was assessed by MTT assay. ATG13 KO MEF cells and 
corresponding WT MEFs were transfected with N-glycanase siRNA or the non-targeting 
control. Figure 4.11 shows the formazan absorbance for each cell type was normalised to the 
formazan absorbance of the non-targeting siRNA and absorbance was compared to day 0 
post-transfection. A significant decrease was observed following day 3; WT MEFs absorbance 
at 97% compared to day 0 with ATG13 KO MEFs at 62 % of the control and a final reduction 
to 46 % by day 7 while WT MEFs were at 86 %. These results demonstrate that functional 
autophagy is important for survival under N-glycanase knockdown.  
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Figure 4.11 MTT of ATG13 KO and WT MEFs transfected with NGLY1 siRNA  or non-targeting 
control (25 nM). Values normalised to cells transfected with non-targeting siRNA (25 nM) 
and percentage of Day 0. One-way ANOVA, Dunnett’s post hoc, error bars ± SEM, n=3, P < 
0.05.
 
4.3.7 Genetic ablation of N-glycanase does not induce cellular stress  
N-glycanase is closely involved in ERAD by removing glycan chains from misfolded proteins 
destined to be degraded by the proteasome. Disruption or slowing of this process has been 
hypothesised to result in ER stress responses (Misaghi et al. 2005, Martinet et al. 2006b). 
This hypothesis is based upon the observations that the ERAD substrate RTAΔm is stabilised 
under N-glycanase deficiency (Huang et al. 2015) indicating the possibility of aggregates and 
therefore activation of the UPR. Recent evidence from murine models however has found 
no evidence for ER stress in the absence of N-glycanase activity concluded by the absence of 
protein aggregation staining of Congo red and PAS (Fujihira et al. 2017) but no measure of 
protein markers associated with ER stress. In order to evaluate if ER stress/activation of the 
UPR occurs under N-glycanase genetic ablation two approaches were employed. The levels 
of characteristic ER stress markers (CHOP, BiP, ATF4 and EDEM) were examined by RTq-PCR. 
In addition, ER Ca2+ homeostasis following genetic ablation of N-glycanase activity was also 
quantified. A last measure of stress measured was oxidative stress (which has been reported 
to be linked to ER stress (Mota et al. 2015, Dandekar et al. 2015, Rinnerthaler et al. 2015).   
Total RNA was extracted from cells 3, 4 and 5 days post transfection with N-glycanase or non-
targeting siRNA or a positive control for the UPR, MG132 (100 nM, 18 h) and RT-qPCR was 
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used to determine levels of CHOP, BiP, ATF4 and EDEM. Figure 4.12 shows the log10 fold 
change in expression compared to the non-targeting control. There was no significant 
difference in mRNA levels of these stress markers in cells exposed to N-glycanase siRNA.  The 
proteasome inhibitor MG132 (100 nM, 18 h) was used as a positive control (Velentzas et al. 
2013)). Significant upregulation of the ER stress markers, CHOP, BiP and ATF4, was observed 
in the presence of MG132. The results obtained suggest that siRNA knockdown of N-
glycanase does not induce ER stress and activation of the UPR.  
 
Figure 4.12 RT-qPCR anlaysis of CHOP, BiP, ATF4 and EDEM levels in cells transfected with 
NGLY1 siRNA  or non-targeting siRNA (25 nM, 3-5 d). mRNA levels normalised to GAPDH 
and a non-targeting siRNA control. Log10 fold change is presented with error bars ± SEM, 
**** P < 0.0001, P < 0.05, n=3. Data anlysed using ΔΔCt method. One-way ANOVA followed 
by Dunnett’s post hoc comparing experimental to MG132 positive control.
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Changes in ER Ca2+ homeostasis provide an additional means of quantifying ER stress. 
Treatment of cells with Thapsigargin, a sesquiterpene lactone which acts as a potent non-
competitive inhibitor of SERCA, results in inability of the ER to replenish ER Ca2+ stores. As 
Thapsigargin also induces the influx of calcium ions from the extracellular media into cytosol 
(Huang et al. 2011), the quantification of ER Ca2+ profile was carried out in calcium-free 
imaging buffer supplemented with EDTA (1 mM) (Cameron et al. 2016, Gigout et al. 2005). 
Figure 4.13 shows HEK cells after siRNA knockdown of N-glycanase and non-targeting siRNA 
loaded with Fura-2 AM (1 µM) and incubated in calcium free media for 5 min prior to imaging. 
ER Ca2+ leak was simulated by the addition of Thapsigargin (1 µM) after 180 s. As intracellular 
Ca2+ increases the fluorescence 340/380 ratio increases.  
 
 
Figure 4.13 Traces of intracellular Ca2+ in calcium free buffer after the addition of 
Thapsigargin (1 µM) at 180 s. HEK cells transfected with either, a) NGLY1 siRNA or, b) non-
targeting control (25 nM, 3-5 d). Error bars ± SEM, n=3. 
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To quantify any differences in Ca2+ handling the total peak area, peak height and baseline 
measurements were quantified (Figure 4.14). Figure 4.14a shows the total peak area was 
measured by taking the area under the curve (AUC). This gives a measure of the total Ca2+ 
released from the ER. There was no significant differences in N-glycanase targeted siRNA 
compared to the non-targeting control. Due to no changes in the AUC, the faster Ca2+ 
mobilises from the ER the taller the Fura-2 peak. There were no significant changes 
compared to the non-targeting control (figure 4.14b). The baseline level of Fura-2 
fluorescence was recorded for 3 min prior to the addition of Thapsigargin (1 µM). The 
measuring of basal not only gives information about the role of ER Ca2+ but also of basal Ca2+ 
levels during rest (figure 4.14c). There were no significant differences measured in baseline 
cytosolic Ca2+ levels in N-glycanase knocked down cells compared to the non-targeting 
control.   
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Figure 4.14 HEK cells transfecetd with NGLY1 siRNA or non-targeting siRNA (25 nM, 3-5 d). 
toatal peak area was calculated by the AUC. Hieight of peak was calculated by the heighest 
reading. Baseline calcium levels were calculated from the average of the first eight readings 
in calcium free imaging buffer. Error bars ± SEM, n=3. Two-way ANOVA, no significant 
differences.
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Mitochondria, as the main energy source of the cell are good indicators of cellular health, 
and functioning can be affected by other organelles (Marchi et al. 2014, Malhotra and 
Kaufman 2011). The mitochondria are a major source of ROS leading to oxidative stress 
(Zorov et al. 2014). Oxidative stress has been defined as a dysfunction in the homeostasis 
between reactive oxidant species production and antioxidant defences (Betteridge 2000). 
Oxidative stress is initiated by the presence of increased reactive oxygen species (ROS), such 
as hydrogen peroxide, nitric oxide, superoxide, hydroxyl and monoxide radicals. ROS levels 
were quantified by flow cytometry using the ROS indicator ROS BriteTM 570 shown in figure 
4.15. There were no significant differences between N-glycanase targeting siRNA and the 
non-targeting control. However, when comparing within the N-glycanase siRNA treatment, 
there was a significant increase after day 3 with an increase from an average of 16 FI units to 
21 for days 4 and 5. This is a small increase and is not significant compared to the non-
targeting siRNA controls.  
 
 
Figure 4.15 HEK cells transfecetd with NGLY1 siRNA or non-targeting siRNA (25 nM, 3-5 d) 
and incubated with Ros Brite 570 (5 µM, 30 min). Two-way ANOVA, Tukey’s post hoc. * P 
< 0.05, Error bars ± SEM, n=3. 
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4.3.8 Expression of O-GlcNAc homeostasis enzymes are unchanged under N-glycanase 
knockdown 
Increased levels of O-GlcNAc impacts the expression of the enzymes that control them. OGT 
and OGA which catalyses the addition and removal of O-GlcNAc respectively. Thiamet G, an 
inhibitor of OGA has been used to study the increase of O-GlcNAc and expression levels of 
OGA and OGT. Inhibition of OGA results in an increase in O-GlcNAc and OGA measured by 
western blot (Zhang et al. 2014). It was further confirmed that Thiamet G increased mRNA 
transcript level of OGA after 6 h in HELA, SH-SHY5y and K562 cell lines (Zhang et al. 2014). If 
there is an increase in GlcNAc being detected in the cell this may have an impact on the 
GlcNAc modifying enzymes, especially on OGA levels.  
To assess changes in O-GlcNAc signalling, mRNA levels were measured by RTq-PCR. HEK cells 
were transfected with N-glycanase or control siRNA and total RNA extracted after 3, 4 and 5 
d. Figure 4.16a shows the log10 fold change in expression levels of OGA and in figure 4.16b, 
OGT levels. Expression was analysed using the ΔΔCt method using GAPDH as the 
housekeeping gene and compared to an untreated control. There were no significant 
differences in OGT or OGA mRNA expression levels after knockdown over day’s 3-5 post 
transfection. This indicates that O-GlcNAc homeostasis is not altered under N-glycanase 
knockdown.  
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Figure 4.16 OGA and OGT mRNA levels in HEK cells transfected with NGLY1 siRNA or non-
targeting siRNA (25 nM, 3-5 d). a) OGA levels, b) OGT levels. GAPDH was used as the 
housekeeping gene and values normalised to an untreated control. Fold change was 
calculated using the ΔΔCt method. Two way ANOVA. Error bars ± SEM. 
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4.4 Discussion 
 
The main situations in which off-target effects of siRNA may be observed include partial 
complementary binding to other mRNA targets and, saturation of endogenous microRNA 
machinery by synthetic siRNA leading to changes in endogenous processing (Fiszer-
Kierzkowska et al. 2011). In this study, a pool of four different siRNA sequences targeting N-
glycanase were used simultaneously. It has been shown that pools of siRNAs targeting the 
same gene minimise off-target effects compared to single siRNA (Hannus et al. 2014). The 
greater the number of siRNA sequences in each siPool means a lower concentration per 
individual sequence thus diluting the sequence specific off-target effects of each sequence 
(Hannus et al. 2014).  
The results from this series of experiments can be compared to the effects of treatment with 
the pharmacological inhibitor, Z-VAD-fmk treated cells. Kinetics of N-glycanase inhibition 
varies between experiments as Z-VAD-fmk is a much faster inhibitor compared to mRNA 
degradation. The effects of Z-VAD-fmk and N-glycanase siRNA have similar effects on HEK 
cells despite this difference in time-course. Both treatments resulted in a significant decrease 
in the fluorescence of the ddVENUS construct, indicating inhibition and KD of N-glycanase.  
In addition, both treatments showed no significant loss in cell viability measured by MTT 
assay < 100 µM Z-VAD-fmk or, over 7 d post-transfection with siRNA. There were no 
significant changes in the lectin binding profile of whole cell lysates under either 
pharmacological or genetic inhibition of N-glycanase, indicating no major defects in the 
glycosylation of proteins. 
Under Z-VAD-fmk inhibition there was a consistent transient increase in ThT after 48 h with 
decrease to basal levels at 72 h. Transfection of N-glycanase siRNA resulted in increased 
variation in ThT fluorescence resulting in a significant increase in ThT fluorescence compared 
to non-targeting control at 4 d measured by microscopy. Significant variation was also seen 
between days 3, 4 and 5 of the non-targeting control indicating transfection may have an 
effect. ThT measured by flow cytometry showed no significant changes in ThT fluorescence 
compared to the non-targeting control, although 5 d post-transfection showed an increase 
in ThT fluorescence closer to the positive control than the rest of the samples. There were 
changes in ThT under genetic ablation but variation between samples was more than with Z-
VAD-fmk.  
Under Z-VAD-fmk inhibition increased autophagosome number coincided with the reduction 
in ThT, suggesting that autophagy was activated by increased misfolded proteins. N-
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glycanase knockdown also found an increase in autophagosome number after 5 d compared 
to the non-targeting control, suggesting that increased autophagy levels can be linked to 
reduction in N-glycanase activity (rather than other effects of Z-VAD-fmk). Although the 
interaction with ThT is less clear due to the increased variation, increased presence of 
misfolded proteins is not likely to be the only explanation for increased autophagosomes. 
Again, stress signals that may be induced after increased protein aggregation or increased 
ER-load were studied. Both N-glycanase KD and Z-VAD-fmk found no increase in UPR-
associated gene upregulation, Ca2+ ER handling or ROS levels. This supports the evidence that 
N-glycanase deficiency in HEK cells does not cause classical protein aggregates or the 
concomitant cellular response and, is likely to not be a major cause of aggregates in 
unstressed, highly proliferative cells.  
OGA and OGT expression levels were analysed by rt-qPCR. There was no change in OGA or 
OGT indicating no global change in O-GlcNAcylation.  This was also confirmed by sWGA and 
WGA lectin dot blots.  
This chapter aimed to compare the results from Z-VAD-fmk treated HEK cells and siRNA 
mediated knockdown of N-glycanase to unpick the effects Z-VAD-fmk and the effects of N-
glycanase deficiency in a cell culture model. It can be concluded that N-glycanase deficiency 
can be linked to an increase in autophagy in HEK cells and could potentially explain 
phenotypes in other cell lines which have used Z-VAD-fmk as a caspase inhibitor. For 
example, L929 cells have been reported to exhibit cell toxicity following Z-VAD-fmk 
treatment (Cheng et al. 2008, Chen et al. 2011, Wu et al. 2008b). L929 has a dividing time of 
120 h, which compared to the HEK cells (which have a doubling time of 21.3 h) in this study 
could indicate that division helps cells deal with the effects of N-glycanase inhibition and, 
that this can be managed by increased levels of autophagy. In L929 cells, stress resulting from 
aggregates or dysfunctional organelles cannot be ameliorated by division as quickly and it 
has been reported that autophagy has led to autophagic cell death (Chen et al. 2011, Wu et 
al. 2008b).  
Both Z-VAD-fmk and siRNA mediated gene silencing of N-glycanase are transient methods to 
examine N-glycanase deficiency. Short-term inhibition or siRNA knockdown can give 
information of the importance of N-glycanase in cellular functions. However, transfections 
with siRNA may vary from experiment to experiment depending on the efficiency of siRNA 
introduction to the cell and nucleic-acid complexing. Gene silencing mediated by siRNA also 
has an increased knockdown time as the cell has to first degrade the active protein present 
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in the cell (which could have a half-life of around 30 h). This can lead to difficulty in measuring 
modest changes that are time dependent. Furthermore, short term inhibition does not look 
at how cells adapt over long periods of time. To examine this, efforts were then made to use 
CRISPR-mediated genome editing to create a stable KO of N-glycanase. Such a tool would 
enable the study of N-glycanase deficiency over a longer period of time, which may more 
closely resembling the clinical disorder.  
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Chapter 5. 
5.1 Introduction 
The Type II Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) system is an 
integral part of the prokaryotic and archaea adaptive immune defence system against viral 
infection (Rath et al. 2015a, Carter and Wiedenheft 2015, Barrangou and Marraffini 2014). 
The CRISPR region is an area of DNA found on both chromosomes and plasmids, made up of 
short repeated sequences which are separated by spacers (Figure 5.1). During infection, 
pathogenic DNA is incorporated into the spacers and transcribed into CRISPR RNAs (crRNA). 
The crRNA hybridise with transactivating CRISPR RNA (tracrRNA) and form a complex with 
the endonuclease CRISPR associated protein 9 (Cas9).  
 
 
 
Figure 5.1 Schematic representation of the CRISPR/Cas9 system (Rath et al. 2015b) Open-
access article distributed under the terms of the Creative Commons Attribution Licence (CC 
BY).
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The crRNA targets the Cas9 to the pathogenic DNA subject to the presence of a protospacer 
adjacent motif (PAM) (usually NGG where N is any amino acid) (Sander and Joung 2014, 
Louwen et al. 2014). Since the pathogenic DNA has been incorporated into the prokaryotic 
genome, upon the next infection with the same pathogen the CRISPR defence system is 
ready to go and provides memory to the immune system making it adaptive. As the targeting 
of the CRISPR/Cas9 system depends on short RNA sequences which share homology with 
target DNA, it can be exploited in the laboratory as a method for generating programmable 
genetic mutations in cells. There are three types of CRISPR systems, type I, II and II. The most 
commonly used is Type II (from Streptococcus pyogenes) (Li et al. 2016, Ran et al. 2013) as it 
requires the fewest number of proteins to be functional and is thus easier to apply to a 
laboratory setting.  
To create a mutation, the Cas9 endonuclease is used to make a cut in the DNA at a point 
determined by a short guide RNA (sgRNA) approximately 3-4 base pairs upstream of a PAM 
sequence. The sgRNA binds to complementary gDNA and brings the Cas9 endonuclease into 
contact with the DNA to create a double stranded break (DSB). As DNA can become damaged 
by the sometimes harsh environment of the cell (such as exposure to stressors like radiation 
damage and oxidative stress) DNA repair mechanisms are needed to maintain DNA stability.   
The cell has two methods of DNA repair following DSBs; non-homologous end joining (NHEJ) 
and homology directed repair (HDR) (Figure 5.2).   NHEJ repair is the most commonly used 
repair mechanism for DSBs in human cells (Williams et al. 2014). DSBs are recognised by the 
Ku70/80 heterodimer that recruits other NHEJ proteins to the site of the break including a 
DNA ligation complex. Repetitive cutting and repairing of a site results in insertion and 
deletion mutations (indels). For the incorporation of specific mutations, homology directed 
repair (HDR) is employed. A donor template containing the desired mutation with homology 
arms on either side (up to 100 bp) of the expected cut site is introduced into the cell.  Repair 
events result in the insert of a precise sequence.   
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Figure 5.2 Process of non-homologous end-joining repair and homology directed 
repair.Reprinted with permission from Macmillan Publishers Ltd (Ran et al. 2013).
 
WT Cas9 has two domains which exhibit nuclease activity, the RuvC1 and HNH domains 
shown in Figure 5.3 which together result in the cleavage of both strands of gDNA resulting 
in a double-strand break (DSB).  Three S. pyogenes Cas9 variants are commonly used. The 
wildtype (WT Cas9) creates a double stranded break in DNA, whereas a ‘nickase’ variant 
(Cong et al. 2013, Sander and Joung 2014) creates single stranded breaks.  The third variant 
exhibits no endonuclease activity.  In a laboratory setting, the endonuclease activity negative 
Cas9 allows targeting of DNA without cleavage. In this case Cas9 can act as a silencer, 
promotor or visualizer of the target region.  
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Figure 5.3 Crystal structure of S. pyogenes Cas9 showing RuvC and HNH active site. 
Reprinted with permission from AAS (Jinek et al. 2014)
The nickase variant contains a mutation in one of the two nuclease active sites of the 
WTCas9. This mutation results in an endonuclease which produces single stranded breaks in 
the DNA. Single strand DNA breaks are the most commonly found DNA damage and 
(Caldecott 2008) are repaired by higher fidelity methods less likely to create indels compared 
to NHEJ. WT Cas9 results in blunt DSB, however, to create a DSB using nickase Cas9, two 
nickase Cas9 variants need to be introduced with different but nearby guide sequences. This 
results in the formation of ‘sticky ends’. Although it is unknown how NHEJ treats sticky end 
DSB repair there is evidence to suggest longer sticky end DSBs (5 bp vs 3 bp overhang) 
enhances mutagenesis (Caldecott 2008). The nickase Cas9 systems also show more 
specificity than the WT counterparts because nickase uses two guide sequences rather than 
one. This makes it less likely that two sequences which share enough homology are near 
enough to create a DSB apart from at the target site, therefore decreasing off target effects 
compared to the WT Cas9. If there is sequence homology in other parts of the genome, these 
will only create single stranded breaks which are then repaired by the high fidelity HDR 
pathway which is less likely to introduce mutations. 
 
The timeline for generating CRISPR mediated genetically edited cells is shown in Figure 5.4. 
Design of guide sequences have been simplified by use of online bioinformatics resources 
(Lei et al. 2014, Brazelton et al. 2015) that calculate sequences next to PAM sites and 
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calculate off target effects. Cloning of guide sequences into the Cas9 plasmids is typically in 
the order of one week, whereas isolating clonal cells and expansion can take up to a month.  
 
CRISPR methods have several advantages over other techniques employed for targeted gene 
editing. CRISPR Cas9 is easily targeted depending on the guide sequence, as a new oligo can 
be synthesised and ligated in to the plasmid. This is significantly less time consuming than 
construction of transcription activator-like effector nucleases (TALENs) genes. The cut site 
for Cas9 is also reliable and predictable; Cas9 effects cleavage three base pairs upstream 
from the PAM site between the seventeenth and eighteenth nucleotide of the guide 
sequence on the target gene. Targeting does require a PAM site to be immediately 
downstream of the target site which may cause problems. Guide sequences can also 
potentially target other areas of the genome but off-target effects can be reduced using 
shorter guide sequences or nickase Cas9 variants.  
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Figure 5.4 Timeline of CRISPR mediated knockout protocol. Reprinted by permission from 
Macmillan Publishers Ltd (Ran et al. 2013).
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5.2 Aims and Objectives 
Whereas previous work studying the effect of inhibition and deficiency of N-glycanase has 
used methods resulting in short-term perturbation (pharmacological inhibition or siRNA 
knockdown), the aim of this chapter is to generate a genetic knockout of N-glycanase for the 
use in examining any effects related to long-term N-glycanase deficiency.  To explore effects 
which may be associated with long-term N-glycanase deficiency, CRISPR plasmids containing 
WT Cas9 (or the nickase variant) and guide sequences to target the N-glycanase gene were 
used in an attempt to create both general knockouts and the specific R401X N-glycanase 
mutation in cells. Based on the findings that a double knockout of N-glycanase and ENGase 
have a less severe phenotype (Huang et al. 2015), attempts were made to create an ENGase 
knockout cell line.  
 
5.3 Results 
In this chapter, the generation of guide DNA sequences for introduction into the WT and 
nickase Cas9 plasmids for the knockout of N-glycanase and ENGase will be discussed. Also 
discussed will be the efficiency of genomic editing in HEK 293 cells and determination of N-
glycanase activity in CRISPR Cas9 transfected cells and potential phenotypic differences. The 
WT and nickase Cas9 plasmids used in this work were developed by Ran et al. (2013), are 
human codon-optimised to increase translation of the Cas9 protein and contain a nuclear 
localisation sequence to target the Cas9 to the nucleus.  The nickase construct used in this 
study contains an aspartate to alanine point mutation (D10A) (Ran et al. 2013).   
 
5.3.1 Guide sequences for N-glycanase and ENGase were cloned into WT or 
nickase Cas9 plasmids  
 
WT Cas9 and nickase plasmids were generated containing guide sequences for N-glycanase 
and ENGase. Plasmids were created using two different guide sequences for each target 
(denoted A and B). Two sets were used to target N-glycanase. The constructs denoted PNG 
were designed to target areas close to the beginning of the protein. The constructs denoted 
RX were designed to target the area of the gene containing the most commonly found clinical 
mutation, R401X/c.1201A>T. In addition to the targeting Cas9 to form indel mutations, an 
insertion oligonucleotide containing the R401X mutation was designed for use with the RX 
plasmids for HDR editing. For each area, two sequences were designed, A and B. In WT Cas9 
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plasmids each one can be transfected to generate a DSB. However, they were also designed 
to target areas in close proximity so as when cloned into a nickase Cas9 plasmid backbone 
and co-transfected together a DSB could be effected (Table 5.1). Guide sequences were also 
generated for ENGase, another glycan processing enzyme (Huang et al. 2015) implicated in 
deglycosylation of misfolded glycoproteins in the absence of N-glycanase.  As ENGase and N-
glycanase double KO had a less severe phenotype it would be useful to also create an ENGase 
and N-glycanase KO cell line.  Sequences of the targeting DNA can be seen in Figure 5.5. 
Plasmid maps can be found in Appendix A.2, Figure A3 and A4.  
 
Table 5.1 Nomenclature of CRISPR constructs  
Cas9 Mutation Guide Sequence 
WT PNG A or B 
RX 
ENG 
Nickase PNG A and B co-transfected 
RX 
ENG 
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Primers were designed over the region of editing to facilitate sequencing of the area. Figure 
5.5 shows the areas of interest in N-glycanase and ENGase sequences. Magenta indicates the 
position of the primers while blue indicates guide sequence B and green indicates guide 
sequence A and yellow shows the position of the PAM site. For the RX mutation sequence, 
red text indicates the overlap region of the designed insertion oligo.  
 
 
Figure 5.5 Position of the guide DNA sequences in genomic DNA of N-glycanase and 
ENGase. Magenta indicates primer sequences, Blue indicates guide sequence A, green 
indicates guide sequence B and yellow indicates PAM sequences.
600 bp
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Primers were initially tested on WT HEK gDNA to ensure specificity (sequences can be found 
in Chapter 2, Table 2.4). Sequences were amplified using the KAPA High Fidelity polymerase 
(Kapa Biosystems) at 60 °C annealing temperature for all primers and run on a DNA agarose 
gel stained with Midori green (Figure 5.6). Despite a non-specific band in the PNGRX 
annealing temperature resulted in specific amplification of the sections. This allows 
amplification of the sequences that will be mutated and thus ensures that they can be 
sequenced to detect genome changes.   
 
  
Figure 5.6 PCR products of HEK gDNA amplified with sequencing primers. Primers are 
specific for the sequence. 
 
Table 5.2 Expected band size for each mutation 
Mutation Expected band size 
RX 570 
PNG 655 
ENG 629 
 
  
600 bp600 bp 
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5.3.2 Design of a repair template to introduce R401X mutation  
An oligonucleotide was designed in order to introduce the R401X (A1201T) mutation, the 
most common deleterious mutation associated with NGLY1 disorder.  This sequence was 
designed with homology arms of at least 50 bp each side of the mutation.  A restriction 
enzyme site (BSiWI) was introduced in this sequence, to ensure that there existed a means 
of analysing the resultant oligonucleotide insertion. Figure 5.7 shows the design of the 
oligonucleotide sequence for the insertion of the R401X (A1201T) mutation. The bottom 
sequence indicates the genomic DNA sequence of N-glycanase. The top sequence (shown in 
red) indicates the oligonucleotide. The primer positions for sequencing are shown in pink, 
whereas the guide sequences are highlighted in blue and green. PAM sites are displayed in 
yellow. The oligonucleotide contains a site for the restriction enzyme, BSiWI (shown as blue 
text). The important A to T mutation which gives rise to the A>T 1201 (R401X) clinical 
mutation is within the BSiWI cut site, and is underlined.  
 
Figure 5.7 Sequence of the repair template for use with RX plasmids to increase the 
homology directed repair pathway. Black indicates the gDNA of NGLY1. Red indicates the 
oligonucleotide sequence. Green indicates guide sequence A. Blue highlight indicates guide 
sequence B. Yellow indicates PAM sequence. Pink indicates primer sequences. Blue text 
indicates the BsiWI restriction enzyme site in the oligonucleotide. The underlined T 
indicates the mutation forming the A>T 1201 (R401X) clinical mutation.
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5.3.3. The surveyor assay was unable to determine genetic editing in HEK 293 
cells transfected with Cas9 constructs  
HEK cells were transfected with plasmids containing the WT Cas9 with the guide sequences 
A or B or the nickase pair using JetPei (3 µg total DNA per well in a 6 well plate). After 48 h, 
transfection efficiency was determined by observing the GFP signal. If transfection was found 
to be above 75%, genome stability was assessed using a surveyor assay. The surveyor assay 
is a technique used to measure mutations and contains an endonuclease which recognises 
mismatched DNA. Genomic DNA is amplified from WT control cells and test cells. The 
samples are mixed, denatured and hybridised. If mutations have occurred in the test sample 
there will be a mixed sample with some hetero-duplexes which contain mismatched 
sequences. The endonuclease can cut at these sites and the DNA can be analysed by agarose 
gel. WT sequences will have no cut sites but if the CRISPR method has been successful, the 
test sample can contain multiple fragments.  This process is presented schematically in Figure 
5.8.  
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Figure 5.8 Schematic representation of the surveyor assay. Cells are transfected with Cas9 
construct. The genomic DNA is extracted after several days and the area for genomic 
editing occurs is amplified by PCR. WT and edited DNA are denatured and hybridised 
together to form heteroduplexes. If the transfected DNA contains indel mutations this will 
form a mismatch in the sequence, which the surveyor nuclease recognises and makes a 
cut. The results can be visualised on DNA agarose gels. 
 
After transfection with the Cas9 RX and PNG constructs the surveyor assay did not detect 
mutations in this system. Figure 5.9 shows the results of the surveyor assay carried out on 
gDNA from isolated WT cells, HEK transfected with RXA plasmid, RXB plasmid and RXAB 
nickase pair from (left to right). Increased levels of transfected DNA were used to see if there 
were any low levels of cut DNA present.  The results from this assay do not show evidence 
of DNA cleavage. It is possible that the mutation rate was very low (as to be barely detectable 
against the background of uncleaved DNA) or, that the endonuclease did not cut.  
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Figure 5.9 Surveyor assay results from WT DNA (lane 2), WT Cas9 PNGrx guide sequence A 
(lane 3), WT Cas9 PNGrx guide sequence B (lane 4) and nickase Cas9 guide sequences A and 
B (lane 5).  MW markers (lanes 1 and 6)
 
5.3.4. Co-transfection with R401X oligo was unsuccessful  
To create the R401X mutation, an oligonucleotide sequence with the change from A > T at 
1201was generated. Double stranded DNA breaks around the area of the target mutation 
following co-transfection with the oligosaccharide should promote homology mediated 
repair. As well as the clinical mutation, a restriction enzyme site for BsiWI was designed into 
the oligonucleotide sequence. On incorporation into the genome, the area is amplified by 
PCR and incubated with BsiWI which results in a cut in edited cells but not in WT sequences. 
A successful cut will generate fragments of 237 bp and 333 bp compared to the 570 WT 
sequence. WT Cas9 guide sequences A and B were transfected and or nickase Cas9 guide 
sequence A and B co-transfected into HEK 293 cells and co-transfected with single stranded 
oligosaccharide. The established protocols for this systems (Ran et al. 2013) recommend 1 µl 
of oligo (10 µM) per 0.5 µg plasmid DNA transfected. The conditions per transfection are 
summarised in Table 5.3.  
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Table 5.3 Conditions for homology directed repair transfection 
Transfection 
reagent 
Plasmid 
DNA 
(µg) 
Oligo 
volume 
(µL) 
Digestion 
conditions 
JetPEI 
0.5 1 
18 h  55 °C 
 5 
1 1 
 5 
JetPRIME 
0.5 1 
 5 
1 1 
 5 
 
Under all conditions tested the DNA agarose gels showed no evidence of successful cleavage. 
A representative gel of HEK 293 cells transfected with 1 µg plasmid DNA with 5 µl oligo by 
JetPEI and digested with BsiWI at 55 °C for 18 h is shown in Figure 5.10.  As the incorporation 
of the cut site could not be confirmed, further transfections were studied using the PNG 
mutation guide sequences rather those targeting the clinical mutation. 
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Figure 5.10 Representative gel of HEK 293 cells transfected (JetPEI) with 1 µg plasmid DNA 
with oligo (5 µL) and digested with BsiWI (55 °C, 18 h).
 
5.3.5. Transfection with PNG guide DNA in WT Cas9 plasmids lead to genomic 
editing in the N-glycanase gene  
HEK cells were transfected with the PNG plasmids and the transfection efficiency was 
determined by recording the number of GFP positive cells with respect to the total 
population. gDNA was extracted 48 h post transfection and, the area of editing was amplified 
by PCR. The PCR product was sequenced and the raw sequencing files compared to those 
obtained from WT DNA using the Tracking of Indels by Decomposition (TIDE) analysis web 
tool (Brinkman et al. 2014). TIDE analysis looks at the difference of a mixed population of 
cells, calculates where the expected cut site is from the guide DNA sequence and calculates 
the percentage of edited sequences. For the first round of tests HEK cells were transfected 
with PNG plasmids, however, the quality of the DNA extracted was not suitable for the 
analysis. For analysis using the TIDE web tool, high quality sequencing is essential for 
detection of genomic editing as the tool relies upon peak fidelity and confidence levels of a 
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chromatogram to determine changes from a control sequence. Initially DNA was extracted 
from agarose gels but by removing this step and applying a nucleotide removal kit (NEB) 
increased DNA quality was achieved. The sequence prior to the PAM site is expected to be 
unmodified. For a good quality sequence, the percentage of aberrant sequences before the 
cut site is expected be below 10 %. After the cut site, the control sequence should remain 
below 10 % aberrant sequences and this level should be increased in the test sample.  
 
Previous research (Richardson et al. 2016) has shown that by co-transfecting non-
homologous DNA, such as bacterial plasmids, salmon sperm DNA and oligonucleotides with 
no homology for the target genome, the percentage of indels significantly increases. This 
method also increases the number of homozygous indels. A study testing different non-
homologous DNA with CRISPR mutations found HEK cells transfected with just the Cas9 
plasmid with guide DNA it was found to have around 60 % editing efficiency, all of which 
were heterozygous. With the addition of non-homologous oligonucleotides, editing 
efficiency increased to 40% heterozygous and 60% homozygous mutations (Richardson et al. 
2016).  
 
To ensure a high level of efficacy, HEK cells were co-transfected with PUC18 plasmid with 
either the PNG A or B WT Cas9 constructs (3 µg of DNA per well, 6 well plate). After 48 gDNA 
was extracted and the target site amplified and sequenced. Transfection efficiency for WT 
Cas9 PNG A was assessed using the TALI image based cytometer (Figure 5.11). 
 
 
 
 
Figure 5.11 Transfection of HEK cells with WT Cas9 construct guide sequence A after 48 h 
as assessed by quantification of the fluorescence signal a) representative histogram 
produced by TALI image based cytometer b) corresponding representative image of 
transfection generated by TALI image based cytometer. 
a b 
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The sequence data obtained for HEK cells transfected with WT Cas9 PNG guide sequence A 
and co-transfected with PUC18 plasmid were analysed by TIDE analysis. Figure 5.12a shows 
the TIDE analysis and Figure 5.12b shows the quantitation of indels formed. The graph 
indicates the number of insertion or deletion of nucleotides and the percentages of 
sequences that show these indels. WT HEK sample is represented in black and has a low level 
of aberrant sequences across the decomposition window while the test sample has a 
significant increase after the expected cut site, indicating genomic editing. There was a total 
efficiency of 33.9 %, with the highest possible editing being a +1 bp insertion of a cytosine 
residue.  
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Figure 5.12 TIDE analysis of HEK 293 cells transfected with WT Cas9 PNG guide sequence A 
a) TIDE decomposition window for WT Cas9 PNG guide sequence A seqeunce. b) 
quantitation of insertion and deletion percentages.
 
Under these conditions 12.9 % of the sequences were found to have a +1 bp insertion. Of 
these insertions, the most common insertion was a cytosine at 93.5 %. The original 
chromatograms of the wild type HEK cells transfected with PUC18 and cells transfected with 
WT cas9 with guide sequence A and co-transfected with PUC18 are shown in figure 5.13. The 
arrow indicates the predicted cut site where after this the quality of the sequence decreases.  
 
a 
b 
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Figure 5.13 Chromatograms from sequencing data HEK cells transfected with PUC18 (WT) 
and mixed population of WT Cas9 PNG guide sequence A and co- transfected with PUC18 
cells.
 
The same experiment was performed using WT Cas9 PNG guide sequence B construct co-
transfected with PUC18. Figure 5.14 shows the transfection efficiency of HEK cells 
transfected with guide sequence B.  
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a           b 
 
 
 
Figure 5.14 Transfection of HEK cells with WT Cas9 construct guide sequence B after 48 h 
a) panel histogram generated by TALI image-based cytometer b) representative image of 
transfection imaged using a TALI image-based cytometer 
Figure 5.15a shows the TIDE analysis for WT and Cas9 PNG sequence B and the indel 
quantitation in figure 5.15b. There was a total efficiency of 56.1 %, the greatest mutation a 
+1 bp, with a 65.8 % being a thymine residues. Before the expected cut site at 216 bp only a 
low level of aberrant sequences with a significant increase after the cut site are observed, 
and a low level throughout indicating good sequence quality. 
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Figure 5.15 TIDE analysis of HEK 293 cells transfected with WT Cas9 PNG guide sequence 
B.a) TIDE decomposition window for WT Cas9 PNG guide sequence B seqeunce. b) 
Percentage of sequences found for mutations. 
 
Chromatograms used for the TIDE analysis are shown in Figure 5.16. The cut site is estimated 
at 216 bp. In the PNGB + PUC18 chromatogram there is a clear decrease in sequence quality.  
This indicates a mixed population of sequences compared to the WT sequence.  
b 
a 
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Figure 5.16 Chromatograms showing HEK cells transfected with PUC18 (WT) and mixed 
population of WT Cas9 cells (PNG guide sequence B co- transfected with PUC18).
 
5.3.6 Clonally expanded cells show low viability, viable clonal cells exhibit 
different phenotypes to WT HEK 
Individual cells were isolated to ensure a clonal final population. HEK cells were diluted in 
two concentrations (5 or 1 cell per well in 96 well plates). Wells were analysed daily to 
identify wells containing a single cell. Many of the singly diluted cells did not survive. Of the 
single cells which proliferated under these conditions, colonies were expanded. Several 
clones proved to be non-viable after sub-culturing.  
 
Some mutations can cause degradation of the mRNA associated with the target protein. Of 
the surviving colonies (numbered 1-12) generated from the WT Cas9 PNG B transfection 
(which showed the greatest editing efficiency) RNA was extracted and mRNA of N-glycanase 
was examined. The results are presented in Figure 5.17.  Little difference in mRNA was 
observed between the clones, with the greatest change being a ~3 fold increase in clone 9. 
Levels of mRNA do not always indicate levels of active protein (Greenbaum et al. 2003), in 
this instance both immunoblotting and immunofluorescence (both anti-NGLY1 antibodies: 
ab73984 and ab197107) techniques failed to produce definitive results.  
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Figure 5.17 RT-qPCR of N-glycanase mRNA in clonally isolated HEK cells transfected with 
PNG WT Cas9 guide sequence B and PUC18. Data normalised to GAPDH and PUC18 
transfected WT HEK cells. n=1.
 
Since autophagy impaired cells had lower viability compared to WT cells under Z-VAD-fmk 
inhibition and N-glycanase knockdown, cells lacking a functional N-glycanase may be more 
susceptible to autophagy inhibition. Clones were treated with 3-MA at a concentration 
previous established as non-toxic to WT cells (5 mM, 24 h), and compared to the vehicle.  
Clones 3, 4, 5, 6 and 7 exhibited increased sensitivity to 3-MA compared to the WT (Figure 
5.18). A decrease in formazan absorbance (indicating reduced cell viability) of 43, 42, 33, 56 
and 37 % was observed for clones 3, 4, 5, 6 and 7 respectively. 
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Figure 5.18 MTT assay against clones isolated from a population of cells transfected with 
WT Cas9 PNG guide sequence B.  Cell were treated with 3-MA (5 mM, 24 h). Student’s t-
test between vehicle and 3-MA treated. Error bars ± SEM, n=3, * P < 0.05, ** P < 0.01, *** 
P < 0.001, **** P < 0.0001. 
 
Clones 3 and 7 from WT Cas9 PNG B populations latterly survived expansion and repeated 
sub-culture. In order to quantify any potential changes in deglycosylation activity using 
fluorescence, clones 3 and 7 were transfected with the ddVENUS construct. The transfected 
cells were treated with increasing amounts of Z-VAD-fmk (1-300 µM). The IC50 for WT HEK 
was previously established as 68.14 µM (Figure 5.19). Clone 3 and 7 had decreased IC50 values 
of 5.67 and 59.97 µM respectively, however the lowest level seen in WT HEKs was a decrease 
in fluorescence by 58 % whereas in clone 3 and 7 the lowest decrease was recorded as 52 % 
and 32 % respectively (Figures 5.20 and 5.21). This indicates a lower sensitivity to Z-VAD-fmk 
and decreased N-glycanase activity. Furthermore, the fit of the curve was reduced in clones 
3 and 7. To measure the goodness of fit R2 was measured with 1 indicating a perfect fit and 
0 indicating a horizontal line being the best fit. WT HEK cells had a R2 of 0.92 indicating a good 
fit while clones 3 and 7 had R2 values of 0.47 and 0.44 respectively indicating that the data 
does not follow a trend as well as WT HEKs. Furthermore, this assay has not been validated 
against other glycan processing enzymes. A number of proton pump inhibitors have been 
identified as ENGase inhibitors (Bi et al. 2017). This assay, if it is to be used as an assay for 
specifically N-glycanase activity needs to be validated against other deglycosylated enzymes.  
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Figure 5.19 ddVENUS assay of WT HEK cells. HEK cells were transfected with ddEVNUS 
construct and treated with Z-VAD-fmk (1-300 µM, 24 h) followed by MG132 (8 µM, 6 h). 
The median ddVENUS fluorescence was calculated. Error bars ± SEM, n=3, R2 0.92, IC50 
68.14 µM.
 
 
Figure 5.20 ddVENUS assay of Clone 3 HEK cells. Clone 3  HEK cells were transfected with 
ddEVNUS construct and treated with Z-VAD-fmk (1-300 µM, 24 h) followed by MG132 (8 
µM, 6 h). The median ddVENUS fluorescence was calculated. Error bars ± SEM, n=3, R2 0.47, 
IC50 5.67 µM.
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Figure 5.21 ddVENUS assay of Clone 7 HEK cells. Clone 7 HEK cells were transfected with 
ddEVNUS construct and treated with Z-VAD-fmk (1-300 µM, 24 h) followed by MG132 (8 
µM, 6 h). The median ddVENUS fluorescence was calculated..Error bars ± SEM, n=3, R2 0.44, 
IC50 59.97 µM.
 
5.3.7. Increased sensitivity  of clone 3 and 7 to cell stressors was not rescued 
by pharmacological inhibition of ENGase  
ENGase knockout in conjunction with N-glycanase deficiency has been identified as 
resulting in less severe phenotypes in murine models compared to N-glycanase 
knockout alone (Huang et al. 2015, Fujihira et al. 2017). A number of proton pump 
inhibitors (such as lansoprazole and omeprazole) have been identified as ENGase 
inhibitors; the IC50 of lansoprazole  determined to be 24.38 µM in vitro using human 
ENGase (Bi et al. 2017). Based on these findings, if clone 3 and 7 have a deficiency in N-
glycanase it may be postulated inhibition of ENGase may result in an increase cell 
viability under conditions of cellular stress. The cell  viability of the WT and clonal cells 
for lansoprazole was determined using MTT assay.  IC50 values of 123.1, 174.1 and 52.1 
µM were recorded for WT HEK, clone 3 and clone 7 respectively (Figure 5.22).  
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Figure 5.22 MTT of HEK cells with lansoprazole. HEK 293 cells were treated with 
lansoprazole (24 h). Data normalised to the average of the vehicle. n=3, error bars ± SEM. 
Bottom panel shows representative images (bright-field, 20X objective) of cells treated 
with lansoprozole (25 µM, 24 h). 
HEK cells were treated with increasing concentrations of the proteasome inhibitor 
MG132 in the presence or absence of lansoprazole (10 µM) for 24 h to determine the 
effect of MG132 and lansoprazole co-treatment on WT cells and clones 3 and 7. MG132 
has been identified as resulting in increased cell toxicity in N-glycanase deficient cells 
as it has been linked to Nrf1 activation in WT cells (Tomlin et al. 2017). Nrf1 is 
responsible for upregulation of proteasome proteins under proteasome inhibition. Cells 
deficient in N-glycanase are unable to induce proteasome gene transcription and 
therefore exhibit increased sensitivity to proteasome inhibition. HEK cells were treated 
with increasing concentrations of MG132 (Figure 5.23a). No significant decrease in 
formazan absorbance compared to the WT was observed for clones 3 and 7. A significant 
increase was observed for clone 3 (CC50 of 24 nM compared to the WT 14 nM). HEK cells 
were treated with increasing concentrations of MG132 with or without a non-toxic level of 
lansoprazole (10 µM) (Figure 5.23b-d).  A summary of CC50 values is presented in Table 5.4. 
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Figure 5.23 MTT of HEK cells treated with MG132 (24 h) in the presence or absence of 
lansoprazole (10 µM). a) WT HEK, clone 3 and clone 7 cells treated with MG132 (0.1-15 µM, 
24 h), b) HEK cells treated with MG132  (0.1-15 µM, 24 h) or without lansoprazole (10 µM), 
c) Clone 3 HEK cells treated with MG132  (0.1-15 µM, 24 h) or without lansoprazole (10 
µM), d) Clone 7 HEK cells treated with MG132  (0.1-15 µM, 24 h) or without lansoprazole 
(10 µM). Data was normalised to the average of the vehicle. Two-way ANOVA, Dunnett’s 
post hoc. n=3, error bars ± SEM.
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Table 5.4 CC50 values of WT HEK cells, clone 3 and clone 7 HEK cells treated with MG132(24 
h) in the presence or absence of lansoprazole (10 µM) 
Condition 
CC50 
(nM) 
Fold change 
(WT) 
Fold change 
(lansoprazole) 
WT HEK 14  0.4 
WT HEK + Lansoprazole (10 
µM) 
5.4   
Clone 3 24 1.7 1.6 
Clone 3 + Lansoprazole (10 
µM) 
38   
Clone 7 6 0.4 1.6 
Clone 7 + Lansoprazole (10 
µM) 
10   
  
No significant decreases in formazan absorbance compared to the WT were observed, which 
suggests that clones 3 and 7 are not deficient in N-glycanase. There was also no significant 
difference in formazan absorbance in WT HEKs and clone 3 between MG132 and MG132 co-
treated with lansoprazole. A small difference in the viability of clone 7 when treated with 
MG132 (10 nM) (Figure 5.23d) was noted.  
 
The experiment was repeated using Menadione, which serves to induce apoptosis through 
mitochondrial dysfunction and increased ROS production (Monteiro et al. 2013).  HEK cells 
were first treated with Menadione to establish cell viability in the presence of the inhibitor 
(Figure 5.24a).  
 
 
197 
 
 
 
 
 
Figure 5.24 MTT of HEK 293 cells treated with menadione (24 h) with or without 
lansoprozole. a)  HEK 293, clone 3 and clone 7 cells were treated with menadione (1-200 
µM, 24 h). b) HEK cells were treated with menadione (1-200 µM, 24 h) in the presence or 
absence of lanzoprazole (10 µM)  c) Clone 3 HEK 293 cells were treated with menadione (1-
200 µM, 24 h) in the presence or absence of lanzoprazole (10 µM). d) Clone 7 HEK 293 cells 
were treated with menadione (1-200 µM, 24 h) in the presence or absence of lanzoprazole 
(10 µM).Data was normalised to the average of the vehicle. Two-way ANOVA, Dunnett’s 
post hoc. Error bars ± SEM, n=3, P < 0.05. 
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Figure 5.25 Representative images (bright field, 20X objective) of WT, clone 3 and clone 7 
cells treated with Menadione (25 µM, 24 h) in the presence or absence of lanzoprazole (10 
µM).
 
A summary of the IC50 are presented in Table 5.5. Clones 3 and 7 showed significantly lower 
formazan absorbance compared to the WT (0.12 and 0.2 fold change respectively compared 
to the WT). These results suggest that clones 3 and 7 are more susceptible to mitochondrial 
damage than WT HEK cells. All cell lines also had a significant decrease in formazan 
absorbance following the addition of lansoprazole (10 µM). 
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Table 5.5 IC50 values of WT HEK cells, clone 3 and clone 7 HEK cells treated with Menadione 
(25 µM) in the presence or absence of lanzoprazole (10 µM) 
Condition 
CC50 
(nM) 
Log2 Fold 
change 
(WT) 
Log2 Fold change 
(lansoprazole) 
WT HEK 361.16  -4.06 
WT HEK + Lansoprazole (10 
µM) 
23.23   
Clone 3 43.51 -3.06 -1.12 
Clone 3 + Lansoprazole (10 
µM) 
20.16   
Clone 7 74.15 -2.32 -3.84 
Clone 7 + Lansoprazole (10 
µM) 
5.8   
 
 
To further investigate mitochondrial function in these cell lines, cells were grown under high 
glucose (DMEM media with L-glutamine and Pen/Strep with high glucose (4.5g/L, 25 mM)) 
or galactose media (DMEM: no glucose supplemented with 10 mM D-galactose) or a 50:50 
mix. To avoid recording changes in growth due to initial changes in acute availability of 
carbohydrates for metabolism, cells were grown for six days under each different media 
conditions to allow them to stabilise prior to measuring growth rates. Many highly 
proliferating cell lines are grown under high glucose levels in laboratories and, as a 
result of this, have adapted to produce energy via aerobic glycolysis and not oxidative 
phosphorylation (OXPHOS) (Aguer et al. 2011, Marroquin et al. 2007, Rodriguez-Enriquez et 
al. 2001). Substituting galactose for glucose in media is thought to push cells to produce 
energy via OXPHOS; increasing mitochondrial load and thus increasing sensitivity to 
mitochondrial toxicants (Marroquin et al. 2007). If clone 3 and 7 have defects in 
mitochondrial function or are sensitive to mitochondrial toxicants (possibly due to reduced 
N-glycanase activity) there may be a change in phenotype when grown in galactose. Cells 
were plated at 2000 cells per well in a 24 well plate, and were counted post subculture over 
15 days. The doubling times were calculated for the linear phase of the growth curves. WT 
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HEK cells exhibited comparable growth rates in high glucose media, the 50:50 mix and the 
media supplemented with galactose (Figure 5.26).  This indicates that the galactose does not 
inhibit the growth of WT HEK cells.  This confirms the observations (Cannino et al. 2012) that 
galactose supplementation does not significantly increase the doubling times of WT HEK 
cells.  The doubling times of clones 3 and 7 under each condition are presented in Figures 
5.27 and 5.28.   
 
 
Figure 5.26 Growth curve of WT HEK in high glucose (4.5 g/L), Galactose (10 mM) or 50:50 
glucose: galactose media. Cells were counted by haemocytometer and are expressed as log 
(cell number) per well post sub-culturing. Error bars ± SEM, n=4.
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Figure 5.27 Growth curve of Clone 3 HEK in high glucose (4.5 g/L), Galactose (10 mM) or 
50:50 glucose: galactose media. Cells were counted by haemocytometer and are expressed 
as log (cell number) per well post sub-culturing. Error bars ± SEM, n=4.
 
 
Figure 5.28 Growth curve of Clone 7 HEK in high glucose (4.5 g/L), Galactose (10 mM) or 
50:50 glucose: galactose media. Cells were counted by haemocytometer and are expressed 
as log (cell number) per well post sub-culturing. Error bars ± SEM, n=4.
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The WT HEK, clone 3 and clone 7 were found to have doubling times of 21.0, 22.0 and 14.4 
h respectively when grown in media supplemented with glucose. When grown in media 
supplemented 50:50 with glucose and galactose, the doubling times were 18.9, 16.3 and 11.0 
h for the WT HEK cells, clone 3 and clone 7 respectively. However, when cells were grown in 
galactose supplemented media (10 mM), growth times for clones 3 and 7 were significantly 
increased (63.9 h and 30.7 h respectively) whilst that of the WT HEK cells remained similar.  
These results are further summarised in Figure 5.29. 
 
 
 
 
Figure 5.29 Clones 3 and 7 had significantly longer doubling times when grown in the 
absence of glucose. Doubling times calculated from the linear range of the growth curve. 
Error bars ± SEM, n=4, P < 0.05. One-way ANOVA within cell types, Tukey’s post hoc. 
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5.3.8   Sequencing identified no changes in gDNA sequences of Clone 3 and 
Clone 7 compared to WT HEK cells  
Whilst carrying out functional assays to characterise the properties of the surviving clones, 
sequencing was carried out on the amplified region spanning the predicted cut site. The PCR 
product was confirmed as a single band by agarose gel. Extra nucleotides and contaminants 
were removed using Monarch® PCR and DNA Clean-up Kit (NEB) and the product sequenced 
by Source Bioscience (Oxford, United Kingdom). The chromatograms for WT HEK cells, clone 
3 and clone 7 spanning the target cut site at 216 are shown in Figure 5.30.  
 
 
Figure 5.30 Chromatograms of WT HEK and clone 3 and clone 7 genomic DNA sequences 
spanning the expected cut site at position 216. 
 
Although the sequences showed perfect alignment, TIDE analysis was carried out as there 
may be heterozygous mutations found. HEK cells are pseudo-triploid and can have up to five 
copies of a gene (Lin et al. 2014).  The TIDE analysis and summary of any changes of the 
sequence are summarised in Figure 5.31.  There were no significant changes between clone 
3 and clone 7 compared to the WT sequence detected. Any changes detected in the 
chromatograms compared to the WT sequence were extremely small, with less than 1 % of 
the sequences having any changes. 
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Figure 5.31 TIDE analysis of a) clone 3 HEK cell compared to WT HEK cells and b) clone 7 
HEK cells compared to WT HEK cells. 
 
5.3.9 Shotgun proteomics analysis  by liquid chromatography tandem mass 
spectrometry (LCMS-MS) 
Although no difference was identified in the sequence of N-glycanase there are significant 
phenotypic differences between the cell lines. Shotgun proteomics was performed to 
examine differences in protein levels between the clonal populations and the WT. Shotgun 
proteomics refers to the characterisation of a mixture of peptides cleaved by proteolysis.  In 
this study, shotgun proteomics was used to profile the proteome of clone 3, clone 7 and WT 
HEK cell lines described above. Shotgun (bottom-up) proteomics analysis by liquid 
chromatography tandem mass spectrometry was employed to investigate if changes in the 
phenotype could be explained by differences in the proteome.  Such methods provide a wide 
coverage of the proteome, particularly important for the detection of proteins of low 
abundance, or those which are under-represented in sampling and provides a means to 
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examine up/down regulation of proteins. In this method, three biological replicates of each 
cell pellet were lysed, digested by FASP and analysed by Ultimate 3000 RSLC nano liquid 
chromatography system coupled to a Q-Exactive mass spectrometer with two technical 
replicates. Peptides were mapped onto proteins using MaxQuant against Swissprot Human 
database with an FDR of 1 % and intensities were assessed by label free quantification.  
The average LFQ intensity for N-glycanase is shown in figure 5.32. As previously shown (figure 
5.30) there were no changes in N-glycanase sequence and no significant differences in 
intensity between cell lines.  
 
 
Figure 5.32 Average intensity of N-Glycanase 1 in WT, clone 3 and clone 7 cell lines. One-
way ANOVA
5.3.10 Off-target effects  identified by the guide sequence were significantly 
different in Clones 3 and 7 compared to the WT population  
 To elaborate on the causes of phenotypic differences of the cell lines, the off-target effects 
of the CRISPR/Cas9 targeting sequence were examined. Off-target effects occur when the 
guide sequence of the target gene closely matches the sequence of another part of DNA and 
is able to bind. The CRISPR design web tool calculates potential off-target effects allowing up 
to four mismatched bases (Zhang 2017). PNG B WT guide sequence has an estimated 12 
genic off-target effects listed in Table 5.6. The intensity levels of these off-target sequences 
was examined. Of the off-target effects identified all had 4 mismatches.  Off-target genes 
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were searched for in the proteomics dataset and the LFQ intensity for each was plotted. Of 
the 12 possible off-target genes only 7 were identified in the dataset and 2 were significantly 
different in clone 3. P-value was calculated using multiple student’s t-test with Benjamini-
Hochberg FDR between the WT and clone 3. 
Table 5.6 Off-target effects of PNG guide sequence B including the log2 fold change in clone 
3 compared to the WT population. Multiple t-tests with Benajmini-Hochberg FDR 
correction. NA indicates protein was not identified through proteomics analysis
 Off-target 
genes 
Number of 
mismatches 
Log2 fold change 
clone 3 
P-value 
1 UNC79 4 NA NA 
2 GPRASP1 4 -0.4737 0.103446 
3 SDE2 4 0.183099 0.050965 
4 IFT122 4 -0.26224 0.781510 
5 WDR90 4 NA NA 
6 FAM96A 4 0.287852 0.504386 
7 MAP1B 4 -0.34819 0.000036 
8 IQGAP3 4 -0.75487 0.000010 
9 GSKIP 4 -0.32019 0.454528 
10 ZNF276 4 NA NA 
11 EPG5 4 NA NA 
12 SSTR3 4 NA NA 
 
Comparing the off-target for clone 7 in Table 5.7, again only 2 targets were significantly 
different with IQGAP3 (figure 5.33) common to both clone 3 and clone 7.  Due to the different 
off target effects it is likely that clone 3 and clone 7 have different genetic mutations.  
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Table 5.7 Off-target effects of PNG guide sequence B including the log2 fold change in clone 
7 compared to the WT population. Multiple t-tests with Benjamini-Hochberg FDR 
correction. NA indicates protein was not identified through proteomics analysis.
 Off-target 
genes 
Number of 
mismatches 
Log2 fold 
change clone 7 
P-value 
1 UNC79 4 NA NA 
2 GPRASP1 4 -0.37933 0.000849 
3 SDE2 4 -0.03929 0.652650 
4 IFT122 4 -2.13538 0.331070 
5 WDR90 4 NA NA 
6 FAM96A 4 0.505333 0.652222 
7 MAP1B 4 -0.0769 0.183848 
8 IQGAP3 4 -0.89716 0.000004 
9 GSKIP 4 0.143625 0.688025 
10 ZNF276 4 NA NA 
11 EPG5 4 NA NA 
12 SSTR3 4 NA NA 
 
The average LFQ values for each significant different off-target effect is shown, and the 
position of the off-target binding site. IQ Motif Containing GTPase Activating Protein 3 
(IQGAP3) was decreased in both clone 3 and clone 7. IQGAP3 is preferentially located in 
epithelial cells at cell-cell contact sites. Dysregulation has been associated with a number of 
cancers including breast, liver and gastric, pancreatic cancer (Hu et al. 2016, Qian et al. 2016, 
Oue et al. 2017, Xu et al. 2016). IQGAP3 has also been associated with cell proliferation, KO 
studies in epithelial cells inhibits proliferation and ERK activity (Nojima et al. 2008, Cagnol 
and Chambard 2010). In Eph4 cultures, IQGAP3 reduces expression upon cell contact, 
slowing proliferation. In RNAi KD experiments cell proliferation was decreased by around a 
third (Nojima et al. 2008). Under cell culture conditions, HEK cells and clones 3 and 7 grow 
at similar rates in glucose containing media and were collected at the same time which 
should reduce effects of cell culture technique on protein expression. However, if IQGAP3 
contains a mutation in clone 3 and clone 7, this may explain differences in cell proliferation 
under different conditions.   
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9644-GGCTGCAGGTAAGGACTAGGCTCTGCCCTGCCAGGAGTAGGCTCAATGCGTATGGGAGGG-9704 
Figure 5.33 LFQ averages of IQGAP3 in WT, clone 3 and clone 7. Error bars ± SEM, n=3. One-
way ANOVA, Tukey’s post hoc. **** P < 0.0001. Highlighted genomic sequence indicates 
off target binding site, underlined sequence indicates exon. Binding site is within an intron 
on IQGAP3.
Microtubule Associated Protein 1B (MAP1B), shown in figure 5.34 interacts with the 
cytoskeleton and is involved in the trafficking of cellular components including proteins, 
vesicles and organelles (Bodaleo et al. 2016, Jiménez-Mateos et al. 2006). This was 
significantly decreased in clone 3 but only had a minor decrease of 0.12 fold change in clone 
7.  
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91760-CTGAAAATGGGCCAACTGAAGTGGACTACAGTCCTTCTGACATGCAGGACTCCAGTTTAT-91820 
 
Figure 5.34 LFQ averages of MAP1B in WT, clone 3 and clone 7 Error bars ± SEM, n=3. One-
way ANOVA, Tukey’s post hoc. ** P < 0.0001. Highlighted genomic sequence indicates off 
target binding site, underlined sequence indicates exon. Binding site is within an exon.
Most of the literature on GRIP1 associated protein 1 (GRASP1) is associated with neuronal 
function, but is likely to be involved in vesicular trafficking/fusion as GRASP1 KO results in 
endosome recycling dysfunction at synapses (Hoogenraad and van der Sluijs 2010, Ye et al. 
2000). These changes in vesicle trafficking proteins may be involved in the increased 
sensitivity to autophagy blockers (figure 5.35).  
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5400-CTGGTTCTGGAAAGAAGATGAAGCCATTTCAGAGGCTACTGACAGAGAAGAGTCCAGGCC-5460 
 
Figure 5.35 LFQ averages of GRASP1 in WT, clone 3 and clone 7. Error bars ± SEM, n=3. One-
way ANOVA, Tukey’s post hoc. *** P < 0.001. Highlighted genomic sequence indicates off 
target binding site, underlined sequence indicates exon. Binding site is within an exon on 
GRASP1.
To identify off-target mutations, the DNA around the site of the potential cut-site would be 
amplified and sequenced. Although there are significant decreases in these highlighted 
proteins, it does not identify gene-editing.  Differences could result from mutation sites on 
other proteins that do not have a significantly different protein concentration and 
dysfunction could cause knock-on effects. However, as a screening trial to identify mutations, 
it is best to start with those that are significantly different.   
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5.3.11 Global proteome analysis of C lone 3 
As well as off-target effects, the global proteasome for each cell line was analysed in 
comparison to the WT population. Figure 5.36 shows the up and downregulated proteins of 
clone 3 compared to the WT. The dotted line indicates a p-value of 0.05. Protein IDs 
highlighted in red indicate a greater than 4 fold change compared to the WT.  
 
Figure 5.36 Volcano plot of protein intensity identified in clone 3 were compared to 
intensity in WT samples by Student’s t-test with Benjamini-Hochberg correction. P-value 
was plotted against log2 fold change in expression. Black and red circles indicate protein 
ID’s where p < 0.05 and a greater than log2 2 fold change difference. 
Proteins that were significantly different and were greater 4-fold different are summarised 
in Table 5.8 with key functions highlighted. A number of these proteins are associated with 
cell cycle and metabolism which link to decreased cell proliferation under low glucose 
conditions. Furthermore, GPC4 is a GRIPS family protein which could be involved in the 
interaction with GRASP1 but are not known interactors. STRING database analysis did not 
identify a significant number of interactions. However, CNOT6 and PRKG1 do show an 
interaction and ANXA1 with the off-target ID, SSTR3. 
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Table 5.8 Summary of proteins significantly up or downregulated in clone 3 compared to 
WT. Gene names marked in red indicate proteins shared in both clone 3 and clone 7. 
 
 
 
Gene Name 
(clone3) 
p-value  Log2 fold 
change 
Function Reference 
GPC4 0.03047 2.436071 GRIPS family, cell cycle 
and growth regulation 
(Karihaloo et 
al. 2004) 
BTBD2 0.015382 2.613466 Binding partner to 
topoisomerase I 
(Xu et al. 
2002) 
FAM117B 0.009688 2.122745 Lateral Sclerosis (Hadano et al. 
2001) 
ZFAND5 0.005952 2.134269 Anchors Ub proteins 
to proteasome 
(McCourt et 
al. 2018) 
PRKG1 0.001383 -2.1752 Serine/threonine 
kinase, NO/cGMP 
signalling pathways 
(Durnin et al. 
2017) 
CNOT6 0.001352 2.446814 mRNA degradation, 
transcriptional 
regulation.  
(Wahle and 
Winkler 2013) 
QPRT 9.24E-05 -2.26403 Catabolism of 
quinolinate 
(Ullmark et al. 
2017) 
CRABP2 6.52E-05 -2.93548 Retinoic acid binding 
protein 
(Percicote et 
al. 2018) 
TYMS 5.55E-06 2.154701 Methylation of DNA, 
required for DNA 
replication and repair 
(Krushkal et 
al. 2016) 
FAR1 9.49E-07 2.699748 Reduction of fatty 
acids to alcohols.  
(Rizzo 2014) 
ANXA1 2.01E-09 -3.48942 Anti-inflammatory 
response 
(He et al. 
2017) 
MID1 1.8E-09 -2.65142 E3 Ub ligase  (Du et al. 
2013) 
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5.3.12 Global proteome analysis of C lone 7 
Figure 5.37 shows the up/downregulated proteins of clone 7 compared to the WT. The 
dotted line indicates 0.05, any protein ID above this line indicates a p-value > 0.05 calculated 
by a multiple t-tests with Benjamini-Hochberg correction. Protein IDs highlighted in red 
indicate a greater than 4 fold change compared to the WT. Clone 7 showed decreased cell 
proliferation in galactose supplemented media and increased cell toxicity when treated with 
lansoprazole and 3-MA. There is a phenotypic difference that is not due to targeted mutation 
of N-glycanase.  
 
Figure 5.37 Volcano plot of protein intensity identified in clone 7 were compared to 
intensity in WT samples by Student’s t-test with Bonferroni correction. P-value was plotted 
against log2 fold change in expression. Black and red circles indicate protein ID’s where p < 
0.05 and a greater than log2 2 fold change difference. 
Based on STRING analysis there was no significant interactions between proteins significantly 
upregulated in clone 7. Only MAP1B is shown as an interactor of MAP1LC3B which is 
upregulated in clone 7. This could indicate increased autophagy and play a role in clone 7 
sensitivity to 3-MA. Again, GPC4 was upregulated which may be involved in GRASP1 pathway 
and CDC123 involved in cell cycle.  
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Table 5.9 Summary of proteins significantly up or downregulated in clone 7 compared to 
WT. Gene names marked in red indicate proteins identified in both clone 3 and clone 7. 
Gene 
names 
(clone 7) 
p-value Log2 fold 
change 
Function Reference 
GPC4 0.023856 2.630387 GRIPS family, cell cycle 
and growth regulation 
(Karihaloo et al. 
2004) 
CAMLG 0.010717 2.542715 Calcium signalling (Jakobsen et al. 
2008) 
CNOT6 0.00608 2.469235 mRNA degradation, 
transcriptional 
regulation. 
(Wahle and 
Winkler 2013) 
FAM117B 0.005504 2.252368 Lateral Sclerosis (Hadano et al. 
2001) 
MAP1LC3B 0.003133 2.004566 Autophagy marker (Barth et al. 2010) 
ZFAND5 0.001765 2.388114 Anchors Ub proteins to 
proteasome 
(McCourt et al. 
2018) 
TYMS 1.7E-06 2.448217 Methylation of DNA, 
required for DNA 
replication and repair 
(Krushkal et al. 
2016) 
CDC123 6.03E-07 2.100386 Required for entry into 
S-phase 
(Perzlmaier et al. 
2013) 
FAR1 1.67E-07 3.0744 Reduction of fatty acids 
to alcohols. 
(Rizzo 2014) 
HMGCS1 2.56E-09 2.37906 Forms HMG-CoA (Mathews et al. 
2014) 
METAP2 2.27E-09 2.069096 Removes N-terminal 
methionine from 
nascent proteins.  
(Frottin et al. 2016) 
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Identification of the increased DNA repair protein, TYMS, is probably not surprising as both 
clone 3 and clone 7 were transfected with Cas9 designed to break DNA. Proteins involved in 
cell cycle and metabolic processes could be involved in the changes in growth in galactose 
media. This could also indicate OXPHOS dysregulation. FAM117B is involved in the KEAP1 
complex which plays a role in the Nrf2 antioxidant response (Hast et al. 2013) which could 
also be involved in mitochondrial function. However, to categorically identify the cause of 
these changes, mutation sites need to be sequenced.  
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5.4 Discussion  
This chapter describes the steps and strategies towards establishing a stable N-
glycanase deficient cell line using CRISPR mediated genomic editing targeted towards 
both N-glycanase. Firstly, the tools used to initiate genome editing were described 
following by the efficacy of delivery and editing efficiency measured by TIDE analysis . 
From initial transfections clonal populations were isolated and characterised using 
various methods to try to identify the mutations achieved. Unfortunately, difficulties, 
in the detection of gene-editing lead to delayed analysis of clonal populations, leading 
to increased sub-culturing of unknown populations. Because of this, attempts to create 
a cell line deficient in N-glycanase resulted in the isolation of only two populations of 
cells with phenotypic differences from the WT cell line despite no detectable differences 
in the NGLY1 gDNA. Although gene editing technologies are becoming a more common 
method to create stable cell-culture models, as a technique it presents a number of 
logistical challenges. Isolation of single colonies and confirmation of genomic changes 
were the main challenges of this project. 
 
This study used CRISPR plasmids specifically designed to introduce sgDNA into cell 
culture models. This is a fast and easy way of creating a high number of different 
targeting plasmids as only the 25-nucleotide targeting sequence needs to be made for 
different targets. The availability and use of online guide sequence design tools further 
streamlines this approach. Other methods can use direct transfection of the Cas9 
protein complexed with guide sequence (Liang et al. 2015), however, plasmid 
transfection is a common method and has been demonstrated to a high efficiency in 
HEK cells. Transfection efficiency was followed by GFP signal. While transfection of 
plasmids alone showed a good transfection efficiency, the addition of the HDR repair 
template decreased transfection efficiency. Methods to enrich transfected cells, such 
as FACs sorting based on the GFP signal would reduce the number of cells needed to  be 
screened during clonal isolation. Co-transfection of the oligo alongside the RX plasmids 
did not yield incorporation of the restriction site into the genome. HDR occurs less 
frequently than NHEJ during S and G2 phase and only results in incorporation of around 
0.5-20 % using just Cas9 plasmids and an oligo. However, methods are emerging that 
increase the efficiency of HDR. Inhibition of the NHEJ protein DNA ligase IV has been 
found to increase incorporation of oligo in a dose dependent manner in MelJuSo cells 
with an increase in efficiency of up to 19-fold compared to an untreated control 
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(Maruyama et al. 2015). Another study has reported cold-shock treatment significantly 
increases HDR in mc-iPSCs (Guo et al. 2018) which could be used in conjunction with the 
introduction of non-homologous DNA method used in this study.  
 
Difficulties in the analysis of genome editing of mixed cells proved problematic in this 
system. The commonly used surveyor assay did not show obvious annealing of and 
cutting of different species. No positive control was present so it is unclear whether this 
was due to low-zero genome editing or incorrect experimentation. Genome editing was 
assessed by TIDE analysis. This involves the comparison of high quality sequences, which 
required optimisation and would be more costly to screen a large number of individual 
populations compared to other PCR based assays. A simpler method uses PCR with the 
primer based over the Cas9 restriction site (Harayama and Riezman 2017). As the cut 
site of Cas9 is very predictable this is not difficult to do. Loss of binding of the primer 
indicates mutation and indicates populations to analyse further.  
 
Further difficulties developed from the clonal isolation of populations. Many of the 
clonally derived cells resulting from transfection with PNG-B plasmid did not survive 
isolation and several populations perished after several subcultures. For isolation of 
single cells, serial dilutions in 96-well plates were used. Many cells do not survive 
isolation, as was evident in this system. This is not likely due to any mutations caused, 
N-glycanase KO models are not known to be lethal apart from the case of one mouse 
model (Fujihira et al. 2017).  Other methods of isolation that have shown to improve 
cell health include the use of conditioned media. Media collected from healthy cells can 
be centrifuged to remove debris and used to dilute transfected cells. This media 
contains molecules secreted from cells during growth and can help maintain cells at a 
low density. Colony picking is another method of isolating clonal populations that 
reduces the risk of cell death due to isolation. Cells are plated in a large tissue plate at 
a low density so that instead of a monolayer, colonies form. Colonies can be picked using 
cloning rings or the tip of a pipette tip. However, this can be difficult to see individual 
colonies.  An agarose-cloning method is similar to this but involves pouring a layer of 
agarose and media mixture onto the cells (Mathupala and Sloan 2009). Once the agarose 
has solidified colonies can be picked with truncated pipette tips and transferred to a 
multi well plate. This increases cell picking as the plate can be moved without dislodging 
colonies, prevents cells from drying and aids in sticking to the pipette tips. Isolation is 
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one of the most important steps and as shown in Figure 5.4, isolation and expansion of 
clonal populations is the most-time consuming step. 
 
The characterisation of mutations in monoclonal populations proved difficult. Although 
TIDE analysis was used successfully for mixed populations, sequences for individual cell 
lines following clonal selection were not of sufficient quality to categorically identify 
mutations or WT sequences. Furthermore, the nature of HEK cells can complicate 
analysis. HEK cells are pseudo-triploid and the more copies of a gene, the less likely a 
difference in one will be seen by chromatogram.  HEK cells also have a high degree of 
diversity, even within clonal populations, differences in karyotype have been observed 
(Lin et al. 2014).  Due to difficulty in sequencing, surviving clones 3 and 7 were 
characterised to identify any phenotypic differences. Initially, N-glycanase mRNA levels 
were tested to try and identify KO but no clones exhibited significant decrease in mRNA, 
but this does not discount a reduction in protein levels. Western blot proved 
unsuccessful due to high levels of background. Phenotypic characterisation by cell 
viability in response to autophagy inhibitor 3-MA, the proteasome inhibitor MG132 and 
ROS activator Menadione and cell proliferation studies in different growth media did 
not identify mutations in the cell lines but were used to identify if any phenotypic 
differences were present during optimisation of sequencing was performed. Once 
sequencing was optimised, it was identified there was no editing in the N-glycanase 
gene. However, the phenotypic differences in the cells was intriguing and shotgun 
proteomics of the cell lines was performed.  
 
This method is used to identify changes in protein intensity compared to the WT 
population. One caveat of these phenotypic changes and proteomics analysis is that 
clone 3 and clone 7 have undergone clonal expansion, however, the WT cells represent 
a mixed population. To properly control for these experiments, several isolated colonies 
of WT cells would need to be analysed to identify if these changes could be due to 
individual population differences. As mentioned, HEK cells are very diverse (Lin et al. 
2014). With that in mind, shotgun proteomics allowed measurement of N-glycanase 
levels in cells and also allowed identification of possible mutations in  off-target effects. 
To further characterise the use of these cells, off-target mutations need to be analysed. 
This can be done by amplifying the expected mutation site and sequencing the gDNA. 
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Significant differences in the intensity levels of four out of twelve of the genic off-target 
effects have already been identified.  
 
In conclusion, this chapter identified that plasmid inducible CRSIPR/Cas9 gene editing is 
possible and the efficacy of the PNGB guide sequence. Further optimisation of HDR 
using a donor repair sequence is needed as are more robust methods for clonal 
expansion.   
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Chapter 6. 
6.1 Introduction  
Under basal conditions, autophagy maintains a healthy pool of proteins and organelles 
(Nixon 2013b). Under conditions of cellular stress or nutrient starvation, autophagy has been 
shown to selectively target different organelles such as mitochondria, ER, ribosomes and 
peroxisomes (Ding and Yin 2012, Overbye et al. 2007, Cebollero et al. 2012, Waite et al. 
2016). Studies have used different approaches to identify core autophagic proteins (along 
with factors specific to different conditions and disorders) including bioinformatics, protein 
identification by tandem mass spectrometry (proteomics) and microscopy co-localisation 
(Dengjel et al. 2012, Pugsley 2017).   
In yeast cells, eighteen autophagy related proteins have been identified in starvation induced 
autophagy and these play roles throughout autophagosome initiation, elongation and 
membrane closure (Suzuki et al. 2017) and are conserved throughout eukaryotic cells. 
However, autophagy pathways have been described that do not require all these factors, 
termed non-canonical mechanisms. For example, BECLIN-1, ULK1 or AMPK independent 
autophagy (Codogno et al. 2011, Cheong et al. 2011, Alers et al. 2012) have all been 
identified. Another important facet of autophagy are autophagy receptor proteins, which 
recognise selective cargo by binding target cargo and recruiting autophagic membranes, 
usually via an LC3-interacting domain (LIR) (Jacomin et al. 2016, Johansen and Lamark 2011). 
Table 6.1 shows a number of known autophagy receptors and specific targets for 
degradation.   
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Table 6.1 Autophagy receptor proteins and their targets  
Autophagy receptor protein Target Reference 
P62 ubiquitin (S. Chen et al. 2014) 
NCO4 ferritin (Mancias et al. 2014) 
NDP52 bacteria via ubiquitin (Verlhac et al.) 
NBR1 mitochondria (Johansen and Lamark 2011) 
OPTN mitochondria via ubiquitin (Wong and Holzbaur 2014) 
BNIP3/NIX mitochondria (Gao et al. 2015) 
CCPG1 ER (Smith et al. 2018) 
TRIM20 and TRIM21 inflammasome (Kimura et al. 2015) 
PHB2 mitochondria (Wei et al. 2017) 
 
Proteomics approaches employ tandem mass spectrometry as a tool to quantitatively study 
how the proteome changes. This method has been used to identify core autophagy proteins 
under different conditions or effects on the cellular proteome by autophagic events (Dengjel 
et al. 2012, Zimmermann et al. 2010, Mathew et al. 2014, Li et al. 2017, Overbye et al. 2007). 
Dengjel et al. (2012) examined the core autophagy proteins in MCF-7 cells under known 
autophagy inducing conditions to identify core proteins shared by different stimuli (Dengjel 
et al. 2012). To achieve this, autophagy was induced by amino acid starvation, rapamycin 
and then an untreated control group all treated with concanamycin A (to prevent 
degradation of autophagosomes) (Merkulova et al. 2014, Dengjel et al. 2012). 
Autophagosomes were isolated either by iodixanol density gradient or immunoprecipitation 
of GFP-LC3. Of the 728 biologically relevant proteins, 94 were identified in all stimuli, 42 of 
which are known interactors of autophagy related proteins including LC3, p62 and 
GABARAPL2 (Dengjel et al. 2012). Under the conditions described in this study, only 
autophagosome membrane proteins were identified as of interest. However, the cargo of 
autophagosomes can also give an insight in to the type of selective autophagy or changes in 
function under different conditions.  
Different conditions can result in the removal of different cellular compartments. Starvation 
induces a bulk removal of cytosolic components, however, certain stressors such as those 
resulting from damaged organelles and protein aggregates require selective recognition and 
degradation of targets. In some cases, increased autophagosome production does not 
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always correlate to increased cargo degradation (Martinez–Vicente et al. 2010). Several 
studies have found increased autophagy in Huntington’s disease, but have found that cargo 
is not efficiently recognised (Tang and Sulzer 2014, Martinez–Vicente et al. 2010, S. Chen et 
al. 2014). In a study using two Huntington’s disease mouse models along with human 
lymphoblast’s from Huntington patients, proteolysis in autophagic compartments was found 
to be impaired (Martinez–Vicente et al. 2010). Electron microscopic images of the neurons 
of Huntington’s disease mouse models indicated increased double membrane bound vesicles 
compared to controls, but these structures had decreased electron density without 
identifiable cargo. To confirm this, autophagosomes from mice livers were isolated by 
differential centrifugation and cargo and membrane proteins were separated by hypotonic 
shock. The fractions were separated by bi-dimensional electrophoresis and revealed 
markedly less proteins in the lumen of the autophagosomes in the HD mice compared to 
controls (Martinez–Vicente et al. 2010), indicating a defect in cargo recognition. These 
results suggest that an increase in autophagosomes alone is not enough to correctly identify 
organelle and protein cargo for autophagic degradation.  
6.2 Aims and Objectives 
An increase in the number of autophagosomes was identified following Z-VAD-fmk and 
genetic KD of N-glycanase. To gain insight into autophagy processes in this system, 
autophagosomes were purified from cellular material, digested with trypsin and examined 
by liquid chromatography-tandem mass spectrometry (LC-MS/MS) to identify the proteins. 
This method will allow the detection of not just autophagy related proteins but also cargo 
proteins. Z-VAD-fmk and N-glycanase KD induced autophagy will be compared to other 
known methods of autophagy induction including amino acid starvation, rapamycin and 
basal autophagy.   
6.3 Results 
In this chapter, autophagosomes induced by Z-VAD-fmk and N-glycanase KD by siRNA were 
compared to autophagy induction by amino acid starvation, rapamycin and basal autophagy 
in HEK293 cells. The first section of the chapter describes the method development of 
autophagosome analysis, identifying how the method of sample preparation, mass 
spectrometry equipment and data analysis software used was refined. The latter part of this 
chapter looks at identification of biologically relevant proteins to examine differences 
between N-glycanase inhibition/KD compared to other autophagy models. Proteins were 
223 
 
identified as enriched by having a greater than twofold increase in intensity over the binding 
control and assigned by a minimum of two razor or unique peptides. Enriched proteins were 
analysed using Go Ontology terms identified by either DAVID Bioinformatics Functional 
annotation tool (Huang et al. 2008) or STRING database (Szklarczyk et al. 2017). The dataset 
was also examined for LC3 interacting proteins against iLIR database (Jacomin et al. 2016) to 
identify autophagy adaptor proteins involved in different conditions.  
6.3.1. Method development  
To study the composition of autophagosomes formed under N-glycanase inhibition 
compared to other forms of autophagy induction, stably transfected GFP-LC3 HEK293 cells 
were utilised. Autophagy was induced by Z-VAD-fmk treatment for 72 h or N-glycanase KD 
by siRNA for 5 d, rapamycin for 6 h, amino acid starvation for 6 h and an untreated control. 
All samples were then treated with Bafilomycin (100 nM, 4 h) to enrich autophagosomes and 
prevent degradation of cargo. Autophagosomes were purified by immunoprecipitation of 
GFP-LC3 and prepared for proteomics analysis. Figure 6.1 summarises the development of 
the autophagosome analysis methodology by the isolation method of autophagosomes, the 
method of proteomics sample preparation, the mass spectrometry equipment used and the 
method employed for data processing and analysis. The isolation method was optimised, to 
ensure efficient and specific isolation of autophagosomes are needed for meaningful analysis 
of proteins. As MS detection relies on the detection of peptides from which protein IDs are 
assigned, an efficient digestion protocol is needed. Mass spectrometers also have different 
sensitivity.  In this study, increasingly sensitive mass spectrometers were used, along with 
increasingly stringent data analysis software.   
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Figure 6.1 Diagram showing method development of autophagosome isolation and 
analysis.
 
The initial test (Test 1) isolated autophagosomes using anti-GFP conjugated Protein G 
magnetic beads (Surebeads BioRad). Protein G is an Ig binding, bacterial protein isolated 
from Streptococci sp. that binds to the non-variable Fc region (Yang et al. 2003), allowing 
conjugation of different antibodies to the same bead. The aim is to co-precipitate intact 
autophagosomes rather than LC3 alone. For this reason, a non-ionic detergent was used to 
lyse cells that preserves protein-protein interactions along with a protease inhibitor cocktail 
to avoid protein degradation. The anti-GFP antibody (BioLegend FM264G rat anti-GFP, 2 µg) 
was attached to 1 mg of magnetic beads as per manufacturers’ instruction followed by 
incubation with cellular lysate. All tests contained a mock IP as a binding control. Although 
the magnetic beads were conjugated to a specific antibody, other proteins can associate with 
the antibody or the magnetic beads non-specifically. To control for this, magnetic beads were 
conjugated with a rat IgG for FLAG proteins (BioLegend L5 Rat anti-FLAG, 2 µg). In this system, 
proteins identified at comparable intensities on the anti-FLAG conjugated beads as the anti-
GFP conjugated beads, were identified as contaminating proteins and then excluded from 
analysis, proteins with intensity of twofold or greater were identified as enriched. After 
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isolation of GFP-LC3 tagged autophagosomes, samples were prepared for LC-MS/MS 
analysis. Proteomics relies on the analysis of peptides to identify proteins and proteins need 
to be digested with a specific protease (usually trypsin) prior to analysis. Test 1 used an in-
gel digestion technique where IP samples are separated and visualised by SDS-PAGE before 
being digested. For digestion, each lane was split into five and analysed separately to 
increase the number of peptides identified in each condition. Proteins were digested with 
trypsin to generate tryptic peptides. Protein digests were then analysed using a Bruker 
AmaZon Ion Trap LC-MS/MS system. Peptides were assigned protein IDs using the MASCOT 
algorithm (Matrix Science) by searching against the SwissProt database restricted to human 
proteins. In this test, only a limited number of proteins were identified, on average only 74 
proteins were identified in the anti-GFP pull down experiments and 53 identified in the anti-
FLAG mock IP. However, LC3 was identified in all anti-GFP IP samples, indicating that the 
immunoprecipitation was successful.  
To increase the number of protein identifications, several changes were made to the initial 
protocol. The starting material was increased 6-fold, along with the concentration of 
antibody per mg of beads and total amount of beads was doubled. The method of digestion 
was changed to a FASP tryptic digestion protocol (Wisniewski et al. 2009) to decrease 
potential loss of material occurring in in-gel digestion which can leave peptides trapped in 
the gel matrix. The previous study also found a high number of protein identifications in the 
binding control. Wash steps were increased from three to seven to remove non-specific 
proteins. Samples were prepared by the FASP method using a comparison between an in-
house protocol and a commercial FASP kit (Expedeon). Although this method may reduce 
material loss during digestion, a single injection is used per sample instead of five used for 
the in-gel digestion protocol resulting in fewer peptides per sample. The mass spectrometer 
was also changed to a more sensitive model to increase protein identification. The LTQ 
Orbitrap XL has a higher scan speed and higher mass accuracy (due to the Orbitrap mass 
analyser) allowing more peptides to be identified successfully. The raw data were processed 
and analysed using the MaxQuant software which allows for label free quantification (LFQ) 
to identify and quantify proteins which are up or downregulated between experimental 
conditions (Wisniewski et al. 2009). This optimised approach increased the number of 
proteins identified, but still produced high background levels.  
To further improve autophagosome purification (test 3), starting material was increased to 
80 million GFP-LC3 HEK293 cells per sample. Protein lysates from GFP-LC3 HEK293 cells 
underwent a further centrifugation step to remove cytosolic LC3. In tests 1 and 2 lysates 
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underwent a soft spin to remove cell membranes. After lysis and soft spin, the supernatant 
of test 3 was removed and centrifuged at 17 000 g for 20 min at 4 °C to pellet 
autophagosomes. The supernatant was removed and the pellet was gently re-suspended in 
ice-cold sterilised PBS (Dengjel et al. 2012) and the immunoprecipitation was performed 
using this sample.  
GFP-Traps® (ChromeTek) were also used in place of GFP antibody coupled magnetic beads.  
GFP-Traps® are manufactured with GFP antibodies derived from the Camelidae family, which 
lack any light chains and the non-variable region (nanobodies) are coupled to agarose beads. 
These were used in conjunction with centrifugal filters (pore size 20 µm) designed to retain 
the beads but not unbound proteins. Peptides were analysed using an LTQ Orbitrap Velos, 
and MaxQuant was used to process and analyse mass spectrometry raw data.  
6.3.2 TEST 2: LTQ Orbitrap XL analysis revealed increased le vels of 
mitochondrial proteins in Z-VAD-fmk treated samples 
To identify the best FASP protocol a commercial kit was tested against an in-house method. 
This experiment was performed with two technical replicates per LC-MS/MS analysis. These 
methods performed comparably in terms of the number of proteins identified. To limit the 
impact of stochastic peak picking and thereby limitations to consistent protein identification 
in the data-dependent (DDA) LC-MS/MS analysis approach, the protein IDs for technical 
replicates and for both FASP digestion protocols were pooled. The normalised raw and LFQ 
protein intensities that were found in both samples were averaged. Contaminating proteins 
are expected to be present in both the FLAG sample and GFP sample in comparable 
quantities. Proteins identified with a greater than two-fold change were classed as enriched 
and protein intensity scatterplots as a function of log(2)-fold change for experiment/control 
are shown in figure 6.2. The value for LC3 has been highlighted in all plots.   
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Figure 6.2 Proteins enriched over binding controls. Log2 fold change of raw protein 
intensity in proteins from GFP-IP compared to binding control a) untreated b) amino acid 
starvation c) rapamycin d) Z-VAD-fmk treated cells. 
A number of proteins present in the experimental conditions were absent from the binding 
control. Proteins are identified by assigning peptide fragments to the ID. To avoid inclusion 
of ambiguously identified IDs, proteins assigned using only a single peptide were excluded 
from analysis (Cottrell 2011).  
Proteins were compared between groups. Twenty-four proteins were found to be shared in 
all four conditions (Figure 6.3). As expected, LC3 along with ATG proteins, ATG7 and ATG3, 
were found in all conditions. ATG3 and ATG7 are involved in the attachment of LC3 to 
phosphatidylethanolamine (PE) which drives autophagosome maturation (Nath et al. 2014). 
Pro-LC3 is cleaved by ATG4B resulting in LC3 I, ATG7 binds to the C-terminus of LC3 I, ATG3 
binds and ATG7 dissociates. ATG3 catalyses the addition PE to form LC3 II (Gao et al. 2013). 
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It is usual to see these proteins together, several co-IP experiments examining LC3 have also 
identified ATG7 and ATG3 in mammalian cells (Komatsu et al. 2007, Behrends et al. 2010, 
Tanida et al. 2001). Furthermore, ATG7 has been identified in p62 positive aggregates (Gao 
et al. 2013). Figure 6.3b shows a small cluster of ribosomal proteins were identified in all four 
groups. Ribosomes are commonly found in many proteomics samples as they are very 
abundant proteins. However, degradation of ribosomes has also been reported under 
starvation conditions and rapamycin treatment (Heinrichs 2008, Waite et al. 2016).  
a      b 
 
Figure 6.3 Comparison of proteins identified in all conditions. a) VENN diagram showing 
overlap of enriched protein IDs. b) STRING diagram of proteins shared by all groups 
(Szklarczyk et al. 2017).  
Protein identifications found to be enriched in each group were pooled and analysed by 
DAVID Bioinformatics Functional Annotation Tool (Huang et al. 2008) to identify enriched 
cellular components. Of the highest, extracellular exosomes contained a high number of HSP 
and vesicle or vesicle trafficking proteins such as RAB family proteins, Clathrin and MAP 
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proteins which are also associated with other processes. The dataset also contained a high 
number of heat shock proteins (HSPs), histones and ribonuclear proteins.   
 
 
 
Figure 6.4 Protein IDs assessed as enriched in each condition were pooled to identify 
enriched protein groups across the experiment. Protein IDs were annotated using DAVID 
Bioinformatics Tool (Huang et al. 2008) against Gene Ontology: Cellular Components. 
 
Of the enriched protein IDs across all four conditions, 13 % were identified as mitochondrial 
based on the Go Ontology (GO) term GO:0005739 mitochondrion. The sum LFQ intensity of 
all mitochondrial proteins is shown in Figure 6.5 and found a significant increase in 
mitochondrial protein intensity in amino acid starved and Z-VAD-fmk treated cells compared 
to the untreated control. This indicates more mitochondria were in autophagosomes 
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induced by amino acid starvation and Z-VAD-fmk treatment. Amino acid starvation has 
previously been linked to the induction of mitophagy in multiple cell models (Bartolomé et 
al. 2017, Mauro-Lizcano et al. 2015).  
 
Figure 6.5 Amino acid starvation and Z-VAD-fmk show increased mitochondria in 
autophagosomes. Sum LFQ intensity of mitochondrial proteins identified. Average of two 
technical replicates. One-way ANOVA, Tukey’s post hoc. 
The protein identifications are summarised in Figure 6.6. This shows the fold over maximum 
intensity. In this display the protein ID with the highest intensity across all conditions equals 
1 while 0 indicates an absent ID. Z-VAD-fmk treated cells had the highest intensity and 
number of proteins identified. The majority of these proteins represent mitochondrial 
membrane proteins such as translocases of the inner and outer membrane proteins (TIMM 
and TOMM proteins). The majority of the proteins identified in the untreated and Rapamycin 
treated cells represent ribosomal proteins such as Mitochondrial ribosomal protein L14 and 
L16 (MRPL14 and 16).  
Interestingly, an autophagy receptor implicated in mitophagy was identified in both amino 
acid starvation and Z-VAD-fmk, PHB2 (Lahiri and Klionsky 2017, Wei et al. 2017). Mitophagy 
is the specific removal of mitochondria via the autophagic machinery and maintains a healthy 
pool of mitochondria, the entire protein content of mitochondria are turned over every few 
days indicating a basal level of mitochondria degradation by autophagy (Chan et al. 2015).  
Whole mitochondria are engulfed in double membrane vesicles and degraded via lysosomes. 
This process uses the same core machinery as canonical autophagy. There are two main 
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types of mitophagy, ubiquitin mediated mitophagy (involving the PINK1/Parkin system) and 
receptor mediated removal, which involves mitophagy adaptor proteins such as NIX, BNIP3, 
PHB2 and FUNDC1 and the recruitment of autophagy membranes.  
 
Ubiquitin mediated mitophagy causes stabilisation of PINK1 on the outer mitochondrial 
membrane (OMM) upon mitochondrial membrane depolarisation. PINK1 phosphorylates 
ubiquitin at Ser65 (Kondapalli et al. 2012) which activates parkin, an ubiquitin ligase which 
attaches ubiquitin chains to OMM proteins such as MFN1 and MFN2 to amplify the PINK1 
signal. Autophagy receptors including NBR1 and P62 all have LIR and UB domains to further 
recruit autophagic machinery (M. Lazarou et al. 2015). There are two main mitochondrial 
receptor families which mediate mitophagy, NIX and BNIP3 family and FUNDC1. NIX and 
BNIP3 are not highly expressed under normal conditions but are upregulated under hypoxic 
conditions and are localised to both mitochondrial and ER membranes (Zhang et al. 2008). 
Under hypoxic conditions hypoxia-inducible factor 1 (HIF-1) upregulates BNIP3 and NIX 
(Zhang et al. 2008) and under starvation conditions FOXO3 binds to BNIP3 and NIX promoter 
regions (Bakker et al. 2007). Both proteins contain a LIR domain, allowing recruitment of LC3. 
FUNDC is also located on the OMM. The N-terminus contains a LIR domain and faces the 
cytoplasm. Similarly to BNIP3 and NIX, removal of the LIR domain results in abolishment of 
LC3 binding and defects in mitophagy. Prohibitin 2 however, is located on the inner 
mitochondrial membrane (IMM). Prohibitin 2 can increase PINK1/Parkin mitophagy by 
binding autophagy membranes once the membrane has been recruited but can also bind 
directly to LC3 upon OMM rupture (Wei et al. 2017).  
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Figure 6.6 Fold over maximum LFQ intensity of mitochondrial proteins.1 indicates highest 
intensity, 0 indicates absent. Average of two technical replicates where 0 values were 
discounted. 
6.3.3 TEST 3: LTQ Orbitrap Velos  
The final autophagosome-IP proteomics experiment (Test 3) used GFP-Trap® isolation of 
GFP-LC3 in combination with FASP digestion from cells treated with amino acid starvation, 
Z-VAD-fmk, N-glycanase siRNA KD cells and an untreated control. This experiment was 
performed with three biological replicates. Overall, this method identified 1018 unique 
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protein IDs. As well as an increased number of proteins identified in each test condition, 
there was a decrease found in the agarose bead binding controls shown in Figure 6.7.  
 
 
Figure 6.7 Number of proteins identified in the GFP-Trap agarose beads and agarose bead 
binding control for cells treated with Z-VAD-fmk (50 µM, 72 h), transfected with NGLY1 
siRNA (25 nM, 5 d), amino acid starvation for 4 h or untreated cells. All conditions were 
treated with Bafilomycin (100 nM) for 4h before collection. Error bars ± SEM, n=3, P < 0.05. 
The proteins identified in each group were compared within biological replicates of sample. 
Figure 6.8 shows the number of proteins shared between replicates. There is a good level of 
reproducibility between all biological replicates in N-glycanase siRNA transfected samples 
and Z-VAD-fmk treated cells, with 79 % and 60 % of proteins identified in all three replicates 
respectively. Untreated cells and amino acid starved samples showed increased variation 
with only 28 % and 8 % of protein identifications shared across all replicates respectively. 
However, in the untreated control the majority or proteins, 76 %, were identified in two or 
more replicates. For this reason, when averaging data, 0 values were excluded so as to not 
reduce protein intensity in the case of a missing value from a replicate.  
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Figure 6.8 Comparison of protein IDs found in biological replicate of  cells treated with Z-
VAD-fmk (50 µM) for 72 h, transfected with NGLY1 siRNA (25 nM) for 5 d, amino acid 
starvation for 4 h or untreated cells with 2 or more razor and unique peptides. All 
conditions were treated with Bafilomycin (100 nM) for 4h before collection. Proportional 
VENN diagrams show the total number of proteins identified in each group. Pink indicates 
replicate 1, Blue striped indicates replicate 2 and clear indicates replicate 3. 
Proteins were identified as enriched if the experimental intensity was twofold or higher than 
the binding control. The majority of proteins identified were only present in the experimental 
IP and absent in the binding control. Proteins are identified by assigning peptide fragments 
to the ID. To avoid inclusion of ambiguously identified IDs, proteins assigned using only a 
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single peptide were excluded from analysis. Protein intensity scatterplots as a function of 
log(2)-fold change for experiment/control are shown in Figure 6.9. A number of autophagy 
related enriched proteins are highlighted. In all samples LC3B shows increased enrichment 
compared to the control samples which indicates success of the GFP-LC3 IP. Other enriched 
proteins include ATG3, p62, FYCO1 and MAP1B involved in autophagy and vesicle transport. 
ATG3 is involved in the conjugation of LC3-PE for autophagosome maturation (Nath et al. 
2014). The autophagy receptor, p62 links ubiquitinated substrates to the autophagic 
membrane via a LIR domain (Peng et al. 2017). MAP1B and FYCO1 links vesicles via the 
microtubule network and FYCO1 links specifically LC3 via a LIR domain to microtubules to 
facilitate transport (Amaya et al. 2015).  
 
 
  
Figure 6.9 Proteins enriched over binding controls a) untreated cells b) amino acid 
starvation c) cells treated with Z-VAD-fmk (50 µM, 72 h) d) Cells transfected with NGLY1 
siRNA (25 nM, 5 d). Proteins with greater than two-fold increase were identified as 
enriched.  
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Proteins identified as enriched over the binding control and containing one or more peptide 
assignment were analysed. Based on the averages of three biological replicates, excluding 0 
values, the protein IDs were compared between the four conditions. The majority of the 
proteins identified in this experiment were identified in all three conditions shown in figure 
6.10. This suggests that the core machinery and proteins involved in basal, amino acid 
starvation, Z-VAD-fmk and N-glycanase KD induced autophagy are very similar. 
 
 
Figure 6.10 VENN diagram showing the mix of proteins in Untreated cells, amino acid 
starvation, NGLY1 siRNA and Z-VAD-fmk treated cells. 71.7 % of proteins were identified 
in all four conditions. 
Due to the increased number and intensity of mitochondrial proteins identified in Z-VAD-fmk 
and amino acid starvation induced autophagy compared to the untreated control, the 
mitochondrial proteins were analysed in Test 3. Figure 6.11a summarises the mitochondrial 
proteins identified in each sample. The heat map shows the fold over max LFQ intensity, 1 
indicates the highest intensity while 0 indicates ID is missing from the sample. LFQ intensity 
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is based on the average of three biological replicates, excluding 0 values. The sum LFQ 
intensities for the overall mitochondrial content is shown in Figure 6.11b. Due to the 
variation within amino acid starved condition replicates (Figure 6.8), the intensity of proteins 
is significantly decreased compared to Z-VAD-fmk and NGLY1 siRNA. Although there is no 
global change in LFQ intensity in Z-VAD-fmk and NGLY1 siRNA compared to the untreated 
control, there are individual proteins differences shown by the fold over max intensity levels 
in Figure 6.11a.  
 
 
 
 
 
Figure 6.11 Fold over maximum LFQ intensity of mitochondrial proteins (Test 3) Average 
intensity of three biological replicates, excluding 0 values. 0 indicates absence from all 
three replicates, 1 indicates the highest intensity in that condition for that protein b) 
Average of the Sum LFQ intensities of each biological replicate, excluding 0 values. Error 
bars ± SEM.  One-way ANOVA, Tukey’s post hoc. 
To identify individual differences/patterns, mitochondrial proteins were further examined. 
Mitochondria are central to cell survival and sensitive to changes in the cellular environment. 
During the activation of apoptosis, a number of mitochondrial effects have been observed 
including increased permeability of the OMM and release of apoptotic factors including 
cytochrome c and apoptosis-inducing factor Mitochondria associated 1 (AIFM1) (Wang and 
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Youle 2009). Proteins involved in both the positive and negative regulation of apoptosis 
(GO:0043066 and GO:0043065 respectively) were identified. Figure 6.12a shows the fold 
over maximum LFQ intensity of proteins involved in the negative regulation of apoptosis.  
The majority of the proteins identified in this group are heat shock proteins, DNAJA3, 
DNAJA1, HSPA5, HSPA9, HSPD1, that act as chaperones for misfolded proteins to mediate 
stress and exert an anti-apoptotic effect (Lanneau et al. 2008). The interaction of these 
proteins are shown in Figure 6.12b (Szklarczyk et al. 2017) with HSPs highlighted in red. 
Several antioxidant response proteins were also identified including peroxiredoxin (PRDX2 
and PRDX3 and PARK7 which acts as a redox sensitive chaperone, highlighted in blue in figure 
6.12b (Taipa et al. 2016).  Glutathione S-Transferase P (GSTP1) also exerts a protective role 
and detoxifies hydrophobic proteins by conjugating them to glutathione (Aynacioglu et al. 
2004). Similarly to Test 2, the autophagy receptor, PHB2, was also identified. The majority of 
HSPs were also identified as binding to ubiquitin protein ligases, highlighted in green (figure 
6.12b), indicating ubiquitin targeting of cargo. There were no significant difference in protein 
intensity between groups for individual proteins.  
 
 
Figure 6.12 Intensity of proteins involved in the negative regulation of apoptosis.a) 
Summary of the fold over maximum intensity of mitochondrial proteins identified in the 
negative control of apoptosis (GO:0043066) b) String diagram showing interaction of 
proteins. Red: unfolded protein binding, blue: PRDX activity and green: ubiquitin protein 
ligase binding. 
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Several of the HSPs were also identified in the positive regulation of apoptosis (Figure 6.13a). 
Complement 1q-binding protein (C1QBP) is a component of the mPTP complex regulating 
OXPHOS and IMM permeability. Reduction of C1QBP promotes apoptosis (Kai Li et al. 2015). 
BAX is also involved in the permeabilisation of the OMM signalling apoptosis leading to the 
release of cytochrome c and apoptosis inducing factor mitochondria associated 1 (AIFM1). 
Many of these factors are present on the mitochondria at all times, however, BAX is recruited 
to the mitochondria following stress (Maes et al. 2017). There were no significant differences 
in intensity across the groups although there is a trend to increased identification and 
intensity in NGLY1 siRNA and Z-VAD-fmk treated cells of pro-apoptotic proteins, BAX and 
AIFM1. The interaction of these proteins are shown in Figure 6.13b (Szklarczyk et al. 2017). 
The level of interactions show that these proteins were not just identified in the same 
biological process but are also functionally related to each other in the cell.  
 
 
Figure 6.13 Intensity of proteins involved in the positive regulation of apoptosis a) 
Summary of fold over maximum intensity of mitochondrial proteins identified in the 
negative control of apoptosis (GO:0043065) b) String diagram showing interaction of 
proteins. Average of three biological replicates, excluding 0 values. 
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It was noted that this dataset shared a number of protein IDs with proteins found in co-
immunoprecipitation datasets of N-glycanase (Jäger et al. 2011). Table 6.2 summarises genes 
with possible interactions with N-glycanase by co-IP collated from the UCSC Genome 
Browser (Kuhn et al. 2013).  
Table 6.2 Genes identified in co-IP experiments with N-glycanase (Kuhn et al. 2013, Jäger 
et al. 2011). Gene IDs highlighted in green indicate presence in autophagosome isolation. 
ACBD3  AP1M1  APP  ATL3  ATP2A2  ATP2A3  BCAP31  
C20orf24  CALR CAPN1  CHAF1B  CHI3L2  CKAP4  CLGN  
CLN6  CTSD  DERL1  DHCR24  DNAJB11  EMC1  ENDOD1  
ERGIC2  ERGIC  ERLEC1  FAF1  FLOT1  GANAB  GLG1  
HM13  HSPH1  ITGAL  ITGB2  ITM2B  KIR3DL1  KIR3DL2  
LDLR  LMAN1  LMAN2  MESDC2  NPLOC4  NSFL1C  OS9  
PDIA3  PDIA6  PGRMC1  PHB  PHB2  PIP4K2A  PRKCSH  
PSMC1  PSMC2  PTPLAD1  RABGAP1  RAD23A  RAD23B  RAN  
RER1  RHOC  RNF5  SDF2  SDF2L1  SEC61A1  SEC62  
SEH1L SEL1L  SPAG5 SPCS2  SPCS3  SRPK2  SSR4  
SUN1  SURF4  TIMM13  TIMM8A  TIMM8B  TMEM38B  TRBC1  
TRBV12-3  UBC  UFD1L  UGGT1  UGGT2  VAPA  VCP  
RPN1 
      
 
Of these, 19 were also identified in the autophagosome isolation and mainly consisted of ER 
proteins. Figure 6.14 shows the interactions of these proteins. ER proteins are highlighted in 
blue, the proteasome complex in yellow, the Golgi apparatus in green and mitochondrial 
intermembrane space protein transporter in red (Szklarczyk et al. 2017). As a member of 
ERAD (Chantret et al. 2010, Suzuki 2015, Suzuki et al. 2001, Suzuki et al. 2016), N-glycanase 
would be expected to co-precipitate with ER resident proteins and members of the 
proteasome. Inhibition and N-glycanase KD may change the interaction profile of these 
proteins. While inhibition leaves the protein in the cell but reduces activity, siRNA mediated 
KD stops the translation of new proteins, also removing non-deglycosylation functions of the 
protein. 
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Figure 6.14 STRING diagram showing interactions of proteins identified in Table 6.2.Blue: 
Endoplasmic reticulum, Yellow: Proteasome complex, Green: Golgi apparatus, Red: 
Mitochondrial intermembrane space protein transporter complex (Szklarczyk et al. 2017). 
Line thickness indicates confidence of interaction. 
The proteins identified as possible N-glycanase interactors were studied. The average 
(excluding 0) fold over maximum intensity is summarised in Figure 6.15a. Using multiple t-
tests with Benjamini-Hochberg correction, a significant difference in PSMC2 was identified 
between the untreated control and N-glycanase siRNA KD (Figure 6.15b). Proteasome 26S 
subunit ATPase 2 (PSMC2) is a subunit of the regulatory particle of the 26S proteasome. 
PSMC2 has received interest due to its increased expression in osteosarcoma cell lines (Song 
et al. 2017), KD of which halted cell cycle and increased apoptosis in osteosarcoma cell lines 
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(Song et al. 2017) thereby inhibiting tumour growth. This also identifies PSMC2 as an integral 
part of the 26S proteasome.  
 
 
Figure 6.15 Intensity of proteins identified as co-precipitating with N-glycanase. a) Fold 
over maximum intensity, average of three biological replicates excluding 0 values. b) 
Average LFQ intensity of PSMC2 of three biological replicates excluding 0 values in 
Untreated and NGLY1 siRNA KD. P < 0.05. 
Due to the significant decrease in PSMC2 identified in figure 6.15b, other proteins identified 
as partners in the proteasome complex identified from the GO term GO:0000502 were 
examined. RAD23B also identified a significant decrease in N-glycanase siRNA treated cells 
compared to the untreated control (Figure 6.16a). RAD23B is a ubiquitin receptor for the 
proteasome joining ubiquitinated substrates for proteasomal degradation (Wade and Auble 
2010). This trend of decreased proteasome subunits was found in both Z-VAD-fmk and N-
glycanase siRNA mediated KD for PSCM3 and PSCM5 (Figure 6.16b and 6.16c) although no 
significant differences were identified. No obvious decrease was observed in VCP and PSMC6 
(Figure 6.16d and 6.16e).  
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Figure 6.16 LFQ intensities of proteasome complex proteins. Average of three biological 
replicates excluding 0 values a) RAD23B b) PSMC3 c) PSMC5 d) VCP e) PSMC6. Error bars ± 
SEM. One-way ANOVA, Tukey’s post hoc. 
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Since the proteasome is extensively linked to the ER via ERAD, the levels of ER-associated 
proteins was examined. Proteins were identified based on inclusion in the GO term 
GO:0005789, endoplasmic reticulum (figure 6.17a). There was no significant change in ER 
protein associated intensity in N-glycanase KD and Z-VAD-fmk treated cells (figure 6.16b) 
indicating the change in the proteasome complex is not a general effect for ER components. 
Similarly to mitochondrial based proteins, the amino acid starvation condition has a high 
degree of variation due to the two of the replicates containing reduced protein number.  
 
Figure 6.17 ER associated protein IDs a) fold over maximum intensity of the average of 
three biological replicates (excluding 0 values) b) SUM LFQ intensity per condition, average 
three biological replicates, excluding 0 values. Error bars ± SEM.  One-way ANOVA. 
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In order to identify other processes involved in selective autophagy, the dataset was tested 
for proteins containing LC3 interacting regions (LIRs). Selective autophagy is controlled by 
autophagy receptor proteins, most of which recruit cargo to autophagosome via a LIR 
domain (Johansen and Lamark 2011). Protein IDs were checked against the iLIR database and 
IDs that were found in N-glycanase siRNA, Z-VAD-fmk or untreated cells are summarised in 
Table 6.3. (Jacomin et al. 2016). The number of razor and unique peptides indicates the 
number of peptides identified to assign an ID across all conditions. Not all proteins were 
identified in all samples and, the number of replicates is also included.  
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Table 6.3 LIR containing proteins found in enriched proteins in autophagosome 
isolation.The number of razor and unique peptides indicates how many peptides assigned 
to a protein were identified summed across all samples/conditions.  
Uniprot ID Gene Name 
LIR pattern 
 
Razor + 
unique 
peptides 
 
Number of replicates 
identified in 
Q9BQS8 FYCO1 ADYQAL 67 Z-VAD-fmk-3 
siRNA-3 
Untreated- 3 
AA Starve- 1 
E9PGC8 MAP1A AEYDSV 41 Z-VAD-fmk-3 
siRNA-3 
Untreated- 3 
Q99623 PHB2 PGYIKL 
 
11 Z-VAD-fmk-3 
siRNA-3 
Untreated- 3 
AA Starve- 2 
Q13043 STK4 GDYEFL 10 Z-VAD-fmk-2 
siRNA-2 
Untreated- 1 
Q13501 P62 DDWTHL 17 Z-VAD-fmk-3 
siRNA-3 
Untreated- 2 
O75367 H2AFY DGFTVL 9 Z-VAD-fmk-1 
siRNA-2 
Untreated- 2 
AA Starve- 1 
Q96AG4 LRRC59 KEYDAL 8 Z-VAD-fmk-3 
siRNA-3 
Untreated- 2 
AA Starve- 1 
Q13188 STK3 GDFDFL 6 Z-VAD-fmk-2 
siRNA-1 
D6R9P3 HNRNPAB RGFVFI 5 Z-VAD-fmk-2 
siRNA-2 
AA Starve- 1 
J3KN66 TOR1AIP1 GDFEPL 5 Z-VAD-fmk-2 
siRNA-3 
Untreated- 2 
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P42696 RBM34 PVYVPV 5 Z-VAD-fmk-2 
siRNA-2 
AA Starve- 1 
H7C5Q2 ACOT9 ATFVMV 4 Z-VAD-fmk-2 
siRNA-2 
Untreated- 1 
AA Starve- 1 
F6S6P2 BAG6 AEYVEV 3 Z-VAD-fmk-2 
siRNA-2 
Untreated- 2 
Q03252 LMNB2 AEYQEL 3 Z-VAD-fmk-1 
AA Starve- 1 
H7BYX6 NCAM1 LEFILV 2 Z-VAD-fmk-1 
siRNA-1 
AA Starve- 1 
E7EU81 GOLGB1 KEYEIL 2 Z-VAD-fmk-2 
P16152 CBR1 PVYLAL 2 Z-VAD-fmk-1 
siRNA-1 
AA Starve- 1 
Q6P2E9 EDC4 ADFLSL 2 Z-VAD-fmk-2 
AA Starve- 1 
 
FYCO1 was identified as significantly increased in Z-VAD-fmk sample compared to untreated 
control and N-glycanase siRNA treated cells shown in Figure 6.18. FYCO1 is involved in the 
linkage of autophagosomes to microtubules for transport. This increase in FYCO1 in Z-VAD-
fmk treated cells and to a lesser extent, N-glycanase siRNA, may be due to an overall increase 
in autophagy. An increased autophagosome number may indicate a greater need to 
transport autophagosomes to lysosomes for degradation. Amino acid starvation cells only 
contained a single replicate identifying FYCO1. None of the other LIR domain containing 
proteins showed significant differences.  
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Figure 6.18 SUM LFQ Intensity of FYCO1 average of three biological replicates excluding 0 
values. Error bars ± SEM. One-way ANOVA, Tukey’s post hoc. * indicates P < 0.05, ** 
indicates P < 0.01.  
Three of the LIR containing proteins are localised to the mitochondria according to the 
human protein atlas (HPA). Acyl-CoA thioesterase 9 (ACOT9), Leucine-Rich Repeat-
Containing Protein 59 (LRRC59) and Prohibitin 2 (PHB2). Due to the localisation of these 
proteins there may be link to mitophagy. However, this would need to be further validated 
experimentally.   
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6.4 Discussion 
This chapter aimed to identify autophagy-associated and cargo proteins involved in the 
activation of autophagy under Z-VAD-fmk treatment and siRNA KD of N-glycanase. In order 
to examine autophagosomes, GFP-LC3 immunoprecipitation was used and proteomics 
analysis of the IP protein mixture was performed. LC3 is the most commonly used marker for 
identification of autophagosomes and previous studies have successfully used this as a target 
for IP of autophagosomes (Dengjel et al. 2012, Hanna et al. 2012, Martinez-Lopez et al. 2013). 
Firstly, this chapter looks at the method development of autophagosome isolation and 
analysis, followed by functional analysis of clusters assigned by Gene ontology terms. From 
the final test it was found there was an increase of mitochondrial proteins in Z-VAD-fmk and 
N-glycanase KD samples compared to the untreated control with increased intensity of 
proteins associated with the control of apoptosis. Conversely, a significant decrease in the 
proteasome subunit PSMC2 and proteasome ubiquitin receptor, RAB23B was found in N-
glycanase KD compared to the untreated control. This trend was also identified in Z-VAD-fmk 
and other proteasome markers including PSMC3 and PSMC5. However, there were no 
differences identified in ER associated proteins, suggesting this effect was only based on the 
proteasome rather than ERAD. Finally, LIR containing proteins were examined to determine 
selective autophagy across the samples and found a significant increase in the microtubule 
associated protein FYCO1 in Z-VAD-fmk treated cells compared to the untreated control.  
Autophagosomes represent a small fraction of the cellular proteome and efficient and 
specific IP is necessary for meaningful analysis. GFP-LC3 was used as the target for IP which 
is the most common marker for autophagosomes. However, GFP-LC3 is also present in the 
cytosol. Initial tests used a simple lysate clearance, however, the antibody used for the IP 
could be binding to cytosolic LC3 I instead of autophagosomes. To try and remove this, final 
samples were pre-cleared of large debris by centrifugation followed by a hard centrifugation 
to pellet autophagosomes. However, this method may be too harsh for autophagosome 
structures which may become damaged and lyse, releasing cargo that is of interest in this 
study. Other methods of autophagosome isolation could have been used such as purification 
of autophagosomes by density gradient centrifugation followed by immunoprecipitation 
(Dengjel et al. 2012) to increase the specific binding to autophagosomes.  
Proteins were identified as relevant using enrichment over the binding control. Experimental 
proteins with an intensity of twofold or higher in the corresponding binding control were 
used for analysis. For proteins only found in the experiential control, identifications only 
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associated with a single razor and unique peptide were excluded from analysis. This is 
because a single peptide can be mapped onto several proteins. By removing single peptide 
matches, remaining identifications have a minimum of two peptides (Cottrell 2011) 
representing more stringent identification criteria.  
Several approaches were used to identify functional clusters from the enriched dataset. 
Several databases were used to identify Gene Ontology terms including STRING database 
(Szklarczyk et al. 2017) and the DAVID Functional annotation tool (Huang et al. 2008) to 
identify. The Harmonizome was used to identify protein interactions including non-validated 
text mining (Papanikolaou et al. 2015) interactions (Rouillard et al. 2016a). This is especially 
useful when examining proteins with little literature on their protein interaction networks 
and is able to use open access repositories from high-throughput experiments to identify 
possible protein interactions. LIR containing proteins were identified against the iLIR 
database (Jacomin et al. 2016).  
To identify functional clusters of proteins they were annotated using Gene Ontology (GO) 
terms. GO terms are widely used and can be separated into various groupings depending on 
what is of interest, such as cellular components, biological process etc. However, GO terms 
have a high level of redundancy. Figure 6.5 shows the GO cellular components annotations. 
GO terms can show a high level of redundancy; for mitochondria, two sections for 
mitochondrion and mitochondrial inner membrane and for nuclear proteins three sections 
are given over to nucleus, nucleolus and nucleosome which contain multiple copies of the 
same protein IDs. This means groups that may be of interest but contain a lower protein 
count can get lost in the analyses. This has been identified as an issue of the GO terms used 
and protocols aiming to reduce redundancy have been developed (Jantzen et al. 2011). 
STRING database also uses GO terms to categorise protein groups.  
In Test 2, increased numbers of mitochondrial proteins were identified in Z-VAD-fmk treated 
cells compared to the untreated control and the amino acid starved cells. This trend was 
partially replicated in Test 3 with increased protein IDs and intensity in both N-glycanase KD 
and Z-VAD-fmk compared to the untreated control, although this was not significant. 
Increased mitochondrial proteins present in autophagosome isolation may be suggestive of 
selective mitophagy.  Mitophagy can be signalled by a variety of effects and is essential to 
maintain pools of healthy mitochondria for energy production and cellular homeostasis. One 
of the most common signals for mitophagy is oxidative stress, although no increase in 
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reactive oxygen species was detected in the previous Chapters 3 and 4 under Z-VAD-fmk or 
N-glycanase siRNA KD.  
Many of the proteins identified as involved in mitophagy (such as PHB2 and proteins involved 
in regulation of apoptosis such as C1QBP and AIFM1) are already present in mitochondria 
and may be identified as increased because of increased mitochondrial uptake via increased 
levels of autophagy. As such, this cannot be regarded as indicative of activation based on this 
data alone. To identify if mitophagy is truly occurring, further validation is required. As well 
as cargo leading to changes in the autophagosome composition, initiation site may also 
play a role. Several organelles have been implicated in the donation of membranes for 
autophagosomes including the ER, Golgi and mitochondria (Hailey et al. 2010, 
Karanasios et al. 2016, Noda 2017) and should also be considered as a potential source 
of organelle identified membrane proteins. There is little literature based on the protein 
composition of autophagosomes and whether donated membranes retain many of the 
membrane proteins associated with them and contradictory evidence of the origins of 
autophagy membranes also exists (Cook et al. 2014, Nascimbeni et al. 2017, Ding and 
Eskelinen 2014).  
Interestingly, a decrease in proteins involved in the proteasome complex was identified. 
Recently, the N-glycanase dependent regulation of the transcription factor, Nuclear 
respiratory factor 1 (Nrf1) has been identified (Tomlin et al. 2017). Nrf1 is involved in the 
transcription of proteasomal proteins, mitochondrial proteins and redox proteins (Biswas 
and Chan 2010). Nrf1 and 2 are part of the CNC-bZIP family and bind antioxidant response 
elements (AREs), a sequence to initiate transcription of target genes (Digaleh et al. 2013). 
During Nrf1 synthesis the protein is held in the ER membrane with the majority of the protein 
within the ER lumen (Radhakrishnan et al. 2014). Activation depends on p97/VCP, known 
interactors of N-glycanase (Zhao et al. 2007, Christianson et al. 2011) which flips Nrf1 from 
the ER lumen to the cytoplasmic face allowing the proteasome access to break down the 
cytoplasmic face of the protein. It has been identified that N-glycanase is responsible for Nrf1 
activation via a deglycosylation dependent activation route (Tomlin et al. 2017). KO of N-
glycanase halts translocation to the nucleus following proteasome inhibition (Tomlin et al. 
2017). The proposed activation of Nrf1 is shown in Figure 6.19.  
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Figure 6.19 Proposed action of NRf1 activation.Open access article published under ACS 
AuthorChoice. Reprinted from (Tomlin et al. 2017). 
Furthermore, a study of the transcriptome of N-glycanase KO Drosophila have shown an 
increase in stress response proteins such as heat shock proteins but a downregulation in 
oxidation-reduction, proteasome and lipid metabolism, concordant with a disruption of cap 
’n’ collar (Cnc) (Nrf1 drosophila homolog) function (Owings et al. 2018).  
Nrf1 plays an important role in the proteasome recovery pathway (Radhakrishnan et al. 
2010). However, in N-glycanase KO MEF cells Nrf1 was unable to translocate to the nucleus 
and proteolytic cleavage was inhibited (Tomlin et al. 2017). Under basal conditions there are 
no differences found in proteasome activity, however, under proteasome inhibition, PSM 
genes were not induced and N-glycanase KO sensitised cells to proteasome inhibition and 
increased cell death (Tomlin et al. 2017). This could also explain why Z-VAD-fmk or siRNA N-
glycanase knockdown did not cause ER stress as these were performed under basal 
conditions. If Nrf1 cannot leave the ER due to its glycosylation halting further processing of 
the protein, therefore it cannot activate not just proteasome subunits, but other proteins 
involved in the antioxidant response and ER stress. In C. elegans, the NRF1 homolog, SKN-1, 
regulates UPR proteins including homologs of BiP, PERK, IRE1, XBP1, ATF4 and ATF6 under 
ER stress but not oxidative stress (Choe and Leung 2013, Digaleh et al. 2013, Cullinan et al. 
2003, Pajares et al. 2017). In conclusion, inactivation of Nrf1 could affect activation of UPR 
and sensitise cells to a number of different stressors. This could also explain decreased levels 
of proteasome complex proteins; Nrf1 is identified as regulating PSMC1, PSMC3IP, PSMC4,  
PSMC5 and RAD23B (Rouillard et al. 2016b) as transcription of PSM genes may not be as 
efficient.  
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Nrf1 also regulates the expression of a number of mitochondrial proteins. Nrf1 and Nrf2 
promotes expression of the transcription factor Tfam which controls mtDNA replication 
(Jornayvaz and Shulman 2010) and Nrf1 has been shown to directly regulate expression of 
mitochondrial proteins such as TOMM34, TOMM70 and TOMM20 (Blesa et al. 2008). A 
number of the roles of Nrf1 can be partially compensated for by Nrf2 but not completely 
(Digaleh et al. 2013, Cullinan et al. 2003). Nrf1 KO mice exhibits embryonic lethality at E13.5 
(Ohtsuji et al. 2008) leading Nrf1 to be studied in conditional KO models. A mouse model of 
hepatocyte Nrf1 KO described liver damage which was absent in Nrf2 KO, and increases Nrf2 
driven genes was found indicating Nrf2 cannot completely compensate for Nrf1 KO (Ohtsuji 
et al. 2008). This change in Nrf1 activation may also impact mitochondrial function and 
explain the dysregulation in mitochondria observed in (Kong et al. 2018).  
To identify if other autophagy receptors were present in the dataset, comparison 
against the iLIR database was carried out. This retrieved proteins from the dataset 
containing an LC3 interaction domain (LIR), LC3 recognition sequence (LRS) or an Atg8-
interacting motif (AIM) (Jacomin et al. 2016) which are summarised in Table 6.3. This 
method allowed the identification of proteins that are not necessarily known for, or 
where there is little literature about the role of the respective protein in autophagy. 
Proteins identified as enriched in each condition in Test 3 were analysed. A total of 
eighteen proteins with a putative LIR domain for found (although many of which were 
not identified across all conditions). FYCO1 was identified as significantly increased 
compared to the untreated control. FYCO1 links autophagosomes to the microtubule 
network to traffic them to lysosomes for cargo degradation. This increase may be due 
to increased autophagy in Z-VAD-fmk and N-glycanase KD which would require 
increased trafficking of autophagosome to lysosomes.  
To identify if mitochondrial dysfunction leading to increased mitophagy is occurring, 
characterisation of mitochondrial function will be examined.    
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Chapter 7.  
7.1 Introduction 
 
The mitochondrial network is highly dynamic. Mitochondria are trafficked around the cell via 
the microtubule cytoskeleton and undergo multiple fission and fusion events (Tandler et al. 
2018). Fusion is vital to allow distribution of mtDNA throughout the mitochondrial network 
and is mediated via Opa1 and mitofusin 1 and 2. Depolarisation of the membrane results in 
a loss of Opa1 and Mfn 1 and 2 which inhibits fusion and leads to mitochondrial 
fragmentation.  Under different stress and environmental conditions, mitochondria adopt 
different morphologies (shown schematically in Figure 7.1).  Mitochondria are also a major 
source of ROS, and are hence intrinsically linked to the homeostasis of the redox 
environment (Willems et al. 2015). Hydrogen ions are pumped from the matrix into the 
intermembrane space during oxidative phosphorylation generating a proton gradient and a 
highly positive environment, this drives the generation of energy in the form of ATP. 
Disruption in this membrane potential has been linked to decreased ATP production, 
increased ROS production and changes in the redox environment of the cell, mitochondrial 
morphology and signalling and the induction of mitophagy, the specific degradation of 
mitochondria via autophagy (Dimroth et al. 2000, Suski et al. 2012, Ding and Yin 2012, 
Willems et al. 2015).  
 
Figure 7.1 Mitochondrial morphology under different environmental conditions. Reprinted 
from Cell Metabolism (Willems et al. 2015)
Mitophagy is the specific removal of mitochondria via the autophagic machinery.  Whole 
mitochondria are engulfed in double membrane vesicles and degraded via lysosomes. This 
process uses the same core machinery as canonical autophagy. The entire protein content 
of mitochondria is turned over every few days (Chan et al. 2015), which is suggestive of the 
regular bulk degradation of the organelles. There are two main types of mitophagy, ubiquitin 
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mediated mitophagy (involving the PINK1/Parkin system) and receptor mediated removal, 
which involves mitophagy adaptor proteins such as NIX, BNIP3 and FUNDC1 and the 
recruitment of autophagy membranes (Figure 7.2).  
 
The ubiquitin kinase PINK1 is readily degraded under normal physiological conditions 
(Thomas et al. 2014). Upon mitochondrial membrane depolarisation PINK1 is stabilised on 
the mitochondrial outer membrane and phosphorylates ubiquitin at Ser65 (Kondapalli et al. 
2012). Phospho-ubiquitin is structurally different from other ubiquitin chains, and activates 
parkin (Kondapalli et al. 2012), an ubiquitin ligase which attaches extra ubiquitin chains to 
the outer mitochondrial membrane (OMM) proteins like Mfn1 and Mfn2 to amplify the 
PINK1 signal (Rakovic et al. 2011). Damaged mitochondria are trafficked to the perinuclear 
region (Al-Mehdi et al. 2012) where adaptor proteins containing ubiquitin binding domains 
and LIR domains serve to target damaged mitochondria to the autophagic machinery. OPTN, 
NDP52 requires PINK1 activity (but not Parkin) for transport to the mitochondria (Michael 
Lazarou et al. 2015). OPTN, NDP52 (which has just a LIR domain and is also involved in 
xenophagy), NBR1 and P62 all have LIR and UB domains to further recruit autophagy 
machinery by binding of proteins with LIR domains to the cargo to recruit LC3 (M. Lazarou et 
al. 2015). However, the exact mechanism of which adaptors are recruited to damaged 
mitochondria is not completely understood and, p62 knockout studies have found no effect 
on mitophagy (Narendra et al. 2010).  
There are two main mitochondrial receptor families which mediate mitophagy, NIX and 
BNIP3 family and FUNDC1 (Figure 7.2 panel B and C).  NIX and BNIP3 are not highly expressed 
under normal conditions but are upregulated under hypoxic conditions and are localised to 
both mitochondrial and ER membranes (Zhang et al. 2008). One of the main functions of 
BNIP3 and NIX is to regulate cell death through ROS production by removing damaged 
mitochondria. Under hypoxic conditions hypoxia-inducible factor 1 (HIF-1) upregulates 
BNIP3 and NIX (Zhang et al. 2008) and under starvation conditions FOXO3 binds to BNIP3 and 
NIX promoter regions (Bakker et al. 2007). Both proteins contain a LIR domain, allowing 
recruitment of LC3. Mutations in these LIR domains inhibit LC3 binding and genetic knockout 
of NIX have shown defect in mitochondrial degradation in reticulocytes (Novak et al. 2010). 
Phosphorylation of BNIP3 at Ser17 and Ser24 promotes interaction with LC3B to increase 
mitophagy, although the kinase and phosphatase responsible is unknown (Rogov et al. 2017). 
BNIP3 is a Bcl-2 interacting protein and plays a role in apoptosis regulation. In response to 
hypoxic conditions it localises to the mitochondria and disrupts mitochondria function, 
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increasing ROS production, mitochondrial swelling and resulting in depolarisation of the 
membrane and induction of mitophagy to remove the damaged mitochondria. This is a 
survival mechanism, however if there are more damaged mitochondria than the cell can 
dispose of, BNIP3 will activate cell death cascades (Burton and Gibson 2009). 
FUNDC1 is a transmembrane protein localised to the mitochondrial outer membrane. The N-
terminus contains a LIR domain and faces the cytoplasm. Similarly to BNIP3 and NIX, removal 
of the LIR domain results in abolishment of LC3 binding and defects in mitophagy. FUNDC1 
has been shown to mediate hypoxia inducement mitophagy but interestingly, under hypoxic 
conditions, FUNDC1 mRNA and protein levels decrease as mitochondria are degraded. 
FUNDC1 is regulated by phosphorylation at Ser13 and Tyr18, by CK2 and Src kinase 
respectively under normal conditions. Under hypoxic conditions and decreased 
mitochondrial membrane potential FUNDC1 is dephosphorylated by PGAM5 which increases 
the binding affinity to LC3 (Kuang et al. 2016). 
 
Figure 7.2 Methods of autophagic recruitment to mitochondria. A shows PINK1/Parkin 
mediated removal. B shows BNIP3 and NIX mediated recruitment of LC3 and C shows 
FUNDC1 control of LC3 recruitment. Reprinted from The American Physiological Society 
(Moyzis et al. 2015)
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There are several ways in which levels of mitophagy can be assessed. A decrease in 
mitochondrial proteins can give an indication of mitochondrial degradation and can be 
measured by immunoblotting techniques, although methods such as these cannot 
distinguish between degradation pathways. Co-localisation of mitochondria and autophagic 
machinery using fluorescence microscopy and common markers such as TIMM/TOMM 
proteins and LC3 can also be employed (Kobayashi et al. 2016). In some cases, mitochondrial 
DNA can be used a measure of mitochondrial density (Furda et al. 2014), however it should 
be noted that there are some known disorders that affect the copy number of mtDNA (Ding 
and Yin 2012).  
7.1.1 Clinical presentations of N-GLY1 deficiency disorder mirror those of 
mitochondrial disorders 
A meta-analysis of eight transcriptome experiments of human respiratory chain disease 
samples identified N-glycanase as having consistently increased expression (Zhang and Falk 
2014). Patients diagnosed with mitochondrial disorders such as respiratory chain disorders 
and, those diagnosed with NGLY1 also exhibit comparable phenotypic patterns (Enns et al. 
2014, Ohtake et al. 2014). Despite this parity in clinical presentation, analysis of pyruvate 
dehydrogenase and pyruvate carboxylase activity (elements of the mitochondrial electron 
transfer chain and often measured as a marker of mitochondrial dysfunction (Kerr et al. 2012, 
Gray et al. 2014, Patel et al. 2012)) in skin fibroblasts, muscle or liver samples derived from 
NGLY1 patients showed no abnormalities  (Enns et al. 2014).  Conversely, two of the eight 
patients examined in the Enns et al. 2014 study did exhibit abnormal mitochondrial function. 
Patient 3 (c. 1205_1207del and c.1570C>) showed a 39 % decrease in liver mtDNA while 
patient 7 (homozygous c.1201A>T) showed increased tricarboxylic acid cycle (TCA) 
intermediates (Enns et al. 2014).  Another patient (c.1604G>A:c.1910delIT) showed 
abnormal liver mitochondrial morphology and proliferation and, a quadriceps muscle biopsy 
of this patient revealed five-fold increase in citrate synthase activity and 472% increase in 
mtDNA compared to age and tissue matched controls (Kong et al. 2018).  These results are 
suggestive of tissue specific differences.  
Mitochondrial dysfunction has also been observed in N-glycanase deficient C. elegans, MEFs 
and human fibroblasts derived from NGLY1 patients (Kong et al. 2018). N-glycanase KO C. 
elegans have been observed to have a stark decrease in lifespan (53 % reduction), and 
decreased (20 %) mitochondrial content (measured by Mitotracker).  In addition, an 80 % 
decrease in mitochondrial membrane potential (measured by Tetramethylrhodamine ethyl 
258 
 
ester (TMRE) fluorescence intensity) and, a 20 % increased mitochondrial matrix oxidant 
burden (measured by MitoSOXTM fluorescence intensity) was also observed.  
In comparison, N-glycanase KO MEFs and patient fibroblasts (FCL-M1; 
c.1205_1207del:c.1570C>T and FCL-M2; homozygous c.1201A>T) showed no difference in 
MitotrackerTM fluorescence compared to that observed in WT cells under basal conditions. 
However, when grown under conditions which promotes OXPHOS (galactose supplemented 
media) and treated with the mitochondrial RC complex 1 inhibitor rotenone (25 nM, 72 h), 
patient fibroblasts FCL-M1 and FCL-M2 showed a significant reduction in cell viability (5 and 
18 % respectively versus respective controls of 66 and 74 %, determined by CellTiter GloTM). 
Furthermore, when patient fibroblasts were grown in galactose supplemented media, a 9 % 
decrease in TMRE fluorescence and a 65 % increase in ROS (measured by MitoSOXTM 
fluorescence intensity) (Kong et al. 2018) was observed. Differences were also noted in 
respiration levels. MEFs exhibited normal basal respiration but upon addition of the complex 
un-coupler FCCP to achieve maximal oxygen consumption there was a significant decrease 
in maximal oxygen consumption compared to the control. FCL-M2 fibroblasts showed a 
significant decrease (25.7 %) in basal respiration and a drop (22.6 %) in maximal respiration. 
Introduction of ectopic N-glycanase increased mitochondrial content, increased membrane 
potential and effected a reduction of the mitochondrial oxidant burden in MEF cells. In 
patient fibroblasts (FCL-M1) there was no change in mitochondrial content but there was an 
increase in TMRE fluorescence. FCL-M2 fibroblasts however, exhibited a 72 % increase in 
mitochondrial content, a 2.1-fold increase in TMRE fluorescence and, an 80% reduction in 
oxidant burden. Maximal oxygen consumption in both patient fibroblasts, FCL-M1 and FCL-
M2 was rescued when cells were grown in galactose supplemented media (24.9 % and 79 % 
respectively) (Kong et al. 2018).  
7.2 Aims and Objectives 
 
As proteomics analysis indicated increased levels of mitochondrial proteins associated with 
autophagosomes, in this chapter mitochondrial function will be examined in HEK cells under 
both conditions of pharmacological inhibition and genetic ablation of N-glycanase. 
Mitochondrial health will be assessed by examination of the redox environment of the cell, 
mitochondrial membrane potential and determination of levels of mitophagy. Although 
there were no changes in overall lectin binding in whole cell lysates was observed, this does 
not exclude small changes in specific proteins or organelles. To this end, the mitochondria 
lectin binding profile was also examined.  
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7.3 Results 
 
As many cells grown in vitro are grown under conditions of high glucose, they are adapted 
to be highly dependent upon glycolytic metabolism (using the breakdown of glucose for 
energy rather than via mitochondrial oxidative phosphorylation) (Marroquin et al. 2007, 
Diaz-Ruiz et al. 2011). This phenomenon is known as the Crabtree effect (Dell’ Antone 2012, 
Diaz-Ruiz et al. 2011, Marroquin et al. 2007, Rodriguez-Enriquez et al. 2001 
). When studying whether a process or reagent influences mitochondrial function, if the cells 
are adapted to high aerobic glycolysis for energy production then they may be less sensitive 
to mitochondrial assault. Therefore, the conditions need to be adapted to increase 
mitochondrial dependency for energy production.  
 
HEK cells grown in high glucose during exponential growth utilise glucose as the main carbon 
source and is mostly metabolised via glycolysis (Henry et al. 2011, Lin et al. 2014). In HEK 293 
cells it was found most cellular pyruvate (77 %) is converted to lactate, whilst 22 % enters 
the TCA cycle for oxidation (Henry et al. 2011). These cells are therefore less susceptible to 
mitochondrial assault than cells which rely on mitochondrial oxidative phosphorylation for 
their energy needs. Evidence suggests cells switch between aerobic glycolysis and OXPHOS 
depending on glucose availability. Exchanging glucose for galactose changes cellular 
metabolism to rely more on mitochondrial OXPHOS for energy production (Marroquin et al. 
2007). It has been found that several cell types, when grown in the presence of galactose 
instead of glucose, exhibit increased levels of oxidative phosphorylation (Aguer et al. 2011, 
Kase et al. 2013), increased mitochondrial protein expression (Rossignol et al. 2004), and 
contain mitochondria with increased numbers of cristae, but not increased mass (Rossignol 
et al. 2004). Galactose metabolism to pyruvate yields no net ATP and has been suggested to 
force cells to produce ATP via OXPHOS instead (Kase et al. 2013).  
 
To study mitochondrial function in HEK cells under inhibition of N-glycanase and siRNA 
mediated knockdown of N-glycanase, cells were grown in high glucose (25 mM), 
representing standard cell culture conditions, or galactose (10 mM) supplemented media 
(Aguer et al. 2011, Kamalian et al. 2015) to increase dependence on mitochondrial oxidative 
phosphorylation for energy production. MTT reduction was measured under each culture 
condition to identify if N-glycanase inhibition or deficiency affected mitochondria. To confirm 
cell viability and proliferation, propidium iodide exclusion was measured and the number of 
cells under each condition were counted. Further investigation into mitochondrial function 
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was achieved by measurements of mitochondrial membrane potential via TMRE 
fluorescence. As autophagy activation has been identified under N-glycanase knockdown 
and inhibition and a number of mitophagy receptors were identified at low levels following 
proteomics analysis of autophagosomes, the level of mitophagy was examined using 
MitotrackerTM fluorescence, both before and after autophagy inhibition with Bafilomycin.  
7.3.1 Galactose supplemented low glucose media does not affect HEK cell 
proliferation 
To test whether HEK cells grown in media supplemented with galactose instead of glucose 
exhibited different growth patterns, cells were grown for six days in glucose (25 mM) or 
galactose (10 mM) supplemented media. Cells were sub-cultured at 2000 cells per well in a 
48 well plate in either glucose (25 mM) or galactose (10 mM) supplemented media. Cells 
were also grown in media containing 1:1 glucose and galactose. Figure 7.3a shows the 
growth curves of HEK cells in different media compositions. Cells were manually counted 
using a haemocytometer over 15 d. 
The doubling times were calculated during the linear growth phase (between days 3 and 6). 
Figure 7.3b shows the calculated doubling times for each media composition. There were no 
significant differences in cell doubling times. Cells exhibited an average doubling time of 
21.3, 18.9 and 21.5 h for glucose, 1:1 glucose:galactose and galactose supplemented media 
respectively.   
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Figure 7.3 Galactose does not affect HEK cell proliferation. a) growth curve of WT HEK cells 
grown in glucose (25 mM), glucose:galactose (12.5 mM:5 mM) and galactose (10 mM) b) 
calculated doubling time (h).  Error bars indicate ± SEM, n=4. One-way ANOVA.
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7.3.2 HEK cells grown in galactose show decreased MTT reduction when treated 
with Z-VAD-fmk for 72 h but no decrease in cell viability or proliferation  
The MTT assay is commonly used for cell toxicity or proliferation studies (A. van Tonder et 
al. 2015). This is based on the reduction of MTT to coloured formazan by enzymes in actively 
metabolising cells. It is thought that most of the reducing power of metabolically active cells 
comes from the mitochondria (Alet van Tonder et al. 2015). In this study, cells were grown 
in glucose or galactose media and treated with 0-200 µM Z-VAD-fmk or Q-VD-OPh to assess 
whether increased mitochondrial load causes decreased MTT reduction. Figure 7.4a shows 
that cells grown in no glucose, galactose media treated with Z-VAD-fmk showed a significant 
decrease in MTT reduction compared to the vehicle control from just 1 µM. To confirm this 
effect was not due to the effect of Z-VAD-fmk on caspase inhibition, this was repeated with 
Q-VD-OPh shown in Figure 7.4b. There was no significant decrease in MTT reduction under 
Q-VD-OPh treatment.  
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Figure 7.4 MTT of HEK cells grown in DMEM high glucose media (4.5 g/L) or glucose-free 
DMEM supplemented with galactose (10 mM) and treated with a) Z-VAD-fmk (0-200 µM, 
72 h)  b) Q-VD-OPh (0-200 µM, 72 h). One-way ANOVA, Dunnett’s multiple comparison, 
comparing samples to vehicle. Error bars ± SEM, n=3, P < 0.05. 
Lower levels of MTT reduction can result from decreased cell viability, decreased cell 
proliferation or decreased reduction potential. To confirm the reason of the reduced 
formazan absorbance, cell viability was confirmed by propidium iodide exclusion. Propidium 
iodide (PI) is a cell impermeant nuclear fluorescent dye. Dead cells have a disrupted plasma 
membrane allowing PI staining. Cells undergoing apoptosis have a distinct morphological 
phenotype as well as molecular markers such as Annexin V on the outer membrane of the 
a 
b 
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cell which occurs early in the apoptotic pathway whereas PI staining only occurs after a 
membrane has been damaged.  To confirm changes in cell proliferation, the number of cells 
were counted per condition. Cells are plated at 40 000 cells per well and treated with Z-VAD-
fmk or Q-VD-OPh (50 µM, 24-72 h) and detached from wells and counted.  Menadione, a 
potent inducer of apoptosis via increased ROS production (Loor et al. 2010) was used as a 
positive control.   
Figure 7.5a shows the percentage of cells with PI exclusion and therefore viable cells. There 
was no significant difference in Q-VD-OPh or Z-VAD-fmk treated cells to the vehicle control 
and all samples showed a > 80 % viability. Figure 7.5b shows the annexin V staining, although 
there was an increase in staining in cells grown under galactose, there were no significant 
differences between Z-VAD-fmk, Q-VD-OPh and the vehicle. Figure 7.5c shows the number 
of cells per mL counted.  There were no significant differences in cell number, indicating that 
under growth in galactose media, Z-VAD-fmk or Q-VD-OPh does not affect cell proliferation. 
Due to no significant changes in cell viability and cell proliferation the decreased level of MTT 
reduction may suggest differences in the cellular redox environment. 
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Figure 7.5 There are no significant changes in PI exclusion, annexin V staining or cell number 
in WT HEK cells grown in high glucose (25 mM) or galactose (10 mM) DMEM. Cells were 
treated with Q-VD-OPh or Z-VAD-fmk (50 µM, 72 h) or Menadione (100 µM, 24 h) a) 
Percentage PI (10 µg/ml 0.5 h) exclusion b) percentage of FITC annexin V positive cells c) 
cell number per mL. One-way ANOVA, Tukey’s multiple comparison test within each 
condition. Error bars ± SEM, n=3, P < 0.05.
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7.3.3 Knockdown of N-glycanase in HEK cells grown in galactose show decreased 
MTT reduction but no decrease in cell viability or proliferation  
To confirm the effects of Z-VAD-fmk on MTT reduction in galactose supplemented media HEK 
cells were transfected with N-glycanase siRNA. Figure 7.6 shows the formazan absorbance 
of HEK cells grown in either glucose or galactose supplemented DMEM transfected with N-
glycanase or non-targeting control siRNA (siRNA absorbance normalised to percentage of the 
non-targeting control). As before, there is a significant decrease in MTT reduction in HEK cells 
with reduced N-glycanase activity when grown in galactose.  
 
Figure 7.6 MTT assay of HEK cells grown in high glucose DMEM (4.5 g/L) and galactose 
DMEM (10 mM) 7 d post-transfection with NGLY1 siRNA. One-way ANOVA, Dunnett’s post 
hoc against the vehicle control at time 0. Error bars ± SEM, n=3, P < 0.05. 
Cell viability and proliferation were assessed by PI exclusion and cell number. Unlike Z-VAD-
fmk, N-glycanase siRNA has not been identified as targeting caspases and is does not thought 
to interfere in regulation of apoptosis. Annexin V was also measured to give an indication if 
cells were in the early apoptotic stages of cell death. Figure 7.7a shows the percentage of 
cells with PI exclusion, as with Z-VAD-fmk there was no decrease in cell viability in cells with 
decreased N-glycanase compared to the non-targeting control. Figure 7.7b shows there is no 
significant difference in the percentage of annexin V positive cells indicating cells are not 
undergoing apoptosis. Figure 7.7c shows that knockdown of N-glycanase does not affect 
proliferation in HEK cells grown in glucose or galactose media. 
0 2 4 6 8
0
5 0
1 0 0
1 5 0
t im e  (d )
a
b
s
o
rb
a
n
c
e
 (
a
. 
u
.)
* *
* *
H E K  +  g lc
H E K  +  g a l
*
267 
 
 
 
Figure 7.7 Galactose does not affect viability in HEK cells transfected with NGLY1 siRNA. 
There are no significant changes in propidium iodide exclusion as a measure of cell viability, 
annexin V staining or cell number in HEK cells grown in high glucose DMEM (4.5 g/L) or 
galactose DMEM (10 mM). Cells were transfected with NGLY1 siRNA or non-targeting 
siRNA and measured after 3-5 days a) percentage PI (10 µg/ml 0.5 h) exclusion. b) 
Percentage of FITC annexin V positive cells c) cell number per ml. One-way ANOVA, Tukey’s 
multiple comparison test within each condition. Error bars ± SEM, n=3, P < 0.05.
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7.3.4 Galactose, low glucose media does not affect ATG13 KO or WT MEF cell 
proliferation 
Autophagy was identified as a protective measure in cells where N-glycanase activity was 
decreased and, ATG13 KO MEF cells showed decreased MTT reduction in the presence of Z-
VAD-fmk or siRNA mediated N-glycanase knockdown. ATG13 KO MEF cells and WT MEFs 
were further examined to identify to the cause of decreased MTT reduction. To first identify 
if galactose supplemented media affects growth of ATG13 KO or WT MEFs, growth curves in 
glucose (25 mM), galactose (10 mM) or 1:1 glucose:galactose mix DMEM were measured. 
Figure 7.8a and b show the growth curves of WT MEFs and ATG13 KO MEFs respectively. 
 
 
 
Figure 7.8 There are no growth defects in WT MEF cells or ATG13 KO MEF cells in glucose 
or galactose media. a) WT MEFs or b) ATG13 KO MEFs grown in glucose (25 mM) 
glucose:galactose (12.5:5 mM) or galactose (10 mM) c) calculated doubling time (h). Error 
bars ± SEM, n=4. Two-way ANOVA.
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The doubling times were calculated during the linear growth phase. Figure 7.8c shows the 
doubling times for WT and ATG13 KO MEF cells. There were no significant differences in 
growth rates between glucose or galactose media. Doubling times of 30.46, 30.88 and 30.48 
h were recorded for WT MEF grown in glucose supplemented media, 50:50 glucose:galactose 
supplemented media and galactose. Doubling times of ATG13 deficient MEF cells were 
recorded as 23.38, 21.12 and 23.68 h respectively. 
7.3.5 ATG13 KO MEFs show decreased formazan reduction when grown in 
galactose with Z-VAD-fmk treatment 
ATG13 KO MEFs were grown in high glucose DMEM and media supplemented with galactose 
(10 mM) and treated with Z-VAD-fmk (1-200 µM) for 72 h. Similar to previous results (Figure 
3.47) of ATG13 KO MEFs grown in RPMI 1640 media (2 g/L glucose) there was a significant 
decrease in high glucose (4.5 g/L) DMEM at 200 µM Z-VAD-fmk with an IC50 value of 63.2 µM 
(versus an IC50 value of 12.98 µM in glucose containing RPMI 1640). When ATG13 deficient 
MEF cells were grown in galactose supplemented DMEM there was a significant decrease in 
formazan absorbance following treatment with 50, 100 and 200 µM Z-VAD-fmk compared to 
the vehiclecontrol with an IC50 of 40.9 µM (1.5 fold increase) shown in Figure 7.9a. Figure 
7.9b shows the effect of Q-VD-OPh in ATG13 KO MEFs grown in high glucose and galactose 
media. There was no significant decrease in formazan absorbance after treatment with Q-
VD-OPh (1-200 µM) for 72 h. This indicates that autophagy is indeed a protective measure 
and that the effects of decreased formazan reduction are due to a non-caspase inhibitory 
effect of Z-VAD-fmk.  
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Figure 7.9 MTT assay of ATG13 KO MEFs grown in DMEM high glucose media (4.5 g/L) or 
glucose free DMEM supplemented with galactose (10 mM) and treated with a) Z-VAD-fmk 
(0-200 µM, 72 h) b) Q-VD-OPh (0-200 µM, 72 h). One-way ANOVA, Dunnett’s post hoc 
comparing samples to vehicle. Error bars ± SEM, n=3.
Cell viability was confirmed using PI exclusion. ATG13 KO MEFs grown in glucose or galactose 
media had no significant differences in cell viability after treatment with Z-VAD-fmk (50 µM) 
or Q-VD-OPh (50 µM, 24-72 h). Figure 7.10a shows that there were no significant differences 
in cell viability with PI exclusion > 80 %. As with HEK cells, there was a slight increase in 
Annexin V staining in cells grown in galactose but no difference between Z-VAD-fmk and 
vehicle or caspase control as shown in Figure 7.10b. Finally, there was no difference in cell 
a 
b 
271 
 
number between Z-VAD-fmk and vehicle and caspase control, indicating reduction in 
formazan absorbance was due to changes in the reduction potential of cells under N-
glycanase inhibition.  
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Figure 7.10 Galactose does not affect viability of ATG13 KO MEFs treated with Z-VAD-fmk 
No significant changes in propidium iodide exclusion (as a measure of cell viability), 
annexin V staining or cell number in ATG13 KO MEFs grown in high glucose DMEM (4.5 g/L) 
or galactose DMEM (10 mM) were observed. Cells were treated with Q-VD-OPh or Z-VAD-
fmk (50 µM, 72 h), Menadione (100 µM, 24 h) a)  Percentage PI (10 µg/ml 0.5 h) exclusion 
b) percentage of FITC annexin V positive cells c) Cell number per ml. One- way ANOVA, 
Tukey’s post hoc. Error bars ± SEM, n=3, P < 0.05. 
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7.3.6 WT MEFs show decreased formazan reduction when grown in galactose 
with Z-VAD-fmk treatment  
WT MEF cells grown in RPMI 1640 media showed no significant decrease in formazan 
absorbance when treated with Z-VAD-fmk or Q-VD-OPh (1-200 µM). To confirm the effects 
observed in WT HEK and ATG13 KO MEF cells when grown in galactose, this was repeated in 
WT MEF cells. There was a significant decrease in formazan absorbance after 25, 50, 100 and 
200 µM Z-VAD-fmk after 72 h when WT MEF cells were grown in galactose media compared 
to the vehicle control (IC50 of 19.52 µM). There was no significant differences when grown in 
high glucose media (Figure 7.11a). Figure 7.11b shows WT MEF cells treated with Q-VD-OPh 
which showed no significant decreases in formazan absorbance in either high glucose or 
galactose media.  
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Figure 7.11 MTT assay of WT MEF cells grown in DMEM high glucose media (4.5 g/L) or 
glucose free DMEM supplemented with galactose (10 mM) and treated with a) Z-VAD-fmk 
(0-200 µM, 72 h) b. Q-VD-OPh (0-200 µM, 72 h) One-way ANOVA, Dunnett’s post hoc 
comparing samples to vehicle. Error bars ± SEM, n=3, P < 0.05.
Cell viability was tested by PI exclusion. Figure 7.12a indicates there were no significant 
decreases in cell viability in WT MEF cells treated with Z-VAD-fmk (50 µM) or Q-VD-OPH (50 
µM) over 72 h when grown in either glucose or galactose containing media. Figure 7.12b 
shows that there were not significant changes in annexin V staining or (Figure 7.12c) cell 
number.  
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Figure 7.12 Galactose does not affect viability of WT MEFs treated with Z-VAD-fmk. No 
significant changes in propidium iodide exclusion (as a measure of cell viability), annexin V 
staining or cell number in WT MEFs grown in high glucose DMEM (4.5 g/L) or galactose DMEM 
(10 mM) were observed. Cells were treated with Q-VD-OPh or Z-VAD-fmk (50 µM) over 72 h. 
Menadione (100 µM, 24 h) was used as a positive control a) Percentage PI (10 µg/ml 0.5 h) 
exclusion b) percentage of FITC annexin V positive cells c) Cell number per ml. One-way 
ANOVA, Tukey’s post hoc within each condition. Error bars ± SEM, n=3, P < 0.05.
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7.3.7 Genetic knockdown of N-glycanase in ATG13 KO MEF and WT MEF cells  in 
galactose supplemented DMEM reduced MTT reduction but no t cell viability or 
proliferation  
To confirm the effect of reduced formazan reduction under Z-VAD-fmk treatment was due 
to inhibition of N-glycanase and, that caspase inhibition was not influencing cell viability, 
ATG13 KO MEF and WT MEF cells were transfected with NGLY1 siRNA to reduce levels of N-
glycanase. Figure 7.13a shows N-glycanase knockdown in ATG13 KO MEF cells with a 
significant reduction in formazan absorbance from day 2. Figure 7.13b shows the same 
treatment in WT MEF cells. When grown in galactose media there was a significant decrease 
in formazan absorbance from day 4.  
 
 
Figure 7.13 MTT assay of a) ATG13 KO MEF cells b) WT MEF cells grown in high glucose 
DMEM (4.5 g/L) and galactose DMEM (10 mM) 7 days post-transfection with NGLY1 siRNA. 
One-way ANOVA, Dunnett’s post hoc against the vehicle control at time 0. Error bars ± 
SEM, n=3, P < 0.05.
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Figure 7.14 shows the number of viable cells in ATG13 KO cells transfected with N-glycanase 
or non-targeting control siRNA. There were no significant decreases in cell viability (Figure 
7.14a), annexin V staining (Figure 7.14b) or cell proliferation (Figure 7.14c).  
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 Figure 7.14 Galactose does not affect viability of ATG13 KO MEFs transfected with NGLY1 
siRNA. No significant changes in propidium iodide exclusion (as a measure of cell viability), 
annexin V staining or cell number in ATG13 KO MEFs grown in high glucose DMEM (4.5 g/L) 
or galactose DMEM (10 mM). Cells were transfected with NGLY1 siRNA or non-targeting 
siRNA and measured after 3-5 days. Menadione (100 µM) for 24 h was used as a positive 
control a) percentage PI (10 µg/ml 0.5 h) exclusion b) percentage of FITC annexin V positive 
cells c) cell number per ml. One-way ANOVA, Tukey’s post hoc each condition. Error bars ± 
SEM, n=3, P < 0.05.
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Figure 7.15 shows the effect of N-glycanase siRNA knockdown on WT MEF cell viability, 
annexin V staining and cell number. There were no decreases in cell viability (Figure 7.15a), 
annexin V staining (Figure 7.15b) or in cell number (Figure 7.15c).  
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Figure 7.15 Galactose does not affect viability of WT MEFs transfected with NGLY1 siRNA. 
No significant changes in propidium iodide exclusion (as a measure of cell viability), 
annexin V staining or cell number in WT MEF cells grown in high glucose DMEM (4.5 g/L) 
or galactose DMEM (10 mM). Cells were transfected with NGLY1 siRNA or non-targeting 
siRNA and measured after 3-5 days. Menadione (100 µM) for 24 h was used as a positive 
control a) percentage PI (10 µg/ml 0.5 h) exclusion b) percentage of FITC annexin V positive 
cells c) Cell number per ml. One-way ANOVA, Tukey’s multiple comparison test within each 
condition. Error bars ± SEM, n=3, P < 0.05.
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In summary, if cells were grown in either glucose or galactose supplemented media it was 
found that Z-VAD-fmk but not Q-VD-OPh decreased MTT reduction but did not reduce cell 
viability, increase early apoptotic features or affect cell proliferation. Therefore, the change 
in formazan absorbance can be attributed to redox activity in the cell. This trend was 
followed in WT MEF and ATG13 KO MEF cell lines. Furthermore, similar results were seen 
with knockdown of N-glycanase using siRNA, indicating a role for N-glycanase. Since there 
were no increases in annexin V staining in NGLY1 siRNA treated cells (indicating caspase 
inhibitors were not blocking apoptosis) cells were not preparing to undergo apoptosis, even 
in the ATG13 KO MEFs. This change could indicate decreased mitochondrial activity.  
Although MTT was originally thought to be primarily reduced by mitochondrial enzymes, it 
is now known this is not always the case. Using confocal microscopy to examine the 
subcellular location of MTT reduced formazan (compared to TMRE and NAO labelled 
mitochondria) it was found only 25 % formazan signal overlapped labelled mitochondria. 
MTT fluorescence also shows a correlation with MTT reduction and, with glucose 
concentration in cell culture (Alet van Tonder et al. 2015). To further investigate the 
functionality of mitochondria under pharmacological N-glycanase inhibition and siRNA 
knockdown, mitochondrial polarisation was examined.  
7.3.8 Mitochondrial membrane potential is unaffected by inhibition and genetic 
ablation of N-glycanase  
The mitochondrial membrane potential relates to the ATP production capacity of 
mitochondria. Changes in polarisation, whether hyperpolarisation or depolarisation, can be 
an indication of mitochondrial health (Lezi and Swerdlow 2012). Most of the dyes which are 
commonly used to measure mitochondrial membrane potential (ΔΨm) are lipophilic cationic 
compounds. The more polarised, and therefore more negative, the mitochondrial matrix is, 
the more dye accumulates. Under high concentrations of dye, the fluorescence signal 
becomes quenched. In quenching mode, the concentrations of dye are high enough to 
accumulate in the mitochondrial matrix to an extent that it forms aggregates which results 
in lowered fluorescence emission. Depolarisation of the mitochondria under this condition 
results in an increase in fluorescence as the dye concentration drops and the fluorescence is 
unquenched. Hyperpolarisation in this case would result in a further decrease in fluorescence 
as even more dye accumulates in the mitochondrial matrix. This method is very difficult to 
analyse as the fluorescence is not linear compared to the polarisation of the mitochondria. 
In this study, mitochondrial potential was measured using tetramethylrhodamine ethyl ester 
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perchlorate (TMRE) 14 in non-quenching mode. In this case, lower polarisation will have 
lower fluorescence and hyperpolarised cells will have higher fluorescence. Cells are often 
treated with agents that rapidly decrease ΔΨm to ensure expected results with the dye of 
choice. Carbonyl cyanide-4-trifluoromethoxyphenylhydrazone (FCCP) 15 is an oxidative 
phosphorylation un-coupler used to decrease ΔΨm. Mitochondrial uncouplers transport 
protons across the inner membrane into the matrix, bypassing the normal route during 
respiration.  
    
    14         15 
To confirm quenching and non-quenching concentrations of TMRE in HEK cells, cells were 
incubated with increasing concentrations of TMRE 0.5 h and the mean fluorescence was 
measured before and after treatment with FCCP (10 µM, 5 min).  Fluorescence was recorded 
using a TALI image based cytometer. The difference in fluorescence (Δ fluorescence, 
equivalent to TMRE - TMRE fluorescence after FCCP treatment) was calculated. Figure 7.16 
shows the ΔTMRE fluorescence. For measurements recorded on the TALI image based 
cytometer, a concentration of 100 nM TMRE was selected. At concentrations below 100 nM 
the mitochondrial fluorescence is not quenched. 
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Figure 7.16 a) Mean TMRE fluorescence in WT HEK cells measured on TALI image based 
cytometer. Error bars ± SEM, 9 images taken per condition. b) Δ TMRE levels.  
To measure the mitochondrial membrane potential, HEK cells were treated with Z-VAD-fmk 
or Q-VD-OPh (50 µM, 24-72 h) and incubated with TMRE (100 nM, 0.5 h). To ensure TMRE 
accumulation in the mitochondria, cells treated in the same way were incubated with FCCP 
(10 µM, 5 min) before TMRE incubation. Cells were trypsinised and washed twice in ice-cold 
PBS by centrifugation and re-suspended in PBS (500 µL). Figure 7.17a shows the fluorescence 
intensity of TMRE measured using a TALI image based cytometer. There were no significant 
differences in starting TMRE fluorescence between the groups or by how much the FCCP 
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depolarised the samples. Figure 7.17b shows the Δ fluorescence and there no significant 
differences were observed between groups. 
 
 
 
Figure 7.17 Mean TMRE fluorescence of HEK 293 cells treated with Z-VAD-fmk or Q-VD-
OPh (50 µM, 24-72 h) with or without FCCP (10 µM, 5 min) and stained with TMRE (100 
nM, 30 min). a) Fluorescence intensity recorded on a TALI image based cytometer, 9 images 
were taken per condition. b) shows Δ TMRE fluorescence (TMRE-(TMRE+FCCP)). Two-way 
ANOVA.  Error bars ± SEM, n=4.
To confirm this effect, HEK cells were also treated with N-glycanase siRNA and the membrane 
potential calculated. Figure 7.18a shows the mean fluorescence intensity of TMRE before 
and after FCCP treatment. Figure 7.18b shows ΔTMRE fluorescence. There were no 
significant differences in mitochondria membrane potential after N-glycanase knockdown. 
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Figure 7.18 a) mean TMRE fluorescence of HEK 293 cells transfected with NGLY1 siRNA or 
non-targeting siRNA over 3-5 days with or without FCCP (10 µM, 5 min) and stained with 
TMRE (100 nM) for 0.5 h. Fluorescence intensity recorded on a TALI image based 
cytometer, 9 images were taken per condition b) Δ TMRE fluorescence of HEK 293 cells. 
Two-way ANOVA found no significance. Error bars ± SEM, n=4.
When cells were grown in glucose containing media, no changes in MTT reduction was 
observed. This could be because aerobic glycolysis is compensating for mitochondrial 
defects. To test this, cells were grown in zero glucose medium supplemented with 10 mM 
galactose. Again, cells were treated with Z-VAD-fmk or Q-VD-OPh (50 µM, 24-72 h) and 
incubated with TMRE (100 nM) or FCCP (10 µM, 5 min) before incubation with TMRE (100 
nM, 30 min) prior to measurements. Cells were washed in PBS twice and placed on ice 
although the cells treated with FCCP were maintained with FCCP in the solution. Figure 7.19a 
shows the mean TMRE fluorescence intensity before and after FCCP treatment. Figure 7.19b 
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shows the ΔTMRE fluorescence intensity. There was a trend for a slight decrease in in the Z-
VAD-fmk treatment compared to vehicles and Q-VD-OPh with an average delta fluorescence 
reduction of 30 % over 72 h compared to the vehicle and 19 % compared to the Q-VD-OPh 
control; however this was found to be non-significant.  
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Figure 7.19 There is no change in TMRE fluorescence in HEK cells grown in galactose. a) 
TMRE fluorescence of HEK 293 cells grown in galactose (10 mM) DMEM.  Mean 
fluorescence of HEK 293 cells treated with Z-VAD-fmk or Q-VD-OPh (50 µM, 24-72 h) with 
or without FCCP (10 µM, 5 min) and stained with TMRE (100 nM, 0.5 h). FI calculated by 
TALI image based cytometer, 9 images were taken per condition b) Δ TMRE fluorescence 
of HEK 293 cells. Two-way ANOVA found no significance.  Error bars ± SEM, n=3.
HEK cells were grown in galactose and transfected with N-glycanase siRNA as before and the 
mitochondrial membrane potential calculated. Figure 7.20a shows the mean TMRE 
fluorescence before and after FCCP treatment. There were no significant differences in 
starting TMRE fluorescence compared to a non-targeting control. However, there was a small 
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significant decrease in fluorescence observed in N-glycanase knockdown cells after 
treatment with FCCP (compared to non-targeting siRNA control cells treated with FCCP) at 
day 5. Figure 7.20b shows the ΔTMRE fluorescence. This decreased fluorescence in 
knockdown cells compared to controls led to a significant increase in ΔTMRE fluorescence at 
day 5. The opposite of the trend seen in Z-VAD-fmk treated cells which shows a small non-
significant decrease in ΔTMRE fluorescence. Although this is the same trend as siRNA treated 
cell when grown in glucose which showed an average increase of 70 % it was found not to 
be significant.  
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Figure 7.20 a) TMRE fluorescence of HEK 293 cells grown in galactose (10 mM) 
supplemented DMEM.  Mean fluorescence of HEK 293 cells transfected with NGLY1 siRNA 
or non-targeting siRNA over 3-5 days with or without 5 m of FCCP (10 µM) and stained with 
TMRE (100 nM) for 10 min b) Δ TMRE fluorescence of HEK 293 cells. FI calculated by TALI 
image based cytometer, 9 images were taken per condition. Two-way ANOVA, Tukey’s 
multiple comparison test. Error bars ± SEM, n=2, P < 0.05. 
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TALI based measurements of TMRE fluorescence lead to high variation between samples and 
high fluorescence under FCCP treatment. To confirm these changes in mitochondrial 
potential, TMRE fluorescence was measured using methods by flow cytometry. Figure 7.21 
shows increasing concentration of TMRE stained HEK cells. Even at high concentrations the 
median fluorescence intensity continued to increase without showing indications of 
fluorescence quenching.  
 
Figure 7.21 Median TMRE fluorescence of HEK 293 measured by flow cytometry. Error bars 
± SEM, n=3.  
HEK cells were incubated in increasing concentrations of TMRE and imaged to confirm 
quenching concentrations. Cells were imaged every 20 s for 180 s to ensure an even baseline 
level of TMRE fluorescence before the addition of FCCP (10 µM). Figure 7.22 shows the TMRE 
fluorescence of HEK cells loaded with 25-400 nM TMRE. TMRE levels above 100 nM showed 
an increase in fluorescence intensity after the addition of FCCP, indicating TMRE in quenched 
concentration in the mitochondria. Furthermore, the highest concentration, 400 nM, 
showed decreased starting fluorescence compared to lower concentrations (200 and 300 
nM) indicating quenched fluorescence. To ensure the concentration of TMRE did not cause 
quenching, 50 nM was used in flow cytometry analysis of mitochondrial membrane 
potential.  
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Figure 7.22 TMRE fluorescence of HEK 293 cells treated with FCCP (10 µM) as determined 
by microscopy. TMRE fluorescence was measured at 20 s intervals for 12 m. FCCP was 
added after 180 s. Data points show the average of 20 cells measured in one experiment. 
 
As cells grown in galactose supplemented media exhibited the most different changes upon 
Z-VAD-fmk or N-glycanase knockdown, galactose media was used in the flow cytometry 
analysis of TMRE fluorescence. HEK cells were treated with Z-VAD-fmk and Q-VD-OPh (50 
µM, 24-72 h) as before in galactose supplemented media. Figure 7.23a shows the median 
TMRE fluorescence before and after FCCP treatment. There were no significant differences 
between groups, FCCP treated and untreated conditions at the same time point, or within 
conditions or the Δ TMRE fluorescence, shown in Figure 7.23b.   
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Figure 7.23  a) Median fluorescence of HEK cells treated with Z-VAD-fmk or Q-VD-OPh (50 
µM, 24-72 h) with or without FCCP (10 µM, 5 min) and stained with TMRE (100 nM) for 30 
m. Fluorescence intensity calculated by flow cytometry. Cells were grown in DMEM 
supplemented with galactose (10 mM) b) Δ TMRE fluorescence of HEK 293 cells. Two-way 
ANOVA found no significance. Error bars ± SEM, n=3.
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The previously described experiment was repeated following genetic knockdown of N-
glycanase using siRNA. No significant differences were identified (figure 7.24). 
  
 
Figure 7.24 a) mean TMRE fluorescence of HEK 293 cells transfected with NGLY1 siRNA or 
non-targeting siRNA over 3-5 days with or without FCCP (10 µM, 5 min) and stained with 
TMRE (100 nM) for 0.5 h. Fluorescence intensity determined by flow cytometry. Cells were 
grown in DMEM supplemented with galactose (10 mM) b) Δ TMRE fluorescence of HEK 293 
cells. Two-way ANOVA found no significance. Error bars ± SEM, n=3.
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7.3.9 Measurements of mitophagy by flow cytometry were variable between 
experiments 
 
Several mitophagy factors (including PHB2 and p62) were identified in the proteomics 
screen, along with NBR1 and FAM134 in low abundance. The association between increased 
numbers of autophagosomes after treatment with Z-VAD-fmk (50 µM, 72 h) and after 5 d 
post-transfection with N-glycanase siRNA (25 nM) and mitochondria were explored. 
Although no changes in mitochondria membrane potential have been identified in this study, 
there is a change in MTT reduction in galactose supplemented media which is commonly 
used to study mitochondrial function (Aguer et al. 2011, Dott et al. 2014, Kase et al. 2013, 
Marroquin et al. 2007, Rodriguez-Enriquez et al. 2001).  
Mitophagy was assessed using the mitochondrial dye, MitoTracker® Deep Red, and analysed 
by flow cytometry in conjunction with the autophagy inhibitors, bafilomycin and 3-MA (Xiao 
et al. 2016). Under conditions of increased mitophagy, by inhibiting autophagy by either 
reduction of lysosomal degradation (Bafilomycin) or inhibition of autophagosome biogenesis 
(3-MA) it is expected to find increased MitoTracker® staining (Xiao et al. 2016).  
To identify if the increased autophagy previously identified involved the specific removal of 
mitochondria, HEK cells were treated with the known inducer of autophagy, rapamycin (10 
µM, 4 h) and with Bafilomycin (100 nM, 4 h) or 3-MA (5 mM, 4 h) followed by incubation 
with MitoTracker® Deep Red (50 nM, 0.5 h). Figure 7.25a shows the median mitotracker 
fluorescence intensity. Under basal conditions, inhibition of autophagy by bafilomycin or 3-
MA did not increase MitoTracker® fluorescence intensity. However, in cells where autophagy 
is induced by rapamycin, there was an increase in fluorescent intensity after autophagy 
inhibition. Figure 7.25b shows the fold change in fluorescence after autophagy inhibition.  A 
significant increase in fluorescence intensity in rapamycin and 3-MA treated cells compared 
to 3-MA cells treated alone was found. For subsequent experiments, 3-MA was used to 
inhibit autophagy. 3-MA inhibits the formation of the autophagic membrane leaving 
mitochondria in the cytosol which may be more amenable to staining.  
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Figure 7.25 a) mean MitoTrackerTM Deep Red (50 nM, 0.5 h) fluorescence of HEK 293 cells 
treated with bafilomycin (100 nM, 4 h), 3-MA (5 mM, 4 h) in the presence or absence of 
rapamycin (10 µM, 4 h) b) fold change in MitoTracker fluorescence compared to vehicle 
after treatment with bafilomycin (100 nM) or 3-MA (5 mM, 4h). Two-way ANOVA, Tukey’s 
post hoc test. Error bars ± SEM, n=3. P < 0.05.
To identify if inhibition or knockdown of N-glycanase induced mitophagy specifically, HEK 
cells were treated with Z-VAD-fmk or Q-VD-OPh (50 µM, 24-72 h) and treated with or without 
3-MA (5 mM, 4 h). Figure 7.26a shows the median MitotrackerTM fluorescence. There were 
no significant differences in Mitotracker staining before or after autophagy inhibition with 3-
MA or in starting Mitotracker fluorescence. Figure 7.26b shows the fold change fluorescence 
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intensity was calculated following autophagy inhibition. There were no significant 
differences identified between the vehicle, Q-VD-OPh treated and Z-VAD-fmk treated cells.   
 
 
 
Figure 7.26 No increase in MitotrackerTM fluorescence intensity after 3-MA treatement 
with Z-VAD-fmk or Q-VD-OPh was found a) mean MitoTrackerTM (50 nM)  fluorescence 
intensity in HEK 293 cells treated with vehicle, Z-VAD-fmk or Q-VD-OPh (50 µM, 24-72 h) 
with or without 3-MA (5 mM, 18 h). Fluorescence intensity measured by flow cytometry b) 
fold change in MitoTracker (50 nM) fluorescence intensity. Two-way ANOVA. Error bars ± 
SEM, n=4.
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The experiment was repeated on cells transfected with N-glycanase siRNA. Figure 7.27a 
shows the median Mitotracker fluorescence. Similar to the observations in cases of 
pharmacological N-glycanase inhibition, there were no significant differences in 
MitotrackerTM fluorescence following genetic ablation before or after incubation with 3-MA 
shown (Figure 7.27).  
 
 
 
Figure 7.27 No increase in MitotrackerTM fluorescence intensity was found after 3-MA 
treatment in N-glycanase knockdown a) mean MitoTrackerTM (50 nM) fluorescence 
intensity in HEK 293 cells transfected with NGLY1 siRNA or non-targeting control over 3-5 
d with or without bafilomycin (50 nM) for 18 h. Fluorescence intensity measured by flow 
cytometry b) shows fold change in MitoTrackerTM (50 nM) fluorescence intensity after 
Bafilomycin (50 nM) for 18 h. Two-way ANOVA. Error bars ± SEM, n=3.
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7.3.10 Pharmacological inhibition and genetic ablation of N-glycanase does not affect 
mitochondrial lectin profile 
Mitochondria are regulated by developmental signals, at the tissue and organ level and 
intracellularly (Hüttemann et al. 2007). Many mitochondria proteins are regulated by PTMs 
including phosphorylation, acetylation, succinylation and O-GlcNAcylation. It has been 
shown that changes in the glycosylation of proteins can regulate their function and activity 
(Chen et al. 2010, Duan and Walther 2015, Edberg and Kimberly 1997, Fahie and Zachara 
2016) and specifically deglycosylation in the case of Nrf1 activation (Tomlin et al. 2017). No 
study so far has looked at the effect of NGLY1 inhibition on the mitochondrial glycome. Many 
of these glycoproteins have been identified through high throughput proteomics screening 
without secondary verification (Burnham-Marusich and Berninsone 2012). With these, PDH 
E1α, ATP synthase subunit d, OSCP subunit, NDUFS3 and ANT1 are expected to be O-
GlcNAcylated as determined through prediction algorithms, with a potential N-glycosylation 
site identified on ATP synthase subunit d and ANT1, although this has not been confirmed 
(Burnham-Marusich and Berninsone 2012).  
A number of hypotheses have suggested N-glycanase deficiency interferes with the 
regulation of glycoproteins. First, increased N-GlcNAc residues in the cell may disrupt O-
GlcNAc signalling. In another instance mitochondrial proteins may be regulated in an N-
glycanase deglycosylation dependent manner. Thirdly, a number of mitochondrial proteins 
are regulated by the UPS in which case degradation by this process may be halted or slowed 
for specific proteins. These differences could therefore cause changing levels in lectin 
staining profiles, for instance LCA and ConA for high mannose glycans or complex glycans 
with PHA-E.  
To study if the mitochondrial proteins are regulated in this way, mitochondria were purified 
and lectin dot blots were performed to identify differences in mitochondrial glycosylation. 
Mitochondria were purified from HEK cells using the Thermofisher mitochondrial isolation 
kit for cultured cells (as per the manufacturer’s protocol). Confirmation of increased 
mitochondrial proteins was assessed by western blot as shown in Figure 7.28a. There was a 
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> 4 fold increase in TIM23, a mitochondrial import inner membrane protein in the 
mitochondrial fraction compared to the whole cell lysate (Figure 7.28b).   
 
Figure 7.28 Purification of mitochodria using the Thermofisher Mitochondria isolation kit 
for cultured cells a) Mitochondria were purified, samples of the lysate, waste pellet, 
sample supernatant, waste supernatant and final mitochondrial sample were run on a 
4.12% SDS-polyacrylamide gel.  Immunoblotting was carried out against TIM23 (murine 
monoclonal antibody  (SantaCruz, sc-514463) or β-actin murine monoclonal antibody 
(Santa Cruz, sc-58673), followed by incubation with the secondary antibody (Vector 
laboratories, HRP Horse anti-mouse IgG antibody peroxidase cat#PI-2000). Blots were 
visualised by Clarity ECL solution (BioRad) b) shows the quantitiation of TIM23 abundance 
over β-actin abundance. Error bars ± SEM, n=3, Student’s T-test, * P < 0.05. 
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HEK cells were treated with either Q-VD-OPh or Z-VAD-fmk (50 µM, 72 h) or N-glycanase 
siRNA (25 nM, 5 d) and the mitochondria isolated. The purified mitochondria samples were 
lysed, 100 ng spotted onto nitrocellulose membrane and left to dry at room temperature for 
1 h. Membranes were incubated with FITC-conjugated LCA, ConA, PHA-E, WGA and sWGA. 
Figure 7.29 shows the log fold change in lectin binding normalised to an untreated control.  
ConA and LCA lectins typically bind to high mannose glycans associated with N-linked 
glycosylation. No significant changes in ConA or LCA staining of were identified in any of the 
groups. PHA-E lectin also binds mannose, galactose and complex glycan structures. Again, 
there were no significant changes in lectin staining between samples. WGA staining is 
commonly used to probe for O-GlcNAc modified proteins. WGA binds GlcNAc, and has a 
preference for dimers and trimers but is also able to interact with glycans with terminal sialic 
acid residues. To confirm WGA staining to GlcNAc residues, succinylated WGA was also used, 
as this lectin does not bind sialic acid.  No significant differences in WGA or sWGA staining 
was observed between conditions.  
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Figure 7.29 Log2 fold change of FITC 
conjugated lectin fluorescence, ConA, 
LCA, PHA-E, WGA and sWGA (100 ng 
mitochondrial protein) normalised to an 
untreated control. Error bars ± SEM, n=3, 
One-way ANOVA, P > 0.05. 
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7.5 Discussion 
N-glycanase deficiency often exhibits similar clinical presentations to mitochondrial 
respiratory chain (RC) disorders with symptoms including loss of muscle tone, seizures, 
developmental delays and heart and liver disease (Peng et al. 2015). Mitochondrial function 
has been identified as dysregulated in N-glycanase knockout cells and, in model organisms 
including mice and C. elegans (Kong et al. 2018).  In this study mitochondrial function was 
examined by mitochondrial membrane potential and the analysis of mitophagy by the use of 
mitochondrial content dyes.  
Mitochondria are linked to the redox environment of the cell and are a major source of 
reactive oxygen species and NAD is involved in the generation of energy and neutralisation 
of ROS and can be used as an indicator of the intracellular redox environment (Blacker and 
Duchen 2016) and therefore may cause an imbalance in ROS. Previously it was shown that 
under Z-VAD-fmk inhibition (Chapter 3) or N-glycanase knockdown HEK cells did not exhibit 
increased ROS levels. However, this experiment was undertaken in glucose containing media 
which may lessen any mitochondrial effects. In contrast, Kong et al. (2018) found increased 
ROS levels in C. elegans, MEFs and patient fibroblasts (c.1205_1207del;c.1570C>T) compared 
to healthy controls when grown in standard cell culture conditions, with the MEF cells grown 
under 4.5 g/L glucose and the patient fibroblasts grown under 1 g/L glucose (Kong et al. 
2018).  
Cells grown in culture are highly adapted to aerobic glycolysis as the main source of energy. 
By switching cells to glucose free, galactose supplemented media forces cells to rely on 
oxidative phosphorylation for their energy needs. Cells grown in galactose and treated with 
the N-glycanase inhibitor, Z-VAD-fmk or in N-glycanase knockdown mediated by siRNA 
showed significantly decreased MTT reduction to formazan. Although usually a measure of 
cell toxicity or cell proliferation, there was no decrease in cell number or cell viability in 
conditions treated with Z-VAD-fmk or N-glycanase siRNA. Furthermore, there was no 
increase in annexin V staining compared to controls indicating cells were not in the early 
stages of apoptosis. The reduction of MTT is usually attributed to mitochondrial enzymes, 
therefore, less MTT reduction indicates mitochondrial dysfunction. However, there are a 
number of cytosolic reductases capable of MTT reduction. Therefore, changes in MTT 
reduction cannot be solely attributed to mitochondria function.  
NADH is one of the main donors of electrons in the reduction of MTT and has a higher ratio 
of NADH in the cytosol, shown in Figure 7.30. Therefore, changes in NADH levels can lead to 
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increased MTT reduction. The ratio of NAD to NADH is an indicator of the intracellular redox 
environment.  
 
Figure 7.30 Ratios of NAD and NADH in the cytosol and mitochondria. Open access article 
distributed under Creative Commons Attribution Licence (CC-BY) (Anderson et al. 2017). 
The ratio of NAD+/NADH is important in cellular function and homeostasis and regulates 
metabolic pathways. NADH and FADH are both substrates for electron transfer for MTT 
reduction and are needed to move protons into the mitochondrial inner membrane space 
and involved in the electron transport chain, producing the mitochondrial membrane 
potential and ATP for energy consumption (Srivastava 2016) (Figure 7.31). 
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Figure 7.31 Schematic representation of the mitochondrial electron transport chain. Open 
access article distributed under Creative Commons Attribution Licence (CC-BY).(Srivastava 
2016) 
Loss of MTT reduction may suggest an imbalance in NAD+/NADH homeostasis and possibly 
decreased levels of NADH. Decreased NAD+/NADH ratio has been associated with ageing and 
mitochondrial disorders (Srivastava 2016, Imai and Guarente 2016, Fang et al. 2017) and that 
supplementation of NAD+ has alleviated symptoms of age related and mitochondrial 
diseases including AD in mice models (Fang et al. 2017) and in mitochondrial myopathies 
(Lightowlers and Chrzanowska-Lightowlers 2014).  
Other than NAD+/NADH, NADP/NADPH can also influence MTT reduction and also play a role 
in antioxidant defences in the cell (Dey et al. 2016). NADPH can donate electrons to oxide 
radicals to neutralise its charge (Schieber and Chandel 2014). Therefore, changes in 
NADP/NADPH may interfere in the antioxidant pathway leading to increased superoxide 
found in C. elegans, MEFs and patient fibroblasts (Kong et al. 2018). In the autophagosome 
isolation a 3.9 fold increase in superoxide dismutase (SOD1) was identified under N-glycanase 
siRNA knockdown compared to basal cells and, an overall intensity of 2.6 fold and 1.55 fold 
increase oxidative stress associated proteins in N-glycanase siRNA and Z-VAD-fmk treated 
cells respectively, suggesting an increased need for antioxidants or increased mitochondria 
in autophagosomes. In this study, ROSBrite 570TM was used to determine increased levels of 
ROS. This probe preferentially picks up hydroxyl radicals, while Kong et al. 2018 used 
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MitoSOXTM which preferentially binds to superoxide. To identify if the generation of 
superoxide identified in (Kong et al. 2018) was associated in multiple cell models of N-
glycanase deficiency it would be beneficial to look into HEK cells with a superoxide indicator. 
It is notable that superoxide is the ROS species most commonly associated with the initiation 
of autophagy (Chen et al. 2009, Slator et al. 2017, Parajuli and MacMillan-Crow 2012) which 
may help explain the increase in autophagy found in this study.   
An autopsy of two NGLY1 patients (5 y and 9 m) were also noted to have hypoxic-ischemic 
encephalopathy (HIE), a common cause of mortality in neonates and is often found to be 
worsened under increased oxidative stress (Zhao et al. 2016). This symptom is not usually 
associated with mitochondrial disorders but has been associated with secondary 
mitochondrial dysfunction (Lu et al. 2015, Enns et al. 2014). Mitochondrial dysfunction was 
not further investigated in this case due to the absence of evidence of spongiform 
degeneration, which is most typically seen in mitochondrial disorders (Enns et al. 2014). This 
suggests, together with increased superoxide identified in patient fibroblasts, MEF cells and 
C. elegans (Kong et al. 2018) suggests that oxidative stress may play a role in NGLY1 
pathogenesis. Changes in NAD+/NADH and NADP/NADPH may also be involved in the control 
of ROS (Srivastava 2016). It may be that N-glycanase deficiency is in some way linked to 
secondary mitochondrial dysfunction. 
To further characterise mitochondrial function in HEK cells with reduced N-glycanase activity, 
mitochondrial membrane potential was measured. Initially this was studied using the 
mitochondria potential dependent indicator, TMRE and fluorescence intensity measured by 
TALI image based cytometer. No changes in starting TMRE of Δ fluorescence was identified, 
whether grown in high glucose (aerobic glycolysis) or in galactose supplemented media to 
increase mitochondrial load. This method showed low sensitivity for TMRE fluorescence, 
with high fluorescence seen even in cells treated with an FCCP concentration designed to 
elicit maximum depolarisation and loss of fluorescence. To ensure the measurements of 
TMRE fluorescence were due to no change rather than a methodology with decreased 
sensitivity, TMRE fluorescence intensity was measured in HEK cells grown in galactose 
supplemented media and measured by flow cytometry. This method decreased the 
background fluorescence in FCCP treated cells. Again, no significant differences were seen in 
TMRE fluorescence intensity or Δ intensity. In contrast to the findings in HEK cells in this 
study, there has been a decrease in mitochondrial membrane potential found in N-glycanase 
KO MEFs, patient fibroblasts and N-glycanase KO C. elegans compared to controls (Kong et 
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al. 2018). Decreased mitochondria membrane potential is associated with increased 
oxidative stress (Vayssier-Taussat et al. 2002). Although this seems to be cell dependent.  
This study identified an increase in autophagy under both pharmacological inhibition and 
genetic knockdown of N-glycanase in HEK cells. Due to the changes in the redox environment 
found in HEK cells under galactose supplemented media. Autophagy is an essential process 
for the degradation and recycling of cellular components. Autophagy is regulated by nutrient 
availability and cellular stress pathways. Mitophagy, the selective degradation of 
mitochondria is important for maintaining a healthy pool of functioning mitochondria and 
therefore the redox environment of the cell, energy production, Ca2+ homeostasis and 
control of apoptosis (Zhang 2015). In Chapter 6 the proteins identified in the pull-down of 
autophagosomes in basal (Bafilomycin treated cells) and with Z-VAD-fmk inhibition of N-
glycanase and siRNA mediated knockdown of N-glycanase found an average 1.44 and 1.51 
fold increase in mitochondrial protein intensity. The theory that the increased autophagy 
was selective mitophagy was explored. Mitophagy was measured by looking at the 
fluorescence intensity of MitotrackerTM before and after autophagy inhibition which has 
been used to measure the mitophagy in mitochondrial membrane depolarisation and 
starvation in SH-SY5Y and HeLa cells (Xiao et al. 2016, Mauro-Lizcano et al. 2015). No 
significant changes were identified between MitotrackerTM staining before or after N-
glycanase ablation or upon autophagy inhibition with 3-MA and HEK cells stained with 
MitotrackerTM deep red. It should be noted, however, that there was a high degree of 
variation within even the vehicle controls and therefore, it would be prudent to employ other 
methods of detecting mitophagy flux to fully investigate this process.  
Mitophagy can be assessed by looking at specific mitochondrial protein abundance by 
western blotting, mtDNA abundance by PCR or microscopy techniques looking at co-
localisation of mitochondrial proteins and autophagy markers like LC3. In other studies 
looking at MitotrackerTM staining in several models it was found there was no difference in 
MitotrackerTM intensity in N-glycanase KO MEF cells compared to WT control or in patient 
fibroblasts compared to healthy controls (Kong et al. 2018) which may indicate mitophagy is 
not active, although this does not take into account flux. However, there was a significant 
decrease in C. elegans with N-glycanase KO (Kong et al. 2018) although how this is related to 
degradation or mitochondrial biogenesis is not known.  
 Methods of measuring mitophagy can be difficult to interpret because of the dynamic 
nature and the heterogenous population within cells (Ogasawara et al. 2005, Chatre and 
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Ricchetti 2013). Mitochondria differ considerably between organ, tissue and cell type (Huang 
et al. 2004). Variations in levels of mtDNA have been observed in N-GLY1 patients (Enns et 
al. 2014). In one case, a 39 % decrease in liver mtDNA was observed while another patient 
exhibited a 472 % increase in quadricep muscle compared against age and tissue matched 
controls (Enns et al. 2014). How these differences relate to function are unclear. To date, 
there has been no study of mtDNA in cell culture models of N-glycanase deficiency. Kong et 
al. 2018 found increased levels of ROS in C. elegans, N-glycanase KO MEFs and patient 
fibroblasts (Kong et al. 2018). Mitochondrial DNA is reportedly ten times more susceptible 
to mutation and at increased risk from oxidative damage due to proximity of ROS production 
along with it not being protected by histone complexes (Guppy et al. 2002). Therefore, 
increased ROS may increase mitochondrial damage and promote selective mitochondrial 
removal.  
 Oxygen consumption rates (OCR) have also been studied in KO MEF cells and patient 
fibroblasts (Kong et al. 2018). In MEF cells there was no change in basal or leak but a 
reduction in maximal OCR in the KO cell, while patient fibroblasts showed a significant 
decrease in basal, leak and maximal OCR (Kong et al. 2018). The mitochondrial phenotypes 
exhibited in KO MEF cells, patient fibroblasts and C. elegans are often, although not always, 
associated with decreased ATP production (Salin et al. 2015). OCR and ATP production can 
be influenced by the type of reduction substrate used (succinate or pyruvate), proton 
slippage (‘leak’) and the membrane potential (Salin et al. 2015), and as such is not always a 
clear indication of energy metabolism. NAD+/NADH and NADP/NADPH are also involved in a 
number or metabolic processes including glycolysis, TCA cycle and fatty acid oxidation (Wu 
et al. 2016). It would be beneficial to identify if these changes influenced the pathway of ATP 
production or the amount of ATP produced under N-glycanase deficiency. ATP deficiency is 
seen in a number of mitochondrial disorders characterised by decreased ATP synthase 
activity with 5-20 reduction in ATP in ATP6 mutant in patient fibroblasts (Houštěk et al. 2006) 
with one of the key symptoms being muscle weakness (López-Gallardo et al. 2014) which is 
also seen in patients with NGLY1 (Enns et al. 2014, Caglayan et al. 2015).  
Global quantification of MitotrackerTM fluorescence by flow cytometry does not give 
information about the morphology of the mitochondria, a common indicator of 
mitochondrial health and function (Xiao et al. 2016, Saunders et al. 2013, Mauro-Lizcano et 
al. 2015). Mitochondria are highly dynamic and morphology is altered depending on 
environment (Willems et al. 2015). Changes in mitochondrial morphology have been noted 
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in liver cells derived from a single patient with NGLY1 disorder (Enns et al. 2014), and it is 
therefore possible that consideration of changes in morphological features could potentially 
be investigated to provide insights into mitochondrial health. Morphological changes (such 
as mitochondrial swelling) can be studied using a variety of methods, including flow 
cytometry of isolated organelles. In such methods, isolated mitochondria are stained with 
fluorescent mitochondria probes (such as MitotrackerTM or TMRE) and examined using FSC 
and SSC to quantify features such as size and granularity of the mitochondria (Saunders et 
al. 2013). So, although in this study MitotrackerTM fluorescence was quantified, an in-depth 
analysis of morphology under these conditions would be advisable.  
Results from this study suggest that in HEK cells where N-glycanase activity is reduced 
mitochondrial abundance does not change dramatically.  This is in agreement with findings 
from studies in MEF cell and patient fibroblasts (Kong et al. 2018). In contrast, there was no 
significant change in membrane potential in HEK cells while C. elegans, MEF cells and patient 
fibroblasts showed decreased membrane potential (Kong et al. 2018). Additionally, changes 
in the redox environment in HEK cells under N-glycanase inhibition and knockdown were 
identified.  
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Chapter 8. 
8.1 Introduction 
Protein glycosylation is one of the most common post-translational modifications and 
endows proteins with additional structural and functional diversity beyond that which results 
from the protein structure alone.  Disorders resulting from defects in the processing of 
cellular carbohydrates can have a broad and complex clinical presentation. As a result, they 
are often difficult to identify and diagnose with certainty.     
The enzyme peptide:N-glycanase has been identified as a functional component of ERAD 
(Suzuki et al. 2000, Suzuki et al. 2001).  Within the cell, this enzyme cleaves N-glycans from 
terminally misfolded proteins earmarked for degradation via the proteasome. Mutations in 
N-glycanase were found to be the cause of a genetic disorder, N-GLY1 deficiency, first 
identified in 2012. The importance of glycan processing is demonstrated by the severity and 
of symptoms of NGLY1 disorder (Enns et al. 2014, Caglayan et al. 2015, He et al. 2015, Fujihira 
et al. 2017, Suzuki 2015). Since the identification of N-GLY1 disorder in 2012 (Need et al. 
2012) in the order of fifty people worldwide have been identified with this disorder. The aim 
of this study was to identify the effects of N-glycanase deficiency using pharmacological 
inhibition and genetic knockdown, in a well-characterised cellular model to examine the 
cellular effects of N-glycanase deficiency. 
8.2 Findings 
Previous studies using the ddVENUS assay (Grotzke et al. 2013) have confirmed that patients 
with mutations in the NGLY1 gene exhibited decreased deglycosylation activity and reduced 
protein expression (He et al. 2015). In yeast Png1 KO, degradation of mutant 
carboxypeptidase Y protein (CPY) (an ERAD substrate) was delayed (Suzuki et al. 2000). In 
mammalian cells, contradictory evidence has been shown in different models using different 
ERAD substrates. In U373 astrocytoma cells with siRNA mediated knockdown of N-glycanase 
exhibited no change in degradation for TCRα or MHC I heavy chains (Hirsch et al. 2003, Blom 
et al. 2004). However, the rate of degradation of RTAΔm was nearly doubled in NGLY1 KO 
MEFs (Huang et al. 2015) indicating a defect in protein degradation. Furthermore, increased 
RIPA insoluble N-GlcNAc linked proteins indicated the involvement of ENGase. In addition, it 
was hypothesised that N-glycanase deficiency caused ER stress, likely a result of a build-up 
of aggregated material (Misaghi et al. 2005, Martinet et al. 2006).  
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8.2.1 N-glycanase knockdown and inhibition does not cause protein aggregates 
or cellular stress in HEK cells.  
To begin, basic cellular effects of pharmacological and genetic knockdown of N-glycanase 
were characterised in HEK cells (including viability and variation in glycan profile). N-
glycanase activity was also quantified using the ddVENUS assay (Grotzke et al. 2013).  
As the pan-caspase inhibitor Z-VAD-fmk has previously been identified to act as an inhibitor 
of N-glycanase, it was employed as a pharmacological inhibitor in this study.  As a 
comparison, effects were compared to a pan-caspase inhibitor with a similar inhibition 
profile, called Q-VD-OPh (Chauvier et al. 2006) which lacks inhibitory activity against this 
target Effects observed were also compared to N-glycanase KD using siRNA. HEK cells treated 
with either Z-VAD-fmk or N-glycanase siRNA found no decrease in cell viability or change in 
the glycoprotein profile. Both methods of inhibition resulted in a decrease in fluorescence of 
the deglycosylation dependent VENUS construct, suggestive of decreased N-glycanase 
activity.  Q-VD-OPh exhibited no comparable effect on cell viability, glycoprotein profile or 
ddVENUS fluorescence.  
Since N-glycanase is a component of ER-associated degradation, it follows that deficiency in 
this enzyme may influence the efficiency of the ERAD process.  Previous studies have 
suggested that this may result in a change in the ability of the cell to effectively degrade 
misfolded proteins, leading to an accumulation of protein aggregates. Previous models using 
different model ERAD substrates have found contradictory evidence of the rate of protein 
degradation following N-glycanase KO. It should be noted that using model proteins can 
increase ER load and aggregation that is not related to the disorder studied. This can be due 
to constructs resulting in high levels of protein production based on strong promoters 
(Hussain et al. 2014).  
In previous studies, using RTAΔm as an ERAD substrate, detergent insoluble aggregates were 
identified bearing ENGase modified glycan chains resulting in a single N-GlcNAc in NGLY1 KO 
MEF cells (Huang et al. 2015). In this study, to examine protein aggregation a general stain 
(ThT) was used rather than a model protein to look only at endogenous proteins. ThT has 
been reported to stain cross-β-sheets, a motif arising due to the hydrophobic nature of β-
sheets and the readiness to interact with one another, hence often associated with protein 
aggregates. HEK cells treated with Z-VAD-fmk and siRNA mediated N-glycanase knockdown 
showed increases in ThT fluorescence, but no visible protein aggregates were observed. It is 
unknown whether these stimuli would have caused distinct cellular aggregates and, it should 
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be noted the protein concentration in detergent soluble/insoluble fractions was not studied 
in HEK cells under these conditions. The absence of distinct protein aggregates was later 
supported by a mouse KO study using histological staining by Congo red and PAS (Fujihira et 
al. 2017).  
Autopsy results from of a patient with N-GLY1 disorder (homozygous R401X) presented 
ubiquitin positive nuclear and cytoplasmic aggregates in several areas of the brain; including 
the globus pallidus (fine motor control (Telford and Vattoth 2014)), red nucleus (gross motor 
function (Telford and Vattoth 2014)), sub-thalamic nucleus (pacemaker for basal ganglia 
(Telford and Vattoth 2014)), dentate nucleus in the cerebellum, cortex and spinal cord (Enns 
et al. 2014). Conversely, glial cells only showed diffuse nuclear ubiquitin staining (Enns et al. 
2014). This is suggestive that cell type plays an important role in phenotype and, that non-
proliferative cells will display a more severe phenotype. Glial cells are capable of mitosis, 
allowing diffusion of aggregates by division. Although the mitotic nature of neurons is still 
changing, it is typically thought that most are post-mitotic, meaning aggregates cannot be 
dispersed. This effect is common to other protein aggregation disorders, where increased 
cell death is observed in post-mitotic neurons compared to other cells types (Gundersen 
2010, Joshi et al. 2014, Perry et al. 1987). There are a number of post-mitotic containing 
tissues in the body including neurons but also some cardiac cells (Siddiqi and Sussman 2014), 
skeletal muscle (Partridge 2002) and cells of the immune system including monocytes 
(Sugimoto et al. 2006). As well as the effect of N-glycanase deficiency in neurons, the study 
of other post-mitotic cells would also be interesting. A prion model of fatal spongiform 
encephalopathies found non-proliferative myotube cells accumulated more aggregates 
compared to proliferative myoblasts (Herbst et al. 2013). The lack of aggregation found in 
HEK cells may be due to their fast proliferation rate. To study this process in culture, non-
dividing, neuronal cell lines could be used (such as ReNcell VM) which can be differentiated 
to form non-dividing neurons and glial cells (Donato et al. 2007).   
8.2.2 N-glycanase knockdown and inhibition increases autophagy  
Previous studies using Z-VAD-fmk as a caspase inhibitor have found increased autophagic cell 
death or necrosis (Chen et al. 2011, Wu et al. 2008). The effect of N-glycanase deficiency on 
the other main degradation pathway, autophagy, was examined. This study identified an 
increase in autophagy under Z-VAD-fmk and N-glycanase knockdown which has not been 
identified in other models of N-glycanase deficiency. Autophagy can be attributed to the 
removal of protein aggregates and this was an attractive conclusion due to the correlation 
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between decreased ThT fluorescence and increase in autophagosomes under Z-VAD-fmk 
treatment at 72 h, although this pattern was not as correlational when N-glycanase was 
downregulated by siRNA. Autophagy occurs constitutively at basal levels, maintaining 
healthy level of organelles and proteins. Cellular stresses such as starvation, oxidative stress 
and activation of ER stress signalling induce autophagy to mediate stress and maintain 
homeostasis. ER and oxidative stress was examined. No increase in UPR markers was found, 
indicating no ER stress/protein aggregates in HEK cells. This supports the microscopy findings 
that no distinct protein aggregates were found in HEK cells treated with Z-VAD-fmk or N-
glycanase siRNA. Measure of UPR markers have not been directly tested in other models of 
N-glycanase deficiency and is further supported by studies of a Drosophila N-glycanase KO 
model that found no increase in canonical ER stress markers in the transcriptome (Owings et 
al. 2018). Other adaptations allow cells to increase ERAD efficiency without activation of the 
UPR and costly and time-consuming upregulation of proteins. Misfolded proteins in the ER 
may delay turnover of ERAD proteins. Misfolded polypeptides in the ER can inhibit the 
removal of SEL1L and HRD1 complexes which auto-ubiquitinate. If more misfolded proteins 
are available as the preferred substrate, the E3 ligases are stabilised in the membrane (de 
Bie and Ciechanover 2011). This has not been explored under N-glycanase deficiency. ER Ca2+ 
handling was also used as a measure of ER stress (Hammadi et al. 2013, Lomax et al. 2002). 
No change in ER Ca2+ handling under Z-VAD-fmk or N-glycanase siRNA was found. No change 
in oxidative stress was measured by fluorescence intensity of reactive oxygen species 
indicators. This rules out a global effect of ER stress as the cause for increased autophagy. It 
also suggests that there is no severe level of mitochondrial dysfunction as the main cause of 
autophagy activation. The activation of autophagy is likely, at least in part, to be due to other 
factors.  
To examine the role of autophagy further, ATG13 KO MEF cells were used, which found that 
Z-VAD-fmk and N-glycanase KD decreased MTT reduction. Initially this was thought to show 
decreased cell viability. Upon confirmation of viability with PI exclusion and cell number it 
was identified that no change in viability or cell number was identified. Changes in MTT 
reduction not due to cell proliferation or viability are typically attributed to mitochondrial 
function (Surin et al. 2017, Bernas and Dobrucki 2002). However, there are a number of 
cytosolic enzymes capable of this reaction and in some cases there is increased MTT 
reduction in the cytosol which is not affected by the respiratory inhibitor rotenone (Berridge 
et al. 2005). Therefore MTT reduction may come from glycolysis, supported by evidence of 
interference of MTT reduction by glycolysis inhibitors, 2-deoxyglucose and lonidamine (van 
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Tonder et al. 2015). However, mitochondrial involvement is further supported by 
exacerbation of this effect when cells are grown in glucose-free media supplemented with 
galactose used to increase energy production via mitochondria (Marroquin et al. 2007, 
Rodriguez-Enriquez et al. 2001).  
Since ER stress and oxidative stress were not increased in HEK cells treated with Z-VAD-fmk 
or N-glycanase KD there must be another signal increasing autophagy. To identify the signal 
initiating autophagy in the system, the protein content of the autophagosomes was analysed 
by tandem LC-MS/MS.  Autophagosomes were purified from N-glycanase KD and Z-VAD-fmk 
induced cells using GFP-LC3 immunoprecipitation. N-glycanase KD and Z-VAD-fmk showed 
increased numbers and intensities of mitochondrial proteins possibly indicative of increased 
mitochondrial uptake by autophagosomes. There was also in increase in vesicle trafficking 
proteins such as FYCO1 and MAP1A indicative of increased autophagosome trafficking.  
Several of the proteins identified in a co-IP of host factors involved in HIV infection which 
included N-glycanase (Jäger et al. 2011) were also identified in autophagosome proteome 
under N-glycanase inhibition/KD study. These proteins were mainly related to the ER and 
proteasome, including ERAD ubiquitin ligases, ER chaperones and components of the 26S 
proteasome as expected during a viral hijacking of the protein production machinery of the 
cell (Inoue and Tsai 2013). However, the lysosomal protease cathepsin D and mitophagy 
receptor PHB2 which could indicate that N-glycanase may also be involved in the regulation 
of autophagy. There have been multiple studies displaying the crosstalk of the two 
degradation pathways, UPS and autophagy (Senft and Ronai 2015, Rashid et al. 2015, Song 
et al. 2018).  
Previously a number of cell types have identified increased autophagic vesicles after 
treatment with Z-VAD-fmk (Martinet et al. 2006, Chen et al. 2011, Cheng et al. 2008) leading 
to a hypothesis that autophagy induction was due to inhibition of N-glycanase in these 
experiments. This may open further avenues as to why Z-VAD-fmk increased autophagic 
vesicles in different cell types and, depending on the cell type, whether it was pro- or anti-
apoptotic (Chen et al. 2011, Wu et al. 2008).  
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8.2.3. Nrf1 is regulated by deglycosylation  
Interestingly, in the autophagosomes isolation, a number of proteins identified as part of the 
proteasome complex were identified as significantly decreased in N-glycanase KD compared 
to the basal autophagy control. Recently, a study described the N-glycanase dependent 
activation of Nrf1 (Tomlin et al. 2017), a transcription factor regulating expression of 
proteasome genes. Under basal conditions Nrf1 is held in the ER, under proteasome 
inhibition, Nrf1 is flipped to face the cytosol which undergoes N-glycanase dependent 
deglycosylation and proteolytic cleavage to produce active Nrf1 which translocates to the 
nucleus to activate transcription of PSM genes (Tomlin et al. 2017). MEF cells deficient in N-
glycanase halt proteolytic cleavage and translocation of Nrf1 to the nucleus, leading to cells 
sensitive to proteasome inhibition (Tomlin et al. 2017). Nrf1 inactivation could explain the 
decreased levels of proteins identified as part of the proteasome complex in both N-
glycanase and Z-VAD-fmk compared to basal autophagy and amino acid starvation induced 
autophagy.   
8.2.4 Mitochondrial involvment  in N-GLY1 disorder 
To investigate the role of mitochondria in N-glycanase deficiency, mitochondrial function 
was studied. Mitochondrial membrane potential was found to be unchanged while 
measurements of mitophagy require optimisation to draw any conclusions on this. However, 
a change in MTT reduction under cells grown in galactose supplemented media was found, 
which could indicate mitochondrial dysfunction. Mitochondrial dysfunction was considered 
as a potential cause of NGLY1 symptoms, however, the initial study of patients with N-GLY1 
determined the most prominent symptoms associated with mitochondrial disorders were 
absent (Enns et al. 2014). Brain disease was noted during an autopsy of two related patients 
of N-GLY1, patients 5 and 6 with homozygous R401X mutation (Enns et al. 2014). Changes in 
brain structure were consistent with hypoxic-ischemic enchephalopathy (HIE). This can be 
associated with secondary mitochondrial dysfunction but is not usual for inherited 
mitochondrial disorders (Lu et al. 2015, Enns et al. 2014).  
Mitochondrial disease refers to a wide range of disorders that result in defective energy 
production via oxidative phosphorylation. Primary mitochondrial diseases usually result from 
mutations in mtDNA or nDNA that are required for oxidative phosphorylation (Niyazov et al. 
2016). Disorders which have a similar phenotype to primary mitochondrial diseases but are 
not caused by a mutation in OXPHOS related proteins are classed as a secondary 
mitochondrial disease (SMD). SMD can be caused by germline mutations in other genes not 
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known to have a clinical implication in OXPHOS, can be caused by environment or by a pre-
existing disorder (Niyazov, 2016). A study looking at the effect of N-glycanase deficiency in 
multiple models including C. elegans, MEF cultures and patient fibroblasts identified 
mitochondrial dysfunction (Kong et al. 2018). Mitochondrial function in C. elegans, MEFs and 
patient fibroblasts found no change in mitochondrial content measured by Mitotracker, but 
there was a significant decrease in mitochondrial membrane potential in all models (Kong et 
al. 2018). Furthermore, a significant decrease in basal, leak and maximal oxygen 
consumption rate was measured in patent fibroblasts (Kong et al. 2018). Indicating 
dysfunction in mitochondria. Basal OCR is typically controlled by ATP turnover but is not 
affected by maximal OCR or proton leak (Brand and Nicholls 2011), although the effect on 
ATP has not been studied in N-glycanase KO cells. A large increase in proton leak can indicate 
complete uncoupling, although a small change is likely due to a change in membrane 
potential, which was also confirmed to be decreased (Kong et al. 2018).  
In HEK cells, no difference was found in TMRE fluorescence or Mitotracker stained content 
under Z-VAD-fmk or N-glycanase KD. It should be noted that short term 
inhibition/knockdown may not allow sufficient time for effects to be seen as these 
treatments only reduce the activity of N-glycanase and low levels of activity still remain. 
Furthermore, during inhibition the protein is still available in the cell perhaps maintaining 
non-deglycosylating roles of N-glycanase. In the stable KO models the protein is not 
translated. 
8.2.5 N-glycanase and Z-VAD-fmk alters the redox environment of cells grown 
in galactose 
Increased mitochondrial proteins associated with autophagosomes can indicate increased 
mitochondrial degradation. This is usually triggered by some form of cellular stress or 
mitochondrial dysfunction. Mitochondrial function was examined by mitochondrial 
membrane potential and total content. No significant changes were identified in N-glycanase 
KD or Z-VAD-fmk compared to controls. However, a change in MTT reduction was identified 
in cells grown under glucose-free, galactose supplemented media. A change in MTT 
reduction indicates a change in the oxidation-reduction environment of the cell. As well as 
proteasome regulation, NRf1 is also involved in the antioxidant response pathway. The redox 
environment of the cell is vital during development. Changes in oxidation-reduction can 
change the fate of developing cells. Metabolism and ROS signalling are tightly controlled by 
redox pathways. Nrf1 and Nrf2 regulate the expression of enzymes involved in oxidative 
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stress such as glutathione, heme-oxygenase, glutathione peroxidase and superoxide 
dismutase (Biswas and Chan 2010, Sant et al. 2017, Reichard et al. 2007) all of which were 
identified in autophagosomes isolated from basal, Z-VAD-fmk and siRNA knockdown of N-
glycanase induced autophagy. N-glycanase KO models of C. elegans, patient fibroblasts and 
KO MEF cells found increased ROS compared to controls (Kong et al. 2018). No increase in 
ROS was detected in HEK cells treated with Z-VAD-fmk or N-glycanase siRNA. 
ROS are an important signalling pathway and are necessary for various growth factor 
signalling pathways (Schieber and Chandel 2014). However, dysregulation and an increase 
in ROS results in oxidative stress (Kong et al. 2018), the main source of which comes from 
the respiratory chain located on the inner mitochondrial membrane. This process oxidises 
hydrogen from pyruvate and fatty acids with oxygen to form water. Under normal 
conditions, 1-5% of oxygen is converted into ROS (Guo et al. 2013). Therefore, the main point 
of attack for ROS species is at the respiratory chain. Close proximity damages mtDNA leading 
to increased superoxide formation and further damage to the mitochondria and the cell. ROS 
damages proteins by adding oxygen to cysteine residues, changing the structure of the 
proteins. This can be reversed by reduction by thioredoxin and pereredoxin, both of which 
were identified in autophagosomes as part of the negative regulation of apoptosis under Z-
VAD-fmk and N-glycanase KD. Inactivation of Nrf1 may increase cells’ susceptibility to ROS. 
However, increased susceptibility was not explored in this study. Following proteasome 
inhibition, mitochondrial content usually increases in cells (Bragoszewski et al. 2017), similar 
to proteasome proteins. It would be interesting to see whether known mitochondrial targets 
of Nrf1 are still able to increase expression following this stress to identify the extent to which 
Nrf1 regulates mitochondrial proteins in this system. 
As previously noted, Nrf1 regulates a high number of different processes including 
proteasome subunits, mitochondrial genes and the antioxidant response;  11289 targets 
have been identified by CHIP-seq datasets (Rouillard et al. 2016). NRF1 KO mice result in 
embryonic lethality indicating its importance in development, however, NGLY1 KO mice 
models and other models, Drosophila and C. elegans are not always lethal (Fujihira et al. 
2017, Huang et al. 2015, Owings et al. 2018, Kong et al. 2018). This indicates that the 
symptoms caused by NGLY1 deficiency are not entirely due to Nrf1 inactivation. There may 
be other roles of Nrf1 that are not dependent on N-glycanase deglycosylation. However, Nrf1 
conditional KO in mice brains exhibit age-dependent neurodegeneration similar to 
neurodegenerative models (Lieu et al. 2013) and NGLY1 KO mice models (Fujihira et al. 2017). 
Nrf1 KO also exhibited ubiquitin positive aggregates in the cortex and hippocampus and had 
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decreased proteasome function, mirroring aggregates found in NGLY1 patients (Enns et al. 
2014). Nrf1 KO in HeLa cells also exhibited increased p62 and ubiquitin labelled aggregates 
and increased autophagosomes (Tsuchiya et al. 2013). All these symptoms point towards 
protein aggregate disorders, however, the contradiction in evidence may be due to 
experimental design and indicate that under basal conditions cells appear normal but exhibit 
increased sensitivity to stressors. However, in Nrf1 brain KO, no significant difference in 
GSH/GSSG ratios compared to controls indicating redox environment was normal. However, 
in NRF2 KO GSH/GSSG ratio was significantly changed (Lee et al. 2011) indicating Nrf1 is 
important to proteasome function but less so to redox state, indicating other factors are 
involved.  
There is also the potential for crosstalk between Nrf1 function and autophagy. Several 
autophagy regulating pathways also regulate Nrf1. As regulators of the protein degradation 
pathway it follows under conditions that increase one protein degradation pathway also 
control the other. Nrf1 has been shown to increase proteasome expression via mTORC1, an 
inhibitor of autophagy, while increased AMPK activity activates Nrf1 activity and increases 
mitochondrial content (Bergeron et al. 2001) and increases autophagy via phosphorylation 
of BECN1 (Zhang et al. 2016). It is unknown how Nrf1 inactivation affects these systems.  
Nrf2 is thought to be able to partially compensate for Nrf1 inactivation/KO (Ohtsuji et al. 
2008, Sant et al. 2017, Leung et al. 2003, Xu et al. 2005, Chen et al. 2003, McMahon et al. 
2001) especially as part of the antioxidant defence, more so than proteasome ‘bounce-back’. 
Nrf2 is constitutively degraded by the UPS. KEAP1 is an adaptor for the ubiquitin ligase which 
targets Nrf2. During oxidative stress KEAP1 is inactivated, stabilising Nrf2 which moves to the 
nucleus to activate cyto-protective genes. P62 also interacts with the Nrf2 binding site of 
KEAP1, interfering with the KEAP1-Nrf2 interaction. p62 is also one of the genes translated 
during Nrf2 stabilisation. During increased p62, KEAP1 cannot ubiquitinate Nrf2 and the 
protein is stabilised. P62 binding affinity for KEAP1 is weak compared to Nrf2, however, when 
S351 is phosphorylated binding affinity is increased by 30 fold compared to non-
phosphorylated p62 but still lower than Nrf2. Phosphorylated p62 is detectable under basal 
conditions but is significantly upregulated during oxidative stress as well as overall levels of 
p62 with KEAP1 being incorporated into the detergent insoluble fraction in the cell with 
levels dropping indicating KEAP1 is degraded by autophagy. This was confirmed when KEAP1 
and p62 accumulate in ATG7 KO mice but not in a PSMC2 knockout, part of the 26S 
proteasome.  
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8.2.6 Regulation of proteins by deglycosylation  
Nrf1 is not the first case of protein function noted as regulated by N-glycanase dependent 
deglycosylation. EDEM1 is regulated by deglycosylation as it is required for efficient removal, 
although not via the UPS. Deglycosylated EDEM1 forms triton insoluble aggregates that are 
ubiquitinated and degraded by autophagy via association with p62 and NBR1. Glycosylated 
EDEM1 is not ubiquitinated (Park et al. 2014). Z-VAD-fmk in HepG2 cells for 3 h (50 µM) found 
a significant increase in glycosylated EDEM1 (Park et al. 2014). This may increase the amount 
of active EDEM1 in cells. Previously, this study found no increase in EDEM1 mRNA under Z-
VAD-fmk or siRNA knockdown of N-glycanase, however, this does not measure stabilised 
protein concentrations (Park et al. 2014). Overexpression studies of EDEM1 have found that 
increased levels of EDEM1 allows cells to degrade proteins targeted to ERAD with or without 
the glycan and with increased speed of degradation (Shenkman et al. 2013, Molinari et al. 
2003) which may also add to effect of non-delayed glycoprotein turnover identified in N-
glycanase KO models. In Drosophila, upregulation of EDEMs, regardless of mannosidase 
activity resulted in protection against ER proteinopathies and extended lifespan with minimal 
toxicity (Sekiya et al. 2017). It has been shown that proteins can be regulated by 
deglycosylation, but how many are dependent on N-glycanase remains unknown. 
8.2.7 Hexosamine Biosynthetic Pathway and O-GlcNAcylation 
The transcriptome of an Ngly1 Drosophila KO was studied and found downregulation in 
oxidative-reduction process and UPS components which corresponds to Cnc (Nrf1 homolog) 
disruption (Owings et al. 2018). However, other hypotheses of the effects of N-glycanase 
deficiency have highlighted the possibility of a disruption of O-GlcNAc signalling due to 
stabilised N-GlcNAc containing proteins (Huang et al. 2015). An interesting protein that was 
found to be significantly downregulated by 1.7 fold was Gfat1 (homolog of human GFPT1). 
GFPT1 supples the cell with UDP-GlcNAc, the rate limiting step in the hexosamine 
biosynthetic pathway (HBP) shown in Figure 8.1. UDP-GlcNAc is used as a substrate for glycan 
synthesis and O-GlcNAcylation as well as a coenzyme in a number of metabolic reactions 
(Ryczko et al. 2016). There was no change in other HBP pathway proteins including Gfat2 
which plays a similar role and suggests compensation for Gfat1 does not occur.  
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Figure 8.1 Schematic representation of the hexosamine biosynthetic pathway (HBP). 
Reprinted from (Vasseur and Manié 2015) with permission from Elsevier. 
 
Unusually, Ngly1 KO Drosophila showed increased levels of UDP-GlcNAc, the opposite of 
what would be expected with Gfat1 reduction. Increased HBP flux has been shown to 
increase O-GlcNAc levels, oxidative stress and ER stress (Lombardi et al. 2012). Additional 
GlcNAc has been hypothesised to reprogram cellular metabolism via UDP-GlcNAc dependent 
glycosylation signalling (Ryczko et al. 2016) despite increasing GlcNAc in mice has shown to 
increase liver UDP-GlcNAc levels (Ryczko et al. 2016). GlcNAc supplementation in this 
Drosophila model decreased UDP-GlcNAc levels to normal and increased longevity at all 
stages of supplementation, but did not change transcriptome changes. Although there was 
an increase in UDP-GlcNAc levels, there were no global changes in O-GlcNAcylation in healthy 
or KO flies, with or without GlcNAc supplementation (Owings et al. 2018). Which also 
confirms the lack of changes in lectin binding in this and other studies (Huang et al. 2015). 
The human homolog of Gfat1, GFPT1 is a target for Nrf1 (Rouillard et al. 2016) indicating 
downregulation could be due to inactivity of Nrf1. Regulation via Nrf1 rather than a negative 
feedback loop from UDP-GlcNAc would explain why GlcNAc supplementation does not 
change the transcriptome profile while it does normalise UDP-GlcNAc levels. However, this 
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does not explain the increase in UDP-GlcNAc. UDP-GlcNAc levels also regulate the O-
GlcNAcylation homeostasis enzymes, OGA and, specifically OGT (Hanover et al. 2010). The 
OGT catalytic p110 subunit forms homotrimers which exhibit different binding affinities for 
UDP-GlcNAc. This is mediated by a tetratricopeptide repeat region motif (TPR) that is 
involved in the protein-protein interactions in multiprotein complexes. Using a peptide with 
a known O-GlcNAc site allowed kinetic measurements of OGT in response to different UDP-
GlcNAc concentrations (Kreppel and Hart 1999). It was found that depending on the 
concentration of UDP-GlcNAc, OGT different multimerization states changes the affinity of 
OGT for UDP-GlcNAc (Kreppel and Hart 1999). Although no difference was identified in OGT 
mRNA expression levels, UDP-GlcNAc could have an effect on OGT affinity levels for its 
substrate. As well as controlling multimerization, the TPR domain has been shown to confer 
peptide specificity and that different multimeric states also change O-GlcNAcylation kinetics 
towards peptide substrates. (Iyer and Hart 2003). This could lead to substrate specific O-
GlcNAc targeting rather than global changes that have not been evidenced in the literature.  
OGA not only recognises the GlcNAc residue but also recognises the glycosylated hydroxyl 
residue from the serine or threonine to stabilise the protein. N-linked glycosylation presents 
an amide group at the site of glycosylation (Li et al. 2017). There is also evidence of OGA 
removing GlcNAc form different proteins at different rates, indicating a substrate specific 
difference (Li et al. 2017), and whether OGA would be able to recognise N-GlcNAc is 
unknown. However, the changes due to N-GlcNAc are more likely to be a biophysical effect. 
O-GlcNAc modifications can regulate proteins by blocking other PTMs, changing binding 
affinity or biophysical nature of the attached protein. The proteins containing N-GlcNAc have 
not been recognised to regulate protein function in the same way as O-GlcNAc. Despite this, 
however single N-GlcNAc residues may change the structure and physicochemical properties 
of the protein, making them more prone to aggregation. 
8.3 Conclusion 
This thesis describes experiments using short-term inhibition/KD in highly proliferative cells 
to identify the effects of N-glycanase inhibition in a previously unstudied cell culture model. 
Efforts were made to compare short-term inhibition with stable KO generated by CRISPR in 
the same model, although this was unsuccessful. The data provided along with new literature 
that due to the diverse substrates of N-glycanase disruption interferes with a number of 
different pathways including protein degradation pathways, glycosylation PTM regulated 
proteins, mitochondrial function and the hexosamine biosynthetic pathway, although the 
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complex interactions of these pathways are not fully understood. It is also clear many of 
these responses are dependent on cell type, and N-glycanase deficiency will effect different 
cells in different ways, such as the effect on post-mitotic cells that are more susceptible to 
cellular stress (Herbst et al. 2013). Mouse models of N-glycanase KO have shown how 
symptoms increase with age and show similar phenotypes to age-dependent 
neurodegeneration (Fujihira et al. 2017). Autophagy decreases with age in most cells, and 
autophagy has been targeted to alleviate neurodegenerative effects (Cuervo 2008). This 
study has identified autophagy as protective measure and without autophagy, although not 
toxic, N-glycanase inhibition/KD results in changes in the redox environment.  
Together, this data indicates that there is no significant increase in ER stress or ROS in healthy 
dividing cells but dysfunction is most likely related to how cells respond to stress.  It has been 
suggested that such effects may be related tothe dysfunctional activation of Nrf1 (Tomlin et 
al. 2017). Under the system studied in these experiments, N-glycanase was reduced for only 
a short period of time using pharmacological or siRNA reduction while the majority of 
published studies described used stable KO of the enzyme, while only using Z-VAD-fmk to 
confirm decreased ddVENUS fluorescence, allowing the cell to adapt to the KO. 
8.4 Future perspectives  
 
A number of possible targets have been suggested to alleviate N-GLY1 symptoms include the 
use of ENGase inhibitors (Huang et al. 2015, Bi et al. 2017) or GlcNAc dietary supplements 
(Owings et al. 2018). Autophagy has been identified as a protective measure under N-
glycanase inhibition/KD. Furthermore, mitophagy may be involved in maintaining the health 
of the mitochondrial population in HEK cells. Autophagy has been an attractive target for 
protein degradation pathways especially in post-mitotic cells like neurons (Decressac et al. 
2013, Rubinsztein 2007) and may be able to increase cell survival after inhibition of 
proteasome function following Nrf1 inactivation.  
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APPENDIX 
This appendix contains:  
 A.1 Plasmid maps and construct sequences 
A.2 Sequence data confirming cloning of guide sequences into WT or Nickase 
variant CRISPR/Cas9 plasmids 
A.3 Sequences used for TIDE analysis 
A.4 FITC-labelling of RNAse B    
 
A.1 Plasmid maps and construct sequences 
 
Detailed in this section are:  
 
A.1.1 pOPH6 PNGase F plasmid map and sequence (Addgene #40315) 
A.1.2 GFP-LC3 plasmid sequence 
A.1.3 mAPPLE-N1 plasmid map (Addgene #54567) 
A.1.4 Sequence of bacterial PNGase mammalian expression construct BacPNG4 
_pCMVF 
A.1.5 Sequence of bacterial PNGase mammalian expression construct BacPNG5 
_pCMVF 
A.1.6 WT Cas9 CRISPR pSpCas9(BB)-2A-GFP (PX458) plasmid map and sequence 
(Addgene #48138) 
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A.1.1 pOPH6 PNGase F plasmid (Addgene #40315)   
Figure A1 shows the plasmid map of pOPH6 PNGase F plasmid (Addgene pOPH6 #40315).  
Sequencing data for this construct is also presented below. 
 
 
Figure A1 Plasmid map of pOPH6 PNGase F plasmid (reproduced from Addgene, Addgene 
pOPH6 #40315) 
Sequencing of pOPH6 plasmid 
> pOPH6 M13 Forward 
ANNNCANNTACGGCGATGGAGCTCACCGCGGTGGCGGCCGCTCTAGATAACGAGGGCAAA 
AAATGAAAAAGACAGCTATCGCGATAGCAGTGGCACTCGGCTGGTTTCGCTACCGTAGCG 
CAGGCCGGAATTCCAGCTCCGGCAGATAATACCGTAAATATTAAAACATTCGACAAAGTA 
AAAAATGCCTTTGGTGACGGATTGTCCCAAAGTGCGGAAGGAACCTTTACATTTCCGGCC 
GATGTAACAGCCGTAAAAACGATTAAGATGTTCATTAAAAATGAATGTCCTAATAAAACT 
TGTGATGAATGGGATCGTTATGCCAATGTTTATGTAAAAAATAAAACAACAGGTGAGTGG 
TACGAAATAGGACGCTTTATTACTCCATATTGGGTGGGAACGGAAAAATTACCTCGTGGA 
CTGGAAATTGATGTTACAGATTTCAAATCTTTACTATCCGGAAATACAGAACTTAAAATT 
TATACGGAGACATGGCTGGCCAAAGGAAGAGAATACAGTGTAGATTTCGATATTGTATAC 
GGGACACCGGATTATAAATATTCGGCTGTAGTACCTGTAGTTCAGTATAACAAATCATCT 
ATTGACGGAGTCCCTTATGGTAAAGCACATACATTGGCTTTGAAAAAGAATATCCAGTTA 
CCAACAAACACAGAAAAAGCTTATCTTAAAACTACTATTTCCGGATGGGGACATGCTAAG 
CCATATGATGCGGGAAGCAGAGGTTGTGCAGAATGGTGCTTCAGAACACACACTATAGCA 
ATAAATAATTCGAATACTTTCCAGCATCAGCTGGGTGCTTTAGGATGTTCAGCAAACCCT 
ATCAATAATCAGAGTCCGGGAAATTGGACTCCCGACAGAGCCGGTTGGTGCCCGGGAATG 
GCAGTTCCAACACGTATAGATGTACTGAATAATTCTTTAATAGGCAGTACTTTTAGTTAT 
GAATATAAATTCCAGAACTGGACAAATAACGGAACCAATGGAGATGCTTTTTATGCAATT 
TCCAGTTTTGTGATTGCAAAAAGTAATACCCCTATTAGTGCTCCGGTAGTTACAAACTTG 
GATCCGCATCACCATCACCACCATTGACGATCCGGCTGAACAACGACGTGAACGCATGCG 
GTTCCGACGTTCAGGCTGCTAAAGATGACGCAGCTCGTGCTAACCAGCGTCTGGACAAAA 
TGGCTACTAAATACCGCAAGTAATAAAACCTGGGAANTGAAAATGGGGCACATTGGGCGA 
AATTTTTTTTTGGCTGCCGTTTACCGCTAATGGGTCCCGCGTAACATAATC 
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A.1.2 GFP-LC3 plasmid sequence 
Sequencing data for this construct is presented below. 
Sequencing of GFP-LC3 plasmid 
>GFP-LC3_pCMVF 
CTCTCCGAGGANGTCATCAAGGAGTTCATGCGCTTCAAGGTGCGCATGGAGGGCTCCGTGAA
CGGCCACGAGTTCGAGATCGAGGGCGAGGGCGAGGGCCGCCCCTACGAGGGCACCCAGACCG
CCAAGCTGAAGGTGACCAAGGGCGGCCCCCTGCCCTTCGCCTGGGACATCCTGTCCCCTCAG
TTCCAGTACGGCTCCAAGGCCTACGTGAAGCACCCCGCCGACATCCCCGACTACTTGAAGCT
GTCCTTCCCCGAGGGCTTCAAGTGGGAGCGCGTGATGAACTTCGAGGACGGCGGCGTGGTGA
CCGTGACCCAGGACTCCTCCCTGCAGGACGGCGAGTTCATCTACAAGGTGAAGCTGCGCGGC
ACCAACTTCCCCTCCGACGGCCCCGTAATGCAGAAGAAGACCATGGGCTGGGAGGCCTCCAC
CGAGCGGATGTACCCCGAGGACGGCGCCCTGAAGGGCGAGATCAAGATGAGGCTGAAGCTGA
AGGACGGCGGCCACTACGACGCCGAGGTCAAGACCACCTACATGGCCAAGAAGCCCGTGCAG
CTGCCCGGCGCCTACAAGACCGACATCAAGCTGGACATCACCTCCCACAACGAGGACTACAC
CATCGTGGAACAGTACGAGCGCGCCGAGGGCCGCCACTCCACCGGCGCCGGTGGACCGGTCG
CCACCATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTG
GACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTA
CGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCC
TCGTGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAG
CACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAA
GGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACNCCTTGTNGAACC
GCATNNAGCTGAAGGGCATCGACTTTCAGGAAGGACGGNAACATCCTGGGGNCACAAGCTGG
AAGTANANCTT 
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A.1.3 mAPPLE-N1 plasmid map and sequence (Addgene #54567)    
Figure A2 shows the plasmid map of mAPPLE-N1 plasmid (Addgene mAPPLE-N1 #54567).  
  
Figure A2 mAPPLE-N1 plasmid map (reproduced from Addgene, Addgene mAPPLE-N1 
#54567). 
A.1.4 Sequence of bacterial PNGase mammalian expression construct 
BacPNG4 _pCMVF 
Sequencing data for this construct is presented below. 
Sequence of Bacterial PNGase mammalian expression construct, BacPNG4  
> BacPNG4 _pCMVF  
AAAGGGAAGTCTATATAGCAGAGCTGGTTTAGTGAACCGTCAGATCCGCTAGCGCTACCGGA
CTCAGATCTCGAGACCATGGCTCCGGCAGATAATACCGTAAATATTAAAACATTCGACAAAG
TAAAAAATGCCTTTGGTGACGGATTGTCCCAAAGTGCGGAAGGAACCTTTACATTTCCGGCC
GATGTAACAGCCGTAAAAACGATTAAGATGTTCATTAAAAATGAATGTCCTAATAAAACTTG
TGATGAATGGGATCGTTATGCCAATGTTTATGTAAAAAATAAAACAACAGGTGAGTGGTACG
AAATAGGACGCTTTATTACTCCATATTGGGTGGGAACGGAAAAATTACCTCGTGGACTGGAA
ATTGATGTTACAGATTTCAAATCTTTACTATCCGGAAATACAGAACTTAAAATTTATACGGA
GACATGGCTGGCCAAAGGAAGAGAATACAGTGTAGATTTCGATATTGTATACGGGACACCGG
ATTATAAATATTCGGCTGTAGTACCTGTAGTTCAGTATAACAAATCATCTATTGACGGAGTC
CCTTATGGTAAAGCACATACATTGGCTTTGAAAAAGAATATCCAGTTACCAACAAACACAGA
AAAAGCTTATCTTAGAACTACTATTTCCGGATGGGGACATGCTAAGCCATATGATGCGGGAA
GCAGAGGTTGTGCAGAATGGTGCTTCAGAACACACACTATAGCAATAAATAATTCGAATACT
TTCCAGCATCAGCTGGGTGCTTTAGGATGTTCAGCAAACCCTATCAATAATCAGAGTCCGGG
AAATTGGACTCCCGACAGAGCCGGTTGGTGCCCGGGAATGGCAGTTCCAACACGTATAGATG
TACTGAATAATTCTTTAATAGGCAGTACTTTTAGTTATGAATATAAATTCCAGAACTGGACA
AATAACGGAACCAATGGAGATGCTTTTTATGCAATTTCCAGTTTTGTGATTGCAAAAAGTAA
TACACCTATTAGTGCTCCGGTAGTTACAAACTTGGATCCACCGGTCGCCACCATGGTGAGCA
AGGGCGAGGAGAATAACATGGCCATCATCAAGGAGTTCATGCGCTTCAAGGTGCACATGGAG
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GGCTCCGTGAACGGCCACGAGTTCGAGATCGAAGGCAAGGGCGAGGGCCGCCCCTACAAGGC
CTTTCAAACCGCTAAACTGAAGGTGACCAAGGGTGGCCCCCTGCCCTTCGCCTGGGAAATCC
TGGCCCCTCAGTTCAGGTACGGGTCCAAGGTCTACTTTAAGCACCCAGCCGAAATCCCCGAA
TAATTCAAGTTGTCCTTCCCCAAGGGCTTCAGGGGGGAAGCCGTGAAGAACTTCCAGGACGG
GGGCTTTATTCACGTTAACCAGNATTCCTCCCTGGAGGGAAGGGGGGTTCTCTAAAAG 
 
A.1.5 Sequence of bacterial PNGase mammalian expression construct 
BacPNG5 _pCMVF 
Sequencing data for this construct is presented below. 
Sequence of Bacterial PNGase mammalian expression construct, BacPNG5 
> BacPNG5_pCMVF 
ATGGCTCCGGCAGATAATACCGTAAATATTAAAACATTCGACAAAGTAAAAAATGCCTTTGG
TGACGGATTGTCCCAAAGTGCGGAAGGAACCTTTACATTTCCGGCCGATGTAACAGCCGTAA
AAACGATTAAGATGTTCATTAAAAATGAATGTCCTAATAAAACTTGTGATGAATGGGATCGT
TATGCCAATGTTTATGTAAAAAATAAAACAACAGGTGAGTGGTACGAAATAGGACGCTTTAT
TACTCCATATTGGGTGGGAACGGAAAAATTACCTCGTGGACTGGAAATTGATGTTACAGATT
TCAAATCTTTACTATCCGGAAATACAGAACTTAAAATTTATACGGAGACATGGCTGGCCAAA
GGAAGAGAATACAGTGTAGATTTCGATATTGTATACGGGACACCGGATTATAAATATTCGGC
TGTAGTACCTGTAGTTCAGTATAACAAATCATCTATTGACGGAGTCCCTTATGGTAAAGCAC
ATACATTGGCTTTGAAAAAGAATATCCAGTTACCAACAAACACAGAAAAAGCTTATCTTAGA
ACTACTATTTCCGGATGGGGACATGCTAAGCCATATGATGCGGGAAGCAGAGGTTGTGCAGA
ATGGTGCTTCAGAACACACACTATAGCAATAAATAATTCGAATACTTTCCAGCATCAGCTGG
GTGCTTTAGGATGTTCAGCAAACCCTATCAATAATCAGAGTCCGGGAAATTGGACTCCCGAC
AGAGCCGGTTGGTGCCCGGGAATGGCAGTTCCAACACGTATAGATGTACTGAATAATTCTTT
AATAGGCAGTACTTTTAGTTATGAATATAAATTCCAGAACTGGACAAATAACGGAACCAATG
GAGATGCTTTTTATGCAATTTCCAGTTTTGTGATTGCAAAAAGTAATACACCTATTAGTGCT
CCGGTAGTTACAAACTTGGATCCACCGGTCGCCACCATGTTGAGCAAGGGCGAGGAAAATAA
CATGCCCATCATCAAGGAGTTCATGCGCTTCAAGGTGCACATGGAAGGGCTCCGTGAACGGC
CACGAGTTCAAAATCGAAGGCGAAGGGCGAGGGCCGCCCCTAGAAGGCCTTTCAAACCGCTA
AGCTGAAGGGGAACCAAGGGGGGGCCCCCTGGCCCTTCGCCTTGGGACATCCTGGCCCCCTC
AGTTCATGTACGGCTTCCAAGGTCTACATTTAAGCACCCAGCCGAAATTCCCCGAATAATTT
CAAGTTGTCCTTTCCCCGAAGGGTTTCAGGGGGGAAACGCCTGGTTGAAATTTCCAGGAAGG
GGGGCATTAATTCACGTTTAACCAAGGAACTCTCCCCTG 
 
A.1.6 WT Cas9 CRISPR pSpCas9(BB)-2A-GFP (PX458) plasmid map and 
sequence (Addgene #48138) 
Figure A3 shows the plasmid map of WT Cas9 CRISPR pSpCas9(BB)-2A-GFP (PX458) plasmid 
map and sequence (Addgene #48138). 
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Figure A3 WT Cas9 CRISPR pSpCas9(BB)-2A-GFP  (PX458) plasmid map and sequence 
(Addgene #48138)
Sequencing data for this construct is presented below. 
Sequence of WT CRISPR Cas9 plasmid 
pSpCas9(BB)-2A-GFP (PX458) Sequence >U6sponge-F 5’- 
GGACTATCATATGCTTACCGTAACTTGA-3' (Ran et al. 2013) 
tttcgatTTCTtGGCTTtATaTATCTTGTGGAaAGGACGAAACACCGGGTCTTCGAGAAGAC
CTGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGT
GGCACCGAGTCGGTGCTTTTTTGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTC
CGTTTTTAGCGCGTGCGCCAATTCTGCAGACAAATGGCTCTAGAGGTACCCGTTACATAACT
TACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAGTAA
CGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTG
GCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATG
GCCCGCCTGGCATTGTGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCT
ACGTATTAGTCATCGCTATTACCATGGTC 
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A.1.7 WT Cas9 CRISPR pSpCas9(BB)-2A-GFP (PX458) plasmid map and 
sequence (Addgene #48138) 
Figure A4 shows the plasmid map of Nickase Cas9 CRISPR plasmid pSpCas9n(BB)-2A-GFP 
(PX461) (Addgene #48140) 
 
 
 
Figure A4 Nickase Cas9 CRISPR plasmid pSpCas9n(BB)-2A-GFP (PX461) (Addgene #48140)
Sequencing data for this construct is presented below. 
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Sequence of Nickase CRISPR/Cas9 variant plasmid 
pSpCas9n(BB)-2A-GFP (PX461) Sequence  >U6sponge-F 5'-
GGACTATCATATGCTTACCGTAACTTGA-3' (Ran et al. 2013) 
tTTCGAtTTCTtGGCTTTaTaTATCTTGTGGAaAGGACGAAACACCGGGTCTTCGAGAAGAC
CTGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGT
GGCACCGAGTCGGTGCTTTTTTGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTC
CGTTTTTAGCGCGTGCGCCAATTCTGCAGACAAATGGCTCTAGAGGTACCCGTTACATAACT
TACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAGTAA
CGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTG
GCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATG
GCCCGCCTGGCATTGTGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCT
ACGTATTAGTCATCGCTATTACCATGGTCGAGGTGAGCCCCACGTTCTGCTTCACTCTCCCC
ATCTCCCCCCCCTCCCCACCCCCAATTTTGTATTTATTTATTTTTTAATTATTTTGTGCAgC
GATGg  
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A.2 Sequencing confirming cloning of guide sequence into WT or Nickase variant 
CRISPR/Cas9 plasmids 
 
Sequencing confirming cloning of guide sequence into WT or Nickase variant CRISPR/Cas9 
plasmids is presented below. ENGase WT A and PNGKO Nickase B were not successfully 
cloned into CRISPR plasmids.  
PNGKO WT A 
CCCAAAGGCCTTGTTTACAGAAGAAATTGGATTAATTTGACTGTAAACACAAAGATATTAGT
ACAAAATACGTGACGTAGAAAGTAATAATTTCTTGGGTAGTTTGCAGTTTTAAAATTATGTT
TTAAAATGGACTATCATATGCTTACCGTAACTTGAAAGTATTTCGATTTCTTGGCTTTATAT
ATCTTGTGGAAAGGACGAAACACCGGGCTGTGTTTCCAATCCGGAGTTTTAGAGCTAGAAAT
AGCAAGTTAAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGCACCGAGTCGGTGCTTT
TTTGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGTTTTTAGCGCGTGCGCC
AATTCTGCAGACAAATGGCTCTAGAGGTACCCGTTACATAACTTACGGTAAATGGCCCGCCT
GGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAGTAACGCCAATAGGGACTTTCCA
TTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATC
ATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTGTGCC
CAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTAT
TACCATGGTCGAGGTGAGCCCCACGTTCTGCTTCACTCTCCCCCATCTCCCCCCCCCCTCCC
CACCACAGAAAGTATGGGATTAATTTAATTTTTTAATTAACTTAAGCACCACCACACCAGGG
GGGCGGGGGGGGGGGCGGGGGC 
 
PNGKO WT B 
CTTAAAACCGAAAACAACGCTGTTATAGAACACAACTCGGAATTAATTTGACTGTAAACACA
AAGATATTAGTACAAAATACGTGACGTAGAAAGTAATAATTTCTTGGGTAGTTTGCAGTTTT
AAAATTATGTTTTAAAATGGACTATCATATGCTTACCGTAACTTGAAAGTATTTCGATTTCT
TGGCTTTATATATCTTGTGGAAAGGACGAAACACCGACTAGACTCTTGCCTGTCAGGTTTTA
GAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGCACCGA
GTCGGTGCTTTTTTGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGTTTTTA
GCGCGTGCGCCAATTCTGCAGACAAATGGCTCTAGAGGTACCCGTTACATAACTTACGGTAA
ATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAGTAACGCCAATA
GGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACA
TCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCT
GGCATTGTGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTA
GTCATCGCTATTACCATGGTCGAGGTGAGCCCCACGTTCTGCTTCACTCTCCCCATCTCCCC
CCCTCCAACCCCCAATTTTGTATATTATTTTATTTTTTTTAATTTATTTTTGTGCAACCGAA
TGGGGGGCGAGGGGTGGGGGGGCCCTCGCCGCGCCCAAGCCGGGCGCGGGGGCGGGGACTAA
AGGTGTCGGTGCTGTGGGCCGATGCCAAAAATGGACGCGCCAGCCAACCAACTCAGAAGGGG
GGGCGCGTCCACAAAATTTTTTTCCTTTTTAGGGGGGGAAGGGCGGGCGTC 
 
PNGKO Nickase A 
CAAAAGGGCCCTGGTTAGAGAGAAATTGGAATTAATTTGACTGTAAACACAAAGATATTAGT
ACAAAATACGTGACGTAGAAAGTAATAATTTCTTGGGTAGTTTGCAGTTTTAAAATTATGTT
TTAAAATGGACTATCATATGCTTACCGTAACTTGAAAGTATTTCGATTTCTTGGCTTTATAT
ATCTTGTGGAAAGGACGAAACACCGGGCTGTGTTTCCAATCCGGAGTTTTAGAGCTAGAAAT
AGCAAGTTAAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGCACCGAGTCGGTGCTTT
TTTGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGTTTTTAGCGCGTGCGCC
AATTCTGCAGACAAATGGCTCTAGAGGTACCCGTTACATAACTTACGGTAAATGGCCCGCCT
GGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAGTAACGCCAATAGGGACTTTCCA
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TTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATC
ATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTGTGCC
CAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTAT
TACCATGGTCGAGGTGAGCCCCACGTTCTGCTTCACTCTCCCCATCTCCCCCCCCCCTCCCC
ACCCCCCAATTTTGGTATTTATTTATTTTTTTAATTATTTTTGTGCCACAGATGGGGGGCGG
AGGGGGGTGAGGGGGGCCA 
 
PNGRX WT A 
 
TATTGCAAACGATACAATGCTGTTAGAGAGAAATTGGAATTAATTTGACTGTAAACACAAAG
ATATTAGTACAAAATACGTGACGTAGAAAGTAATAATTTCTTGGGTAGTTTGCAGTTTTAAA
ATTATGTTTTAAAATGGACTATCATATGCTTACCGTAACTTGAAAGTATTTCGATTTCTTGG
CTTTATATATCTTGTGGAAAGGACGAAACACCGTTCTTTAACCTTAGTTCTTCGTTTTAGAG
CTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGCACCGAGTC
GGTGCTTTTTTGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGTTTTTAGCG
CGTGCGCCAATTCTGCAGACAAATGGCTCTAGAGGTACCCGTTACATAACTTACGGTAAATG
GCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAGTAACGCCAATAGGG
ACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCA
AGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGC
ATTGTGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTC
ATCGCTATTACCATGGTCGAGGTGAGCCCCACGTTCTGCTTCACTCTCCCCATCTCCCCCCC
CCTCCCCCACCCCCAATTTTGTATTTATTTATTTTTTTAATTATTTTGTGCAGCGATGGTGG
CG 
 
PNGRX WT B 
 
AAATGCAATACGATACACGCTGTTAGAGAGAAATTGGAATTAATTTGACTGTAAACACAAAG
ATATTAGTACAAAATACGTGACGTAGAAAGTAATAATTTCTTGGGTAGTTTGCAGTTTTAAA
ATTATGTTTTAAAATGGACTATCATATGCTTACCGTAACTTGAAAGTATTTCGATTTCTTGG
CTTTATATATCTTGTGGAAAGGACGAAACACCGTACTTCGAGACACTATTAATGTTTTAGAG
CTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGCACCGAGTC
GGTGCTTTTTTGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGTTTTTAGCG
CGTGCGCCAATTCTGCAGACAAATGGCTCTAGAGGTACCCGTTACATAACTTACGGTAAATG
GCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAGTAACGCCAATAGGG
ACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCA
AGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGC
ATTGTGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTC
ATCGCTATTACCATGGTCGAGGTGAGCCCCACGTTCTGCTTCACTCTCCCCATCTCCCCCCC
CATGGAGCACCCCCAATTTTTGTATTTATTTATTTTTTAATTATTTTTGTGCAA 
 
PNGRX Nickase A 
 
CTGCCATACGATACATGCTGTTAGAGAGAAATTGGAATTAATTTGACTGTAAACACAAAGAT
ATTAGTACAAAATACGTGACGTAGAAAGTAATAATTTCTTGGGTAGTTTGCAGTTTTAAAAT
TATGTTTTAAAATGGACTATCATATGCTTACCGTAACTTGAAAGTATTTCGATTTCTTGGCT
TTATATATCTTGTGGAAAGGACGAAACACCGTTCTTTAACCTTAGTTCTTCGTTTTAGAGCT
AGAAATAGCAAGTTAAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGCACCGAGTCGG
TGCTTTTTTGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGTTTTTAGCGCG
TGCGCCAATTCTGCAGACAAATGGCTCTAGAGGTACCCGTTACATAACTTACGGTAAATGGC
CCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAGTAACGCCAATAGGGAC
TTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAG
TGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCAT
TGTGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCAT
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CGCTATTACCATGGTCGAGGTGAGCCCCACGTTCTGCTTCACTCTCCCCATCTCCCCCCCCT
CCCCACCCCCAATTTTGTATTTTATTTTATTTTTTTTAATTATTTTGGGCAGCGATGGGGGC
GGGGGGGGGGGGGGGGGGACCCCCCCCCCAGGGCGGGATCGGAGTCGGTAACGAATGGGCGG
GTCTGAGCCTAAGCCAGAAAAGGGTGCCGGCGCAAGCCATTCCAAAAGTGGCCGCCTCTCCC
GAAAAGT 
 
PNGRX Nickase B 
 
ATACGTGACGTAGAAAGTAATAATTTCTTGGGTAGTTTGCAGTTTTAAAATTATGTTTTAAA
ATGGACTATCATATGCTTACCGTAACTTGAAAGTATTTCGATTTCTTGGCTTTATATATCTT
GTGGAAAGGACGAAACACCGTACTTCGAGACACTATTAATGTTTTAGAGCTAGAAATAGCAA
GTTAAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGCACCGAGTCGGTGCTTTTTTGT
TTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGTTTTTAGCGCGTGCGCCAATTC
TGCAGACAAATGGCTCTAGAGGTACCCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTG
ACCGCCCAACGACCCCCGCCCATTGACGTCAATAGTAACGCCAATAGGGACTTTCCATTGAC
GTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATG
CCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTGTGCCCAGTA
CATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCA
TGGTCGAGGTGAGCCCCACGTTCTGCTTCACTCTCCCCATCTCCCCCCCCTCCCCACCCCAA
ATTTTGTATTTATTTATTTTTTAATTTTTTGGGGCCCCGTTGGGGGCGGGGGGGGGGGGGGG
GTTGTGTTTTATAAAAAAAAAAAGTCCCAAAACCCTTTCCGCACCAAAGCAAAAAAAGGGTT
GGAAAACAAAAAAAAGGGGGGGGTAAAA 
 
ENGase WT B  
CAAAGGGCCTGTTAGAAGAGATAATTGGAATTAATTTGACTGTAAACACAAAGATATTAGTA
CAAAATACGTGACGTAGAAAGTAATAATTTCTTGGGTAGTTTGCAGTTTTAAAATTATGTTT
TAAAATGGACTATCATATGCTTACCGTAACTTGAAAGTATTTCGATTTCTTGGCTTTATATA
TCTTGTGGAAAGGACGAAACACCGGGCGTGGAAGCCCCGCTTGGGTTTTAGAGCTAGAAATA
GCAAGTTAAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGCACCGAGTCGGTGCTTTT
TTGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGTTTTTAGCGCGTGCGCCA
ATTCTGCAGACAAATGGCTCTAGAGGTACCCGTTACATAACTTACGGTAAATGGCCCGCCTG
GCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAGTAACGCCAATAGGGACTTTCCAT
TGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCA
TATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTGTGCCC
AGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATT
ACCATGGTCGAGGTGAGCCCCACGTTCTGCTTCACTCTCCCCATCTCCCCCCCCCCTCCCCA
CCCCCAAATTTTGTATTATATTATATTTTTTATATTATATTTTTGTGCCCCGATGGGGGCGG
GGGCGGGGTAACTCTCGCCCCAATGACGACCCAAACTGTCCAACGTCCGACCCGTCAAGCGA
ATAGGTGCGCCGTCAACCAATCAGAAGGCGGCGCGCTTCCGAAAAG  
 
ENGase Nickase A 
ACGAACCACGGCCTGTTAGAGAGATAATTGGAATTAATTTGACTGTAAACACAAAGATATTA
GTACAAAATACGTGACGTAGAAAGTAATAATTTCTTGGGTAGTTTGCAGTTTTAAAATTATG
TTTTAAAATGGACTATCATATGCTTACCGTAACTTGAAAGTATTTCGATTTCTTGGCTTTAT
ATATCTTGTGGAAAGGACGAAACACCGCAAGTAAAAGCTGATTGGTTGTTTTAGAGCTAGAA
ATAGCAAGTTAAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGCACCGAGTCGGTGCT
TTTTTGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGTTTTTAGCGCGTGCG
CCAATTCTGCAGACAAATGGCTCTAGAGGTACCCGTTACATAACTTACGGTAAATGGCCCGC
CTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAGTAACGCCAATAGGGACTTTC
CATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTA
TCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTGTG
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CCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCT
ATTACCATGGTCGAGGTGAGCCCCACGTTCTGCTTCACTCTCCCCATCTCCCCCCCCTCCCC
ACCCCCAATTTTGTATTTATTTATTTTTTAATTATTTTGTGCAGCGATGGGGGCGGGGGGGG
GGGAGCCCGCCGCGCCAAGCGGGGCGAGGCGGGGCGAGGGGCGGGCGGGCCGAAGCGAAAAG
GTGCGGCCGCAGCCAATTCAAGAAGCGGCGGCGCTCCGAAAGTTTCCCTTTTATGGGCAGAG
G 
 
ENGase Nickase B 
AGACAAACCCAAAACAATGGCTGTTAGAGAGATAATTGGAATTAATTTGACTGTAAACACAA
AGATATTAGTACAAAATACGTGACGTAGAAAGTAATAATTTCTTGGGTAGTTTGCAGTTTTA
AAATTATGTTTTAAAATGGACTATCATATGCTTACCGTAACTTGAAAGTATTTCGATTTCTT
GGCTTTATATATCTTGTGGAAAGGACGAAACACCGGGCGTGGAAGCCCCGCTTGGGTTTTAG
AGCTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGCACCGAG
TCGGTGCTTTTTTGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGTTTTTAG
CGCGTGCGCCAATTCTGCAGACAAATGGCTCTAGAGGTACCCGTTACATAACTTACGGTAAA
TGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAGTAACGCCAATAG
GGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACAT
CAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTG
GCATTGTGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAG
TCATCGCTATTACCATGGTCGAGGTGAGCCCCACGTTCTGCTTCACTCTCCCCATCTCCCCC
CCCCTCCCCACCCCCAATTTTGTATTTATTTATTTTTTATTTATTTTGTGCACCGATGGGGG
CGGGGGGGGGGGGGGGGGCCGCGCCCCAAGCCGGGCCGCGCCGGCCGAGGGTCGGTCGGTCT
AGGCGAAAGTTGCGCGCACCCAATCAAGAGCGGCGCGCTCCGAAGTTTCCTTTTATGGCGAG
G 
A.3 Sequences used for TIDE analysis 
 
The sequences used for TIDE analysis are presented below. 
PNG KO predicted sequence 
GTACCTTAACAGCACAGAATGTAATTTACTGTTTTTACTTATAGTAAAAACAACCATTGGTT
TAGGGAAGAAAGAAAATCAGGTGACTATAAAGGTATACCTAGGTCATGTTTGTTGAAAGTAA
AGTCTTTGAAGAACTATGACCTGGTTTTTTTTATATATAATCAAACTTTTGTTTTTTGTCAG
AAACCCTAATGATGAAAAATATAGATCCATCCGGATTGGAAACACAGCCTTTTCTACTAGAC
TCTTGCCTGTCAGAGGAGCTGTTGAATGTTTATTTGAAATGGGCTTTGAAGAGGTAAGTATG
TTCAAGGATTTCCTCTCCCCTCTTCATGCACAAAGCAGCCATTATCATGTTGGTGAATAATT
GTTTGAATAAGATAATGTTTTTTAATTTATCATTTTGGGAATCAGTAGAAGTAGTTATTTCT
TCATTGATTGGACATTTAAAAATCACAACAAGTATAGTTTAAAATTTCAGTAAAATGTAACA
ACGCTCCACAGAGAAATTCTTACGAGTCTCAGTTCTTTAAAATAAGGGTCATACATGCAACC
CAAGGACCAAATGTGGTTCACTTTAGGCTTTTAGCTAAAACCTGATTTGTGAGCACACATGA
ATACTAATAGAGTCTAGCTACCTGTCTGTAGTAGG 
WT gDNA >PNGF  
CCATTGGTTTAGGGAAGAAAGAAAATCAGGTGACTATAAAGGTATACCTAGGTCATGTTTGT
TGAAAGTAAAGTCTTTGAAGAACTATGACCTGGTTTTTTTTATATATAATCAAACTTTTGTT
TTTTGTCAGAAACCCTAATGATGAAAAATATAGATCCATCCGGATTGGAAACACAGCCTTTT
CTACTAGACTCTTGCCTGTCACAGGAGCTGTTGAATGTTTATTTGAAATGGGCTTTGAAGAG
GTAAGTATGTTCAAGGATTTCCTCTCCCCTCTTCATGCACAAAGCAGCCATTATCATGTTGG
TGAATAATTGTTTGAATAAGATAATGTTGTTTAATTTATCATTTTGGGAATCAGTAGAAGTA
GTTATTTCTTCATTGATTGCACATTTAAAAATCACAACAAGTATAGCTTAAACTTTCTGAAA
AATGTATCAACGTTCAACAGAGAAATTCTTACGNGCTCAGTTCTTTAAAATAAAGGTCTACA
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TGCAACCCAAGGACCAATTGTGGCTCACTTTAGGCTTTTACATAAACCTGATTTGTGAGCTC
CATCAGTACTA 
 
PNGA Mixed population >PNGF 
CTTTTTTCTTTAAGTAAACAACCATTGGTTTAGGGAAGAAGAAAATCAGGTGACTATAAAGG
TATACCTAGGTCATGTTTGTTGAAAGTAAAGTCTTTGAAGAACTATGACCTGGTTTTTTTTA
TATATAATCAAACTTTTGTTTTTTGTCAGAAACCCTAATGATGAAAAATATAGATCCATCCG
/GAATGGAAACCCCGCCTTTTCTCATAAACCCCTGGCTGGCCAAAGAACTTTTGTAAGGTTA
ATTTAAAGGGGTTTTGAAAAAGTAATTAATTTCCCTGTTTTCCCCCCCCCTTTTCATGGAAA
AATCGGGCCTTAACATGGTTGGGAATAAATGGTTTTATAATGTAATTGTTTTTAATTTAATC
TTTTGGGGAACTATAAAACTATGTTTTTCTTCGTTTAATGAAACTCTAAAAATCTAAAATAG
GT 
 
PNGB Mixed population >PNGF 
CTGCAGTCTTAAGTAAAACACCATTGGTTTAGGGAGAAGAAATCAGGTGACTATAAAGGTAT
ACCTAGGTCATGTTTGTTGAAAGTAAAGTCTTTGAAGAACTATGACCTGGTTTTTTTTATAT
ATAATCAAACTTTTGTTTTTTGTCAGAAACCCTAATGATGAAAAATATAGATCCATCCGGAT
TGGAAACACAGCCTTTTCTACTAGACTCTTGCCTGT/TCAAAGGAGCTGTTGAATGTTTATT
TGAAATGGGCTTTGAAAAGGTAAGTATGTTCAAGGATTTCCTCTCCCCTCTTCATGCACAAA
GCAGCCATTATCATGTTGGGGAATAATTGTTTGAATAAGATAATGTTTTTTATTTTATCATT
TTGGGAATCAGTAAAAGTAGTTATTTCTTCATTGATTGGACATTTAAAAATCACAACAAGTA
TACTTTAAAATTTCAGTAAAATGCAACAACGCTCCACAAAAAAATTCTTACGAGTCTCATTT
CTTTAAAATAAGGG 
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A.4 FITC-labelling of RNAse B 
 
RNAseB was conjugated with fluoroscein isothiocyanate.  The protein first was dissolved in 
sodium carbonate buffer (0.1 M, pH 9) to a final concentration of 2 mg/ml.  Fluoroscein 
isothiocyanate (CAS: 3326-32-7, Sigma-Aldrich, catalogue no: F4274) was dissolved in DMSO 
to a final concentration of 1 mg/ml.  The solution of RNAse B (1 mL) was agitated gently on 
a shaker plate, and the FITC solution (50 µl) was added slowly in 5 µL aliquots over 30 min.  
The reaction mixture was wrapped in foil to exclude light and incubated at 4 °C for 8 h.  
Following the incubation, ammonium chloride was added to a final concentration of 50 mM 
and the solution again left to incubate in the dark (4 °C, 2 h).  Glycerol (50 µl) was added, 
along with xylene cyanol FF (CAS: 2650-17-1, Sigma Aldrich, catalogue no: X4126).  The 
labelled protein was separated from unconjugated protein and free label by elution in PBS 
on a PD10 column (GE Healthcare).  The final concentration of protein was determined using 
a NanoDrop.   
 
FITC-labelled RNAse B was incubated with PNGAse F using the conditions for the general 
RNAse B deglycosylation assay previously described.  The results are shown in Figure A5, 
and demonstrate that FITC-labelled RNAse B acts as a suitable substrate for this assay.   
 
 
  
 
Figure A5 RNase B labelled FITC incubated with PNGase F. Lane 1: denatured FITC labelled 
RNase B. Lane 2: denatured FITC labelled RNase B deglycosylated with PNGase F. Lane 3: 
FITC labelled RNase B. Lane 4: FITC labelled RNase B deglycosylated with PNGase F. 
Fluorescence Gel imaged using Syngene Gel:Doc. 
 
 
 
Glycosylated 
Deglycosylated 
1 2 3 4 
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